THERE’S MORE FROM MAIA

Don’t miss out on the data we’re rolling out

Visit Booth #429

Scan for clinical results
ASH® Clinical Practice Guidelines

Evidence-based guidelines covering the prevention, diagnosis, and treatment of blood disorders.

The American Society of Hematology (ASH) Clinical Practice Guidelines support clinicians and their patients with hematologic conditions to make decisions about diagnostic and treatment options based on a systematic review of the best available evidence. The guidelines are published in ASH’s open access scientific journal Blood Advances.

The guidelines are monitored annually for currency by experts. ASH will revise its guidelines when there is new evidence that could substantially change published recommendations.

Mobile Access to Guidelines and Pocket Guides

ASH Guidelines App: Easily access guideline recommendations from all published guidelines from the convenience of your smartphone or tablet, including complete evidence-to-decision tables.

ASH Pocket Guides App: Get interactive versions of all the Society’s clinical pocket guides right on your smartphone. In addition to the pocket guides content, the app includes tools to aid in clinical decision making.

hematology.org/guidelines
# Table of Contents

## About ASH
- ASH Executive and Program Committees 5
- Reviewers of Abstracts and *Hematology 2022* 8
- Corporate Acknowledgements 11
- Recipients of Awards 15

## Guide to Navigating the Meeting
- General Information 21
- Diversity, Equity, and Inclusion at ASH 34
- Maternal Health at ASH 37
- Non-CME Sessions 39

## Meeting Schedule
- Day-At-A-Glance 41

## Invited Speaker Sessions
- General Sessions 65
- Special Interest Sessions 67
- Trainee Activities (Open to Trainees Only) 75

*continued on next page*
# Table of Contents

## Education Program

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education Sessions</td>
<td>81</td>
</tr>
<tr>
<td>Education Spotlight Sessions</td>
<td>89</td>
</tr>
<tr>
<td>How I Treat: Bringing Science to Clinical Dilemmas (Ticketed Sessions)</td>
<td>91</td>
</tr>
</tbody>
</table>

## Scientific Program

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Sessions</td>
<td>97</td>
</tr>
<tr>
<td>Scientific Symposia</td>
<td>101</td>
</tr>
<tr>
<td>Scientific Spotlight Sessions</td>
<td>103</td>
</tr>
<tr>
<td>Scientific Workshops</td>
<td>105</td>
</tr>
<tr>
<td>ASH Poster Walks</td>
<td>109</td>
</tr>
<tr>
<td>Meet the Experts (Ticketed Sessions)</td>
<td>110</td>
</tr>
</tbody>
</table>

## Abstract Sessions

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Categories</td>
<td>113</td>
</tr>
<tr>
<td>Oral Abstract Sessions</td>
<td>115</td>
</tr>
<tr>
<td>Poster Presentations</td>
<td>123</td>
</tr>
</tbody>
</table>

## Exhibitors

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Satellite Symposia</td>
<td>127</td>
</tr>
<tr>
<td>Product Theaters</td>
<td>143</td>
</tr>
<tr>
<td>Industry Theaters</td>
<td>147</td>
</tr>
<tr>
<td>Company Showcases</td>
<td>149</td>
</tr>
<tr>
<td>Exhibitor Directory</td>
<td>151</td>
</tr>
</tbody>
</table>
AMERICAN SOCIETY OF HEMATOLOGY
EXECUTIVE COMMITTEE

STAFF LIAISONS:

Martha Liggett, Esq.
E-mail: mliggett@hematology.org
Matthew Gertzog, MBA, CAE
E-mail: mgertzog@hematology.org
LaFaundra Neville-Ingram, CAP
E-mail: lneville@hematology.org

President: Jane N. Winter, MD
President-Elect: Robert A. Brodsky, MD
Vice President: Mohandas Narla, DSc
Secretary: Cynthia E. Dunbar, MD
Treasurer: Mark A. Crowther, MD

COUNCILLORS:

Belinda Avalos, MD (’22)
Arnold Ganser, MD (’22)
Alison Loren, MD (’23)
Bob Löwenberg, MD, PhD (’23)
Sarah H. O’Brien, MD (’25)
Betty Pace, MD (’24)
Jamile M. Shammo, MD (’24)
Wendy Stock, MD (’25)
PROGRAM COMMITTEE

STAFF LIAISON:
Charles Clayton
E-mail: cclayton@hematology.org

Jane N. Winter, MD ('22) - Chairperson, President
Robert A. Brodsky, MD ('22) - Ex-Officio: President-Elect
Mark A. Crowther, MD ('22) - Ex-Officio: Treasurer
Cynthia E. Dunbar, MD ('24) - Ex-Officio: Secretary
Mohandas Narla, DSc ('24) - Ex-Officio: Vice President
Nancy Berliner, MD ('24) - Liaison, Editor-in-Chief, Blood
Catherine M. Bollard, MD ('26) - Liaison, Blood Advances Editor-in-Chief
Jennifer R. Brown, MD, PhD ('23) - Liaison, Chair, Committee on Educational Affairs
Adam Cuker, MD ('23) - Liaison, Chair, Committee on Quality
Chancellor E. Donald, MD ('23) - Liaison, Chair, Committee on Practice
Christopher R. Flowers, MD ('22) - Liaison, Chair, Committee on Diversity, Equity and Inclusion
Aaron T. Gerds, MD, MS ('23) - Liaison, Editor-in-Chief, ASH Clinical News
Judith Kleinerman, MD ('23) - Liaison, Chair, CME Accreditation Committee
Shaji Kunnathu Kumar, MD ('22) - Liaison, Editor-in-Chief Designee, The Hematologist
Ross Levine, MD ('22) - Liaison, Chair, Committee on Scientific Affairs
Laura Michaelis, MD ('22) - Liaison, Editor-in-Chief, The Hematologist
Eduardo Magalhães Rego, MD, PhD ('23) - Liaison, Chair, International Members Committee
Andrew W. Roberts, MBBS, PhD ('24) - Liaison, Deputy Editor, Blood
Mikkael A. Sekeres, MD ('22) - Liaison, Chair, Committee on Communications
Andrew S. Weyrich, PhD ('26) - Liaison, Blood Advances Deputy Editor
Ted Wun, MD ('22) - Liaison, Chair, Committee on Training
ANNUAL MEETING ACCREDITED
EDUCATION COMMITTEE

STAFF LIAISON:
Ana Velarde
E-mail: avelarde@hematology.org

David M. Bodine, PhD ('22) - 2022 Scientific Program Co-Chair
Catherine J. Wu, MD ('22) - 2022 Scientific Program Co-Chair
David Garcia, MD ('22) - Co-Chairperson, 2022 Education Program Co-Chair
Olatoyosi Odenike, MD ('22) - Co-Chairperson, 2022 Education Program Co-Chair

Jean M. M. Connors, MD ('23) - 2023 Education Program Co-Chair
Amy E. DeZern, MD ('23) - 2023 Education Program Co-Chair
Kojo S.J. Elenitoba-Johnson, MD ('23) - 2023 Scientific Program Co-Chair
Elizabeta Nemeth, PhD ('23) - 2023 Scientific Program Co-Chair
    Hanny Al-Samkari, MD ('24) - Editor, Hematology
    Andrew Artz, MD, MS ('22) - Appointed Member
    Maria "Ken" E. Figueroa, MD ('22) - Appointed Member
    Lynne Kaminer, MD ('22) - Appointed Member
    Allison A. King, MD, PhD, MPH ('22) - Appointed Member
    Judith Kleinerman, MD ('23) - Liaison, Chair, CME Accreditation Committee
    Ann LaCasce, MD ('22) - Appointed Member
    Janice W. Lawson, MD ('22) - Appointed Member
    Thomas P. Loughran, Jr, MD ('22) – Appointed Member
    Jennifer L. McNeer, MD ('22) - Appointed Member
    Aaron Tobian, MD, PhD ('22) - Appointed Member
    Marcin Wlodarski, MD, PhD ('22) - Appointed Member
The Society gratefully acknowledges the time and effort of the following individuals who served as reviewers of abstracts for this meeting and of Hematology 2022, the ASH Education Program.

2022 REVIEWERS

ASH ABSTRACTS COORDINATING REVIEWERS

Inhye E. Ahn
Jo Caers
Ja Min Byun
Jorg Bungert
Ja Caers

ASH ABSTRACTS REVIEWERS

Curtis J. Henry
Kathryn A. Lurain
Robert L. Bowman
Arndt Borkhardt
Peter J.M. Valk

Maria Domenica Domenica
Meghan Drayton Jackson

Richard Rosenquist

Cappellini
Hetty E. Carraway

Delfim Duarte

Joanna S. Yi

Kisumon D. Edwards

Efstathios Kastritis

Sangmoo Jeong

Maria Alice Hollenhorst

W. Keith Hoots

Kate A. Markey

Rossella Marullo

Francesco Maura

Michael Mauro

Jori E. May

Stephan Mielke

Siyun Min

Ashley T. Bryceson

Erin H. Breese

Julie Irving

Tamer Itkin

Sawasnoi

Graham Jackson

Siddhartha Jaiswal

Nisha S. Joseph

Tapan M. Kadia

Thomas G. Knight

Ralf Pawlinski

Juliana Perez Botero

Rachel Philan

Louise E. Purton

Rachel E. Rau

Eduardo M. Rego

4

ASH ABSTRACTS COORDINATING REVIEWERS

Richard Rosenquist

Rebekka K. Schneider

Akshay Sharma

Wendy Stock

Justin Taylor

Tomomi Toubai

Peter J.M. Valk

Peter van Galen

Mireya Paulina Velasquez

Valeria Visconte

Russell E. Ware

Julia T. Warren

Justin Watts

Karina Yazdanbakhsh

Joanna S. Yi

Amer M. Zeidan

ASH ABSTRACTS REVIEWERS

Zaid Abdel Rahman

Mouhamed Yazan Abou-Ismail

Roshini S. Abraham

Sumana Devata

Marta Derecka

Roberta Demichelis

Michael W. Deininger

Susan DeWolf

Kim De Veirman

Sofia De Oliveira

Charles De Bock

Emily K. Curran

Katherine D. Cummins

Christine M. Cserti-Gazdewich

Jorge E. Cortes

Radhika Gangaraju

Nico Gagelmann

Kathleen Freson

Corinne Frere

Matthew J. Frank

Ellen Frant

Matthew J. Frank

Corinne Frere

Kathleen Freson

Nic Gagelmann

Radhika Gangaraju

Miguel Gauza Fernandez

Jacqueline S. Garcia

Ramon Garcia-Sanz

Ulrich Germing

Mark B. Geyer

Paolo Ghia

Paola Ghione

Paolo Ghione

Arnas Ghosh

Alice Giustacchini

James Godfrey

Hartmut Goldschmidt

Kandace Gollomp

Alexandra Gomez

Florian Grebien

Gareth P. Gregory

Emma M. Groarke

Gregory M.T. Guilcher

Guru Subramanian Guru Murthy

Jonathan A. Gutman

Boglarka Gyurkocza

Betty K. Hamilton

Alan M. Hanash

Jakob Werner Hansen

Andrew Hantel

Tanja Nicole Hartmann

Rog He

Michael Heuser

Kyle J. Hewitt

Nobuko Hijiya

Hideyo Hirai

Taro Hitosugi

Peter Hokland

Matthew M. Hsieh

Xiao-Jun Huang

Kristalyn E Hudson

Camelia Iancu-Rubin

Hiroto Inaba

Andrew M. Intlekofer

Andy Itsara

Samantha Jaglowski

Sangmoo Jeong

Samantha Jaglowski

Sangmoo Jeong

Samantha Jaglowski

Sangmoo Jeong

Samantha Jaglowski

Sangmoo Jeong

Jill M. Johnsen

Courtney L. Jones

Mark Juckett

Moonjung Jung

Swetha Kambhampati

Efstathios Kastritis

Antonis Kattamis

Karsten B. Kaufmann

Dickran Kazandjian

Dickran Kazandjian

Dickran Kazandjian

Dickran Kazandjian

Dickran Kazandjian

Dickran Kazandjian

Dickran Kazandjian

Dickran Kazandjian

Dickran Kazandjian

Dickran Kazandjian
<table>
<thead>
<tr>
<th>Reviewers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gina Keiffer</td>
</tr>
<tr>
<td>Saad S. Kenderian</td>
</tr>
<tr>
<td>Michael Keng</td>
</tr>
<tr>
<td>Eugene Khandros</td>
</tr>
<tr>
<td>Miriam Y. Kim</td>
</tr>
<tr>
<td>Sandrina Kinet</td>
</tr>
<tr>
<td>Bérengère Koehl</td>
</tr>
<tr>
<td>Divya Koura</td>
</tr>
<tr>
<td>Motoko Koyama</td>
</tr>
<tr>
<td>Giedre Kreciute</td>
</tr>
<tr>
<td>Vishal Kukrehti</td>
</tr>
<tr>
<td>Austin Kulasekaraj</td>
</tr>
<tr>
<td>Anita Kumar</td>
</tr>
<tr>
<td>Shekhar Kumar</td>
</tr>
<tr>
<td>Daisuke Kurotaki</td>
</tr>
<tr>
<td>Catherine Lai</td>
</tr>
<tr>
<td>Bernhard Lamme</td>
</tr>
<tr>
<td>Karilyn T. Larkin</td>
</tr>
<tr>
<td>Sarah Larson</td>
</tr>
<tr>
<td>Elisa Laurenti</td>
</tr>
<tr>
<td>Allison Barz Leahy</td>
</tr>
<tr>
<td>Catherine J. Lee</td>
</tr>
<tr>
<td>Stanley Chun-Wei Lee</td>
</tr>
<tr>
<td>Claudia Lengerke</td>
</tr>
<tr>
<td>Jessica Leonard</td>
</tr>
<tr>
<td>Harry Lesmana</td>
</tr>
<tr>
<td>Sheng Li</td>
</tr>
<tr>
<td>Richard J. Lin</td>
</tr>
<tr>
<td>Andrew H. Lipsky</td>
</tr>
<tr>
<td>Daihong Liu</td>
</tr>
<tr>
<td>Hien D. Liu</td>
</tr>
<tr>
<td>Hongtao Liu</td>
</tr>
<tr>
<td>Qiifa Liu</td>
</tr>
<tr>
<td>Kah Poh (Melissa) Loh</td>
</tr>
<tr>
<td>Rui Lu</td>
</tr>
<tr>
<td>Jennifer Kimberly Lue</td>
</tr>
<tr>
<td>Tiago C. Luis</td>
</tr>
<tr>
<td>Tracy C. Lund</td>
</tr>
<tr>
<td>Advaitha Madireddy</td>
</tr>
<tr>
<td>Silvia Maria Meira Magalhaes</td>
</tr>
<tr>
<td>Nadim Mahmoud</td>
</tr>
<tr>
<td>Harry L. Malech</td>
</tr>
<tr>
<td>Luis Enrique Malpica Castillo</td>
</tr>
<tr>
<td>Maksim Mamontkin</td>
</tr>
<tr>
<td>Salomon Manier</td>
</tr>
<tr>
<td>Gabriel N. Mannis</td>
</tr>
<tr>
<td>Kate Manos</td>
</tr>
<tr>
<td>Bridge K. Marcellino</td>
</tr>
<tr>
<td>Enrica Marchi</td>
</tr>
<tr>
<td>Guido Marcucci</td>
</tr>
<tr>
<td>Anna E. Marneth</td>
</tr>
<tr>
<td>Maria Paola Martelli</td>
</tr>
<tr>
<td>Thomas Martin</td>
</tr>
<tr>
<td>Matthew J. Matasar</td>
</tr>
<tr>
<td>Masanori Matsumoto</td>
</tr>
<tr>
<td>Kathy McGraw</td>
</tr>
<tr>
<td>Catherine E. McGuinn</td>
</tr>
<tr>
<td>Zoe McQuilten</td>
</tr>
<tr>
<td>Hirshikesh M. Mehta</td>
</tr>
<tr>
<td>Afua Adjeiwa Mensah</td>
</tr>
<tr>
<td>Maximilian Merz</td>
</tr>
<tr>
<td>Lekha Mikkilinen</td>
</tr>
<tr>
<td>Hanna Mikkola</td>
</tr>
<tr>
<td>Filippo Milano</td>
</tr>
<tr>
<td>Alice S. Mims</td>
</tr>
<tr>
<td>Eliana C. M. Cristina Martins</td>
</tr>
<tr>
<td>Miranda</td>
</tr>
<tr>
<td>Yasushi Miyazaki</td>
</tr>
<tr>
<td>Gulham Rehman Mohyuddin</td>
</tr>
<tr>
<td>Patrizia Mondello</td>
</tr>
<tr>
<td>Eugenio Montini</td>
</tr>
<tr>
<td>Eugenio Morelli</td>
</tr>
<tr>
<td>Gareth J. Morgan</td>
</tr>
<tr>
<td>Marek Mraz</td>
</tr>
<tr>
<td>Martha-Lena Mueller</td>
</tr>
<tr>
<td>Nicola J. Mutch</td>
</tr>
<tr>
<td>Markus Müschen</td>
</tr>
<tr>
<td>Satish Nandakumar</td>
</tr>
<tr>
<td>Sunita Nathan</td>
</tr>
<tr>
<td>Marquita Nelson</td>
</tr>
<tr>
<td>Andreas Neubauer</td>
</tr>
<tr>
<td>Dang Hai Nguyen</td>
</tr>
<tr>
<td>Florence Nguyen-Khac</td>
</tr>
<tr>
<td>Taiga Nishihori</td>
</tr>
<tr>
<td>Zohra Nooruddin</td>
</tr>
<tr>
<td>Foluso Joy Ogunside</td>
</tr>
<tr>
<td>Rebecca L. Olin</td>
</tr>
<tr>
<td>Olalekan O. Oluwole</td>
</tr>
<tr>
<td>Olubosola Oluwole</td>
</tr>
<tr>
<td>Victor M. Orellana-Noia</td>
</tr>
<tr>
<td>Joseph H. Oved</td>
</tr>
<tr>
<td>Sandhya Panch</td>
</tr>
<tr>
<td>Nicki Panoskaltis</td>
</tr>
<tr>
<td>Anna L. Parks</td>
</tr>
<tr>
<td>Sant-Rayn Pasricha</td>
</tr>
<tr>
<td>Freda H. Passam</td>
</tr>
<tr>
<td>Ami B. Patel</td>
</tr>
<tr>
<td>Dilan Anil Patel</td>
</tr>
<tr>
<td>Shyam Ajay Patel</td>
</tr>
<tr>
<td>Melinda Pauly</td>
</tr>
<tr>
<td>Fabiana Perna</td>
</tr>
<tr>
<td>Florian Perner</td>
</tr>
<tr>
<td>Aurore Perrot</td>
</tr>
<tr>
<td>Anamarjia M. Perry</td>
</tr>
<tr>
<td>Christine L. Phillips</td>
</tr>
<tr>
<td>Yana Pikman</td>
</tr>
<tr>
<td>Sandra Pinho</td>
</tr>
<tr>
<td>Steven W. Pipe</td>
</tr>
<tr>
<td>Nicola Polverelli</td>
</tr>
<tr>
<td>Mortimer Poncz</td>
</tr>
<tr>
<td>Matthew H. Porteus</td>
</tr>
<tr>
<td>Tirthadipa Pradhan-Sundu</td>
</tr>
<tr>
<td>Bethan Psiala</td>
</tr>
<tr>
<td>Ching-Hon Pui</td>
</tr>
<tr>
<td>Dražen Pulaníc</td>
</tr>
<tr>
<td>Muna Qayed</td>
</tr>
<tr>
<td>Chittalsinh Raulji</td>
</tr>
<tr>
<td>Patrick M. Reagan</td>
</tr>
<tr>
<td>Michele S. Redell</td>
</tr>
<tr>
<td>Andreas Reiter</td>
</tr>
<tr>
<td>Raffaele Renella</td>
</tr>
<tr>
<td>Suely M. Rezende</td>
</tr>
<tr>
<td>Katy Rezvani</td>
</tr>
<tr>
<td>Joanna Robles</td>
</tr>
<tr>
<td>Lindsey E. Roeker</td>
</tr>
<tr>
<td>Kerry A. Rogers</td>
</tr>
<tr>
<td>Laura Rosinol Dachs</td>
</tr>
<tr>
<td>Adriana Rossi</td>
</tr>
<tr>
<td>Lisa Giulino Roth</td>
</tr>
<tr>
<td>Giovanni Roti</td>
</tr>
<tr>
<td>Alicia Roov</td>
</tr>
<tr>
<td>Jacob M. Rowe</td>
</tr>
<tr>
<td>Robert Grant Rowe</td>
</tr>
<tr>
<td>Anindita Roy</td>
</tr>
<tr>
<td>Jeremy Rubinstein</td>
</tr>
<tr>
<td>Giovanna Russo</td>
</tr>
<tr>
<td>Sarah C. Rutherford</td>
</tr>
<tr>
<td>Brooke Sadler</td>
</tr>
<tr>
<td>Sheila Saint Fleur-Lominy</td>
</tr>
<tr>
<td>Ioanna Sakellari</td>
</tr>
<tr>
<td>Bethany T. Samuelson Bannow</td>
</tr>
<tr>
<td>Mehmet K. Samur</td>
</tr>
<tr>
<td>Takaomi Senda</td>
</tr>
<tr>
<td>Kristen M. Sanfilippo</td>
</tr>
<tr>
<td>David Sanford</td>
</tr>
<tr>
<td>Veena Sangkhae</td>
</tr>
<tr>
<td>Santosh L. Saraf</td>
</tr>
<tr>
<td>Jean-Emmanuel Sarry</td>
</tr>
<tr>
<td>Goro Sashida</td>
</tr>
<tr>
<td>Jennifer N. Saulitz</td>
</tr>
<tr>
<td>Yazeed Sawalha</td>
</tr>
<tr>
<td>Jordan K. Schaefer</td>
</tr>
<tr>
<td>Gary J. Schiller</td>
</tr>
<tr>
<td>Martin Schrappe</td>
</tr>
<tr>
<td>David W. Scott</td>
</tr>
<tr>
<td>Craig D. Seaman</td>
</tr>
<tr>
<td>Bijal D. Shah</td>
</tr>
<tr>
<td>Urvi A. Shah</td>
</tr>
<tr>
<td>Aditi Shastri</td>
</tr>
<tr>
<td>Joseph J. Shatzel</td>
</tr>
<tr>
<td>Sujit Sheth</td>
</tr>
<tr>
<td>Kristin A. Shimano</td>
</tr>
<tr>
<td>Roni Shouval</td>
</tr>
<tr>
<td>Federico Simonetta</td>
</tr>
<tr>
<td>B. Douglas Douglas Smith</td>
</tr>
<tr>
<td>Melody Smith</td>
</tr>
<tr>
<td>Pieter Sonneveld</td>
</tr>
<tr>
<td>Marcel Spaargaren</td>
</tr>
<tr>
<td>Philipp B. Staber</td>
</tr>
<tr>
<td>Tatjana Stankovic</td>
</tr>
<tr>
<td>Robert M. Stern</td>
</tr>
<tr>
<td>Anna Sureda</td>
</tr>
<tr>
<td>Raphael Szalat</td>
</tr>
<tr>
<td>Natasha Szuber</td>
</tr>
<tr>
<td>Ali T. Taher</td>
</tr>
<tr>
<td>Koichi Takahashi</td>
</tr>
<tr>
<td>Aimee C. Taller</td>
</tr>
<tr>
<td>HweI-Fang Tien</td>
</tr>
<tr>
<td>Douglas Tremblay</td>
</tr>
<tr>
<td>Celine M. Vachon</td>
</tr>
<tr>
<td>Karin Vanderkerken</td>
</tr>
<tr>
<td>Cindy Varga</td>
</tr>
<tr>
<td>Ingrid Verhamme</td>
</tr>
<tr>
<td>Luis Maria Villala-Martinez</td>
</tr>
<tr>
<td>Ly P. Vu</td>
</tr>
<tr>
<td>Diane Ward</td>
</tr>
<tr>
<td>Katja C. Weisel</td>
</tr>
<tr>
<td>Kamille West-Mitchell</td>
</tr>
<tr>
<td>Hope P. Wilson</td>
</tr>
<tr>
<td>Nicole Wong Doo</td>
</tr>
<tr>
<td>Gary Woods</td>
</tr>
<tr>
<td>Julia Z. Xu</td>
</tr>
<tr>
<td>Deborah Yallop</td>
</tr>
<tr>
<td>J Christine Ye</td>
</tr>
<tr>
<td>David T. Yeung</td>
</tr>
<tr>
<td>Musa Yilmaz</td>
</tr>
<tr>
<td>David J. Young</td>
</tr>
<tr>
<td>Joanna Zurko</td>
</tr>
</tbody>
</table>

**HEMATOLOGY 2022 REVIEWERS**

<table>
<thead>
<tr>
<th>Reviewers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anjali S. Advani</td>
</tr>
<tr>
<td>Ranjana Advani</td>
</tr>
<tr>
<td>Cern Akin</td>
</tr>
<tr>
<td>Monzr M. Al Malki</td>
</tr>
<tr>
<td>Aref Al-Kali</td>
</tr>
<tr>
<td>Frederick Appelbaum</td>
</tr>
<tr>
<td>Eugenia Vicky Asare</td>
</tr>
<tr>
<td>K. Scott Baker</td>
</tr>
<tr>
<td>Paul M. Barr</td>
</tr>
<tr>
<td>Nancy L. Bartlett</td>
</tr>
<tr>
<td>Renato Bassan</td>
</tr>
<tr>
<td>Shannon Bates</td>
</tr>
<tr>
<td>Lisa Baumann Kreuziger</td>
</tr>
<tr>
<td>Rafael Bejar</td>
</tr>
<tr>
<td>Jesus G. Berdeja</td>
</tr>
<tr>
<td>Smita Bhatia</td>
</tr>
<tr>
<td>Andrea Biondi</td>
</tr>
<tr>
<td>Larissa Bornikova</td>
</tr>
<tr>
<td>Jennifer R. Brown</td>
</tr>
<tr>
<td>Natalie S. Callander</td>
</tr>
<tr>
<td>Gunnar Cario</td>
</tr>
<tr>
<td>Shannon Carpenter</td>
</tr>
<tr>
<td>Marc Carrier</td>
</tr>
<tr>
<td>Giancarlo Castaman</td>
</tr>
<tr>
<td>Eric J. Chow</td>
</tr>
<tr>
<td>Adam D. Cohen</td>
</tr>
<tr>
<td>Claudia S. Cohn</td>
</tr>
<tr>
<td>Nathan T. Connell</td>
</tr>
<tr>
<td>Jorge Cortes</td>
</tr>
<tr>
<td>Charles Craddock</td>
</tr>
<tr>
<td>Stacy E. Croteau</td>
</tr>
<tr>
<td>Adam Cuker</td>
</tr>
<tr>
<td>Corey S. Cutler</td>
</tr>
<tr>
<td>Agnieszka Czechowicz</td>
</tr>
<tr>
<td>Anita D'Souza</td>
</tr>
<tr>
<td>Alexey V. Danilov</td>
</tr>
<tr>
<td>Faith E. Davies</td>
</tr>
<tr>
<td>Amy E. DeZern</td>
</tr>
<tr>
<td>Sunny H. Dzik</td>
</tr>
<tr>
<td>Yvonne A. Efebera</td>
</tr>
<tr>
<td>Matthew Ehrhardt</td>
</tr>
<tr>
<td>Toby Andrew Eyre</td>
</tr>
<tr>
<td>Joshua Field</td>
</tr>
<tr>
<td>Courtney D. Fitzhugh</td>
</tr>
<tr>
<td>Christopher R. Flowers</td>
</tr>
<tr>
<td>Annemarie E. Fogerty</td>
</tr>
<tr>
<td>Jacqueline S. Garcia</td>
</tr>
<tr>
<td>James N. George</td>
</tr>
<tr>
<td>Tracy I. George</td>
</tr>
<tr>
<td>Irene M. Ghabrial</td>
</tr>
<tr>
<td>Gerald J. Gleich</td>
</tr>
<tr>
<td>Victor R. Gordeuk</td>
</tr>
<tr>
<td>Jed B. Gorlin</td>
</tr>
<tr>
<td>Jason Gotlib</td>
</tr>
<tr>
<td>Erin M. Guest</td>
</tr>
<tr>
<td>Sumit Gupta</td>
</tr>
<tr>
<td>Sandra L. Haberichter</td>
</tr>
<tr>
<td>Claire N. Harrison</td>
</tr>
<tr>
<td>Andreas Hochhaus</td>
</tr>
<tr>
<td>Timothy P. Hughes</td>
</tr>
<tr>
<td>Ibrahim Musa Idris</td>
</tr>
<tr>
<td>Tania Jain</td>
</tr>
<tr>
<td>Andra H. James</td>
</tr>
<tr>
<td>Paula D. James</td>
</tr>
<tr>
<td>Jill M. Johnsen</td>
</tr>
<tr>
<td>Moonjong Jung</td>
</tr>
<tr>
<td>Brad S. Kahl</td>
</tr>
<tr>
<td>Julie Kanter</td>
</tr>
</tbody>
</table>
2022 Reviewers

Raj S. Kasthuri
Richard Kaufman
Alok A. Khorana
Adam S. Kittai
Jan-Henning Klusmann
Rami S. Komrokji
John Koreth
Johanna A. Kremer Hovinga
Amrita Y. Krishnan
Michael H. Kroll
Rebecca Kruse-Jarres
Roshni Kulkarni
Kevin H.M. Kuo
John Kuruvilla
David J. Kuykendall
Ola Landgren
Alfred I. Lee
Lai Heng Lee
Howard Allen Liebman
R. Coleman Lindsay
Sagar Lonial
Izidore S. Lossos
Kami Maddocks
Paul Mansfield
John O. Mascarenhas
Michael J. Mauro
Eileen Grace Merriman
Reid W. Merryman
Joseph Mikhail
Alice S. Mims
Alison J. Moskowitz
Kasiani C. Myers
Loretta J. Nastoupil
Robert S. Nickel
Omar Niss
Kristen M. O'Dwyer
Adam Jan Olszewski
Monica B. Pagano
Lydia H. Pecker
Kristen M. Pettit
Tycel Jovelle Phillips
Allyson Pishko
Jerald P. Radich
Delphine Rea
Josep-Maria Ribera
Paul G. Richardson
Jacob M. Rowe
Jeffrey E. Rubnitz
Sana Saif Ur Rehman
David A. Sallman
Kristen Sanfilippo
Santosh L. Saraf
Sharon A. Savage
Farzana Sayani
Mikkael A. Sekeres
Nina Shah
Urvi A. Shah
Joseph J. Shatzel
Bronwen E. Shaw
Shalini Shenoy
Nicholas J. Short
Sonali M. Smith
Gerald A. Soff
Stephen R. Spellman
Sarah K. Tassign
Jeffrey W. Taub
Philip A. Thompson
Darrell J. Triulzi
Suzanne Trudel
Lucie M. Turcotte
Geoffrey L. Uy
Emile Van Schaftingen
Sumithira Vasu
Tzu-Fei Wang
Jonathan Webster
Oliver Weigert
Matthew J. Wieduwilt
Tanya Wildes
Raymond Siu Ming Wong
Jennifer C. Yui
2022 ASH Annual Meeting Foundation Run/Walk Supporters

**PREMIER**
- AstraZeneca
- Biomea Fusion, Inc
- Gilead and Kite Oncology
- Global Blood Therapeutics/Pfizer
- GSK
- ImmunoGen, Inc.
- Syndax Pharmaceuticals

**LEAD**
- AbbVie
- Seagen Inc.

2022 ASH Annual Meeting Education Supporters

*ASH would like to acknowledge the following companies for the educational grants provided in support of the 2022 ASH Annual Meeting:*

**Hematology 2022: The Education Program**
- AstraZeneca
- GSK
- Jazz Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Novartis Pharmaceuticals

**General Education Grant**
- AbbVie
- AstraZeneca
- GSK
- Incyte Corporation
- Jazz Pharmaceuticals, Inc.
- Lilly USA, LLC
- Merck & Co., Inc.
- Novartis Pharmaceuticals
- Pfizer Inc.
- Syndax Pharmaceuticals Inc.
2022 ASH Independent Medical Education Supporters

ASH would like to acknowledge the following companies for their support:

AbbVie
Agios Pharmaceuticals Inc.
Astellas Pharma US, Inc.
Bristol Myers Squibb
Daiichi Sankyo, Inc.
Forma Therapeutics, Inc.
Global Blood Therapeutics/Pfizer Inc.
Graphite Bio
Illumina, Inc.
Imara
Janssen Scientific Affairs, LLC
Kite Pharma Inc.
Novartis Pharmaceuticals
Pharmacyclics LLC
Syneos Health
Vertex Pharmaceuticals Incorporated

2022 Annual Meeting Corporate Supporters

ASH would like to acknowledge the following companies for their support of the 2022 Annual Meeting:

AbbVie
ASH Alexa
ASH Wellness Studio Theater
Astellas Pharma US, Inc.
Mobile Device Charging Stations
AstraZeneca
Exhibit Hall Aisle Signs
Hand Sanitizing Stations
Daiichi Sankyo, Inc.
Hydration Stations
Mobile App
Mobile Device Charging Stations
PosterCast
Eli Lilly and Company
Photo Zone and Social Media Wall

2022 ASH Award Supporters
ASH would like to acknowledge and thank the following companies for supporting the ASH Bridge Grant, Minority Recruitment Initiative and Scholar Award programs:

- AstraZeneca
- Bristol Myers Squibb
- Janssen Biotech, Inc.
- Merck & Co., Inc.
- Novartis Pharmaceuticals
- Pharmacyclics LLC

2022 ASH Global Initiatives

ASH would like to acknowledge and thank the following companies and foundation for supporting ASH’s international consortia:

**Consortium on Newborn Screening in Africa**

- Novartis
- PerkinElmer

**International Consortium on Acute Leukemia**

- Torsten Haferlach Leukemia Diagnostics Foundation
- Illumina

2022 ASH Corporate Friends

ASH Corporate Friends are dedicated partners of the Society and their support to advance hematology research, education, training, and advocacy initiatives throughout the year is sincerely appreciated. ASH is grateful for the generous support of the following companies:

**PREMIER CIRCLE**

- Pfizer, Inc.
- Regeneron Pharmaceuticals

**PARTNER CIRCLE**

- AstraZeneca
- Bristol Myers Squibb
- Kite, a Gilead Company
- Eli Lilly and Company
- Takeda
- Vertex Pharmaceuticals
2022 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 19, 2022.

ADVOCATE CIRCLE
Agios Pharmaceuticals
Amgen
Astellas
Genentech
GSK
Janssen Oncology
Merck & Co, Inc.
Pharmacyclics LLC
Sanofi

INSIDER CIRCLE
Atara Biotherapeutics, Inc.
bluebird bio
Graphite Bio
Kura Oncology
Omeros Corporation
Orca Bio
Rigel Pharmaceuticals

2022 ASH Health Equity Collective
The Health Equity Collective represents a cooperative enterprise of support opportunity areas for organizations seeking to help stop the trajectory and minimize the impact of health care inequality. Building on ASH’s work over the last 20 years to combat health inequity, and through the support of partnering organizations, participating members of the Collective have taken tangible steps to dismantle inequitable practices within the health care community. ASH is grateful for the support and recognizes the inaugural members for their laudable work:

Daiichi Sankyo
GSK
Janssen Oncology
Novartis
Pfizer, Inc.
Sanofi
Taiho
Vertex Pharmaceuticals
### RECIPIENTS OF AWARDS

#### WALLACE H. COULTER AWARD FOR LIFETIME ACHIEVEMENT IN HEMATOLOGY

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>Irving Weissman</td>
<td>2016</td>
<td>Thalia Papayannopoulou</td>
</tr>
<tr>
<td>2021</td>
<td>Harvey Lodish</td>
<td>2015</td>
<td>Aaron Marcus</td>
</tr>
<tr>
<td>2020</td>
<td>Mohandas Narla</td>
<td>2014</td>
<td>Kanti Rai</td>
</tr>
<tr>
<td>2019</td>
<td>Richard H. Aster</td>
<td>2013</td>
<td>Sir David John Weatherall</td>
</tr>
<tr>
<td>2018</td>
<td>Victor Hoffbrand</td>
<td>2012</td>
<td>James George</td>
</tr>
<tr>
<td>2017</td>
<td>Marshall A. Lichtman</td>
<td>2011</td>
<td>David G. Nathan</td>
</tr>
<tr>
<td>2010</td>
<td>Volker Diehl</td>
<td>2009</td>
<td>H. Franklin Bunn</td>
</tr>
<tr>
<td>2008</td>
<td>Robert Kyle</td>
<td>2007</td>
<td>Ernest Beutler</td>
</tr>
</tbody>
</table>

#### ERNEST BEUTLER LECTURE AND PRIZE

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>John Atkinson and Peter Hillmen</td>
<td>2017</td>
<td>Luigi Naldini and Marina Cavazzana</td>
</tr>
<tr>
<td>2021</td>
<td>Margaret Shipp and Stephen Ansell</td>
<td>2016</td>
<td>Hugues de Thé and Zhu Chen</td>
</tr>
<tr>
<td>2020</td>
<td>Courtney DiNardo and Ari Melnick</td>
<td>2015</td>
<td>Alfred Goldberg and Paul Richardson</td>
</tr>
<tr>
<td>2019</td>
<td>Sriram Krishnaswamy and Jeffrey I. Weitz</td>
<td>2014</td>
<td>Michael R. DeBaun and Robert P. Hebbel</td>
</tr>
<tr>
<td>2018</td>
<td>Alan D’Andrea and Neal Young</td>
<td>2013</td>
<td>Kenneth Kaushansky and David J. Kuter</td>
</tr>
<tr>
<td>2017</td>
<td>Luigia Naldini and Marina Cavazzana</td>
<td>2012</td>
<td>Bruce R. Blazar and Carl H. June</td>
</tr>
<tr>
<td>2016</td>
<td>Margaret Shipp and Stephen Ansell</td>
<td>2011</td>
<td>Janet D. Rowley and Brian J. Druker</td>
</tr>
<tr>
<td>2015</td>
<td>Courtney DiNardo and Ari Melnick</td>
<td>2010</td>
<td>Barry S. Collier and Joel S. Bennett</td>
</tr>
<tr>
<td>2014</td>
<td>Sriram Krishnaswamy and Jeffrey I. Weitz</td>
<td>2009</td>
<td>Yuet Wai Kan and Thomas Maniatis</td>
</tr>
</tbody>
</table>

#### E. DONNALL THOMAS LECTURE AND PRIZE

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>Bruce Blazar</td>
<td>2011</td>
<td>George Q. Daley</td>
</tr>
<tr>
<td>2021</td>
<td>Connie Westhoff</td>
<td>2010</td>
<td>Leonard I. Zon</td>
</tr>
<tr>
<td>2020</td>
<td>Toshio Suda</td>
<td>2009</td>
<td>John E. Dick</td>
</tr>
<tr>
<td>2019</td>
<td>Philip D. Greenberg</td>
<td>2008</td>
<td>Neal S. Young</td>
</tr>
<tr>
<td>2018</td>
<td>Connie J. Eaves</td>
<td>2007</td>
<td>Hal Broxmeyer</td>
</tr>
<tr>
<td>2016</td>
<td>David Scadden</td>
<td>2005</td>
<td>Rainer Storb</td>
</tr>
<tr>
<td>2015</td>
<td>Barbara C. Furie and Bruce Furie</td>
<td>2004</td>
<td>Donald Metcalf</td>
</tr>
<tr>
<td>2014</td>
<td>Tomas Ganz</td>
<td>2003</td>
<td>Ernest Beutler</td>
</tr>
<tr>
<td>2013</td>
<td>Katherine A. High</td>
<td>2002</td>
<td>Kenneth Mann</td>
</tr>
<tr>
<td>2012</td>
<td>Timothy J. Ley</td>
<td>2001</td>
<td>Samuel E. Lux, IV</td>
</tr>
<tr>
<td>2000</td>
<td>David Ginsburg</td>
<td>1999</td>
<td>Irving Weissman</td>
</tr>
<tr>
<td>1998</td>
<td>Stuart H. Orkin</td>
<td>1997</td>
<td>Robert Rosenberg</td>
</tr>
<tr>
<td>1996</td>
<td>Stanley Korsmeyer</td>
<td>1995</td>
<td>Charles Esmon</td>
</tr>
<tr>
<td>1994</td>
<td>Thomas P. Maniatis</td>
<td>1993</td>
<td>Thomas P. Stossel</td>
</tr>
<tr>
<td>1992</td>
<td>Stuart Kornfeld</td>
<td>1991</td>
<td>Thomas P. Stossel</td>
</tr>
</tbody>
</table>

#### WILLIAM DAMESHEK PRIZE

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>Irene Ghobrial</td>
<td>2003</td>
<td>Gary Gilliland</td>
</tr>
<tr>
<td>2021</td>
<td>Elizabetha Nemeth</td>
<td>2002</td>
<td>Catherine Verfaillie</td>
</tr>
<tr>
<td>2020</td>
<td>Adolfo Ferrando</td>
<td>2001</td>
<td>Brian Druker</td>
</tr>
<tr>
<td>2019</td>
<td>Emmanuelle Passegué</td>
<td>2000</td>
<td>David A. Williams</td>
</tr>
<tr>
<td>2018</td>
<td>Ross L. Levine</td>
<td>1999</td>
<td>Salvador Moncada</td>
</tr>
<tr>
<td>2017</td>
<td>Benjamin L. Ebert</td>
<td>1998</td>
<td>J. Evan Sadler</td>
</tr>
<tr>
<td>2016</td>
<td>Charles Mullighan</td>
<td>1997</td>
<td>Björn Dahlbäck</td>
</tr>
<tr>
<td>2015</td>
<td>John Byrd</td>
<td>1996</td>
<td>Kenneth Kaushansky</td>
</tr>
<tr>
<td>2014</td>
<td>Scott Armstrong</td>
<td>1995</td>
<td>James Ile</td>
</tr>
<tr>
<td>2013</td>
<td>Andrew Wezych</td>
<td>1994</td>
<td>George J. Broze, Jr.</td>
</tr>
<tr>
<td>2012</td>
<td>Margaret A. Goodell</td>
<td>1993</td>
<td>Owen Witte</td>
</tr>
<tr>
<td>2011</td>
<td>Christoph Klein</td>
<td>1992</td>
<td>Richard D. Klausner</td>
</tr>
<tr>
<td>2010</td>
<td>David T. Scadden</td>
<td>1991</td>
<td>Makio Ogawa</td>
</tr>
<tr>
<td>2009</td>
<td>Louis M. Staudt</td>
<td>1990</td>
<td>Thalia Papayannopoulou and George Stamatoyannopouls</td>
</tr>
<tr>
<td>2008</td>
<td>Kenneth Anderson</td>
<td>1989</td>
<td>Samuel E. Lux IV</td>
</tr>
<tr>
<td>2006</td>
<td>Riccardo Dalla-Favera</td>
<td>1987</td>
<td>Charles Sherr</td>
</tr>
<tr>
<td>2005</td>
<td>John Dick</td>
<td>1986</td>
<td>Stuart Orkin</td>
</tr>
<tr>
<td>2004</td>
<td>Ronald Levy</td>
<td>1985</td>
<td>Thomas F. Deuel</td>
</tr>
<tr>
<td>1984</td>
<td>Barbara C. and Bruce Furie</td>
<td>1983</td>
<td>Thomas P. Stossel</td>
</tr>
<tr>
<td>1982</td>
<td>Janet D. Rowley</td>
<td>1981</td>
<td>Philip W. Majerus</td>
</tr>
<tr>
<td>1979</td>
<td>Yuet Wai Kan</td>
<td>1978</td>
<td>Robert D. Rosenberg</td>
</tr>
<tr>
<td>1977</td>
<td>Yale Nemerson</td>
<td>1976</td>
<td>Robert I. Weed</td>
</tr>
<tr>
<td>1975</td>
<td>Charlotte Friend</td>
<td>1974</td>
<td>Robert C. Gallo</td>
</tr>
</tbody>
</table>
## ASH Award for Leadership in Promoting Diversity

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>James Gavin and David Wilkes</td>
</tr>
<tr>
<td>2021</td>
<td>Deepika Darbari</td>
</tr>
<tr>
<td>2020</td>
<td>Edward J. Benz Jr.</td>
</tr>
<tr>
<td>2019</td>
<td>Griffin P. Rodgers</td>
</tr>
<tr>
<td>2018</td>
<td>Cage S. Johnson and José A. López</td>
</tr>
<tr>
<td>2017</td>
<td>Betty Pace</td>
</tr>
</tbody>
</table>

## Henry M. Stratton Medal

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>Timothy Ley and Robert Montgomery</td>
</tr>
<tr>
<td>2021</td>
<td>Kwaku Ohene-Frempong and Denisa Wagner</td>
</tr>
<tr>
<td>2020</td>
<td>Maria Domenica Cappellini and Michelle Le Beau</td>
</tr>
<tr>
<td>2019</td>
<td>William Allen Eaton and Richard A. Larson</td>
</tr>
<tr>
<td>2018</td>
<td>Brunangelo Falini and Freda K. Stevenson</td>
</tr>
<tr>
<td>2017</td>
<td>Josef Tomas Prchal and Sherrill J. Slichter</td>
</tr>
<tr>
<td>2016</td>
<td>J. Evan Sadler and Ayalew Tefferi</td>
</tr>
<tr>
<td>2015</td>
<td>Nancy Speck and Karl Welte</td>
</tr>
</tbody>
</table>

## ASH Outstanding Abstract Achievement Awards

The American Society of Hematology is pleased to recognize the following abstract presenters who received the highest ranking in their categories of undergraduate student, medical student, graduate student, resident physician, and post-doctoral fellow.

### Undergraduate Student
- Nina Shaver
  - Georgia Institute of Technology

### Medical Student
- Varun Sudunagunta, BA
  - Columbia University

### Graduate Student
- Alexandra Preston
  - University of Oxford

### Post-Doctoral Fellow
- Richard Voit, MD, PhD
  - Harvard Medical School

### Resident Physician
- Lauren Meyer, MD, PhD
  - University of Washington

## Abstract Achievement Awards

### ASH Mentor Award

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>Michael Caligiuri and Christopher Flowers</td>
</tr>
<tr>
<td>2021</td>
<td>Anthony Goldstone and Jonathan Licht</td>
</tr>
<tr>
<td>2020</td>
<td>Judith Gasson and Wendy Stock</td>
</tr>
<tr>
<td>2019</td>
<td>Michael R. DeBaun and Leonard I. Zon</td>
</tr>
<tr>
<td>2018</td>
<td>John E. Dick and Reed E. Drews</td>
</tr>
<tr>
<td>2017</td>
<td>Ronald Hoffman and Oliver W. Press</td>
</tr>
<tr>
<td>2016</td>
<td>Laurence Boxer and Ralph L. Nachman</td>
</tr>
<tr>
<td>2015</td>
<td>Curt Civin and Craig Kitchens</td>
</tr>
<tr>
<td>2014</td>
<td>Grover C. Bagby Jr. and John F. DiPersio</td>
</tr>
<tr>
<td>2013</td>
<td>John Adamson and Stanley Schrier</td>
</tr>
<tr>
<td>2012</td>
<td>Beverly S. Mitchell and Rainer F. Storb</td>
</tr>
<tr>
<td>2011</td>
<td>Nancy C. Andrews and Malcolm K. Brenner</td>
</tr>
<tr>
<td>2010</td>
<td>Mary M. Horowitz and Harvey F. Lodish</td>
</tr>
<tr>
<td>2009</td>
<td>Arthur Nienhuis and Stuart H. Orkin</td>
</tr>
<tr>
<td>2008</td>
<td>George R. Buchanan and Timothy J. Ley</td>
</tr>
<tr>
<td>2007</td>
<td>Edward J. Benz Jr and Harold R. Roberts</td>
</tr>
<tr>
<td>2006</td>
<td>Samuel E. Lux and Deane F. Mosher</td>
</tr>
</tbody>
</table>

## Abstract Achievement Awards

### Undergraduate Student
- Nina Shaver
  - Georgia Institute of Technology

### Medical Student
- Varun Sudunagunta, BA
  - Columbia University

### Graduate Student
- Alexandra Preston
  - University of Oxford

### Post-Doctoral Fellow
- Richard Voit, MD, PhD
  - Harvard Medical School

### Resident Physician
- Lauren Meyer, MD, PhD
  - University of Washington
**ASH-BRITISH SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD**

This annual award in partnership with the British Society of Hematology (BSH) is granted to up to three British trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of BSH and reside in the United Kingdom.

Niels Asger Jakobsen, BM, BCh, MRCP  
University of Oxford  
Anna Santarsieri, MBBS  
Cambridge University Hospitals  
Shuchi Agrawal Singh, PhD  
Cambridge Institute for Medical Research

**ASH-FRANK TOOHEY ABSTRACT ACHIEVEMENT AWARD FOR MYELODYSPLASTIC SYNDROMES**

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of MDS, with a preference for highly rated abstracts related to older populations. This annual award is made possible by donations from Mary McGrane in memory of Frank Toohey.

Sofia Toribio Castello, MSc  
Universidad de Salamanca

**ASH-HEMATOLOGY SOCIETY OF AUSTRALIA AND NEW ZEALAND ABSTRACT ACHIEVEMENT AWARD**

This annual award in partnership with the Haematology Society of Australia and New Zealand (HSANZ) is granted to up to two Australian or New Zealander trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of HSANZ and reside in Australia or New Zealand.

Chanukya Colonne, MBBS, PhD  
University of Sydney

**ASH-IPIG ABSTRACT ACHIEVEMENT AWARD FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)**

This annual award in partnership with International Paroxysmal Nocturnal Hemoglobinuria (PNH) Interest Group (IPIG) is granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious PNH focused abstracts submitted in the fields of Red Cells and Erythropoiesis or Bone Marrow Failure.

Carmelo Gurnari, MD  
University of Rome  
Naomi Kawashima, MD, PhD  
Cleveland Clinic Foundation

**ASH-JAPANESE SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD**

This annual award in partnership with the Japanese Society of Hematology (JSH) is granted to up to three Japanese trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be members of JSH and reside in Japan.

Shinpei Harada  
Hokkaido University Faculty of Medicine  
Yuta Yamada, MD  
The University of Tokyo  
Takao Yogo, MD  
The University of Tokyo

**ASH-SOCIETY ITALIANA DI EMATOLOGIA ABSTRACT ACHIEVEMENT AWARD**

This annual award in partnership with the Society Italiana di Ematologia (SIE) is granted to up to Italian two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be members of SIE and reside in Italy.

Giovanni Marconi, MD  
IRCCS Istituto Scientifico  
Laura Notarfranchi, MD  
University of Parma

**JOANNE LEVY, MD, MEMORIAL AWARD FOR OUTSTANDING ACHIEVEMENT**

This award was established in 2006 to recognize the current ASH Scholar with the highest scoring abstract for the ASH annual meeting. This award is given in honor of a past Scholar Award recipient and distinguished member of ASH, Joanne Levy, who passed away in 2004. This annual award is made possible by the Levy family to continue her legacy and promote excellence in hematology research.

Aaron Viny, MD  
Columbia University
MARY RODES GIBSON MEMORIAL AWARD IN HEMOSTASIS AND THROMBOSIS

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of hemostasis and thrombosis. This annual award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson who suffered from severe, type 3 von Willebrand’s disease.

Sean Quinn, PhD
Children’s Hospital of Philadelphia

MINORITY GRADUATE STUDENT ABSTRACT ACHIEVEMENT AWARD

Each year, the American Society of Hematology offers merit-based Minority Graduate Student Abstract Achievement Awards to select graduate students to acknowledge the accomplishments of and recruit and retain minority graduate students in the field of hematology.

Kemi Akinnola
Albert Einstein College of Medicine

Nicole Arellano
The University of Chicago

Ginette Balbin-Cuesta
University of Michigan

Sergio Barajas
Indiana University School of Medicine

Ariel Blakey
Boston University

Giovanni Botten
The University of Texas Southwestern

Claudia Cabrera
Washington University in Saint Louis

Luis Correa
University of Michigan

Caroline Kuczynski
Wake Forest School of Medicine

Richard Marrero
University of Florida

Carlos Munoz
University of California, San Diego

Rolando Vedia
The University of Texas, MD Anderson Cancer Center

ASH ABSTRACT ACHIEVEMENT AWARDS

Each year, the American Society of Hematology offers merit-based Abstract Achievement Awards to select individuals to acknowledge the accomplishments of hematologists-in-training. This year’s Abstract Achievement Awards recognize undergraduate students, medical students, graduate students, resident physicians, and post-doctoral fellows who are both first author and presenter of an abstract.

Minaam Abbas

Nancy Arthur

Bimzarhan Assatova

Jonathan Avery

Batia Avni

Shady Awad

Francesca Baatza

Rory Bade

Waled Bahay

Kayla Baker

Natasha Bala

Aria Bales

Soheib Ball

Suzy Bangudi

Bella Banjanin

Alicia Bao

Daniela Barbier

Barbara Barion

Marine Baron

Anais Barthe

Anthony Battman

Abdul-Hamid Bazarbachi

Alexandre Bazinet

Nana Adjoa Ben-Crements

Josh Bennett

Eduardo Benzi

Daniel Berger

Philipp Berning

Eline Bertrums

Jan Bewersdorf

Rahul Bhangali

Pawan Bhat

Giulia Biancon

Sarah Bird

Lara Bischof

Jannis Bjeje

Franziska Blaescheke

Joshua Bombszyk

Christopher Booth

Roisin Borrill

Giovanni Botten

Eileen Boyle

Lisa Brandmeier

Lara Breiter

Jennifer Brown

Maja Bueno

Ayesha Butt

Poojitha Byreddy

Angelo Cabal

Xuan Cai

Martin Calabro

Ismael Can

Lei-Ming Cao

Gabriela Casirati

Giuliana Cavallaro

Laura Ceja Ramirez

Eliska Ceznerova

Mousumi Chakraaborty

Courtney Chambers

Reem Chamseddine

Fiorella Charles Cano

Lei Chen

Zhenhua Chen

Chuan Chen

Wanshu Chen

Xiaomin Chen

Qi Chen

Zhaoqin Chen

Marling Chen

Changhan Chen

Michelle Chin

Benjamin Chin-Yee

Monika Chojnacka

Fabiha Chowdhury

Anthos Christofides

Yurou Chu

Bernadette Anne Chua

Jean-Sebastien Claveau

Patricia Colom Diaz

Anna Maria Corella

Kadiyie Cogson

Amanda Costa

Krysta Coyle

Christina Crosscut-Thambiah

Stephanie Crowley

Nataly Cruz-Rodriguez

Xiaojing Cui

Jian Cui

Tyler Cunningham

Gandhar Datar

Ryan Day

Jonathan Day

Fleur De Groot

Alejandro De Janon

Madelen de Jong

A. Vera de Jonge
ABSTRACT ACHIEVEMENT AWARDS

Guido Ghilardi
Gaia Gentile
Georgina Gener-Ricos
Andrea Garofalo
Beatriz Garcia-Torres
Filip Garbicz
Ya-Juan Gao
Saravanan Ganesan
Irene Ganan-Gomez
Gaia Gentile
Guido Ghilardi

Dongxu Jiang
Aisha Jibril
Jin Jin
Dylan Jochum
Isla Johnson
Astrun Jonsdottir
Julia Joo
Maxime Jullien
Nuzhat Kabir
Radoslaw Kaczmarek
Ilja Kalashnikov
Takahiro Kamiya
Adam Kanack
Hyndavi Kandala
Chiraag Kapadia
Nilesh Kapoor
Yuta Katal
Alana Keller
Tariq Kewan
Timothy Keyes
Faizan Khan
Abdullah Khan
Abdul Moiz Khan
Shrijan Khanal
Reham Khedr
Wannakorn Khopanler
Joseph Kim
Taehyun Kim
Min Young Kim
Katherine Knorr
Trine Knudsen
Camille Kockerols
Shuhei Koide
Tim Kong
Tiago Koppe
Charlotte Korst
Joseph Krambs
Frederike Kramer
Stefanie Kreutmair
Benjamin Kroger

Sarah Lindner
Suzum Liu
Jiye Liu
Qiang Liu
Lawrence Liu
Feng-Qi Liu
Xiaoyu Liu
Yingyue Liu
Min Yen Lo
Marissa Locastro
Alberto Lopez
Yadith Lopez-Garcia
Matthew Lordo
Kevin Lu
Danny Luan
Sofie Lundgren
Xiurui Lv
Liem Lv
Wald Macaron
Eduardo Magalhaes
Harinad Maganti
Elias Mai
Catarina Maia
Kamal Mandal
William Mannherz
Xujin Mao
Francisco Marchi
Anna Marmeth
Jasmin Martin
Grace McAuley
John McClatchy
Cameron McDonald-Hyman
Dylan McNally
Dino Mehic
Yihan Mei
Ashley Melnick
Johanna Melo-Cardenas
Jonny Mendoza-Castrejon
Gao Mengge
Leo Meriranta
Nico Michmerhuizen
Adrian Minson
Abu-Sayyef Mirza
Jayna Mistry
Safa Mohammad
Razan Mohty
Florian Moik
Patrizia Mondello
Skye Montoya
Eugenio Morelli
David Moreno
Anna Sophia Moret
Takuto Mori
Bettina Nadorp
Aishath Naem
Keiki Nagaharu
Patrice Nasnas
Amin Nassar
Karthik Nath
Suzanne Neppelenbroek
Austen Newsam
Lok Lam Ngai
Aithanh Nguyen
Arman Niknafs
Masashi Nishikubo
Troy Noordenbos
ABSTRACT ACHIEVEMENT AWARDS

Michael Northend  
Brittany Notice  
Jessica Nunes  
Petra Nygren  
Anjali Oberoi  
Cristiana O’Brien  
Kevin O’Connor  
Olisaemeka Oguede  
Ayobami Olanrewaju  
Anne Olazabal Herrero  
Jose Oliveira  
Olubusola Oluwole  
Faustine Ong  
Anna Østergaard  
Jad Othman  
Inge Oudaert  
Michael Ozga  
Sandeep Padala  
Dakshin Padmanabhan  
Aswin Pal  
Garima Pandey  
Sun Park  
Kanak Parmar  
Salma Parvin  
Erica Pasceetti  
Helene Pasquier  
Ruchi Patel  
Vivek Patel  
Kanisha Patel  
Richard Pelzl  
Claudia Perez Carretero  
Megan Perrett  
Luiza Perucci  
Michael Pfeffer  
Lisa Pfeuffer  
Keir Pickard  
Andrea Pioletto  
Heribert Playa-Albinyana  
Andrea Poletti  
Grace Power  
Landon Power  
Edward Poynton  
Shravani Prakhya  
Alessandra Prezotti  
Raja Prince  
Jessica Pritchard  
Kemar Prussien  
Adnan Qamar  
Jialei Qi  
Qingyuan Qu  
David Qualls  
Qurat Ul Ain Qureshi  
Zoya Qureshy  
Denise Ragusa  
Sunniyat Rahman  
Sandeep Raj  
Hannah Raj  
Hari Raman  
Jyoti Rana  
Eliot Rapoport  
Christian Rausch  
Kai Rejeski  
Kehan Ren  
Simon Renders  
Kevin Reyes  

Abigail Rich  
Ana Rio-Machin  
Elena Riva  
Troy Robinson  
Hope Robinson  
Luis Gerardo Rodriguez-Lobato  
Margot Roeten  
Lisa Rohrbacher  
Gabriel Roman Souza  
James Ropa  
Milad Rouhimoghadam  
Fernanda Roversi  
Danielle Roy  
Gordon Ruan  
Leo Ruhnke  
Xianliang Rui  
David Russler-Germain  
Christine Ryan  
Joseph Saad  
Susheer Sahoo  
Reona Sakemura  
Mariani Salinas  
Nina Samuel  
Anna Santarsieri  
Marta Sarchi  
Akihiro Sawa  
Lama Sawalha  
Caner Saygin  
Ann-Kristin Schmalert  
Haley Schmidt  
Walker Schmidt  
Constance Schneider  
Tina Schnoeder  
Joseph Schroers-Martin  
David Scott  
Jayla Scott  
Yuichiro Semba  
Jayastu Senapati  
Hajime Senjo  
Julieta Sepulveda Yanez  
Katie Seu  
Amy Sexauer  
Rushil Shah  
Mohamed Shahin  
Haroon Shaikh  
Malini Sharma  
Victoria Shelton  
Lilia Shen  
Angela Sheng  
Steven Sher  
Dalia Sheta  
Lauren Shevell  
Pedro Silva  
Wellington Silva  
Martha Sim  
Catia Patricia Simoes  
Sayantani Sinha  
Vaishnavi Siripurapu  
Khanittha Sintham  
Olivia Sirpilla  
Ying Ting Sit  
Surabhi Sivaratnam  
Romanos Sklaventis-Pistolidis  
Thomas Smits  
Danielle Sohai  

Harshini Siriram  
Karan Srisurapanont  
Daniel Srole  
Alexander Stanisic  
Sara Stefani  
Simon Steiger  
Maximilian Steinhardt  
Dominique Sternal  
Anna Sternberg  
Carli Stewart  
Lucille Stuani  
Robert Stuvier  
Shruthi Subramanian  
Takeshi Sugio  
Fumou Sun  
Lu Sun  
Divya Sundar  
Arvind Suresh  
Yutaro Suzuki  
Connor Sweeney  
Emily Symes  
Cristian Taborda  
Sabrin Tahir  
Shuichiro Takahashi  
Erika Tarasco  
Lara Tavernari  
Trisha Tee  
Elisa Ten Hacken  
Phaik Ju Teoh  
Toshiki Terao  
Jesse Tettero  
Santiago Thibaud  
Erik Thiele Orberg  
Nicole Thomas  
Toby Thomas  
Rachelle Thompson  
Sigrun Thorsteinsdottir  
Remi Tilmont  
Molly Tokaz  
Lidiane Torres  
Kathryn Tringale  
Billy Truong  
Peter Truong  
Jonathan Tsai  
Brandon Tse  
Sven Turkaj  
Anudishi Tyagi  
Caden Ulschmid  
Kelsey Uminski  
Socheatrosmy Ung  
Marc Usart  
Bryan Valcarcel  
Thijs van Bergen  
Niek Van Der Maas  
Myrthe van Dijk  
Victoria Vardell  
Ying Tiang  
Xiaoshuai Zhang  
Aobei Zhang  
Jingliao Zhang  
Christine Zhang  
Jingliao Zhang  
Congxiao Zhang  
Aobel Zhang  
Xiaoshuai Zhang  
Peng Zhao  
Duoduo Zhao  
Hao Zhao  
Yichao Zhou  
Xiang Zhou  
Xianghui Zhou  
Bachios Ziccheddu
AMERICAN SOCIETY OF HEMATOLOGY
64TH ASH® ANNUAL MEETING
AND EXPOSITION

MEETING DATES: DECEMBER 10-13, 2022

GENERAL INFORMATION

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

PURPOSE OF ASH SCIENTIFIC AND EDUCATIONAL MEETINGS

The mission of the American Society of Hematology (ASH) is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training and advocacy in hematology. In accordance with this mission, the primary purpose of scientific meetings organized by ASH, including the Society’s annual meeting, is to facilitate the exchange of scientific information and clinical results related to the field of hematology. Another important goal of ASH-organized meetings is to assist physicians and scientists in developing and maintaining academic collaborations that will generate new knowledge, ultimately benefiting patients.

TWO WAYS TO ATTEND THE 64TH ASH ANNUAL MEETING

ASH is pleased to offer the 64th ASH Annual Meeting and Exposition as a hybrid experience where participants can decide to attend in person in New Orleans or participate from home using ASH’s virtual meeting platform. All participants, regardless of location will have access to the virtual meeting platform built for learning, collaboration, and networking. The platform will connect those in New Orleans with those at home. Access to the virtual platform will begin on December 7, 2022 via annualmeeting.hematology.org.

ASH ANNUAL MEETING HEALTH AND SAFETY PROTOCOLS

We encourage you to monitor the ASH Health and Safety Protocols (www.hematology.org/annual-meeting/safety) online to stay abreast of the latest updates.

VACCINATION

The safety of meeting attendees is ASH’s top priority, and we believe the most effective way to ensure the safety of all attendees is for them to be fully vaccinated against COVID-19. Please note that proof of vaccination will be required for all in-person meeting attendees prior to traveling to New Orleans.

For those unable to travel or meet the vaccination requirement, ASH offers several virtual meeting registration options.

PROTECTIVE MASKS

The wearing of protective masks is required of all attendees, ASH staff, and convention center workers, regardless of whether it is required by law at the time of the meeting. Masks must be worn properly (always covering both mouth and nose) except as noted below. The indoor mask requirement applies to the convention center, hotels, shuttle buses, or anywhere an in-person ASH event is being held. Masks are not required outdoors.

Masks may be removed briefly in the following situations:

- When actively eating or drinking
- When speaking at the lectern. Speakers should put their masks back on when not actively presenting or answering a question (i.e., sitting at the head table).
- When being photographed or interviewed on camera by registered media or ASH staff.

In-person attendees will be provided with three KN95 masks in their registration bag to use if they wish, and additional supplies will be available in bins placed throughout the meeting venue.

Attendees who are not properly masked will be refused admittance to ASH sessions and events and may have their badges revoked.

PHYSICAL DISTANCING

Meeting rooms will be set up to accommodate those attendees who prefer more personal space as well as those who prefer to sit closer together.

SANITIZATION

Even though the science shows that COVID-19 transmission is unlikely to occur from touching surfaces touched by multiple persons (i.e., lecterns and internet stations), staff will clean these regularly to promote healthy sanitation overall.
COVID-19 TESTING
Unlimited, complimentary COVID-19 testing will be available for those who experience symptoms on site and for travelers who must show proof of a recent negative COVID-19 test in order to board their return flight. Testing will be performed by Safe Expo via one testing station within the convention center and one testing station at the Hilton New Orleans Riverside, so that attendees who are symptomatic do not need to return to the convention center to get tested.

Individuals who test positive while on site will not be permitted to continue attending the meeting in person until a negative test is produced and must follow CDC guidance on quarantine and isolation.

ON-SITE QUARANTINE SUPPORT AND TRAVEL RESOURCES
ASH will offer a complimentary Quarantine Support Concierge service to assist any attendees who must quarantine while attending the meeting in New Orleans. Support will include:
• Twice-daily wellness phone calls to check on the individual.
• Assistance with modifying hotel arrangements in New Orleans to extend the check-out date to the end of the quarantine period.
• Assistance with modifying travel arrangements to return home after the quarantine period.
• Coordination with the hotel for the contactless delivery of water, food, beverages, and housekeeping supplies, since housekeeping service will cease.
• Coordination of contactless delivery of other items needed from non-hotel sources (i.e., pharmacy or grocery stores).

INTERNATIONAL ATTENDEES
International attendees should always check current travel restrictions to the U.S. on the Centers for Disease Control and Prevention (CDC) website (https://www.cdc.gov/coronavirus/2019-ncov/travelers/international-travel-during-covid19.html) before planning your travel, to make sure you will be able to enter the U.S. In addition, please monitor local regulations at home to ensure that you will be able to return from the U.S.

GENERAL INFORMATION
All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

REGISTRATION
ASH is offering multiple registration options for the annual meeting. Both in-person and virtual registration packages include access to live sessions, Q&A, networking, CME/MOC, exhibit halls, and more. If an attendee chooses to participate in person, they will also receive complimentary access to the virtual meeting platform through January 1, 2023 but can extend their access by upgrading the subscription to an option with longer access for an additional fee.

Registration is available now at hematology.org/meetings/annual-meeting/registration-information. Those who have previously registered may upgrade their subscription selection at any time by contacting the Registration Center.

IN-PERSON MEETING
When you register for the in-person meeting, you will receive complimentary access to the virtual meeting platform through January 1, 2023. In-person registrants have the option to extend their access to the virtual meeting platform for an additional fee. Registration for the in-person meeting must be done in advance before arriving to the Ernest N. Morial Convention Center. This is a continuation of the new practice instituted last year that requires participants to register online and in advance.

ASH has developed health and safety protocols for the meeting and all participants will be expected to adhere to these protocols. All attendees of the in-person meeting must provide proof that they are vaccinated in order to attend, along with wearing of a protective facial mask. Participants are asked to upload their proof of vaccination to a secure website in advance of travelling to New Orleans. After uploading the proof documentation, a health pass will be issued, and participants will need to show this health pass upon arrival and to pick up their badge and attend the meeting. Full details regarding the health and safety protocols and instructions are available at www.hematology.org/annual-meeting/safety.

VIRTUAL ACCESS REGISTRATION PACKAGE OPTIONS
The ASH annual meeting virtual access registration packages were designed to give attendees maximum flexibility. Each option below provides access to the meeting’s virtual platform including Preview Days that will begin on December 7, 2022. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform. The platform will also include on-demand (recorded) sessions as well as access to networking, exhibits, and more. In-person registrants can upgrade their virtual access to Extended Flexibility or Best Value.

• **Real-Time Experience: Access through January 1, 2023**
  Provides access during peak dates and hours of the meeting with the largest number of participants at a given time, maximizing opportunities for interactions and networking. CME/MOC can be claimed through April 14, 2023 by viewing qualifying sessions on the virtual platform.

• **Extended Flexibility: Access through February 1, 2023**
  Provides ongoing access to continue watching on-demand session after the meeting ends. CME/MOC can be claimed through April 14, 2023 by viewing qualifying sessions on the virtual platform.

• **Best Value: Access through March 1, 2023**
  Provides maximum flexibility: the ability to participate in all live sessions and networking events during the core dates of the meeting, plus extended access to on-demand content, at the best price per day of access. CME/MOC can be claimed through April 14, 2023 by viewing qualifying sessions on the virtual platform.
**General Information**

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

### LATE PURCHASE REGISTRATION FEES (BEGINNING OCTOBER 27)

<table>
<thead>
<tr>
<th>Registration Category</th>
<th>In-Person or Real-Time Experience (Virtual access through January 1, 2023)</th>
<th>Extended Flexibility (Virtual access through February 1, 2023)</th>
<th>Best Value (Virtual access through March 1, 2023)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member (Active and International)</td>
<td>$800</td>
<td>$900</td>
<td>$1,000</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$1,400</td>
<td>$1,500</td>
<td>$1,600</td>
</tr>
<tr>
<td>ASH Associate or International Member</td>
<td>$125</td>
<td>$150</td>
<td>$175</td>
</tr>
<tr>
<td>Resident Member</td>
<td>$125</td>
<td>$150</td>
<td>$175</td>
</tr>
<tr>
<td>Graduate/Medical Student Member</td>
<td>$125</td>
<td>$150</td>
<td>$175</td>
</tr>
<tr>
<td>Non-Member in Training</td>
<td>$1,400</td>
<td>$1,500</td>
<td>$1,600</td>
</tr>
<tr>
<td>Allied Health Professional</td>
<td>$700</td>
<td>$800</td>
<td>$900</td>
</tr>
<tr>
<td>Spouse/Guest (in person only)</td>
<td>$125</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Honorary/Emeritus (before 1/1/15)</td>
<td>$0</td>
<td>$50</td>
<td>$100</td>
</tr>
<tr>
<td>Honorary/Emeritus (after 1/1/15)</td>
<td>$125</td>
<td>$150</td>
<td>$175</td>
</tr>
<tr>
<td>Non-Profit Patient Advocacy Organization Representative (Application for approval is required in advance)</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
</tbody>
</table>

### BADGE COLORS

Each badge holder at the ASH annual meeting is color-coded for easy identification of participants:

- Member .......................... Red
- Non-Member ........................ Green
- Associate Member ................. Blue
- International Associate Member .... Blue
- Non-Member in Training ............ Blue
- Graduate/Medical Student Member ... Blue
- Resident Member .................. Blue
- Honorary/Emeritus Member ........... White
- Allied Health Professional ......... Purple
- Exhibitor Booth Personnel .......... Black
- Spouses/Guest ........................ Yellow
- Media ................................ Lime & Blue

### BADGES

Badges will not be mailed in advance of the meeting. They will be provided to in-person participants only and will be issued upon arrival and after showing your health pass at registration. ASH reminds in-person participants to bring this health pass with them as it will be needed to obtain the badge. Your name badge contains a barcode that stores your name and address provided at the time of registration. It can be used by the exhibitors, with your consent, to register your visit to their booths and to send you additional information on their products and services. Your name badge also provides the information you require to access CME stations or receipt stations. You may pick up your badge at one of two primary registration locations: the Ernest N. Morial Convention Center Great Hall Pre-Function or the Louis Armstrong International Airport baggage claim area. ASH-a-Palooza participants may also pick up their badges at Mardi Gras World on Friday, December 9 only.
GENERAL INFORMATION

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

ANNUAL MEETING VIRTUAL PLATFORM

Beginning December 7, 2022, the ASH annual meeting will be available to all registered participants at annualmeeting.hematology.org

All registered attendees are encouraged to log in early to get acquainted with the site’s navigation. To log into the platform, you will need your ASH username and password used to register for the meeting.

WHO TO CONTACT

If you are having difficulty accessing the virtual meeting platform, please contact the ASH Customer Relations Department by emailing customerservice@hematology.org or calling 866-828-1231 (U.S. toll free) or 001-202-776-0544 (for international callers), Monday through Friday, from 8:30 a.m. to 5:00 p.m. Eastern time.

If you have successfully accessed the platform but are having difficulty with one of its features, please use either the online Chatbot, Help, or Contact Us link features within the platform for technical assistance.

PRE-MEETING AND OFFICIAL MEETING DAYS: December 9–13, 2022

There are pre-meeting activities scheduled on Friday, December 9, 2022.

**Friday, December 9**
- 7:00 a.m. - 10:00 p.m. Central time
  - ASH-a-Palooza
  - Friday Satellite Symposia
  - Scientific Workshops

The 64th ASH Annual Meeting and Exposition schedule will list all times in the Central time zone.

**Saturday, December 10**
- Refer to schedule-at-a-glance and the mobile app for specific session times

**Sunday, December 11**
- Refer to schedule-at-a-glance and the mobile app for specific session times

**Monday, December 12**
- Refer to schedule-at-a-glance and the mobile app for specific session times

**Tuesday, December 13**
- All sessions will occur in the general session room beginning at 8:45 a.m. Central time
- The meeting concludes at 2:15 p.m. Central time

All sessions will be presented at the in-person meeting in New Orleans. During the meeting and for the duration of your subscription to the platform, you will be able to access all annual meeting content including:

- Special-Interest Sessions with Q&A
- Special-Interest Sessions
- Education Program and Scientific Program Sessions
- Spotlight Sessions
- Oral Abstract Sessions
- Poster Presentations
- Award Lectures
- Select Friday Satellite Symposia
- Scientific Workshops (until December 16)
- Exhibits and Industry including the Exhibit Hall
- Corporate Presentations (Product Theaters, Industry Theaters, and Company Showcases)
POST-MEETING EVENTS: December 14–15, 2022

BINGE WATCHING—CATCH UP ON CONTENT
Participants will be able to watch presentation recordings on demand for sessions and posters that were presented earlier in the meeting.

SEARCH FOR SESSIONS AND FILL YOUR CALENDAR

SESSION SEARCH AND FILTERS
To help you navigate to the sessions you want to experience, the virtual meeting platform will feature detailed filters that will narrow down available sessions based on your desired areas of interest. Once on the sessions page, choose one or more filters from the left margin to see all sessions on a specific topic (or topics).

To further narrow your search, use the search bar to look for a specific topic.

ADDING SESSIONS TO CALENDAR
When you identify a session of interest, select “Export to Calendar” and choose your preferred calendar application to add an appointment to your personal calendar.

NETWORKING
ASH understands that connecting with colleagues is one of the most important reasons that people love attending the ASH annual meeting. For in-person participants, there will be plenty of networking events to maximize your reunion time with colleagues.

ASH's annual meeting virtual platform makes it easy to connect with colleagues in New Orleans and all around the world. All participants can schedule and host video chat meetings with each other, including the ability to schedule these in advance.

ASH COMMUNITY COLLAGE
Visit the ASH Community Collage to view and contribute to the real-time scientific conversation and engage with colleagues on a variety of topics. This year, the Collage will feature a daily leaderboard ranking the top 10 most prolific tweeters who use the featured annual meeting hashtags (#ASH22, #ASHRunWalk, #ASHKudos, and #ASHaiku). The leaderboard will reset each day, giving you ample opportunity to join the online discourse.

CONNECT WITH PARTICIPANTS
From the virtual meeting main page, visit the “Networking” page to find your friends and colleagues, engage in direct instant message chat with them or set up virtual video chats on a one-on-one basis, or organize group discussions for up to 50 people.

WATCH WITH FRIENDS AND COLLEAGUES
A feature unique to the ASH meeting is the ability to watch sessions with other attendees. Invite your mentees, collaborators, or friends to watch together so you can share your thoughts in real time.

SPEAKER INFORMATION

SPEAKER READY ROOM
The Speaker Ready Room will be located in ASH Central in Hall F of the Ernest N. Morial Convention Center.

Speaker Ready Room Hours
Thursday, December 8 . . . . 3:00 p.m. – 6:00 p.m.
Friday, December 9 . . . . . . 7:00 a.m. – 9:00 p.m.
Saturday, December 10 . . . 6:30 a.m. – 6:00 p.m.
Sunday, December 11 . . . . 6:30 a.m. – 6:00 p.m.
Monday, December 12 . . . 6:00 a.m. – 6:00 p.m.
Tuesday, December 13 . . . 6:30 a.m. – 1:00 p.m.
CONFLICT-OF-INTEREST POLICY

ASH is committed to providing quality, objective, balanced, and scientifically rigorous continuing medical education activities that are free from commercial and non-commercial bias. In accordance with the rules of the Accreditation Council for Continuing Medical Education (ACCME), ASH policy requires that all meeting session chairs, speakers, and moderators disclose in writing prior to the meeting any financial relationships they may hold with companies in the healthcare and biotechnology industries. Poster presenters are likewise required to disclose in writing any financial relationships they may have prior to the meeting and display their disclosures as a part of their poster presentation. If bias, actual or perceived, occurs during the presentations, session attendees are encouraged to address such bias during the question-and-answer periods following the presentations.

All ASH annual meeting presenters (including invited chairs and speakers, and abstract presenters and moderators) are asked to disclose any relationships of the following types: Employment, Consultancy, Equity Ownership, Research Funding, Honoraria, Patents & Royalties, Speakers Bureau, Membership on an entity’s Board of Directors or advisory committee, and any other financial relationship including Travel Support.

Any questions about this policy or concerns regarding disclosures should be directed to CME@hematology.org.

CONTINUING MEDICAL EDUCATION INFORMATION

EDUCATIONAL OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Employ the knowledge gained regarding the diagnosis and treatment of benign and malignant hematologic disorders to improve patient care;
• Discuss state-of-the-art research in hematology; and
• Analyze the potential contribution of novel, not-yet-approved modalities of therapy to current evidence-based management of hematologic disorders.

ACCREDITATION

The American Society of Hematology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Hematology designates this Other [blended live and on-demand content] activity for a maximum of 60 AMA PRA Category 1 Credits™.

CME CERTIFICATE ELIGIBILITY

ASH is accredited to provide AMA PRA Category 1 Credits™ to physicians only. The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country.

Physicians not licensed in the United States who participate in this CME activity are also eligible for AMA PRA Category 1 Credits™.

HOW TO OBTAIN A CME CERTIFICATE

A processing fee of $30 will be charged for CME certificates. Attendees may complete the Annual Meeting Evaluation Surveys to claim their CME credits and print their CME certificates through the ASH website (www.hematology.org) by clicking the CME link on the homepage. The online process for claiming CME credits and printing a CME certificate for the 64th ASH Annual Meeting must be completed no later than April 14, 2023.

ABIM MOC

Participation in this CME activity enables the attendee to earn up to 60 Medical Knowledge points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Attendees will earn MOC points equivalent to the amount of CME credits claimed for the activity. You will be asked to submit a reflective statement on how you intend to change your practice based on the knowledge you gained from participation in the meeting. Upon review and approval, your points will be submitted to the ACCME by ASH and will appear in your ABIM Physician Portal within 24 hours. In order to receive ABIM MOC points for the 64th ASH Annual Meeting, the online process for claiming CME/ABIM MOC credits must be completed by April 14, 2023.

CERTIFICATE OF ATTENDANCE

Non-physicians and other health-care professionals attending the meeting can receive a Certificate of Attendance by completing the Annual Meeting Evaluation Surveys through the ASH website (www.hematology.org) beginning Saturday, December 10, 2022. The online process of filling out the annual meeting survey must be completed no later than April 14, 2023. There is no charge to meeting registrants for this service.

EUROPEAN BOARD OF ACCREDITATION IN HEMATOLOGY CME CREDIT

ASH is applying for accreditation with the European Board of Accreditation in Hematology (EBAH). If you plan to claim EBAH-CME credit for attending the meeting, please check the appropriate box during the registration process or after the meeting in the online evaluation site. There is no fee required in order to be eligible for EBAH-CME Credit Points. For additional information about EBAH-CME Credit points, visit the EBAH website (http://ebah.org). For information about claiming EBAH CME for the 64th ASH Annual Meeting email cme@hematology.org.

QUALIFYING SESSIONS

Physician attendees can claim CME for viewing qualifying live sessions as they are broadcast or after they have concluded. Accredited sessions will be labeled in the print and online meeting materials, as well as in on-site digital signage.
GENERAL INFORMATION

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

ATTENDEE SERVICES

ASH CENTRAL

ASH Central, a place where hematologists can gather to collaborate, is located in Hall F of the Ernest N. Morial Convention Center. Within ASH Central, you can learn about ASH membership, purchase ASH products at the ASH Store, or donate to the ASH Foundation. The following resources are also offered at ASH Central: ASH Health Equity Studio, fASHion boutique for the hematologist with style, ASH Live: Remote Session Viewing, ASH Research Collaborative Kiosk, ASH Store, Collaboration Rooms, Whiteboard Wall, Headshot Alley, Photo Zone, Power Nap @ ASH, Trainee Lounge, and the ASH Wellness Studio. Additional seating and charging areas are also offered in ASH Central.

ASH Health Equity Studio

As part of our commitment to promoting and nurturing a diverse and inclusive hematology community, the American Society of Hematology (ASH) is offering the ASH Health Equity Studio, located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution. These micro-sessions will also be available on the virtual meeting platform.

ASH Live: Remote Session Viewing Area

A designated seating area that will enable attendees to experience select sessions in progress elsewhere without having to navigate through the building. This viewing area will have television monitors/screens displaying the slides from a selection of sessions. Participants will be provided with a set of headphones so they may listen to the selected session’s speakers. Note: Not all sessions will be broadcast into the remote session viewing area. Check the annual meeting mobile app or ASH News Daily for more information on which sessions are available remotely.

ASH Research Collaborative Kiosk

Visit with the ASH Research Collaborative staff and volunteer leaders to learn more about the Data Hub and the Sickle Cell Disease Clinical Trials Network and how your institution might benefit from participation.

ASH Store

ASH offers a variety of products to aid hematologists in their professional development. Stop by to peruse the latest ASH educational products, which will be available for a discounted on-site rate. These items will also be available for purchase in the online ASH Store at (www.hematology.org/Store).

ASH Wellness Studio

In between sessions and throughout the day, ASH will feature informal micro-learning workshops on various aspects of resiliency and wellness in the ASH Wellness Studio, where there will be short presentations and stand-up audience participation. Topics in the studio will be geared towards helping professionals attain a balanced, productive, and healthy work life balance through wellness. These micro-sessions will also be available on the virtual meeting platform.

Collaboration Rooms

Small conference rooms will be available for attendees to meet and collaborate in a more private setting. These small conference rooms, equipped with a table, chairs, flat screen monitor, and a cable to connect your own laptop to the monitor, can accommodate groups of up to 20 people and are free to reserve for up to 45 minutes. Each reservation starts at the top of the hour and lasts 45 minutes and each attendee will be limited to one 45-minute reservation per day. For the courtesy of all attendees, multiple, back-to-back reservations cannot be accommodated. Outside food and beverage and/or additional audiovisual equipment may not be brought into a Collaboration Room. Visit the ASH website (www.hematology.org) via the mobile application or the Collaboration Room Help Desk in Hall F to reserve a Collaboration Room.

Collaboration Room Hours

Friday, December 9 . . . . . 7:00 a.m. – 5:45 p.m.
Saturday, December 10 7:00 a.m. – 5:45 p.m.
Sunday, December 11 7:00 a.m. – 5:45 p.m.
Monday, December 12 7:00 a.m. – 5:45 p.m.
Tuesday, December 13 7:00 a.m. – 1:45 p.m.

fASHion

For the hematologist with style! Visit the fASHion boutique for ASH-branded apparel, including an ASH-themed soccer jersey to commemorate this year’s World Cup, fleece jackets and vests, athletic wear, golf polos, hematology specialty socks, bow and neck ties for men, scarves for women, and warm hats for all. Items will be available for purchase in an array of sizes while supplies last.

Headshot Alley

Staffed by professional photographers that provide lighting, a backdrop, and props, Headshot Alley is available for anyone seeking a professional headshot.

Photo Zone

Join the selfie craze and stop by the Photo Zone in ASH Central to take photos in front of New Orleans-themed backgrounds with unique props.

Trainee Lounge

Attendees with a blue badge are invited to visit the Trainee Lounge in ASH Central, a relaxing place for trainees to meet with colleagues and recharge with complimentary refreshments.

ASH ATTENDEE TECHNOLOGY TO ENHANCE YOUR EXPERIENCE

Alexa, Ask ASH Meeting

ASH is continuing the use of Amazon’s personal-assistant technology, Alexa, to attendees by answering ASH-specific questions. Alexa will be able to connect you with “live”
customer service agents that are available to answer questions from their secret Alexa backstage location. Be sure to start by saying “Alexa, ask ASH Meeting” followed by your question. Here are some example questions you can ask Alexa:
• Alexa, ask ASH Meeting: when do the shuttle buses operate?
• Alexa, ask ASH Meeting: where is ASH Central located?
• Alexa, ask ASH Meeting: does ASH offer child care?

Mobile App
ASH’s mobile application will provide program and exhibitor information, messaging capability, and general information happening with the 2022 annual meeting. The application includes the full text of the abstracts and the manuscripts available in Hematology 2022, the ASH Education Program. The application will allow users to add a session to their device’s calendar which will build their itinerary for the meeting. A login is no longer required to view application content; a login is only required to contact other attendees and view Education Program articles.

The following smartphones are supported: iPhone and Android; the application will also support the iPad and Google tablets.

ASH FOUNDATION DONOR LOUNGE
Gifts of all amounts to the ASH Foundation are always helpful and appreciated. With cumulative annual giving of $250 or more, you can access the ASH Foundation Donor Lounge during the annual meeting. Please visit the ASH Foundation page for more information. The Donor Lounge will be located in Ma Maison, a meeting space located above the Hall C Lobby Atrium Food Court.

ASH MANAGEMENT OFFICE
The ASH Staff Office is located in Room 238-239 of the Ernest N. Morial Convention Center.

ASH PARK @ THE PLAZA
This year we will make use of three outdoor spaces for ASH Park @ the Plaza. These areas will feature early morning yoga, life-sized games, World Cup viewing on Friday and Saturday, lunch time musical entertainment on Saturday, Sunday and Monday, and lounge furniture. ASH will arrange for seating and tables outdoors for those who wish to remove their protective facial mask while eating meals or visiting with colleagues over coffee.

BUSINESS CENTER
The Ernest N. Morial Convention Center provides full-service business needs for your convenience. The business center is run by UPS and is located in the Hall E lobby of the Ernest N. Morial Convention Center. The business center provides attendees with photocopying, faxing, computer workstations, and printing services. Office supplies are also available for purchase.

CHILD CARE ROOM
ASH has made arrangements with KiddieCorp to provide child care services for children ranging in age from six months to 12 years at the meeting. KiddieCorp has been caring for children at the ASH annual meeting for 23 years and offers a wide range of activities to keep children entertained while you attend the ASH sessions. KiddieCorp staff come prepared with age-appropriate games, souvenirs, and crafts projects, toys, and entertainment. KiddieCorp staff members are bonded and trained child care specialists. Additionally, KiddieCorp utilizes a photo identification system to check your child in and out of the room. There will also be a refrigerator in this room for nursing mothers to store milk after using the lactation room. The deadline for reserving space for your child is November 18.

For safety reasons, there are some new COVID-19 considerations this year:
• Vaccination is required for all children 6 months of age or older. Please bring your child’s vaccine card with you to check them into the child care room.
• ASH will follow the CDC guidance for indoor mask wearing, which means that all children 2 years or older must wear a protective facial mask in order to be enrolled in the indoor child care.
• All staff working in the child care room will also be vaccinated and will wear protective facial masks.

The cost for child care service is completely free and is subsidized by ASH, however a cancellation penalty will be assessed if you cancel after the November 18 pre-registration deadline. Snacks, light meals, and beverages will be provided each day. Pre-registration is recommended to ensure participation. This service will be available from Friday, December 9, through Tuesday, December 13.

The child care room is located in Room 383-385 at the Ernest N. Morial Convention Center.

Child Care Room Hours
Friday, December 9 . . . . . . 6:30 a.m. – 7:30 p.m.
Saturday, December 10 . . . . 6:30 a.m. – 7:30 p.m.
Sunday, December 11 . . . . . 6:30 a.m. – 8:00 p.m.
Monday, December 12 . . . . 6:30 a.m. – 8:00 p.m.
Tuesday, December 13 . . . 7:30 a.m. – 3:00 p.m.

COAT/BAG CHECK
Check coats for $2 each and bags for $3 each at the coat/bag checks located in the Rivergate Room near the Julia Street entrance to the Ernest N. Morial Convention Center and in Hall G Lobby. Electronic items will not be accepted.

Coat/Bag Check Hours
Friday, December 9 . . . . . 7:00 a.m. – 8:30 p.m.
Saturday, December 10 . . . 7:00 a.m. – 8:00 p.m.
Sunday, December 11 . . . . 7:00 a.m. – 8:30 p.m.
Monday, December 12 . . . 7:00 a.m. – 8:30 p.m.
Tuesday, December 13 . . . 7:00 a.m. – 3:30 p.m.

FRIENDS OF BILL W.
A meeting room for the Friends of Bill W. is located in Room 203 of the Ernest N. Morial Convention Center.

HEMATOLOGY MEETUPS
To encourage interaction among attendees, “Hematology MeetUp” areas consisting of public meeting spaces with couches, chairs, and tables will be placed in the convention center. Where possible and permissible, portable concession carts will be located nearby offering coffee and quick grab-and-go food. These locations will be indicated on the campus maps so that attendees can coordinate meeting up with each other at a specific location.
GENERAL INFORMATION

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

INTERNET STATIONS
Internet Stations are placed throughout the Ernest N. Morial Convention Center. Attendees can utilize the Internet and do any of the following at all Internet Stations:

• Check email
• Print a boarding pass
• Print a registration receipt
• Access ASH Job Center
• View the Annual Meeting Program online
• Complete the Meeting Evaluation
• Obtain a Certificate of Attendance
• Register for the ASH Foundation Run/Walk (up to 6:00 p.m. on Saturday night)

LOST AND FOUND
Contact the ASH Security Main Office for all lost items and inquiries. The ASH Security Main Office is located in Room 206 of the Ernest N. Morial Convention Center.

NURSING MOTHERS’ LOUNGES
Dedicated lounges will be available for nursing mothers in safe, accessible areas throughout the Ernest N. Morial Convention Center and Hilton New Orleans Riverside. Each nursing mothers’ lounge will provide a private, comfortable area equipped with lockable doors, furniture, and power outlets to use for pumping sessions during the ASH annual meeting.

There is a complimentary refrigerator located in the Child Care Room in Room 383-385 at the Ernest N. Morial Convention Center.

Nursing Mothers’ Lounges Locations
Ernest N. Morial Convention Center:
• Hall B Lobby
• Hall H Lobby
• Built Meeting Room in Room 256 Foyer

Hilton New Orleans Riverside:
• Built Meeting Room in Grand Salon Foyer

QUIET ROOMS
Two quiet rooms are located in the Ernest N. Morial Convention Center. Room 211 is designated as the Female Quiet Room and Room 212 is designated as the Male Quiet Room.

PRESS ROOM
The Press Room, open to registered members of the media, is located in Room 256-257 in the Ernest N. Morial Convention Center.

Press Room Hours
Friday, December 9 .......... 9:00 a.m. – 5:00 p.m.
Saturday, December 10 .... 7:00 a.m. – 6:00 p.m.
Sunday, December 11 ...... 7:00 a.m. – 6:00 p.m.
Monday, December 12 ...... 7:00 a.m. – 6:00 p.m.
Tuesday, December 13 ..... 7:00 a.m. – 1:00 p.m.

RESTAURANTS/CONCESSIONS
Centerplate at the Ernest N. Morial Convention Center offers a wide variety of dining options, including cafes in the public lobbies, concessions in the Exhibit Hall, and a food court offering a wide variety of cuisines.

A variety of restaurants are located near the Ernest N. Morial Convention Center. Please stop by the New Orleans Information Desk located in Lobby A at the Ernest N. Morial Convention Center for complimentary restaurant reservation services and more! The desk is open during the following hours:

Friday, December 9 – Monday, December 12
9:00 a.m. - 5:00 p.m.

Tuesday, December 13
9:00 a.m. - 2:30 p.m.

TRAVEL INFORMATION AND OFFICIAL SHUTTLE SERVICE

VISITOR SAFETY
To stay safe during your visit to New Orleans, please follow the tips provided below:

• Follow the health and safety protocols implemented by ASH due to COVID-19
• Follow the protocols implemented by hotels, restaurants and transportation companies (taxi, Uber, Lyft)
• Always lock your front and/or patio doors in your hotel room. Use the safety chain/lock for security.
• Never open your room door unless you know who is there. If you did not call for the hotel service offered by the person at the door, call hotel security or the front desk to see if they have sent someone to your room.
• Place valuables in a safety deposit box in your room or at the hotel office. Do not leave valuables in your car.
• When checking into a hotel, consult the floor plan on the back of your room door to familiarize yourself with fire and emergency exits.
• When driving, keep all car doors locked. If taking an Uber or Lyft, verify the car’s license plate and have the driver correctly state your name before entering the car.
• Never hand your cell phone to a stranger.

ASH will be providing complimentary shuttle service for 75 hotels; additionally, 13 hotels are within walking distance of the Ernest N. Morial Convention Center. All passengers on the shuttle service are required to wear a protective facial mask. Staff will be available to remind passengers of this requirement.

Shuttle Locations
Shuttle Routes 1-7
Ernest N. Morial Convention Center Shuttle Hub
Shuttle Routes 8-12
Ernest N. Morial Convention Center Parking Lot G
**General Information**

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

**Shuttle Hours**

- **Thursday, December 8** . . . . . . . . . . . . . . . No shuttle service
- **Friday, December 9** . . . . . . . . . . . . . . . . . 6:30 a.m. – 10:30 p.m.
- **Saturday, December 10** . . . . . . . . . . . . . 6:30 a.m. – 9:30 p.m.
- **Sunday, December 11** . . . . . . . . . . . . . . . . . 6:30 a.m. – 9:30 p.m.
- **Monday, December 12** . . . . . . . . . . . . . . . . . 6:30 a.m. – 9:30 p.m.
- **Tuesday, December 13** . . . . . . . . . . . . . . . . 6:30 a.m. – 3:00 p.m.

Service frequency will vary throughout the day. Look for detailed shuttle bus schedules in each hotel lobby.

Service will not be provided for the following hotels, located within walking distance of the Ernest N. Morial Convention Center:
- Cambria New Orleans Downtown Warehouse District
- Courtyard New Orleans Downtown/Convention Center
- Embassy Suites New Orleans Convention Center
- Hampton Inn & Suites New Orleans Convention Center
- The Higgins Hotel New Orleans, Curio Collection by Hilton
- Hilton Garden Inn New Orleans Convention Center
- Hyatt Place New Orleans
- Marriott New Orleans Warehouse Arts District
- The Mercantile Hotel
- Omni Riverfront New Orleans
- Renaissance New Orleans Arts Warehouse District
- Sonesta ES Suites New Orleans Convention Center
- SpringHill Suites New Orleans Downtown/Convention Ctr.

**AirPort Shuttle Information**

The official shuttle provider, Kushner & Associates, will offer one-way direct shuttle service every 30 minutes between the Ernest N. Morial Convention Center and Louis Armstrong International Airport. All passengers on the airport shuttle service are required to wear a protective facial mask. Staff will be available to remind passengers of this requirement.

Tickets are sold on site at the ASH Airport Shuttle Desk in the Hall G Lobby, of the Ernest N. Morial Convention Center. Tickets cost $25.

**Tickets Sales Hours**

- **Monday, December 12** . . . . . . . . . . . . . . . . 9:00 a.m. - 7:00 p.m.
- **Tuesday, December 13** . . . . . . . . . . . . . . . . 7:00 a.m. - 2:45 p.m.

**Shuttle Hours**

- **Monday, December 12** from 12:00 p.m. - 6:00 p.m. on the hour and half hour
- **Tuesday, December 13** from 9:00 a.m. - 3:00 p.m. on the hour and half hour

**Departure Location:** Ernest N. Morial Convention Center Shuttle Hub, End of Sidewalk

**Parking**

On-site private vehicle parking is available in various lots and garages near the Ernest N. Morial Convention Center. For detailed parking information, visit [https://mccno.com/visitors/getting-here/](https://mccno.com/visitors/getting-here/).

**Public Transportation**

The area’s public bus system - RTA - has routes servicing the Ernest N. Morial Convention Center with connections to Louis Armstrong International Airport and downtown New Orleans. To plan your journey and obtain the latest fares, visit [https://www.norta.com/](https://www.norta.com/).

A taxi ride from the airport to the Central Business District or French Quarter costs $36 for up to two passengers. For 3 passengers or more the fee is $15 per person.

**Exposition**

Nearly 300 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and nonprofit organizations will be participating in the 2022 ASH Annual Meeting and Exposition. The state-of-the-art exhibit hall will feature the latest technology and research as well as a wide range of products and services. The exposition will be held in Halls G-J in the Ernest N. Morial Convention Center. Badges will be required for entrance. For safety and liability reasons, ASH does not permit children 12 years of age or younger at any time in the exhibit areas. During move-in or move-out, NO ONE under the age of 18 will be permitted within the exhibit areas.

**Exhibit Hours**

- **Saturday, December 10** . . . . . . . . . . . . . 11:00 a.m. – 5:00 p.m.
- **Sunday, December 11** . . . . . . . . . . . . . . . . . 10:00 a.m. – 5:00 p.m.
- **Monday, December 12** . . . . . . . . . . . . . . . . . 10:00 a.m. – 2:00 p.m.

**Lunch Available Sunday and Monday**

Your “ticket” for lunch is encoded in your badge, which will be scanned for entry into the “ticketed” event. Simply present your badge to access the complimentary light lunch offered on Sunday and Monday in the Exhibit Hall. Lunch will be served from the ASH Café area located in Hall J.

**Lunch Hours**

- **Sunday, December 11** . . . . . . . . . . . . . . . . 11:00 a.m. – 12:30 p.m.
- **Monday, December 12** . . . . . . . . . . . . . . . . 12:00 noon – 1:30 p.m.

**ASH Booth (#1333) – Your Gateway to All ASH Has to Offer**

ASH is more than just an annual meeting; it is the premier hematology organization in the world. ASH is proud to offer its members many valuable resources. Come say hello and see what the Society has to offer at the ASH Booth (#1333).

Get the latest information on grants and awards, publications, educational materials, and ASH meetings and find out how you can help move hematology forward with a contribution to ASH Foundation programs. Be sure to pick up the most recent issues of Blood, see what materials are available to hematologists around the world, and discover free online ASH resources. Our friendly staff will be glad to answer any questions and hear your feedback about the annual meeting or the Society. Consider this an open invitation to visit the booth Saturday, Sunday, and Monday to see how ASH can do more for you. Be sure to pick up a small giveaway as a token of our appreciation for attending the annual meeting.
CORPORATE PRESENTATIONS
Corporate Presentations include Product Theaters, Industry Theaters, and Company Showcases, which feature new products, research findings, and company overviews presented to small groups of annual meeting attendees (no more than 150) and are located within the Exhibit Hall Theater (Hall J) of the Ernest N. Morial Convention Center. Check the mobile app for the specific theater number you wish to attend; Theaters are numbered one through seven. The sessions offered at the times listed below will be solely promotional in nature; therefore, continuing medical education credits will not be offered.

Theater Hours
Saturday, December 10
11:30 a.m. – 12:30 p.m.
1:30 p.m. – 1:45 p.m.
3:30 p.m. – 3:45 p.m.

Sunday, December 11
8:00 a.m. – 9:00 a.m.
11:30 a.m. – 12:30 p.m.
4:00 p.m. – 4:15 p.m.

Monday, December 12
8:00 a.m. – 9:00 a.m.
10:15 a.m. – 10:30 a.m.
12:15 p.m. – 1:15 p.m.

Please see page 143 for detailed Corporate Presentation program information.

POSTER SESSIONS
Poster sessions are held in Hall D of the Ernest N. Morial Convention Center. Receptions are scheduled Saturday, Sunday, and Monday evening during the poster sessions, and badges will be required for entrance.

Saturday, December 10
9:00 a.m. – 7:30 p.m. .......Poster Session I – Viewing
5:30 p.m. – 7:30 p.m. .........Poster Session I – Presentations

Sunday, December 11
9:00 a.m. – 8:00 p.m. .......Poster Session II – Viewing
6:00 p.m. – 8:00 p.m. .........Poster Session II – Presentations

Monday, December 12
9:00 a.m. – 8:00 p.m. .......Poster Session III – Viewing
6:00 p.m. – 8:00 p.m. .........Poster Session III – Presentations

SOCIAL EVENTS

POSTER HALL RECEPTIONS
Saturday, December 10 .......5:30 p.m. – 7:30 p.m.
Sunday, December 11 .........6:00 p.m. – 8:00 p.m.
Monday, December 12 .........6:00 p.m. – 8:00 p.m.

Abstracts selected for poster presentations feature new advancements in hematologic research and are considered among the best of the thousands submitted for the 2022 ASH Annual Meeting. ASH invites meeting attendees to take advantage of these special opportunities to meet the abstract authors, discuss their research, and ask them questions. Light snacks and beverages will be provided.

ASH FOUNDATION RUN/WALK
Sunday, December 11, 2022, 7:00 a.m. – 9:00 a.m.
Corner of Julia Street and Convention Center Blvd.
Start your day in a healthy, fun, and philanthropic way by participating in the ninth annual ASH Foundation Run/Walk before attending the Sunday sessions on December 11. Participants may run or walk through the designed event course along the waterfront in New Orleans, choosing a 3K or 5K route. Not attending the meeting in-person? Don't worry; you too can participate virtually. Proceeds from all individual and group registration fees and individual donations benefit ASH's Global Programs Fund. ASH and the ASH Foundation may opt to designate a portion or all corporate sponsorship revenues associated with the Run/Walk to help support the event’s administration cost. Learn more and register at https://runsignup.com/Race/LA/NewOrleans/ASHFoundationRunWalk
CODE OF CONDUCT
ASH is committed to providing a welcoming meeting environment for all attendees. This Code of Conduct applies to all in-person and virtual participants, including members, volunteers, guests, exhibitors, vendors, staff, and any other attendee.

All attendees will conduct themselves in a collegial and respectful manner, free from any form of discrimination, harassment, or retaliation. Attendees will commit to creating a safe, inclusive, and professional atmosphere. Inappropriate conduct, including but not limited to harassment; threatening physical or verbal actions; or disorderly or disruptive conduct, will not be tolerated.

If you or anyone you know is being treated inappropriately, feels unsafe, and/or witnesses any unacceptable behavior, please contact customerservice@hematology.org as soon as possible. ASH will do its best to respond in a timely manner and determine the appropriate next steps.

PARTICIPATION REQUIREMENTS
Admission to all official ASH events will require a proper display of registration badges. Badges should always be worn and are non-transferable. False certification of individuals as paid ASH meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any in-person or virtual meeting event, or inappropriate conduct according to the Code of Conduct, will not be tolerated and will be just cause for repossessing badges of any individuals involved and/or revoking access to the meeting or virtual meeting platform. As a result, ASH reserves the right to expel all parties involved and has no obligation to refund registration fees paid.

Below are the policies that all in-person participants of the annual meeting will be required to acknowledge and agree to as part of the badge pick-up process at the Ernest N. Morial Convention Center:

1. I understand and agree that there is inherent risk in participating in any in-person activity and that, due to the circumstances created by COVID-19, there is a heightened degree of personal risk and responsibility. The ASH Annual Meeting is no exception. Although ASH will be taking reasonable legal, prudent, and advisable measures to reduce the risk of virus/illness transmission between people attending the annual meeting, I understand that ASH cannot reduce the level of risk to zero. I acknowledge the risks presented by COVID-19, and the other risks inherent in attending the ASH Annual Meeting and agree to take full personal responsibility for them. I agree that I will not hold anyone else accountable, including ASH, should I become ill or otherwise injured as a result of any act or omission arising out of my decision to attend and participate in the ASH Annual Meeting.

2. I am an adult over the age of 18, and I knowingly and voluntarily assume any and all risks and dangers that may occur pursuant to my attendance and participation in the ASH Annual Meeting, including the risk of illness, injury, death, or property damage and I release ASH and the Ernest N. Morial Convention Center from any and all such liability. I agree, for myself and any heirs, not to sue ASH or the Ernest N. Morial Center or otherwise assert any claim for damages arising out of any illness (including COVID-19 or other communicable disease or illness), personal injury, temporary or permanent disability, death, damages, liabilities, or expenses I or they may sustain arising out of my attendance and participation in the ASH Annual Meeting.

3. I agree to follow the health and safety protocols established by ASH for the meeting and have read and understand all of these protocols.

4. To the best of my knowledge, I do not have COVID-19 as of this date. I have not tested positive for COVID-19 in the fourteen days prior to the date of this attestation, nor have I experienced any of the following symptoms during that period: fever or chills; cough; shortness of breath or difficulty breathing; fatigue; muscle or body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting; or diarrhea. If I become symptomatic, I agree that I will get tested for COVID-19 immediately and cease participation in the meeting and all related events. Even if the COVID-19 test results are negative, I will cease participation in the meeting and all related events until I am asymptomatic.

5. I agree that if the COVID-19 test results are positive, I will cease participation in the meeting and follow the Centers for Disease Control and Prevention (CDC) guidelines for quarantining.

6. I agree that I will not pass my registration badge to another individual, or otherwise allow anyone else to use my badge, since the recipient would not have completed the requirement to show proof of vaccination to ASH before a badge is issued. I understand that violating this requirement will result in immediate revocation of my access to the meeting, and possibly future meetings.

PARTICIPATION OF FINANCIAL PROFESSIONALS
Financial professionals and other individuals whose principal reason for attending the meeting is to seek business opportunities or obtain information affecting investment positions are welcome to register for the meeting. However, the educational and scientific aspects of the meeting are always top priority. Financial professionals are required to identify themselves when speaking with presenters, particularly when asking questions for which the answers may have implications for corporate valuation or positions in equity markets. Speakers and moderators are also asked to give preference to questioners with scientific or clinical inquiries.

ANNUAL MEETING DATA COLLECTION
As a participant of the meeting, you have read and agreed to the following privacy policies and/or terms of service:

- American Society of Hematology
  - Privacy Policy (hematology.org/about/privacy-policy)
  - Terms of Service (hematology.org/about/terms-of-service)
- SPARGO (ASH Registration and Housing provider)
  - Privacy Policy (https://spargoinc.com/privacy-statement)
- Freeman (Virtual Meeting Platform provider)
  - Privacy Policy (https://www.freeman.com/privacy-policy/)

GENERAL INFORMATION
All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.
All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

- Terms of Service (https://www.freeman.com/terms/)

Attendees who have questions or concerns can contact ashregistration@spargoinc.com.

PROHIBITED SESSION ROOM BEHAVIOR

In crowded sessions, please honor the instructions provided by ASH staff. You may be told not to stand against the walls in these rooms or not to block the aisles. Please note that if a room reaches full capacity, you may be denied entry, as ASH must obey the guidelines established by the Fire Marshall.

CHILDREN

For safety reasons, children under the age of 12 (including infants in carriers and strollers, or hand-carried infants and toddlers) are not permitted the exhibit hall or poster sessions. Additionally, ASH prohibits all children and infants in the sessions, as they may distract the speakers and disrupt other attendees. Attendees should contact ASH for assistance with childcare options in advance of the meeting.

RADIO FREQUENCY IDENTIFICATION (RFID) BADGE SCANNING IN USE

As part of ASH’s ongoing efforts to improve the member experience, RFID-enabled badges will be used at the ASH annual meeting. No identifying personal information will be stored in the RFID badge, only an ID number. Data collected will only be used for program planning purposes and will not be shared or sold to other entities. Attendees who have questions or concerns can contact ashregistration@spargoinc.com.

PHOTOGRAPHY AND RECORDING OF COPYRIGHTED MATERIAL AT THE ASH ANNUAL MEETING

A. General

Materials presented at the American Society of Hematology ("ASH") annual meeting, including all slides, written and oral presentations, posters, and other materials displayed, shown, or otherwise published during the ASH annual meeting (the “Meeting Materials”), are protected by copyright and may not be publicly displayed or republished (including social media) without the express written consent of the copyright owner, ASH, or (in the case of the slides and posters) the presenter or author except as expressly provided in this Policy.

B. Photographs and Audio Recording

1. Limited Right to Share: Except as provided in Sections A and B.2 of this Policy (hematology.org/meetings/annual-meeting/attendee-resources/photography-and-recording#b2), attendees of the ASH annual meeting may take photographs and make audio recordings (but no video recordings or live-streaming) of Meeting Materials for personal, non-commercial use, which are licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license (available in its entirety at http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode). This means that, except as provided in Sections A and B.2 of this Policy, attendees may share a limited number of photographs or short audio recordings of the Meeting Materials in a reasonable manner, as determined by ASH, in any medium or format subject to the following terms:

   • Attribution: an attendee must give appropriate credit to the original author, and may not in any way suggest that the original author endorses the attendee or his or her use;
   • Non-Commercial: an attendee may not use the Meeting Materials for commercial purposes; and
   • No Derivatives: if an attendee remixes, transforms, or builds upon the Meeting Material, he or she may not distribute or publish the modified material.
As a global hematology community, ASH understands the importance of having individuals with diverse perspectives and experiences in all areas of the field. Through various ASH programs and committees, ASH continues its long-standing commitment to combating inequities in hematology, supporting scientists and clinicians from backgrounds underrepresented in medicine, and embracing diverse voices across the patient and health care communities. ASH's efforts in diversity, equity, and inclusion apply to everyone, regardless of race, ethnicity, religion, age, sexual orientation, gender identity or expression, ability, national origin, or other attributes. Join us for the following events at the 64th ASH Annual Meeting to support and strengthen diversity, equity, and inclusion in medical research on hematologic diseases and disorders and in the practice of hematology.

**ASH HEALTH EQUITY STUDIO**

<table>
<thead>
<tr>
<th>Saturday, Sunday, Monday</th>
<th>Hall F</th>
</tr>
</thead>
<tbody>
<tr>
<td>As part of our commitment to promoting and nurturing a diverse and inclusive hematology community, the American Society of Hematology (ASH) is offering the ASH Health Equity Studio, located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution.</td>
<td></td>
</tr>
</tbody>
</table>

**SCIENTIFIC WORKSHOP ON DECENTRALIZED CLINICAL TRIALS**

<table>
<thead>
<tr>
<th>Friday 2:00 p.m. – 5:00 p.m.</th>
<th>275-277</th>
</tr>
</thead>
<tbody>
<tr>
<td>This workshop will convene key stakeholders in the clinical trial enterprise to help define and improve the understanding of decentralized clinical trials (DCTs), including the role of DCTs in hematology and opportunities for future incorporation and engagement. The workshop will also identify successful approaches to DCTs and discuss areas for continued access and improvement of this clinical trial approach for hematologic diseases.</td>
<td></td>
</tr>
</tbody>
</table>

**SCIENTIFIC WORKSHOP ON HEMATOLOGY AND AGING**

<table>
<thead>
<tr>
<th>Friday 2:00 p.m. – 5:00 p.m.</th>
<th>278-282</th>
</tr>
</thead>
<tbody>
<tr>
<td>This workshop will be a forum for the presentation of novel research related to the biology of aging and hematologic disorders as it relates to the geriatric population. It will also foster interaction and engagement among aging scientists and investigators conducting research at the interface of hematology and aging and provide opportunities for early career investigators to participate and interact with established leaders in the field of hematology and aging.</td>
<td></td>
</tr>
</tbody>
</table>

**SCIENTIFIC WORKSHOP ON EPIDEMIOLOGY: LEVERAGING DIGITAL TECHNOLOGY TO MODERNIZE AND ENHANCE OBSERVATIONAL STUDIES**

<table>
<thead>
<tr>
<th>Friday 2:00 p.m. – 5:00 p.m.</th>
<th>298-299</th>
</tr>
</thead>
<tbody>
<tr>
<td>This workshop will explore methods and examples of studies using artificial intelligence (AI) and machine learning to better capture information efficiently from medical records, histopathological materials, and big data, and use of social media to expand participation and increase representativeness of underserved minorities.</td>
<td></td>
</tr>
</tbody>
</table>
DIVERSITY, EQUITY, AND INCLUSION AT ASH

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

GRASSROOTS NETWORK LUNCH

Saturday  11:15 a.m. – 12:15 p.m.  St. James Ballroom, Hilton New Orleans Riverside

The ASH Grassroots Network Lunch provides a forum for interested members to learn how they can participate in ASH’s advocacy efforts, communicate with Congress and their elected officials, become effective advocates for hematology, and discuss the Society’s legislative and regulatory priorities. An overview of the Society’s 2022 advocacy accomplishments and a preview of the Society’s 2023 advocacy agenda will also be provided.

Given ASH’s commitment to policy issues impacting maternal health and hematology, the keynote speaker for this year’s event is Veronica Gillispie-Bell, MD, a board-certified obstetrician & gynecologist at Ochsner Health System in New Orleans, LA. She currently serves as the Senior Site Lead and Section Head of Obstetrics and Gynecology at Ochsner Kenner and is the Director of Quality for Women’s Services and Medical Director of the Minimally Invasive Center for the Treatment of Uterine Fibroids. Additionally, she is the Medical Director for the Louisiana Pregnancy Associated Mortality Review and Perinatal Quality Collaborative within the Louisiana Department of Health. Dr. Gillispie-Bell will speak to the important connection between hematology and oncology/gynecology and will also provide her perspective regarding ways ASH members can be involved at the state and local levels to impact change aimed at improving health outcomes.

PROMOTING MINORITIES IN HEMATOLOGY: PRESENTATIONS AND RECEPTION

Saturday  6:30 p.m. – 9:00 p.m.  The District Foyer, Hilton New Orleans Riverside

ASH invites all interested meeting attendees to this event, which will showcase training and research opportunities geared toward increasing the diversity of scholars in the field of hematology. The highlight of the session will be scientific presentations from the ASH Minority Medical Student Award, Minority Resident Hematology Award, ASH Minority Graduate Award, and the ASH Minority Fellowship Award program participants. A reception will follow the presentations.

LGBTQIA+ COMMUNITY NETWORKING BRUNCH

Sunday  11:15 a.m. – 12:15 p.m.  Gravier AB, Marriott New Orleans Warehouse Arts District

This brunch is an informal community-building and networking event for members of the LGBTQIA+ community attending the meeting. The event is hosted by the ASH Diversity, Equity, and Inclusion (DEI) Programs Subcommittee and aims to create a sense of belonging and allyship and where possible identify opportunities to learn more about the experiences and needs of the community to allow us to have a greater impact in our DEI efforts.

ASH HEALTH EQUITY ROUNDS LUNCH (FOR IN-PERSON PARTICIPANTS)

Sunday  11:30 a.m. – 12:30 p.m.  Cypress, Marriott New Orleans Warehouse Arts District

This series examines the impact of implicit bias and systemic racism in hematology through interactive, case-based discussions, and an interdisciplinary panel that includes hematologists, health equity/public health experts, patients, and patient advocates. Attendees will discuss various disease cases and provocative health equity topics, and participate in experiential learning, breakout sessions, and interactive lectures.

OBSTETRIC MANAGEMENT AND COMPLICATIONS IN SICKLE CELL DISEASE IN HIGH-AND LOW-INCOME COUNTRIES

Sunday  4:30 p.m. – 6:00 p.m.  243-245

Pregnancy in women with sickle cell disease (SCD) is a life-threatening condition. In a pooled analysis from recent obstetric and hematology studies conducted in low- and middle-income settings, maternal death in women with SCD is approximately 2,393 and 4,300 deaths per 100,000 live births with and without multidisciplinary care, respectively. In comparison, the USA and Northern Europe’s general maternal mortality rate is approximately 23.8 and 8 deaths per 100,000 live births, respectively.
DISABILITY COMMUNITY NETWORKING BREAKFAST

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>7:30 a.m. – 9:00 a.m.</td>
<td>Gravier EF, Marriott New Orleans Warehouse Arts District</td>
</tr>
</tbody>
</table>

This breakfast is an informal community-building and networking event for members of the disability community attending the meeting. The event is hosted by the ASH Diversity, Equity, and Inclusion (DEI) Programs Subcommittee and aims to create a sense of belonging and allyship and where possible identify opportunities to learn more about the experiences and needs of the community to allow us to have a greater impact in our DEI efforts.

MATERNAL HEALTH IN HEMATOLOGY – CURRENT RESOURCES AND FUTURE ADVOCACY

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>10:30 a.m. – 12:00 p.m.</td>
<td>Hall E</td>
</tr>
</tbody>
</table>

Maternal morbidity and mortality closely intersect with hematology. In 2021, ASH indicated that the time is right—given greater awareness, as well as attention to health disparities and their intersection with diversity, equity, and inclusion (DEI)—to explore opportunities for the Society to engage in these important public health issues more fully. The session will cover the current efforts, programs, and resources (including but not limited to guidelines), as well as present upcoming plans and opportunities for engagement by the hematology community. Additionally, this session will also touch on the current political climate around the right to maternal healthcare and well-being and ways to be an effective advocate. The session will include case studies highlighting ways to bring attention to hematology and maternal health research and practice issues impacted by public policy decisions.

WOMEN IN HEMATOLOGY NETWORKING DINNER (FOR IN-PERSON PARTICIPANTS)

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>7:30 p.m. – 9:30 p.m.</td>
<td>Jefferson Ballroom, Hilton New Orleans Riverside</td>
</tr>
</tbody>
</table>

The networking event provides a space where all can gather in an informal environment, interact with peers, connect with role models and potential mentors, and become inspired and empowered to overcome the challenges women face in hematology.
Because maternal morbidity and mortality closely intersect with hematology, ASH is committed to supporting the right to maternal health care that addresses hematologic disorders; advocating for access to reproductive health services for all people; and supporting clinicians who serve vulnerable populations, including those at risk of maternal health conditions. Given the greater awareness of and attention to health disparities, the time is right for ASH to engage fully in these important public health issues. Join us for the following events at the 64th ASH Annual Meeting to help improve maternal healthcare that addresses hematologic disorders.

### WHITEBOARD WALL

**Saturday, Sunday, Monday**

Located within ASH Central, the Whiteboard Wall will feature live artists drawing the answers to specific questions that ASH will present to attendees. In-person attendees may watch as the artists bring these answers to life!

There are two Whiteboard Walls this year, one will focus on maternal health. Questions on the maternal health wall will be:

- What are the key knowledge gaps in maternal health for hematologists?
- What does comprehensive maternal health care look like to you?
- If you had a grant focused on maternal health, what would you research?

### GRASSROOTS NETWORK LUNCH

**Saturday 11:15 a.m. – 12:15 p.m.**

The ASH Grassroots Network Lunch provides a forum for interested members to learn how they can participate in ASH’s advocacy efforts, communicate with Congress and their elected officials, become effective advocates for hematology, and discuss the Society’s legislative and regulatory priorities. An overview of the Society’s 2022 advocacy accomplishments and a preview of the Society’s 2023 advocacy agenda will also be provided.

Given ASH’s commitment to policy issues impacting maternal health and hematology, the keynote speaker for this year’s event is Veronica Gillispie-Bell, MD, a board-certified obstetrician & gynecologist at Ochsner Health System in New Orleans, LA. She currently serves as the Senior Site Lead and Section Head of Obstetrics and Gynecology at Ochsner Kenner and is the Director of Quality for Women’s Services and Medical Director of the Minimally Invasive Center for the Treatment of Uterine Fibroids. Additionally, she is the Medical Director for the Louisiana Pregnancy Associated Mortality Review and Perinatal Quality Collaborative within the Louisiana Department of Health. Dr. Gillispie-Bell will speak to the important connection between hematology and oncology/gynecology and will also provide her perspective regarding ways ASH members can be involved at the state and local levels to impact change aimed at improving health outcomes.

### REPRODUCTIVE AND SEXUAL HEALTH IN SICKLE CELL DISEASE

**Sunday 9:30 a.m. – 10:45 a.m.**

Reproductive and sexual health challenges associated with sickle cell disease (SCD) are common but under-recognized morbidities. Both males and females with SCD suffer from the disease- or therapy-related challenges impacting negatively on their reproductive and sexual health. Priapism, otherwise rare in the general population, is common among adolescent and adult males with SCD with attendant sequelae of erectile and sexual dysfunctions. Treatment with a disease-modifying agent, hydroxyurea, potentially damages the gonads (testes and ovaries) and could result in infertility. Both SCD and hydroxyurea therapy could damage ovaries, resulting in diminished ovarian reserve and infertility. Curative treatments such as stem cell transplants and gene therapy also pose a significant risk of infertility to both males and females. These challenges have made decision-making on fertility choices difficult for the affected individuals. In this educational session, we will discuss the epidemiology and trends in the management of priapism. We will elaborate on fertility challenges affecting individuals, most especially females, with SCD and provide a template of strategies for engaging patients and their families to guide them in making an informed decision about their treatment choices, mainly as they affect fertility.
## OBSTETRIC MANAGEMENT AND COMPLICATIONS IN SICKLE CELL DISEASE IN HIGH- AND LOW-INCOME COUNTRIES

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>243-245</td>
</tr>
</tbody>
</table>

Pregnancy in women with sickle cell disease (SCD) is a life-threatening condition. In a pooled analysis from recent obstetric and hematology studies conducted in low- and middle-income settings, maternal death in women with SCD is approximately 2,393 and 4,300 deaths per 100,000 live births with and without multidisciplinary care, respectively. In comparison, the USA and Northern Europe’s general maternal mortality rate is approximately 23.8 and 8 deaths per 100,000 live births, respectively.

## MATERNAL HEALTH IN HEMATOLOGY – CURRENT RESOURCES AND FUTURE ADVOCACY

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>10:30 a.m. – 12:00 p.m.</td>
<td>Hall E</td>
</tr>
</tbody>
</table>

Maternal morbidity and mortality closely intersect with hematology. In 2021, ASH indicated that the time is right—given greater awareness, as well as attention to health disparities and their intersection with diversity, equity, and inclusion (DEI)—to explore opportunities for the Society to engage in these important public health issues more fully. The session will cover the current efforts, programs and resources (including but not limited to guidelines), as well as present upcoming plans and opportunities for engagement by hematology community. Additionally, this session will also touch on the current political climate around the right to maternal healthcare and well-being and ways to be an effective advocate. The session will include case studies highlighting ways to bring attention to hematology and maternal health research and practice issues impacted by public policy decisions.

## WOMEN IN HEMATOLOGY NETWORKING DINNER (FOR IN-PERSON PARTICIPANTS)

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>7:30 p.m. – 9:30 p.m.</td>
<td>Jefferson Ballroom, Hilton New Orleans Riverside</td>
</tr>
</tbody>
</table>

The networking event provides a space where all can gather in an informal environment, interact with peers, connect with role models and potential mentors, and become inspired and empowered to overcome the challenges women face in hematology.
ASH is committed to continuously re-evaluating our policies and processes to ensure that they align with the Accreditation Council for Continuing Medical Education’s (AACME) increasingly stringent standards. The ACCME defines Ineligible Companies (IC), also known as commercial interests, as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Pharmaceutical and biotechnology companies, including biomedical startups and diagnostic laboratories with proprietary products, are classified as ineligible companies and, per ACCME, any presentation given by employees of industry is considered to be promotional in nature and therefore ineligible to be accredited.

There are a number of programs and sessions in the program that are not accredited for CME. Please note that oral and poster abstracts are no longer included in the accredited programming.

The final list of non-CME sessions is subject to change. Accredited sessions will be labeled on the virtual platform, and an up-to-date list of sessions will also be available.

General Sessions
- Best of ASH
- Ernest Beutler Lecture and Prize
- Late-Breaking Abstracts Session
- Plenary Scientific Session

Special Interest Sessions
- AI and Machine Learning: A New Frontier in Hematology
- ASH Foundation Run/Walk
- ASH Health Equity Rounds Lunch
- Blood Advances Meet the Editors
- Blood Advances Presents: How to Peer Review a Scientific Paper
- Blood and Beyond
- Blood Presents: How to Get Published in a Peer Review Journal
- Disability Community Networking Breakfast
- Grassroots Network Lunch
- Hemostasis and Thrombosis Community Networking Reception
- LGBTQIA+ Community Networking Brunch
- Meet the Blood Editors
- Promoting Minorities in Hematology: Presentations and Reception
- Women in Hematology Networking Dinner

Spotlight Sessions
- Platelet Factor 4-Mediated Immunothrombosis: Insights from the Novel Syndrome of Vaccine-Induced Thrombosis and Thrombocytopenia (VITT)
- Sowing the Seeds of Leukemia Before Birth

Non-CME Programs
All sessions in the following programs are not accredited for CME credit:
- ASH Poster Walks
- ASH Wellness Studio
- ASH-a-Palooza
- ASH Health Equity Studio
- Company Showcases
- How I Treat: Bringing Science to Clinical Dilemmas
- Industry Theaters
- Meet the Scientist
- Oral and Poster Abstracts
- Product Theaters
- Scientific Program
- Scientific Symposia
- Scientific Workshops
- Trainee Activities and Services
Targeting MLLr with a covalent inhibitor

Covalency aims to achieve

- Higher Selectivity
- Deeper Target Engagement
- Greater Therapeutic Window

Biomea Fusion is developing an investigational, oral, covalent menin inhibitor (BMF-219) specifically designed for patients with mixed lineage leukemia harboring rearrangements (MLLr). We are a biopharmaceutical company focused on discovering and developing covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. **Visit us at Booth 3342**

To learn more about Biomea Fusion’s covalent menin inhibitor (BMF-219) clinical trials, contact us at 1-844-245-0490, clinicaltrials@biomeafusion.com or visit clinicaltrials.gov.
MEETING SCHEDULE
All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

**THURSDAY, DECEMBER 8, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 p.m. – 7:00 p.m.</td>
<td>Registration (for in-person participants)</td>
</tr>
<tr>
<td></td>
<td>Great Hall Pre-Function</td>
</tr>
<tr>
<td>3:00 p.m. – 7:00 p.m.</td>
<td>ASH COVID-19 Testing Centers (for in-person participants)</td>
</tr>
<tr>
<td></td>
<td>228-230 (Convention Center)</td>
</tr>
<tr>
<td></td>
<td>Hilton New Orleans Riverside, Eglington Winton</td>
</tr>
</tbody>
</table>

**FRIDAY, DECEMBER 9, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m. – 6:00 p.m.</td>
<td>Registration (for in-person participants)</td>
</tr>
<tr>
<td></td>
<td>Great Hall Pre-Function</td>
</tr>
<tr>
<td>7:00 a.m. – 6:00 p.m.</td>
<td>ASH COVID-19 Testing Centers (for in-person participants)</td>
</tr>
<tr>
<td></td>
<td>228-230 (Convention Center)</td>
</tr>
<tr>
<td></td>
<td>Hilton New Orleans Riverside, Eglington Winton</td>
</tr>
<tr>
<td>7:00 a.m. – 10:00 a.m.</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td></td>
<td>A Thread to Pull: Unraveling the Complexities of Myeloid Malignancies</td>
</tr>
<tr>
<td></td>
<td>VIRTUAL PROGRAM</td>
</tr>
<tr>
<td></td>
<td>Acute Myeloid Leukemia: Reviewing Current Best Practice and Exploring</td>
</tr>
<tr>
<td></td>
<td>Novel Paradigms Ahead</td>
</tr>
<tr>
<td></td>
<td>Hyatt Regency New Orleans, Celestin EFGH</td>
</tr>
<tr>
<td></td>
<td>Application of the Latest Data in CLL/SLLL: Guidance for Current</td>
</tr>
<tr>
<td></td>
<td>Future Treatment Strategies</td>
</tr>
<tr>
<td></td>
<td>Hyatt Regency New Orleans, Elite B</td>
</tr>
<tr>
<td></td>
<td>Demystifying Cold Agglutinin Disease: A Visual Exploration of</td>
</tr>
<tr>
<td></td>
<td>Mechanism, Diagnosis, and the Role of Complement Inhibition in</td>
</tr>
<tr>
<td></td>
<td>Addressing Unmet Needs</td>
</tr>
<tr>
<td></td>
<td>Sheraton New Orleans, Grand Ballroom A/B</td>
</tr>
<tr>
<td></td>
<td>Fixing the Target on Aggressive Lymphoma: Insights on the Next</td>
</tr>
<tr>
<td></td>
<td>Phase of Integrating Targeted Agents into MCL and DLBCL Management</td>
</tr>
<tr>
<td></td>
<td>Hyatt Regency New Orleans, Empire CD</td>
</tr>
<tr>
<td></td>
<td>Maintaining ‘Intensity’ for Better Outcomes in AML: Guidance on</td>
</tr>
<tr>
<td></td>
<td>Modern, Intensive Upfront Platforms in Challenging Patient</td>
</tr>
<tr>
<td></td>
<td>Populations</td>
</tr>
<tr>
<td></td>
<td>Sheraton New Orleans, Napoleon B 1-3 + Corridor A/B</td>
</tr>
<tr>
<td>9:00 a.m. – 11:00 a.m.</td>
<td>2022 World Cup Soccer Viewing (outside)</td>
</tr>
<tr>
<td></td>
<td>ASH Park @ the Plaza 2</td>
</tr>
</tbody>
</table>
## Day-At-A-Glance

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 9:00 a.m. – 12:00 p.m. | **Training Program Directors Workshop**  
Marriott New Orleans Warehouse Arts District, Cypress |                                               |
| 11:00 a.m. – 2:00 p.m.  | **Satellite Symposia**  
A Conversation With the Myeloma Experts: Making Sense of the Evolving Treatment Landscape  
Hyatt Regency New Orleans, Elite B  
Acute Lymphoblastic Leukemia Data and Case Discussion on the Use of Asparaginase Therapy in Young and Older Adults  
Sheraton New Orleans, Napoleon C 1-3 + Corridor C/D  
Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia - What Clinicians Want to Know (Part 1 of a 3-part CME-accredited Symposia Series)  
Hyatt Regency New Orleans, Celestin ABCD  
Advances in the Treatment of T-Cell Lymphomas: A Forum for Data and Case Discussion  
Sheraton New Orleans, Rhythms Ballroom  
Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias  
243-245  
An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches  
Sheraton New Orleans, Napoleon B 1-3 + Corridor A/B  
VIRTUAL PROGRAM  
Complement Clinical Cases: Navigating Care for Patients with aHUS, PNH, and HSCT-TMA  
Hyatt Regency New Orleans, Empire B  
Elevating Equity in Caring For Patients With Hematologic Malignancies  
Hyatt Regency New Orleans, Celestin EFGH  
Expert Illustrations & Commentaries™️: Visualizing New Treatment Pathways for Anemia in Chronic Kidney Disease  
217-219  
Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/Refractory Disease?  
Great Hall B/C  
Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care with Groundbreaking Treatment  
Hyatt Regency New Orleans, Empire A  
How We Do It™️: Application of State-of-the-Art MF and PV Care Today... With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow  
Sheraton New Orleans, Grand Ballroom DE  
Medical Crossfire™️: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult  
La Nouvelle Orleans Ballroom C  
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes  
343-345 |
| 12:30 p.m. – 5:00 p.m. | **ASH-a-Palooza (Open to Trainees Only)**  
Mardi Gras World, River City Ballroom  
ASH Talk Opening Song and Welcome  
ASH Talk #1: Learning in a Virtual Space: How trainees can capitalize social media and virtual tools  
ASH Talk #2: The Resilient Trainee  
Blood Drops  
Blood Buddies |
| 12:30 p.m. – 1:00 p.m. | **ASH-a-Palooza (Open to Trainees Only)**  
Mardi Gras World, River City Ballroom  
ASH Talk Opening Song and Welcome |
| 1:00 p.m. – 1:20 p.m. | **ASH-a-Palooza (Open to Trainees Only)**  
Mardi Gras World, River City Ballroom  
ASH Talk #1: Learning in a Virtual Space: How trainees can capitalize social media and virtual tools |
| 1:00 p.m. – 3:00 p.m. | **2022 World Cup Soccer Viewing (outside)**  
ASH Park @ the Plaza 2 |
| 1:30 p.m. – 1:40 p.m. | **ASH-a-Palooza (Open to Trainees Only)**  
Mardi Gras World, River City Ballroom |
| 1:30 p.m. – 2:00 p.m. | **ASH-a-Palooza (Open to Trainees Only)**  
Mardi Gras World, River City Ballroom |
| 1:50 p.m. – 2:00 p.m. | **ASH-a-Palooza (Open to Trainees Only)**  
Mardi Gras World, River City Ballroom |
All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

2:00 p.m. – 5:00 p.m.  **Scientific Workshops**

<table>
<thead>
<tr>
<th>Workshop</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Workshop on Advancing Decentralized Clinical Trials in Hematology</td>
<td>Sheraton New Orleans, Napoleon B 1-3 + Corridor A/B</td>
</tr>
<tr>
<td>Scientific Workshop on Bedside to Bench: Dissecting Emergent CAR T-cell Toxicities beyond CRS and ICANS</td>
<td>Hyatt Regency New Orleans, Elite B</td>
</tr>
<tr>
<td>Scientific Workshop on Gene Editing in Hematology: Here to Stay</td>
<td>La Nouvelle Orleans Ballroom C</td>
</tr>
<tr>
<td>Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure</td>
<td>Hyatt Regency New Orleans, Empire A</td>
</tr>
<tr>
<td>Scientific Workshop on Hematology and Aging</td>
<td>Sheraton New Orleans, Grand Ballroom C</td>
</tr>
<tr>
<td>Scientific Workshop on Interplay between Coagulation and Malignancy</td>
<td>Hyatt Regency New Orleans, Empire CD</td>
</tr>
<tr>
<td>Scientific Workshop on Leveraging Digital Technology to Modernize and Enhance Observational Studies</td>
<td>Let’s Talk: Community Perspectives on Acute Myeloid Leukemia and Myelodysplastic Syndrome</td>
</tr>
<tr>
<td>Scientific Workshop on Myeloid Development</td>
<td>Hyatt Regency New Orleans, Celestin EFGH</td>
</tr>
<tr>
<td>Scientific Workshop on Thrombotic Microangiopathies</td>
<td>Medical Crossfire®: Maximizing Our Clinical Practices for Hodgkin Lymphoma: Integration of Recent Data Sets in Real Word Settings</td>
</tr>
<tr>
<td>Scientific Workshop on Translational Molecular Diagnostics: Genomic Reclassification of Blood Cancer</td>
<td>Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy</td>
</tr>
</tbody>
</table>

2:10 p.m. – 3:10 p.m.  **ASH-a-Palooza (Open to Trainees Only)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASH Talk #2: The Resilient Trainee</td>
<td>Mardi Gras World, River City Ballroom</td>
</tr>
<tr>
<td>ASH-a-Palooza (Open to Trainees Only)</td>
<td>Mardi Gras World, River City Ballroom</td>
</tr>
<tr>
<td>ASH-a-Palooza (Open to Trainees Only)</td>
<td>Mardi Gras World, River City Ballroom</td>
</tr>
<tr>
<td>ASH-a-Palooza (Open to Trainees Only)</td>
<td>Mardi Gras World, River City Ballroom</td>
</tr>
</tbody>
</table>

3:00 p.m. – 6:00 p.m.  **Satellite Symposia**

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Light at the End of the Treatment Tunnel – Exploring the Potential Role for Gene Therapy in Hemophilia B</td>
<td>Sheraton New Orleans, Rhythms Ballroom</td>
</tr>
<tr>
<td>A Review of Next-Generation Therapeutics and Contemporary Management of Myelofibrosis</td>
<td>Sheraton New Orleans, Celestin ABCD</td>
</tr>
</tbody>
</table>

4:35 p.m. – 5:00 p.m.  **ASH-a-Palooza (Open to Trainees Only)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Let’s Talk: Community Perspectives on Acute Myeloid Leukemia and Myelodysplastic Syndrome</td>
<td>Hyatt Regency New Orleans, Celestin EFGH</td>
</tr>
<tr>
<td>Medical Crossfire®: Maximizing Our Clinical Practices for Hodgkin Lymphoma: Integration of Recent Data Sets in Real Word Settings</td>
<td>Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy</td>
</tr>
<tr>
<td>The Future is Now in MDS: Guidance on Integrating Innovative, Risk-Adapted Therapeutic Options into Patient Management</td>
<td>Navigating New Terrain in Chemotherapy-Induced Anemia: Hem/Onc Perspectives and Evidence-Supported Strategies for Improving Care with Intravenous Iron</td>
</tr>
</tbody>
</table>

5:00 p.m. – 7:00 p.m.  **Trainee Welcome Reception**

<table>
<thead>
<tr>
<th>Reception</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trainee Welcome Reception</td>
<td>Mardi Gras World, Float Den</td>
</tr>
</tbody>
</table>

Day-At-A-Glance  ---  43
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 p.m. – 10:00 p.m.</td>
<td>Satellite Symposia \nAddressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know (Part 3 of a 3-part CME-accredited Symposia Series) \nHyatt Regency New Orleans, Celestin ABCD</td>
</tr>
<tr>
<td><strong>SATURDAY, DECEMBER 10, 2022</strong></td>
<td></td>
</tr>
<tr>
<td>7:00 a.m. – 6:00 p.m.</td>
<td>Registration (for in-person participants) \nGreat Hall Pre-Function</td>
</tr>
<tr>
<td>7:00 a.m. – 6:00 p.m.</td>
<td>ASH COVID-19 Testing Centers (for in-person participants) \n228-230 (Convention Center) \nEglington Winton, Hilton New Orleans Riverside</td>
</tr>
<tr>
<td>7:00 a.m. – 7:45 a.m.</td>
<td>ASH Wellness Studio \nASH Yoga (for in-person participants) \nASH Park @ the Plaza 1</td>
</tr>
<tr>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>Meet the Experts (Ticketed Sessions) (for in-person participants)</td>
</tr>
<tr>
<td>8:30 a.m. – 9:30 a.m.</td>
<td>How I Treat: Bringing Science to Clinical Dilemmas (Ticketed Sessions) \nCan We Move Toward a Precision Medicine Approach for the Treatment of Higher Risk Myelodysplastic Syndromes \nHilton New Orleans Riverside, Marlborough A \nITP/TTP – and Other Scary Causes of Thrombocytopenia - Saturday \nHilton New Orleans Riverside, Camp \nSickle Cell Disease – Where do Gene Therapy and Hematopoietic Cell Transplantation Fit into the Future Landscape \nHilton New Orleans Riverside, Commerce \nThe Case for MRD Testing and the Relevance to Treatment Decisions and Outcomes in AML \nHilton New Orleans Riverside, Canal</td>
</tr>
<tr>
<td>9:00 a.m. – 9:30 a.m.</td>
<td>Health Equity Studio \nDefining Inequity and Root Causes of Health Inequity \nHall F</td>
</tr>
<tr>
<td>9:00 a.m. – 11:00 a.m.</td>
<td>2022 World Cup Soccer Viewing (outside) \nASH Park @ the Plaza 2</td>
</tr>
<tr>
<td>9:05 a.m. – 9:15 a.m.</td>
<td>ASH Wellness Studio \nBringing Joy to Your World \nHall F</td>
</tr>
<tr>
<td>9:15 a.m. – 9:25 a.m.</td>
<td>ASH Wellness Studio \nBreathe Well to Feel Well \nHall F</td>
</tr>
<tr>
<td>9:30 a.m. – 10:45 a.m.</td>
<td>Education Sessions \nAutoimmune Hemolytic Anemias (AIHA) \n291-292 \nControversies in Aggressive NHL \nHall E \nJAK/STAT Inhibition and Beyond in Ph Negative MPNs \n293-294 \nMultiple Myeloma: Assessing the Patient and the Disease \nGreat Hall A/D</td>
</tr>
<tr>
<td>9:30 a.m. – 10:45 a.m.</td>
<td>Scientific Sessions \nAplastic Anemia, Dysimmunity, and Mutant Clones (Scientific Committee on Bone Marrow Failure) \n288-290 \nEmerging Technologies in Hemostasis (Scientific Committee on Hemostasis) \n265-268</td>
</tr>
<tr>
<td>9:30 a.m. – 11:00 a.m.</td>
<td>Oral Abstract Sessions \n114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Novel Therapies \n391-392 \n201. Granulocytes, Monocytes, and Macrophages II \n295-296</td>
</tr>
</tbody>
</table>
All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Special Populations and Long-term Outcomes in ITP 275-277

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Practice-changing Information from Datasets and Registries on Bleeding Disorders 271-273

401. Blood Transfusion: Molecular Mechanisms and Novel Therapies 393-396

602. Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies 353-355


612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Management of Novel ALL Subsets in Different Age Groups 243-245

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication for Patients with Acute Myeloid Leukemia 208-210


622. Lymphomas: Translational–Non-Genetic: Tumor Microenvironment in Lymphoid Malignancies: Composition, Biology, and Prognostic Significance New Orleans Theater C

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological I La Nouvelle Orleans Ballroom C

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Agents 217-219

636. Myelodysplastic Syndromes—Basic and Translational: Clonal Trajectories and Novel Therapies 260-262

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations La Nouvelle Orleans Ballroom AB

801. Gene Therapies: Addressing Challenges & Opportunities in Pre-clinical Settings Great Hall B/C

903. Health Services and Quality—Myeloid Malignancies I 388-390

11:00 a.m. – 12:30 p.m. Open Time for Lunch

11:00 a.m. – 12:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants) ASH Park at the Plaza 3

11:00 a.m. – 5:00 p.m. Exhibits Open Hall G-J

11:05 a.m. – 11:15 a.m. ASH Wellness Studio Money Issues are Burning You Out Hall F

11:15 a.m. – 11:45 a.m. Health Equity Studio Recognizing and Addressing Implicit Bias Hall F

11:15 a.m. – 12:15 p.m. Blood Presents: How to Get Published in a Peer Review Journal 252-254

11:15 a.m. – 12:15 p.m. Blood Presents: How to Get Published in a Peer Review Journal Hilton New Orleans Riverside, St. Charles Ballroom

11:15 a.m. – 12:15 p.m. Career Development Lunch (Open to Trainees Only) Hilton New Orleans Riverside, St. James Ballroom

11:20 a.m. – 11:30 a.m. ASH Wellness Studio One Breath to the Most Kind, Compassionate, and Grateful You! Hall F

11:30 a.m. – 12:30 p.m. Industry Theaters Emerging AstraZeneca Hematology Pipeline (for in-person participants) Hall J - Theater 5

Investigating the Biological Mechanisms of HR-MDS: Role of the Immune System During Disease (for in-person participants) Hall J - Theater 3

Pfizer Oncology: Pursuing Scientific Breakthroughs for Patients With Hematologic Malignancies (for in-person participants) Hall J - Theater 7
All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>Product Theaters</td>
</tr>
<tr>
<td>Are Higher Factor Levels a Rising Consideration When Selecting a Hemophilia Treatment? (for in-person participants)</td>
<td>Hall J - Theater 6</td>
</tr>
<tr>
<td>Data Worth Stopping For: New 5-year Follow-Up Data for an Oral-Based CLL Regimen with a Fixed Treatment Duration (for in-person participants)</td>
<td>Hall J - Theater 1</td>
</tr>
<tr>
<td>Evolving Treatment Expectations in PNH (for in-person participants)</td>
<td>Hall J - Theater 2</td>
</tr>
<tr>
<td>Treatment Options in Relapsed/Refractory Multiple Myeloma: Clinical Studies and Patient Cases (for in-person participants)</td>
<td>Hall J - Theater 4</td>
</tr>
<tr>
<td>11:35 a.m. – 11:45 a.m.</td>
<td>ASH Wellness Studio</td>
</tr>
<tr>
<td>Fix the Way You Sit</td>
<td>Hall F</td>
</tr>
<tr>
<td>12:00 p.m. – 1:30 p.m.</td>
<td>Oral Abstract Sessions</td>
</tr>
<tr>
<td>332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Controversies in Anticoagulation and Venous Thromboembolism</td>
<td>Great Hall B/C</td>
</tr>
<tr>
<td>605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting Transcription, Translation, and Epigenetics</td>
<td>288-290</td>
</tr>
<tr>
<td>653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma</td>
<td>R02-R05</td>
</tr>
<tr>
<td>704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Lymphoma</td>
<td>La Nouvelle Orleans Ballroom AB</td>
</tr>
<tr>
<td>905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in Plasma Cell Disorders and Transplant</td>
<td>243-245</td>
</tr>
<tr>
<td>12:30 p.m. – 1:30 p.m.</td>
<td>Ham-Wasserman Lecture: Leukemogenesis in Infants and Young Children with Trisomy 21</td>
</tr>
<tr>
<td>1:00 p.m. – 3:00 p.m.</td>
<td>2022 World Cup Soccer Viewing (outside)</td>
</tr>
<tr>
<td>1:30 p.m. – 2:00 p.m.</td>
<td>Health Equity Studio</td>
</tr>
<tr>
<td>Strategies to Overcome Healthcare Disparities</td>
<td>Hall F</td>
</tr>
<tr>
<td>1:30 p.m. – 1:45 p.m.</td>
<td>Company Showcases</td>
</tr>
<tr>
<td>Powering Better Decisions: A Comprehensive Hematopathology Analysis Case Study</td>
<td>Hall J - Theater 6</td>
</tr>
<tr>
<td>1:30 p.m. – 2:00 p.m.</td>
<td>Coffee Break in Exhibit Hall (for in-person participants)</td>
</tr>
<tr>
<td>1:35 p.m. – 1:45 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>A Simple Way to More Resilience</td>
<td>Hall F</td>
</tr>
<tr>
<td>1:45 p.m. – 1:55 p.m.</td>
<td>ASH Wellness Studio</td>
</tr>
<tr>
<td>Financial Order of Operations</td>
<td>Hall F</td>
</tr>
<tr>
<td>2:00 p.m. – 3:00 p.m.</td>
<td>Blood Advances Meet the Editors (for in-person participants)</td>
</tr>
<tr>
<td>Marriott New Orleans Warehouse Arts District, Julia</td>
<td></td>
</tr>
<tr>
<td>2:00 p.m. – 3:15 p.m.</td>
<td>Education Sessions</td>
</tr>
<tr>
<td>Late Effects of Curative Therapy for Sickle Cell Disease</td>
<td>Hall E</td>
</tr>
<tr>
<td>Prophylactic Platelet Transfusions</td>
<td>243-245</td>
</tr>
<tr>
<td>Thrombosis and Anticoagulation: Clinical Considerations in Selected Populations</td>
<td>Great Hall A/D</td>
</tr>
<tr>
<td>Von Willebrand Disease</td>
<td>208-210</td>
</tr>
<tr>
<td>Where Are We Headed in Hodgkin Lymphoma?</td>
<td>New Orleans Theater AB</td>
</tr>
<tr>
<td>2:00 p.m. – 3:15 p.m.</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>Overcoming T-cell Burnout and Exhaustion (Scientific Committee on Immunology and Host Defense)</td>
<td>271-273</td>
</tr>
<tr>
<td>2:00 p.m. – 3:15 p.m.</td>
<td>Scientific Symposia</td>
</tr>
<tr>
<td>Biology and Translation of NK Cells</td>
<td>293-294</td>
</tr>
<tr>
<td>Genetic and Functional Heterogeneity in Megakaryocytes and Platelets</td>
<td>252-254</td>
</tr>
</tbody>
</table>
2:00 p.m. – 3:30 p.m. Special Symposium on Quality: Quality Improvement Education and Training

295-296

2:00 p.m. – 3:30 p.m. Oral Abstract Sessions

113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Cognitive Deficit, Pain, and Inflammation in Sickle Cell Disease: What We Learned from Mouse Models

275-277

114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Hydroxyurea Treatment

278-282

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Looking Forward: Novel Therapies and Diagnostic Modalities for Bleeding Disorders

288-290

508. Bone Marrow Failure: Acquired: Biology

260-262

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Targeted Protein Degradation and Emerging Small Molecule Inhibitors in Myeloid Neoplasms

343-345

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting BH3, BTK, and CDK

388-390

614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Clinical Trials

265-268

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: New Approaches to Combination Chemotherapy and Venetoclax Plus Hypomethylating Agent Therapy in AML

Great Hall B/C

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Lesions and Therapeutic Implications

291-292

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III

New Orleans Theater C

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Latest Data for Combination and Emerging Targeted Therapies in Myelofibrosis

217-219

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational

R06-R09

652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (R姚M) R02-R05

703. Cellular Immunotherapies: Basic and Translational I

La Nouvelle Orleans Ballroom C

705. Cellular Immunotherapies: Novel Predictors of Response or Toxicity to Cellular Therapies

La Nouvelle Orleans Ballroom AB

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Real World Studies Based on Database Analyses

391-392

802. Chemical Biology and Experimental Therapeutics I

353-355

906. Outcomes Research—Myeloid Malignancies II

220-222

3:30 p.m. – 3:45 p.m. Company Showcases

Ultra-low Frequency Variant Detection in AML with Duplex Sequencing Technology
(for in-person participants)

Hall J - Theater 6

3:30 p.m. – 4:00 p.m. Health Equity Studio

Overcoming Lack of Diversity in Clinical Trials

Hall F

3:30 p.m. – 4:00 p.m. Coffee Break in Exhibit Hall (for in-person participants)

Hall G-J

3:35 p.m. – 3:45 p.m. ASH Wellness Studio

Workday Tension Timeout

Hall F

3:45 p.m. – 3:55 p.m. ASH Wellness Studio

Use Your Character Strengths to Get Through Trying Times

Hall F

4:00 p.m. – 5:15 p.m. Education Sessions

Anxiety Provoking Consultations: Mast Cells and Eosinophils

295-296

Are Alternative Donors Now Mainstream in Allogeneic Transplant?

Great Hall B/C

Immunotherapy in Multiple Myeloma

Hall E

Managing Thrombocytopenia in Challenging Situations

243-245

Novel Approaches in MDS

288-290

Update in Hemophilia

291-292

4:00 p.m. – 5:30 p.m. Special Interest Session on Sickle Cell Disease Centers: Ensuring Appropriate Care Across the Patient Lifespan

La Nouvelle Orleans Ballroom AB
<table>
<thead>
<tr>
<th>4:00 p.m. – 5:30 p.m.</th>
<th>Oral Abstract Sessions</th>
</tr>
</thead>
<tbody>
<tr>
<td>101. Red Cells and Erythropoiesis, Excluding Iron I</td>
<td>391-392</td>
</tr>
<tr>
<td>508. Bone Marrow Failure: Acquired: Clinical Studies</td>
<td>260-262</td>
</tr>
<tr>
<td>602. Myeloid Oncogenesis: Basic: Chromatin Organization and Metabolism</td>
<td>293-294</td>
</tr>
<tr>
<td>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Molecular Features and Response to Treatment in AML</td>
<td>388-390</td>
</tr>
<tr>
<td>618. Myelomas: Translational—Molecular and Genetic: Single Cell, Microenvironment, and Treatment Resistance</td>
<td></td>
</tr>
<tr>
<td>La Nouvelle Orleans Ballroom C</td>
<td></td>
</tr>
<tr>
<td>624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Advanced Stage and Relapsed Hodgkin Lymphoma</td>
<td>278-282</td>
</tr>
<tr>
<td>627. Aggressive Lymphomas: Clinical and Epidemiological: Prognostication and Risk Stratification of Aggressive B-cell NHL</td>
<td></td>
</tr>
<tr>
<td>New Orleans Theater AB</td>
<td></td>
</tr>
<tr>
<td>631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Identification of Novel Therapeutic Targets in MPN and CML</td>
<td>275-277</td>
</tr>
<tr>
<td>632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Molecular Predictors and Advanced Phase Disease</td>
<td>265-268</td>
</tr>
<tr>
<td>634. Myeloproliferative Syndromes: Clinical and Epidemiological: Avantgarde and Traditional Prognostic and Response Assessment in MPNs</td>
<td>217-219</td>
</tr>
<tr>
<td>642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Triplet Combinations and Richter’s Transformation</td>
<td>R06-R09</td>
</tr>
<tr>
<td>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational</td>
<td></td>
</tr>
<tr>
<td>New Orleans Theater C</td>
<td></td>
</tr>
<tr>
<td>703. Cellular Immunotherapies: Basic and Translational II</td>
<td>393-396</td>
</tr>
<tr>
<td>704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT</td>
<td></td>
</tr>
<tr>
<td>Great Hall A/D</td>
<td></td>
</tr>
<tr>
<td>721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities III</td>
<td>343-345</td>
</tr>
<tr>
<td>723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence II</td>
<td>353-355</td>
</tr>
<tr>
<td>905. Outcomes Research—Lymphoid Malignancies: Patient Representation and Equity in Hematologic Malignancies</td>
<td>208-210</td>
</tr>
<tr>
<td>906. Outcomes Research—Myeloid Malignancies I</td>
<td>220-222</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4:00 p.m. – 5:53 p.m.</th>
<th>Scientific Sessions</th>
</tr>
</thead>
<tbody>
<tr>
<td>JOINT Session: New Tools to Optimize Platelet Transfusion Therapy (Scientific Committee on Megakaryocytes and Platelets &amp; Scientific Committee on Transfusion Medicine)</td>
<td>252-254</td>
</tr>
<tr>
<td>JOINT Session: Seed and Soil: The Role of Inflammation in Myeloid Malignancies (Scientific Committee on Myeloid Biology &amp; Scientific Committee on Myeloid Neoplasia)</td>
<td>R02-R05</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5:30 p.m. – 7:30 p.m.</th>
<th>Welcome Reception in Poster Hall (for in-person participants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hall D</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5:30 p.m. – 7:30 p.m.</th>
<th>Poster Session I – Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>101. Red Cells and Erythropoiesis, Excluding Iron: Poster I (1003–1017)</td>
<td></td>
</tr>
<tr>
<td>102. Iron Homeostasis and Biology: Poster I (1018–1028)</td>
<td></td>
</tr>
<tr>
<td>112. Thalassemia and Globin Gene Regulation: Poster I (1029–1036)</td>
<td></td>
</tr>
<tr>
<td>113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster I (1037–1054)</td>
<td></td>
</tr>
<tr>
<td>201. Granulocytes, Monocytes, and Macrophages: Poster I (1084–1098)</td>
<td></td>
</tr>
<tr>
<td>203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1099–1107)</td>
<td></td>
</tr>
<tr>
<td>301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I (1109–1126)</td>
<td></td>
</tr>
<tr>
<td>311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1127–1138)</td>
<td></td>
</tr>
<tr>
<td>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I (1147–1171)</td>
<td></td>
</tr>
<tr>
<td>501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1209–1221)</td>
<td></td>
</tr>
<tr>
<td>503. Clonal Hematopoiesis, Aging and Inflammation: Poster I (1222–1233)</td>
<td></td>
</tr>
<tr>
<td>506. Bone Marrow Microenvironment: Poster I (1234–1244)</td>
<td></td>
</tr>
<tr>
<td>508. Bone Marrow Failure: Acquired: Poster I (1245–1257)</td>
<td></td>
</tr>
<tr>
<td>509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1258–1266)</td>
<td></td>
</tr>
<tr>
<td>602. Myeloid Oncogenesis: Basic: Poster I (1267–1299)</td>
<td></td>
</tr>
<tr>
<td>603. Lymphoid Oncogenesis: Basic: Poster I (1300–1314)</td>
<td></td>
</tr>
<tr>
<td>612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I (1367–1380)</td>
<td></td>
</tr>
</tbody>
</table>
All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I (1381–1408)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Hilton New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1409–1419)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1420–1439)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1440–1460)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1461–1500)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1501–1516)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>621. Lymphomas: Translational—Molecular and Genetic: Poster I (1517–1543)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>622. Lymphomas: Translational—Non-Genetic: Poster I (1544–1562)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I (1563–1590)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I (1591–1617)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>625. Chronic Lymphocytic Leukemias: Basic and Translational: Poster I (1674–1700)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>626. Chronic Lymphocytic Leukemias: Clinical and Epidemiological: Poster I (1689–1708)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>627. Chronic Lymphocytic Leukemias: Basic and Translational: Poster I (1700–1709)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>628. Chronic Lymphocytic Leukemias: Clinical and Epidemiological: Poster I (1710–1716)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>629. Chronic Lymphocytic Leukemias: Basic and Translational: Poster I (1741–1754)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>630. Chronic Lymphocytic Leukemias: Clinical and Epidemiological: Poster I (1775–1783)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I (1673–1688)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>632. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I (1689–1708)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>633. Myeloproliferative Syndromes—Basic and Translational: Poster I (1700–1740)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>634. Myelodysplastic Syndromes—Basic and Translational: Poster I (1784–1796)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>635. Myelodysplastic Syndromes—Clinical and Translational: Poster I (1797–1817)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>636. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I (1818–1855)</td>
<td>7:00 a.m. – 5:00 p.m.</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
</tbody>
</table>

**SUNDAY, DECEMBER 11, 2022**

- **7:00 a.m. – 5:00 p.m.** Registration (for in-person participants)
  
- **7:00 a.m. – 5:00 p.m.** ASH COVID-19 Testing Centers (for in-person participants)

**Day-At-A-Glance**

**Hilton New Orleans Riverside, The District Foyer**
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>8:00 a.m. – 9:00 a.m.</strong></td>
<td><strong>Industry Theaters</strong></td>
<td>Gene Therapy for the Hemoglobinopathies: Translating Complex Science to Inform the Physician-Patient Dialogue (for in-person participants) Hall J - Theater 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sanofi Hematology Clinical Pipeline</td>
</tr>
<tr>
<td><strong>8:00 a.m. – 9:00 a.m.</strong></td>
<td><strong>Product Theaters</strong></td>
<td>A Treatment Option for Patients with Myelodysplastic Syndromes (for in-person participants) Hall J - Theater 7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussion on the Treatment of Sickle Cell Disease, Moving Beyond Pain as a Primary Target (for in-person participants) Hall J - Theater 4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gene Therapy for Hemophilia B: A look into new advancements (for in-person participants) Hall J - Theater 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pivotal Phase 3 data in Newly Diagnosed AML: Exploring the Efficacy, Safety, and Patient Management of Evolving AML Treatment Paradigms (for in-person participants) Hall J - Theater 6</td>
</tr>
<tr>
<td><strong>8:00 a.m. – 9:00 a.m.</strong></td>
<td><strong>Meet the Experts (Ticketed Sessions)</strong> (for in-person participants)</td>
<td></td>
</tr>
<tr>
<td><strong>8:00 a.m. – 9:00 a.m.</strong></td>
<td><strong>Coffee and Collaboration in ASH Central</strong> (for in-person participants)</td>
<td>Hall F</td>
</tr>
<tr>
<td><strong>8:30 a.m. – 9:30 a.m.</strong></td>
<td><strong>How I Treat: Bringing Science to Clinical Dilemmas (Ticketed Sessions)</strong> (for in-person participants)</td>
<td>Thrombosis and Anticoagulation – Duration of Therapy, Thrombophilia - Sunday Hilton New Orleans Riverside, Marlborough A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Too Many Mast Cells and Eosinophils – How to Exclude (or Treat) Neoplastic Causes. Hilton New Orleans Riverside, Camp</td>
</tr>
<tr>
<td></td>
<td></td>
<td>vWD and Other Bleeding Disorders – Diagnostic Pitsfalls and Special Situations Hilton New Orleans Riverside, Canal</td>
</tr>
<tr>
<td><strong>9:00 a.m. – 8:00 p.m.</strong></td>
<td><strong>Poster Session II - Viewing</strong></td>
<td></td>
</tr>
<tr>
<td><strong>9:00 a.m. – 9:30 a.m.</strong></td>
<td><strong>Coffee Break in Poster Hall</strong> (for in-person participants)</td>
<td>Hall D</td>
</tr>
<tr>
<td><strong>9:00 a.m. – 9:30 a.m.</strong></td>
<td><strong>Health Equity Studio</strong></td>
<td>Overcoming Disparities in Career Development Hall F</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Build a Bigger Brain and Longer Life Hall F</td>
</tr>
<tr>
<td><strong>9:15 a.m. – 9:25 a.m.</strong></td>
<td><strong>ASH Wellness Studio</strong></td>
<td>Use Your Character Strengths to Get Through Trying Times Hall F</td>
</tr>
<tr>
<td><strong>9:30 a.m. – 10:45 a.m.</strong></td>
<td><strong>Education Sessions</strong></td>
<td>Acute Myeloid Leukemia: Improving Outcomes in Challenging Subsets Great Hall B/C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maximizing Outcomes in CLL 265-268</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reproductive and Sexual Health in Sickle Cell Disease R06-R09</td>
</tr>
<tr>
<td><strong>9:30 a.m. – 11:00 a.m.</strong></td>
<td><strong>ASH Guideline Implementation Champions</strong></td>
<td></td>
</tr>
<tr>
<td><strong>9:30 a.m. – 11:00 a.m.</strong></td>
<td><strong>Oral Abstract Sessions</strong></td>
<td>113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Targeting the Red Blood Cell: Novel Therapeutic Approaches in Sickle Cell Disease 343-345</td>
</tr>
<tr>
<td></td>
<td></td>
<td>321. Coagulation and Fibrinolysis: Basic and Translational 293-294</td>
</tr>
<tr>
<td></td>
<td></td>
<td>503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Animal Models 271-273</td>
</tr>
<tr>
<td></td>
<td></td>
<td>509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Biology to Therapeutics 260-262</td>
</tr>
<tr>
<td></td>
<td></td>
<td>603. Lymphoid Oncogenesis: Basic: Mechanisms in Leukemogenesis 393-396</td>
</tr>
<tr>
<td></td>
<td></td>
<td>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Clinical Care and Observations in Acute Myeloid Leukemia 278-282</td>
</tr>
<tr>
<td></td>
<td></td>
<td>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Treatment-related Biomarkers Hall E</td>
</tr>
</tbody>
</table>
### Day-At-A-Glance

**All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 a.m. – 12:30 p.m.</td>
<td>Live Music and Outdoor Lunch Seating (for in-person participants)</td>
<td>ASH Park @ the Plaza 3</td>
</tr>
<tr>
<td>11:05 a.m. – 11:15 a.m.</td>
<td>ASH Wellness Studio</td>
<td>Hall F</td>
</tr>
<tr>
<td>11:15 a.m. – 11:45 a.m.</td>
<td>Health Equity Studio</td>
<td>Hall F</td>
</tr>
<tr>
<td>11:15 a.m. – 12:00 p.m.</td>
<td>Meet the Blood Editors (for in-person participants)</td>
<td>Marriott New Orleans Warehouse Arts District, Julia</td>
</tr>
<tr>
<td>11:15 a.m. – 12:15 p.m.</td>
<td>Trainee Didactic Sessions (Open to Trainees Only)</td>
<td>Marriott New Orleans Warehouse Arts District, Julia</td>
</tr>
<tr>
<td>11:15 a.m. – 12:15 p.m.</td>
<td>Meet the Blood Editors (for in-person participants)</td>
<td>Marriott New Orleans Warehouse Arts District, Gravier</td>
</tr>
<tr>
<td>11:15 a.m. – 12:15 p.m.</td>
<td>LGTBQIA+ Community Networking Brunch</td>
<td>Marriott New Orleans Warehouse Arts District, Gravier</td>
</tr>
<tr>
<td>11:15 a.m. – 12:30 p.m.</td>
<td>ASH Practice Partnership Lunch - A Return to the Classics: The Need for Classical Hematology</td>
<td>Hilton New Orleans Riverside, St. James Ballroom</td>
</tr>
<tr>
<td>11:20 a.m. – 11:30 a.m.</td>
<td>Feel Better in Your Body</td>
<td>ASH Wellness Studio</td>
</tr>
<tr>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>Industry Theaters</td>
<td>Hall J - Theater 5</td>
</tr>
<tr>
<td>11 Dec 2022 Sunday</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event Description</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>11:30 a.m. - 12:30 p.m.</td>
<td>Product Theaters</td>
<td>Hall J - Theater 4</td>
</tr>
<tr>
<td></td>
<td>Kite, The Leader in Cell Therapy: Leading the Way in Large B-Cell Lymphoma Care</td>
<td>Hall J - Theater 7</td>
</tr>
<tr>
<td></td>
<td>The Clinical Actionability of ClonoSEQ MRD Assessment in Lymphoid Malignancies</td>
<td>Hall J - Theater 1</td>
</tr>
<tr>
<td></td>
<td>Treatment Option in AML</td>
<td>Hall J - Theater 2</td>
</tr>
<tr>
<td></td>
<td>What’s Next for Patients with Relapsed or Refractory Multiple Myeloma after Multiple Lines of Therapy?</td>
<td>Hall J - Theater 6</td>
</tr>
<tr>
<td>11:30 a.m. - 12:30 p.m.</td>
<td>ASH Health Equity Rounds Lunch</td>
<td>Marriott New Orleans Warehouse Arts District, Cypress</td>
</tr>
<tr>
<td>11:35 a.m. - 11:45 a.m.</td>
<td>ASH Wellness Studio</td>
<td>Hall F</td>
</tr>
<tr>
<td>12:00 p.m. - 1:30 p.m.</td>
<td>Oral Abstract Sessions</td>
<td>Hall E</td>
</tr>
<tr>
<td></td>
<td>506. Bone Marrow Microenvironment: Contribution of Immune Signaling to the Microenvironment</td>
<td>Hall E</td>
</tr>
<tr>
<td></td>
<td>602. Myeloid Oncogenesis: Basic: Epigenetics and Transcriptional Regulation</td>
<td>Hall E</td>
</tr>
<tr>
<td></td>
<td>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Long-term Outcomes in Clinically Defined Subgroups of Patients with Acute Myeloid Leukemia</td>
<td>Hall E</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 p.m. - 2:00 p.m.</td>
<td>Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award</td>
<td>Hall E</td>
</tr>
<tr>
<td>2:00 p.m. - 4:00 p.m.</td>
<td>Plenary Scientific Session</td>
<td>Hall E</td>
</tr>
<tr>
<td>4:00 p.m. - 4:15 p.m.</td>
<td>Company Showcases</td>
<td>Hall G-J</td>
</tr>
<tr>
<td>4:05 p.m. - 4:15 p.m.</td>
<td>ASH Wellness Studio</td>
<td>Hall F</td>
</tr>
</tbody>
</table>

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.
**Day-At-A-Glance**

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

<table>
<thead>
<tr>
<th>Time</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:15 p.m. – 4:25 p.m.</td>
<td>ASH Wellness Studio</td>
</tr>
<tr>
<td></td>
<td>Fix the Way You Sit</td>
</tr>
<tr>
<td></td>
<td>Hall F</td>
</tr>
<tr>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>Education Sessions</td>
</tr>
<tr>
<td></td>
<td>Beyond Routine Frontline Therapy of CML</td>
</tr>
<tr>
<td></td>
<td>La Nouvelle Orleans Ballroom C</td>
</tr>
<tr>
<td></td>
<td>Obstetric Management and Complications in Sickle Cell Disease in High- and Low-Income Countries</td>
</tr>
<tr>
<td></td>
<td>243-245</td>
</tr>
<tr>
<td></td>
<td>What’s New in Indolent Lymphoma</td>
</tr>
<tr>
<td></td>
<td>Great Hall B/C</td>
</tr>
<tr>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td></td>
<td>New Therapeutic Targets for Thrombosis That Do Not Cause Bleeding (Scientific Committee on Thrombosis and Vascular Biology)</td>
</tr>
<tr>
<td></td>
<td>293-294</td>
</tr>
<tr>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>Education Spotlight Sessions</td>
</tr>
<tr>
<td></td>
<td>Bone Marrow Failure Syndromes: Diagnostic Principles in 2022</td>
</tr>
<tr>
<td></td>
<td>260-262</td>
</tr>
<tr>
<td></td>
<td>New Horizons for Histiocyte Disorders</td>
</tr>
<tr>
<td></td>
<td>275-277</td>
</tr>
<tr>
<td></td>
<td>Survivorship in adult patients with lymphoma</td>
</tr>
<tr>
<td></td>
<td>Great Hall A/D</td>
</tr>
<tr>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>Scientific Spotlight Sessions</td>
</tr>
<tr>
<td></td>
<td>Platelet Factor 4-Mediated Immunothrombosis: Insights from the Novel Syndrome of Vaccine-Induced Thrombosis and Thrombocytopenia (VITT)</td>
</tr>
<tr>
<td></td>
<td>291-292</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>ASH Guidelines on VTE: Prevention and Treatment in Patients with Cancer</td>
</tr>
<tr>
<td></td>
<td>271-273</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Blood and Beyond: The Great Influenza: The Epic Story of the Deadliest Plague in History</td>
</tr>
<tr>
<td></td>
<td>265-268</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Oral Abstract Sessions</td>
</tr>
<tr>
<td></td>
<td>201. Granulocytes, Monocytes, and Macrophages I</td>
</tr>
<tr>
<td></td>
<td>391-392</td>
</tr>
<tr>
<td></td>
<td>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Von Willebrand Disease and Other Congenital and Acquired Bleeding Disorders</td>
</tr>
<tr>
<td></td>
<td>288-290</td>
</tr>
<tr>
<td></td>
<td>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Genomic Determinants of Prognosis in Patients with Acute Myeloid Leukemia</td>
</tr>
<tr>
<td></td>
<td>353-355</td>
</tr>
<tr>
<td>4:30 p.m. – 6:30 p.m.</td>
<td>Systems-Based Hematology Education and Networking Session</td>
</tr>
<tr>
<td></td>
<td>252-254</td>
</tr>
<tr>
<td>6:00 p.m. – 8:00 p.m.</td>
<td>Poster Hall Reception (for in-person participants)</td>
</tr>
<tr>
<td></td>
<td>Hall D</td>
</tr>
<tr>
<td>6:00 p.m. – 8:00 p.m.</td>
<td>Poster Session II – Presentations</td>
</tr>
<tr>
<td></td>
<td>Hall D</td>
</tr>
<tr>
<td></td>
<td>101. Red Cells and Erythropoiesis, Excluding Iron: Poster II (2322–2336)</td>
</tr>
<tr>
<td></td>
<td>102. Iron Homeostasis and Biology: Poster II (2337–2347)</td>
</tr>
</tbody>
</table>
MONDAY, DECEMBER 12, 2022

7:00 a.m. – 5:00 p.m.  Registration (for in-person participants)
Great Hall Pre-Function

7:00 a.m. – 5:00 p.m.  ASH COVID-19 Testing Centers (for in-person participants)
228-230 (Convention Center)
Eglington Winton, Hilton New Orleans Riverside

7:00 a.m. – 7:45 a.m.  ASH Wellness Studio
ASH Yoga
ASH Park @ the Plaza 1

7:30 a.m. – 9:00 a.m.  Disability Community Networking Breakfast (for in-person participants)
Marriott New Orleans Warehouse Arts District, Gravier EF

8:00 a.m. – 9:00 a.m.  Product Theaters
A Breakthrough For Patients: Complement Inhibition In Cold Agglutinin Disease
(for in-person participants)
Hall J - Theater 6

First and Only: VONVENDI® [von Willebrand factor (recombinant)] for Prophylaxis and More
(for in-person participants)
Hall J - Theater 2

Multidisciplinary Discussion on Incorporating IMBRUVICA® (ibrutinib) Into Treatment Strategies
(for in-person participants)
Hall J - Theater 7

Perspectives on the Treatment of DVT/PE and Reduction in the Risk of Recurrent DVT/PE, Including Patients with Obesity and/or Cancer
(for in-person participants)
Hall J - Theater 5

ZYNLONTA®: The First and Only CD19-Directed ADC For 3L DLBCL
(for in-person participants)
Hall J - Theater 4

9:00 a.m. – 10:00 a.m.  E. Donnall Thomas Lecture and Prize: The Long and Winding Road to Clinically Effective Graft-versus-Host Disease (GVHD) Therapeutics
Hall E

10:00 a.m. – 2:00 p.m.  Exhibits Open
Hall G-J

10:00 a.m. – 10:30 a.m.  Health Equity Studio
Strategies to Overcome Healthcare Disparities
Hall F

10:00 a.m. – 10:30 a.m.  Coffee Break in Exhibit Hall (for in-person participants)
Hall G-J

10:05 a.m. – 10:15 a.m.  ASH Wellness Studio
Bringing Joy to Your World
Hall F

10:15 a.m. – 10:25 a.m.  ASH Wellness Studio
The Real Purpose of Your Purpose
Hall F

10:15 a.m. – 10:30 a.m.  Company Showcases
PICKUP Study: Pneumonia in the ImmunoCompromised – Use of the Karius Test® for the Detection of Undiagnosed Pathogens
(for in-person participants)
Hall J - Theater 6

10:30 a.m. – 11:45 a.m.  Education Sessions
Improving Outcomes in ALL R02-R05

10:30 a.m. – 11:45 a.m.  Scientific Sessions
Childhood Red Cell Disorders: Embracing Technology to Improve How We Manage Challenging Anemias (Scientific Committee on Blood Disorders in Childhood)
343-345

Plasma Cell Dyscrasias: Resistance to Immunotherapy: Mechanisms and Monitoring (Scientific Committee on Plasma Cell Neoplasia)
New Orleans Theater AB
Monday 12 Dec 2022

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

10:30 a.m. – 11:45 a.m. Education Spotlight Sessions
Debate: Most/All Patients with Acquired (Immune) Thrombotic thrombocytopenic purpura (TTP) Receive Caplacizumab
296-296
Underrepresented minorities in clinical trials for hematologic malignancies: what’s the data on the data? R06-R09

10:30 a.m. – 12:00 p.m. ASH-FDA Joint Symposium on Newly Approved Drugs I
Great Hall A/D

10:30 a.m. – 12:00 p.m. Maternal Health in Hematology - Current Resources and Future Advocacy
Hall E

10:30 a.m. – 12:00 p.m. Oral Abstract Sessions
114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Organ Function
353-355
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans
278-282
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Thrombosis and the Endothelium
293-294
321. Coagulation and Fibrinolysis: Basic and Translational
291-292
506. Bone Marrow Microenvironment: Extrinsic Regulators of Hematopoiesis
260-262
603. Lymphoid Oncogenesis: Basic: Mechanisms in Lymphomagenesis
208-210
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Frontline and Maintenance
275-277
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: High-risk T-ALL and Prognostic Biomarkers
291-292

12:00 p.m. – 1:30 p.m. Complimentary Light Lunch in the Exhibit Hall (for in-person participants)
Hall G-J

12:00 p.m. – 1:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)
ASH Park @ the Plaza 3

12:05 p.m. – 12:15 p.m. ASH Wellness Studio
Build a Bigger Brain and Longer Life
Hall F

12:15 p.m. – 12:45 p.m. Health Equity Studio
Overcoming Lack of Diversity in Clinical Trials
Hall F

12:15 p.m. – 1:15 p.m. Industry Theaters
A Clinical Overview of Olutasidenib: An Investigational Therapy, Currently Under FDA Review, For the Potential Treatment of Patients with Relapsed/Refractory mIDH1 AML
Hall J - Theater 4
From Science Fiction to Standard of Care: Developing the next wave of Genomic Medicines for Hematology
(for in-person participants)
Hall J - Theater 6
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 p.m.</td>
<td><strong>Product Theaters</strong></td>
</tr>
<tr>
<td></td>
<td>An Innovative Treatment Option for Appropriate Patients With cGVHD</td>
</tr>
<tr>
<td></td>
<td>(for in-person participants)</td>
</tr>
<tr>
<td></td>
<td>Hall J - Theater 7</td>
</tr>
<tr>
<td></td>
<td>Darzalex &amp; Darzalex Faspro: A Frontline Treatment Approach for a Variety</td>
</tr>
<tr>
<td></td>
<td>of Newly Diagnosed Multiple Myeloma Patient Types</td>
</tr>
<tr>
<td></td>
<td>(for in-person participants)</td>
</tr>
<tr>
<td></td>
<td>Hall J - Theater 5</td>
</tr>
<tr>
<td></td>
<td>DLBCL Treatment Landscape Overview for Fellows and APPs</td>
</tr>
<tr>
<td></td>
<td>(for in-person participants)</td>
</tr>
<tr>
<td></td>
<td>Hall J - Theater 2</td>
</tr>
<tr>
<td>12:15 p.m.</td>
<td>Meet the Blood Editors</td>
</tr>
<tr>
<td></td>
<td>(for in-person participants)</td>
</tr>
<tr>
<td></td>
<td>Marriott New Orleans Warehouse Arts District, Julia</td>
</tr>
<tr>
<td></td>
<td>12:15 p.m. – 1:00 p.m. <strong>ASH Choosing Wisely Campaign: 2022</strong></td>
</tr>
<tr>
<td></td>
<td>243-245</td>
</tr>
<tr>
<td>12:15 p.m.</td>
<td><strong>Trainee Didactic Sessions (Open to Trainees Only)</strong></td>
</tr>
<tr>
<td></td>
<td>Trainee Didactic Session: Entrepreneurship</td>
</tr>
<tr>
<td></td>
<td>217-219</td>
</tr>
<tr>
<td></td>
<td>Trainee Didactic Session: Giving A Scientific Presentation</td>
</tr>
<tr>
<td></td>
<td>220-222</td>
</tr>
<tr>
<td>12:20 p.m.</td>
<td><strong>ASH Wellness Studio</strong></td>
</tr>
<tr>
<td></td>
<td>Amplify Your Heart Brain for Improved Cognitive Function and Emotional Stability</td>
</tr>
<tr>
<td></td>
<td>Hall F</td>
</tr>
<tr>
<td>12:35 p.m.</td>
<td><strong>ASH Wellness Studio</strong></td>
</tr>
<tr>
<td></td>
<td>Feel Better in Your Body</td>
</tr>
<tr>
<td></td>
<td>Hall F</td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td><strong>Health Equity Studio</strong></td>
</tr>
<tr>
<td></td>
<td>Overcoming Disparities in Career Development</td>
</tr>
<tr>
<td></td>
<td>Hall F</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>**Ernest Beutler Lecture and Prize: The Complement System and Medicine: The Good, the Bad,</td>
</tr>
<tr>
<td></td>
<td>the Future</td>
</tr>
<tr>
<td></td>
<td>Hall E</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td><strong>Health Equity Studio</strong></td>
</tr>
<tr>
<td></td>
<td>Strategies to Improve Diversity and Inclusion in Healthcare and Industry</td>
</tr>
<tr>
<td></td>
<td>Hall F</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td><strong>Coffee Break in Exhibit Hall (for in-person participants)</strong></td>
</tr>
<tr>
<td></td>
<td>Hall G-J</td>
</tr>
<tr>
<td>2:35 p.m.</td>
<td><strong>ASH Wellness Studio</strong></td>
</tr>
<tr>
<td></td>
<td>Straight Spine, Big Smile</td>
</tr>
<tr>
<td></td>
<td>Hall F</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td><strong>Education Sessions</strong></td>
</tr>
<tr>
<td></td>
<td>Treatment Approaches for the Multiple Myeloma Patient in 2022</td>
</tr>
<tr>
<td></td>
<td>Great Hall A/D</td>
</tr>
<tr>
<td></td>
<td>Updates in Targeted Therapy in Pediatric Leukemia</td>
</tr>
<tr>
<td></td>
<td>343-345</td>
</tr>
<tr>
<td></td>
<td>What is New in Classical Bone Marrow Failure Syndromes? (focus on management)</td>
</tr>
<tr>
<td></td>
<td>260-262</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td><strong>Scientific Sessions</strong></td>
</tr>
<tr>
<td></td>
<td>Histone Modifications and Chromatin Programs in Clonal Selection and Cancer Emergence</td>
</tr>
<tr>
<td></td>
<td>(Scientific Committee on Epigenetics and Genomics)</td>
</tr>
<tr>
<td></td>
<td>275-277</td>
</tr>
<tr>
<td></td>
<td>Morphology in a Genomic World (Scientific Committee on Hematopathology and Clinical</td>
</tr>
<tr>
<td></td>
<td>Laboratory Hematology)</td>
</tr>
<tr>
<td></td>
<td>208-210</td>
</tr>
<tr>
<td></td>
<td>Iron and Red Cells: A Co-Dependent Relationship</td>
</tr>
<tr>
<td></td>
<td>(Scientific Committee on Iron and Heme)</td>
</tr>
<tr>
<td></td>
<td>265-268</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td><strong>Education Spotlight Sessions</strong></td>
</tr>
<tr>
<td></td>
<td>Immunotherapies for myeloid neoplasms: are we ready for primetime?</td>
</tr>
<tr>
<td></td>
<td>New Orleans Theater AB</td>
</tr>
<tr>
<td></td>
<td>Point/Counterpoint: The case for/against thrombophilia testing in many/most adults with</td>
</tr>
<tr>
<td></td>
<td>unprovoked thrombosis.</td>
</tr>
<tr>
<td></td>
<td>288-290</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td><strong>Scientific Spotlight Sessions</strong></td>
</tr>
<tr>
<td></td>
<td>Sowing the Seeds of Leukemia Before Birth</td>
</tr>
<tr>
<td></td>
<td>271-273</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td><strong>Oral Abstract Sessions</strong></td>
</tr>
<tr>
<td></td>
<td>Building a Nationwide Sickle Cell Disease Data Hub and Learning Community</td>
</tr>
<tr>
<td></td>
<td>217-219</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td><strong>Building a Nationwide Sickle Cell Disease Data Hub and Learning Community</strong></td>
</tr>
<tr>
<td></td>
<td>217-219</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td><strong>Oral Abstract Sessions</strong></td>
</tr>
<tr>
<td></td>
<td>112. Thalassemia and Globin Gene Regulation I</td>
</tr>
<tr>
<td></td>
<td>220-222</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td>114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Women's and</td>
</tr>
<tr>
<td></td>
<td>Clinical Issues</td>
</tr>
<tr>
<td></td>
<td>278-282</td>
</tr>
</tbody>
</table>
### Monday

**12 Dec 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Mechanistic Insights That Suggest Novel Diagnostic or Therapeutic Strategies 353-355</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Basic and Developmental 252-254</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>602. Myeloid Oncogenesis: Basic: DNA Damage and Genetic Evolution 293-294</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Advances in Mutation-targeted Therapy for AML R02-R05</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Venetoclax, HMA, and Response to Treatment in AML R02-R05</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>621. Lymphomas: Translational—Molecular and Genetic: Functional Genomics and Biology 388-390</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>627. Aggressive Lymphomas: Clinical and Epidemiological: Predictors of Outcome La Nouvelle Orleans Ballroom C 243-245</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>637. Myelodysplastic Syndromes – Clinical and Epidemiological I 243-245</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational: Novel Therapeutic Strategies, Characterization of Response Biology, and Consequences Hall E 295-296</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: New Approaches to MRD Assessment Great Hall B/C 295-296</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities II 393-396</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Results of Large Prospective Studies 391-392</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>901. Health Services and Quality—Non-Malignant Conditions: Level Up! Taking Quality Care to the Next Level in Sickle Cell Disease New Orleans Theater C 388-390</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>902. Health Services and Quality—Lymphoid Malignancies: Real World Consequences and Cost of Care La Nouvelle Orleans Ballroom AB 220-222</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>904. Outcomes Research—Non-Malignant Conditions: Sickle Cell Care Across the Lifespan R06-R09 353-355</td>
</tr>
<tr>
<td>3:00 p.m. – 4:00 p.m.</td>
<td>905. Outcomes Research—Lymphoid Malignancies: Outcomes in Childhood Leukemia/Lymphoma 291-292</td>
</tr>
<tr>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>Education Sessions</td>
</tr>
<tr>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>Junior Faculty Career Development Education Session New Orleans Theater AB</td>
</tr>
</tbody>
</table>

---

Late Effects Monitoring for Survivors of Pediatric Hematologic Malignancies 288-290

Thrombosis Prevention and Treatment R02-R05

To Transplant or Not to Transplant in Active or High-Risk Myeloid Disease 343-345

4:30 p.m. – 5:45 p.m. | AI and Machine Learning: A New Frontier in Hematology 275-277 |

Metabolic Regulation and Implications for Red Cells (Scientific Committee on Red Cell Biology) 275-277

4:30 p.m. – 6:00 p.m. | ASH Guidelines on AML in Older Adults: Monitoring Emerging Evidence 295-296 |

4:30 p.m. – 6:00 p.m. | ASH Guidelines on VWD: Impact on Patients, Policy, and Allied Health Professionals 265-268 |

4:30 p.m. – 6:00 p.m. | ASH-FDA Joint Symposium on Newly Approved Drugs II 217-219 |

4:30 p.m. – 6:00 p.m. | Driving Real-World Evidence for Hematologic Malignancy Research – A Joint ASH RC and EU HARMONY Session 217-219 |

4:30 p.m. – 6:00 p.m. | Oral Abstract Sessions 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Mechanisms and Treatment of ITP 220-222 |

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Disease and Aging 393-396 |

503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Human Cohorts and Biosamples 252-254 |


617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease Detection in AML and Single Cell Investigations
New Orleans Theater C

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological II
R06-R09

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Mature T- and NK-cell Lymphomas: Prospective Trials and a Retrospective Analysis
271-273

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Drugs in Development and COVID-19
243-245

652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Disease Monitoring
278-282

703. Cellular Immunotherapies: Basic and Translational III
La Nouvelle Orleans Ballroom C

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Acute Leukemia and Hodgkin Lymphoma
Hall E

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities I
260-262

902. Health Services and Quality—Lymphoid Malignancies: Time for Change: Health Care Delivery and Disparities
La Nouvelle Orleans Ballroom AB

905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in CAR T and Stem Cell Transplantation
291-292

4:30 p.m. – 6:05 p.m.  Scientific Symposia

Special Symposium on the Basic Science of Hemostasis and Thrombosis
208-210

5:30 p.m. – 8:00 p.m.  ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease—Update and Reception (for in-person participants)

Marriott New Orleans Warehouse Arts District, Gravier DEF

6:00 p.m. – 8:00 p.m.  Poster Hall Reception (for in-person participants)

Hall D

6:00 p.m. – 8:00 p.m.  Poster Session III – Presentations
Hall D

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III (3639–3653)
102. Iron Homeostasis and Biology: Poster III (3654–3664)
112. Thalassemia and Globin Gene Regulation: Poster III (3665–3672)
113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster III (3673–3690)
201. Granulocytes, Monocytes, and Macrophages: Poster III (3720–3733)
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III (3734–3742)
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster III (3743–3760)
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III (3761–3773)
321. Coagulation and Fibrinolysis: Basic and Translational: Poster III (3774–3781)
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III (3782–3806)
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III (3817–3836)
503. Clonal Hematopoiesis, Aging and Inflammation: Poster III (3859–3870)
506. Bone Marrow Microenvironment: Poster III (3871–3881)
508. Bone Marrow Failure: Acquired: Poster III (3882–3894)
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III (3895–3902)
602. Myeloid Oncogenesis: Basic: Poster III (3903–3935)
603. Lymphoid Oncogenesis: Basic: Poster III (3936–3950)
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III (4016–4042)
615. Acute Myeloid Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (4054–4073)
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4095–4134)
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4135–4151)
621. Lymphomas: Translational—Molecular and Genetic: Poster III (4152–4178)
622. Lymphomas: Translational—Non-Genetic: Poster III (4179–4197)
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III (4198–4224)
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III (4251–4270)
Monday-Tuesday  
DAY-AT-A-GLANCE  
12-13 Dec 2022

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III (4271–4306)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III (4307–4323)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III (4324–4343)
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III (4344–4376)
636. Myelodysplastic Syndromes—Basic and Translational: Poster III (4377–4389)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III (4390–4417)
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster III (4418–4430)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III (4431–4451)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III (4452–4489)
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster III (4550–4575)
701. Experimental Transplantation: Basic and Translational: Poster III (4576–4594)
703. Cellular Immunotherapies: Basic and Translational: Poster III (4595–4626)
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III (4627–4656)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III (4657–4678)
711. Cell Collection and Processing: Poster III (4679–4685)
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III (4708–4728)
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III (4729–4742)
731. Autologous Transplantation: Clinical and Epidemiological: Poster III (4743–4754)
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (4755–4772)
801. Gene Therapies: Poster III (4773–4787)
802. Chemical Biology and Experimental Therapeutics: Poster III (4788–4801)
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III (4802–4819)
901. Health Services and Quality—Non-Malignant Conditions: Poster III (4820–4843)
902. Health Services and Quality—Lymphoid Malignancies: Poster III (4844–4861)
903. Health Services and Quality—Myeloid Malignancies: Poster III (4862–4872)
904. Outcomes Research—Non-Malignant Conditions: Poster III (4873–4895)
905. Outcomes Research—Lymphoid Malignancies: Poster III (4896–4937)
906. Outcomes Research—Myeloid Malignancies: Poster III (4938–4956)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 p.m. – 7:30 p.m.</td>
<td>Hemostasis and Thrombosis Community Networking Reception (for in-person participants)</td>
</tr>
<tr>
<td></td>
<td>Rivergate Terrace</td>
</tr>
<tr>
<td>7:30 p.m. – 9:30 p.m.</td>
<td>Women in Hematology Networking Dinner</td>
</tr>
<tr>
<td></td>
<td>Hilton New Orleans Riverside, Jefferson Ballroom</td>
</tr>
</tbody>
</table>

TUESDAY, DECEMBER 13, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m. – 1:30 p.m.</td>
<td>Registration (for in-person participants)</td>
</tr>
<tr>
<td></td>
<td>Great Hall Pre-Function</td>
</tr>
<tr>
<td>7:00 a.m. – 1:30 p.m.</td>
<td>ASH COVID-19 Testing Centers (for in-person participants)</td>
</tr>
<tr>
<td>228-230 (Convention Center)</td>
<td>Eglington Winton, Hilton New Orleans Riverside</td>
</tr>
<tr>
<td>8:45 a.m. – 9:00 a.m.</td>
<td>Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals</td>
</tr>
<tr>
<td></td>
<td>Hall E</td>
</tr>
<tr>
<td>9:00 a.m. – 10:30 a.m.</td>
<td>Late-Breaking Abstracts Session</td>
</tr>
<tr>
<td></td>
<td>Hall E</td>
</tr>
<tr>
<td>11:00 a.m. – 12:30 p.m.</td>
<td>Presidential Symposium</td>
</tr>
<tr>
<td></td>
<td>Hall E</td>
</tr>
<tr>
<td>12:30 p.m. – 2:00 p.m.</td>
<td>Best of ASH</td>
</tr>
<tr>
<td></td>
<td>Hall E</td>
</tr>
<tr>
<td>2:00 p.m. – 2:15 p.m.</td>
<td>Business Meeting</td>
</tr>
<tr>
<td></td>
<td>Hall E</td>
</tr>
</tbody>
</table>
WEDNESDAY AND THURSDAY
DECEMBER 14-15, 2022

<table>
<thead>
<tr>
<th>To Be Announced</th>
<th>ASH Poster Walks (virtual platform only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASH Poster Walk on Diversity, Equity, and Inclusion in Hematologic Malignancies and Cellular Therapy</td>
<td>VIRTUAL PROGRAM</td>
</tr>
<tr>
<td>Beyond Hematology: Clinical and Mechanistic Links between Clonal Hematopoiesis and Non-Hematological Disorders</td>
<td>VIRTUAL PROGRAM</td>
</tr>
<tr>
<td>Platelets from Bench to Bedside</td>
<td>VIRTUAL PROGRAM</td>
</tr>
<tr>
<td>The Spectrum of Hemostasis and Thrombosis Research</td>
<td>VIRTUAL PROGRAM</td>
</tr>
<tr>
<td>What’s Hot in Sickle Cell Disease Research 2022</td>
<td>VIRTUAL PROGRAM</td>
</tr>
</tbody>
</table>
CME/MOC Tests

EARN UP TO 40 CME CREDITS OR ABIM MOC POINTS* by completing two 20-credit exams, one on malignant and the other on non-malignant hematology.

▶ Purchase the CME/MOC test at academy.hematology.org

*Accreditation and Credit Designation
The American Society of Hematology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Hematology designates this enduring material for a maximum of 40 AMA PRA Category 1 Credits™. Physicians who participate in this CME activity but are not licensed in the United States are also eligible for AMA Category 1 PRA Credit™.

*ABIM Maintenance of Certification
Successful completion of this CME activity enables the participant to earn up to 40 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Advancing Discovery. Accelerating Access.

City of Hope is rapidly translating hematologic breakthroughs into lifesaving treatments. With our acquisition of Cancer Treatment Centers of America, we are now one of the largest cancer research and treatment organizations in the country, providing patients with timely access to exceptional care, clinical trials and leading-edge innovation.

Visit us at Booth 1547 to learn more

CityofHope.org/ash22
These signature sessions are designed to be of interest to a broad and diverse audience and include the prestigious Plenary Scientific Session, Best of ASH, and the Presidential Symposium. Many of the General Sessions also honor distinguished leaders in the field through awards and special lectures.

**GENERAL SESSIONS**

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

### SATURDAY

**Ham-Wasserman Lecture**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Time</th>
<th>Location</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukemogenesis in Infants and Young Children with Trisomy 21</td>
<td>Saturday</td>
<td>12:30 p.m. – 1:30 p.m.</td>
<td>Hall E</td>
<td>Jane N. Winter, MD, President, American Society of Hematology, Northwestern University, Chicago, IL</td>
</tr>
</tbody>
</table>

**Speaker:**

Irene Roberts, MD, Weatherall Institute of Molecular Medicine, Oxford, England, United Kingdom

### SUNDAY

**ASH-EHA Joint Symposium**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Time</th>
<th>Location</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germline Predisposition and Hereditary Hematopoietic Neoplasia</td>
<td>Sunday</td>
<td>12:30 p.m. – 1:30 p.m.</td>
<td>Hall E</td>
<td>Jane N. Winter, MD, President, American Society of Hematology, Northwestern University, Chicago, IL</td>
</tr>
</tbody>
</table>

**Chairs:**

Elizabeth A. Macintyre, PhD, MD, Tour Pasteur Hospital Necker Enfants Malades, Paris, France

Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Time</th>
<th>Location</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wall of interest to PhD attendees.</td>
<td>Sunday</td>
<td>1:30 p.m. – 2:00 p.m.</td>
<td>Hall E</td>
<td>Jane N. Winter, MD, President, American Society of Hematology, Northwestern University, Chicago, IL</td>
</tr>
</tbody>
</table>

**Announce of Awards:**

Charlotte M. Niemeyer, MD, Albert-Ludwigs-Universitat Freiburg, Freiburg, Germany

Lucy A. Godley, MD, PhD, University of Chicago Medical Center, Chicago, IL

**Plenary Scientific Session**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Time</th>
<th>Location</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sunday</td>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Hall E</td>
<td>Robert A. Brodsky, MD, President-Elect, American Society of Hematology, Johns Hopkins University, Baltimore, MD</td>
</tr>
</tbody>
</table>

**Chair:**

Robert A. Brodsky, MD, President-Elect, American Society of Hematology, Johns Hopkins University, Baltimore, MD

Jane N. Winter, MD, President, American Society of Hematology, Northwestern University, Chicago, IL
MONDAY

E. Donnall Thomas Lecture and Prize

Monday 9:00 a.m. – 10:00 a.m.
Hall E

*The Long and Winding Road to Clinically Effective Graft-versus-Host Disease (GVHD) Therapeutics*

Chair:
Jane N. Winter, MD, President, American Society of Hematology, Northwestern University, Chicago, IL

Speaker:
Bruce R. Blazar, MD, University of Minnesota, Minneapolis, MN

Ernest Beutler Lecture and Prize

Monday 1:30 p.m. – 2:30 p.m.
Hall E

*The Complement System and Medicine: The Good, the Bad, the Future*

Chair:
Jane N. Winter, MD, President, American Society of Hematology, Northwestern University, Chicago, IL

Speakers:
John Atkinson, MD, Washington University, Saint Louis, MO
Basic Science

Peter Hillmen, MD, PhD, St. James's University Hospital, Leeds, United Kingdom
Clinical/Translational Science

TUESDAY

Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals

Tuesday 8:45 a.m. – 9:00 a.m.
Hall E

Chair:
Jane N. Winter, MD, President, American Society of Hematology, Northwestern University, Chicago, IL

Late-Breaking Abstracts Session

Tuesday 9:00 a.m. – 10:30 a.m.
Hall E

Co-Chairs:
David A. Garcia, MD, University of Washington, Seattle, WA

Olatoyosi Odeneke, MD, University of Chicago, Chicago, IL

Presidential Symposium

Tuesday 11:00 a.m. – 12:30 p.m.
Hall E

*What the Hematologist Has Learned from the Pandemic*

Chair:
Jane N. Winter, MD, President, American Society of Hematology, Northwestern University, Chicago, IL
SPECIAL INTEREST SESSIONS

These smaller sessions provide the opportunity for ASH's various communities to focus on specific topics of interest.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

ASH Wellness Studio Hall F (non-CME)

- 7:00 a.m. – 7:45 a.m. ASH Yoga (ASH Park @ the Plaza 1)
- 9:05 a.m. – 9:15 a.m. Bringing Joy to Your World
- 9:15 a.m. – 9:25 a.m. Breathe Well to Feel Well
- 11:05 a.m. – 11:15 a.m. Money Issues are Burning You Out
- 11:20 a.m. – 11:30 a.m. One Breath to the Most Kind, Compassionate, and Grateful You!
- 11:35 a.m. – 11:45 a.m. Fix the Way You Sit
- 1:35 p.m. – 1:45 p.m. A Simple Way to More Resilience
- 1:45 p.m. – 1:55 p.m. Financial Order of Operations
- 3:35 p.m. – 3:45 p.m. Workday Tension Timeout
- 3:45 p.m. – 3:55 p.m. Use Your Character Strengths to Get Through Trying Times

Health Equity Studio Hall F (non-CME)

- 9:00 a.m. – 9:30 a.m. Defining Inequity and Root Causes of Health Inequity
- 11:15 a.m. – 11:45 a.m. Recognizing and Addressing Implicit Bias
- 1:30 p.m. – 2:00 p.m. Strategies to Overcome Healthcare Disparities
- 3:30 p.m. – 4:00 p.m. Overcoming Lack of Diversity in Clinical Trials

Training Program Directors’ Workshop

Friday 9:00 a.m. – 12:00 p.m.
Cypress, Marriott New Orleans Warehouse Arts District (for in-person participants)

Chair:
ALFRED LEE, MD, PhD, Yale University School of Medicine, New Haven, CT

Speakers:
CECELIA CALHOUN, MD, MBA, Yale University, New Haven, CT
ALAN MAST, MD, PhD, Versiti Blood Center of Wisconsin, Milwaukee, WI
Diversity, Equity, and Inclusion

SOO PARK, MD, University of California, San Diego, CA
JOANNE FILICKO-O’HARA, MD, Jefferson University, Philadelphia, PA
Mentorship and Career Development

VALENTINA BAEZ SOSA, MD, MedStar Washington Hospital, Washington, DC
LESLIE ELLIS, MD, MSHPEd, Wake Forest Baptist Hospital, Winston Salem, NC
How the Personal Characteristics of Grit and Resilience Relate to Physician Well-Being

Blood Presents: How to Get Published in a Peer Review Journal (non-CME)

Saturday 11:15 a.m. – 12:15 p.m.
252-254

NANCY BERLINER, MD, Editor-in-Chief, Blood, Brigham and Women’s Hospital, Boston, MA
ANDREW W. ROBERTS, PhD, MBBS, Deputy Editor-in-Chief, Blood, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

of interest to PhD attendees.  CME credit is not offered.
Grassroots Network Lunch

Saturday 11:15 a.m. – 12:15 p.m.
St. James Ballroom, Hilton New Orleans Riverside

Chair:
Jennifer Holter Chakrabarty, MD, University of Oklahoma, Oklahoma City, OK

Speaker:
Veronica Gillispe-Bell, MD, Ochsner Health System, New Orleans, LA
The Intersection of Hematology and Gynecology and How to Get Involved

Blood Advances Meet the Editors

Saturday 2:00 p.m. – 3:00 p.m.
Julia, Marriott New Orleans Warehouse Arts District (for in-person participants)

Speakers:
Margaret V. Ragni, MD, Associate Editor, Blood Advances, University of Pittsburgh, Pittsburgh, PA
Constantine Tam, MBBS, MD, Associate Editor, Blood Advances, Monash University, Clayton, Victoria, Australia

Special Symposium on Quality: Quality Improvement Education and Training

Saturday 2:00 p.m. – 3:30 p.m.
295-296

Chair:
Michael Ken, MD, University of Virginia, Charlottesville, VA

Speakers:
Jose Azar, MD, Indiana University Simon Cancer Center, Indianapolis, IN
Quality Improvement Overview

Ashley E. Rosko, MD, The Ohio State University, Columbus, OH
Quality Improvement Project, Implementing Age-Friendly practices in Older Adults with Hematologic Malignancies

Rachael F. Grace, MD, Boston Children’s Hospital, Boston, MA
Quality Improvement Project, Immune Thrombocytopenia (ITP)

Special Interest Session on Sickle Cell Disease Centers: Ensuring Appropriate Care Across the Patient Lifespan

Saturday 4:00 p.m. – 5:30 p.m.
La Nouvelle Orleans Ballroom AB

Promoting Minorities in Hematology: Presentations and Reception

Saturday 6:30 p.m. – 9:00 p.m.
The District Foyer, Hilton New Orleans Riverside
SUNDAY

ASH Wellness Studio Hall F  
9:05 a.m. - 9:15 a.m.  Build a Bigger Brain and Longer Life
9:15 a.m. - 9:25 a.m.  Use Your Character Strengths to Get Through Trying Times
11:05 a.m. - 11:15 a.m.  Coping With Financial Strain and Gain
11:20 a.m. - 11:30 a.m.  Feel Better in Your Body
11:35 a.m. - 11:45 a.m.  Regulate Your Genes for More Energy and Less Inflammation
4:05 p.m. - 4:15 p.m.  The Greatest Medicine...A True Friend
4:15 p.m. - 4:25 p.m.  Fix the Way You Sit

Health Equity Studio Hall F  
9:00 a.m. - 9:30 a.m.  Overcoming Disparities in Career Development
11:15 a.m. - 11:45 a.m.  Strategies to Improve Diversity and Inclusion in Healthcare and Industry
12:30 p.m. - 1:00 p.m.  Defining Inequity and Root Causes of Health Inequity
4:00 p.m. - 4:30 p.m.  Recognizing and Addressing Implicit Bias

Medical Educators’ Symposium

Sunday  7:30 a.m. – 9:30 a.m.
Cypress, Marriott New Orleans
Warehouse Arts District

Chair:
Sanjay R. Mohan, MD, MSCI, Vanderbilt University,
Nashville, TN

Speakers:
Alfred I. Lee, MD, PhD, Yale University School of
Medicine, New Haven, CT
Burnout and Faculty Engagement
Anish V. Sharda, MBBS, Beth Israel Deaconess Medical
Center, Boston, MA
Mentorship
Srikanth Nagalla, MBBS, MS, Miami Cancer Institute,
Miami, FL
Breakout Session #1: How to Write a Good Test
Question
Tamara Dunn, MD, Stanford University, Stanford, CA
Breakout Session #2: How to Progress in Your
Academic Career as a Medical Educator
Rakesh P. Mehta, MD, Indiana University School of
Medicine, Indianapolis, IN
Breakout Session #3: How to Write a
Good Letter of Recommendation

Leslie Ellis, MS, Wake Forest Baptist Health, Winston
Salem, NC
Breakout Session #4: How Do Programs Collect
Information and Data

ASH Guideline Implementation Champions

Sunday  9:30 a.m. – 11:00 a.m.
353-355

Moderator:
Rachel P. Rosovsky, MD, MPH, Massachusetts General
Hospital, Boston, MA

Speakers:
Jordan K. Schaefer, MD, University of Michigan, Ann
Arbor, MI
Wilson Andres Vasconez Samaniego, MD, University of
Miami/Jackson Memorial Hospital, Miami, FL
Jori E. May, MD, University of Alabama at
Birmingham, Birmingham, AL
ASH Guideline Implementation Project
Meet the Blood Editors

**Sunday**  11:15 a.m. – 12:00 p.m.
Julia, Marriott New Orleans Warehouse Arts District

**Speakers:**
Helen E. Heslop, MD, Associate Editor, Blood, Baylor College of Medicine, Houston, TX
Thomas L. Ortel, MD, PhD, Associate Editor, Blood, Duke University, Durham, NC

Blood Advances Presents: How to Peer Review a Scientific Paper

**Sunday**  11:15 a.m. – 12:15 p.m.
252-254 (for in-person participants)

**Speakers:**
Leslie S. Kean, MD, PhD, Associate Editor, Blood Advances, Boston Children's Hospital, Boston, MA
Andrew Weyrich, PhD, Deputy Editor, Blood Advances, Oklahoma Medical Research Foundation, Oklahoma City, OK

LGBTQIA+ Community Networking Brunch

**Sunday**  11:15 a.m. – 12:15 p.m.
Gravier AB, Marriott New Orleans Warehouse Arts District

ASH Practice Partnership Lunch - A Return to the Classics: The Need for Classical Hematology

**Sunday**  11:15 a.m. – 12:30 p.m.
St. James Ballroom, Hilton New Orleans Riverside

**Chair:**
Chancellor E. Donald, MD, Tulane University School of Medicine, New Orleans, LA

**Speakers:**
Janice W. Lawson, MD, Tallahassee Memorial Hospital, Tallahassee, FL
How to Practice Classical Hematology When It's Outside Your Comfort Zone
David Garcia, MD, University of Washington, Seattle, WA
Justifying the Value of Classical Hematology
Alfred I. Lee, MD, PhD, Yale University School of Medicine, New Haven, CT
Getting Young Hematologists Interested in Classical Hematology

ASH Health Equity Rounds Lunch

**Sunday**  11:30 a.m. – 12:30 p.m.
Cypress, Marriott New Orleans Warehouse Arts District

**Moderator:**
Jacquelyn M. Powers, MD, MSc, Baylor College of Medicine/Texas Children's Hospital, Houston, TX

**Speaker:**
Paula James, MD, Queen's University, Kingston, Ontario, Canada
Gender Disparities in Bleeding Disorders

Blood and Beyond

**Sunday**  4:30 p.m. – 6:00 p.m.
265-268

**Chair:**
Nancy Berlinger, MD, Editor-in-Chief, Blood, Brigham and Women's Hospital, Boston, MA

**Speaker:**
John M. Barry, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, author of The Great Influenza: The Epic Story of the Deadliest Plague in History a #1 New York times best seller and named by the National Academies of Science as the year's best book on science.
The Great Influenza: The Epic Story of the Deadliest Plague in History

ASH Guidelines on VTE: Prevention and Treatment in Patients with Cancer

**Sunday**  4:30 p.m. – 6:00 p.m.
271-273

**Chair:**
Marc Carrier, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada

**Speakers:**
Marc Carrier, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada
Risk Assessment and Prophylaxis
Radhika Gangaraju, MD, University of Alabama, Birmingham, AL
Treatment and Secondary Prevention
Ang Li, MD, MS, Baylor College of Medicine, Houston, TX
Implementation Strategies Regarding Venous Thromboembolism (VTE) in Patients with Cancer
SPECIAL INTEREST SESSIONS

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Systems-Based Hematology Education and Networking Session

**Sunday** 4:30 p.m. – 6:30 p.m.
252-254

**Chair:**
**Marc S. Zumberg**, MD, University of Florida, Gainesville, FL

**Speakers:**
**Michael B. Streiff**, MD, Johns Hopkins Medical Institutions, Baltimore, MD

**A Systems-Based Approach to the Prevention and Management of Cancer-Associated Thrombosis**

**Annette S. Kim**, MD, PhD, Brigham and Women’s Hospital, Boston, MA

**Avoiding Overuse of Molecular/Genetic Testing Via Systems-Level Interventions**

---

**MONDAY**

---

**ASH Wellness Studio Hall F (non-CME)**

- 7:00 a.m. - 7:45 a.m.  
  ASH Yoga (ASH Park @ the Plaza 1)
- 10:05 a.m. - 10:15 a.m.  
  Bringing Joy to Your World
- 10:15 a.m. - 10:25 a.m.  
  The Real Purpose of Your Purpose
- 12:05 p.m. - 12:15 p.m.  
  Build a Bigger Brain and Longer Life
- 12:20 p.m. - 12:30 p.m.  
  Amplify Your Heart Brain for Improved Cognitive Function and Emotional Stability
- 12:35 p.m. - 12:45 p.m.  
  Feel Better in Your Body
- 2:35 p.m. - 2:45 p.m.  
  Straight Spine, Big Smile

---

**Health Equity Studio Hall F (non-CME)**

- 10:00 a.m. - 10:30 a.m.  
  Strategies to Overcome Healthcare Disparities
- 12:15 p.m. - 12:45 p.m.  
  Overcoming Lack of Diversity in Clinical Trials
- 1:00 p.m. - 1:30 p.m.  
  Overcoming Disparities in Career Development
- 4:00 p.m. - 4:30 p.m.  
  Strategies to Improve Diversity and Inclusion in Healthcare and Industry

---

**Disability Community Networking Breakfast (non-CME)**

**Monday** 7:30 a.m. – 9:00 a.m.
Gravier EF, Marriott New Orleans Warehouse Arts District

---

**ASH-FDA Joint Symposium on Newly Approved Drugs I**

**Monday** 10:30 a.m. – 12:00 p.m.
Great Hall A/D
Maternal Health in Hematology - Current Resources and Future Advocacy

**Monday 10:30 a.m. – 12:00 p.m.**
**Hall E**

**Moderator:** Sarah H. O’Brien, MD, Nationwide Children’s Hospital, Columbus, OH

**Speakers:** Jerome D. Winegardner III, MD, St. Joseph Mercy Hospital Cancer Center/Cancer Research Consortium of West Michigan, National Cancer Institute Community Oncology Research Program, Ann Arbor, MI

*Amicus Brief: a Michigan Study*

Mikael A. Sekeres, MD, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL

*Op-ed: a Washington Post Study*

Deva Sharma, MD, Vanderbilt University Medical Center

*Grassroots Advocacy: a Tennessee Study*

---

**Building a Nationwide Sickle Cell Disease Data Hub and Learning Community**

**Monday 2:45 p.m. – 4:15 p.m.**
**217-219**

**Chair:** Alexis A. Thompson, MD, MPH, Children’s Hospital of Philadelphia, Philadelphia, PA

**Speakers:** Alexis A. Thompson, MD, MPH, Children’s Hospital of Philadelphia, Philadelphia, PA

*Introduction*

The Role of a Nationwide SCD Data Hub and Learning Community

Moderated Q&A

Carole Lannon, MD, MPH, Cincinnati Children’s, Cincinnati, OH

*Designing a Nationwide Learning Community*

Amanda M. Brandow, DO, MS, Medical College of Wisconsin, Milwaukee, WI

*Better Quality Through Better Measurement*

Venee N. Tubman, MD, MMSc, Texas Children’s Hospital, Houston, TX

*Building Your Team to Drive Improvement*

Alexis A. Thompson, MD, MPH, Children’s Hospital of Philadelphia, Philadelphia, PA

Moderated Panel Q&A

Conclusion

---

**ASH Choosing Wisely® Campaign: 2022 ASH Choosing Wisely Champions**

**Monday 12:15 p.m. – 1:15 p.m.**
**243-245**

**Chair:** Marc S. Zumberg, MD, University of Florida, Gainesville, FL

**Speakers:**

Julia Fortier, MD, University of Florida, Gainesville, FL

*Reducing Unnecessary Pre-Medication Prior to Parenteral Iron Therapy*

Daanish Hoda, MD, LDS Hospital, Salt Lake City, UT

*Reducing Overtesting and Overdiagnosis of Clostridioides Dificile Infection in the Setting of an HSCT Unit*

Kamal Sahu, MD, DM, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

*Implementation of New Electronic Medical Record Algorithm to Streamline the Appropriate Use of Rasburicase*

---

**ASH-FDA Joint Symposium on Newly Approved Drugs II**

**Monday 4:30 p.m. – 6:00 p.m.**
**Great Hall A/D**
Driving Real-World Evidence for Hematologic Malignancy Research – A Joint ASH RC and EU HARMONY Session

**Monday 4:30 p.m. – 6:00 p.m.**

**Chair:**
William A. Wood Jr., MD, MPH, University of North Carolina, Chapel Hill, NC

**Speakers:**
William A. Wood Jr., MD, MPH, University of North Carolina, Chapel Hill, NC

*Introduction*

Lars Bullinger, MD, PhD, Charité University Medicine Berlin, Berlin, Germany

Adam S. Sperring, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Jesús María Hernández-Rivas, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain

*Impact of Real-World Evidence on Research and Clinical Care: Priorities from ASH RC DataHub and EU HARMONY Alliance*

William A. Wood Jr., MD, MPH, University of North Carolina, Chapel Hill, NC

*Pandemic Preparedness: Highlighting the Role of Real-World Data Hub Programs*

Samuel Rubinstein, MD, Vanderbilt University Medical Center, Chapel Hill, NC

Konstanze Döhner, MD, University Hospital of Ulm, Ulm, Germany

Jan Geissler, Acute Leukemia Advocates Network, Bern, Switzerland

*HARMONY Alliance: Moving Toward Multicenter Real-World Data Capture in the Hematologic Malignancies in Europe (Patient involvement in big data research)*

Donna S. Neuberg, ScD, Dana-Farber Cancer Institute, Boston

Brian J. Huntly, MB ChB, FRCPATH, FMedSci, PhD, University of Cambridge, Cambridge, England, United Kingdom

*Building Real-World Research and Collaborative Practice Networks for Malignant Hematology*

Bindu Kanapuru, Office of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD

*A Regulators View: The Impact of Reliable and Relevant Real-World Data on Measuring Safety and Efficacy*

Lars Bullinger, MD, PhD, Charité University Medicine Berlin, Berlin, Germany

*A Call to Action and Collaboration*

William A. Wood Jr., MD, MPH, University of North Carolina, Chapel Hill, NC

Moderated Q&A

---

AI and Machine Learning: A New Frontier in Hematology

**Monday 4:30 p.m. – 6:00 p.m.**

**Chair:**
Aziz Nazha, MD, Incyte, Wilmington, DE

**Speakers:**
Aziz Nazha, MD, Early Drug Development, Incyte, Westlake, OH

AI 101: Why is AI and Machine Learning Important in Hematology?

Olivier Elemento, PhD, Weill Cornell Medicine, New York, NY

*The Application of Machine Learning in Diagnostic Hematology*

Ilana Goldberg, PhD, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

AI in the Clinic: The Current Translation of Machine Learning Algorithms into Clinical Decision Tools

Shannon K. McWeeney, PhD, Oregon Health & Science University, Portland, OR

AI Challenges in Regulatory Approvals and Explicability

ASH Guidelines on AML in Older Adults: Monitoring Emerging Evidence

**Monday 4:30 p.m. – 6:00 p.m.**

**Chair:**
Mikkael A. Sekeres, MD, University of Miami, Sylvester Comprehensive Cancer, Miami, FL

**Speakers:**
Laura C. Michaelis, MD, The Medical College of Wisconsin, Milwaukee, WI

*Monitoring and Updating of the ASH AML Guidelines*

Mark R. Litzow, MD, Mayo Clinic, Rochester, MN

*Updates on Induction Therapy for Older Adults with AML*

Kristen Marie O’Dwyer, MD, University of Rochester Medical Center, Rochester, NY

*Updates on Post-Remission Therapy for Older Adults with AML*
**ASH Guidelines on VWD: Impact on Patients, Policy, and Allied Health Professionals**

**Monday**  
4:30 p.m. – 6:00 p.m.  
265-268

**Chair:**  
Nathan T. Connell, MD, Brigham and Women’s Hospital, Boston, MA

**Speakers:**  
Jean M. Grow, PhD, Marquette University, Milwaukee, WI  
**Impact of the VWD Guidelines on Patients**  
Leonard A. Valentino, MD, National Hemophilia Foundation, New York, NY  
**Impact of the VWD Guidelines on the Legislative and Policy Agendas**  
Penni Jo Smith, MPA, BSN, RN-BC, Primary Children’s Hospital, Salt Lake City, UT  
**Impact of the VWD Guidelines on Allied Health Professionals**

---

**ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease Update and Reception**

**Monday**  
5:30 p.m. – 8:00 p.m.  
Gravier DEF, Marriott New Orleans Warehouse Arts District

---

**Hemostasis and Thrombosis Community Networking Reception (for in-person participants)**

**Monday**  
6:30 p.m. – 7:30 p.m.  
Rivergate Terrace

---

**Women in Hematology Networking Dinner**

**Monday**  
7:30 p.m. – 9:30 p.m.  
Jefferson Ballroom, Hilton New Orleans Riverside
ASH provides a variety of high-quality educational, career-development, and networking opportunities to help trainees make the most of their meeting experience. The following activities have been identified as most relevant to the unique interests of undergraduates, medical and graduate students, residents, and fellows. These activities are open only to individuals with a blue trainee badge or received invitation.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

FRIDAY

ASH-a-Palooza

**Friday**
12:30 p.m. – 5:00 p.m.
River City Ballroom, Mardi Gras World

This is ASH’s premier trainee event complete with micro-learning sessions, mentorship opportunities, and more! It is only open to trainees wearing a blue badge. ASH Talks are TED Talk style didactic presentations on topical subjects for trainees. Blood Drops are 5-10 minute presentations on various hematology topics that are presented twice. Blood buddies are one-on-one, ten-minute sessions to discuss career tracks and seek advice for faculty members.

ASH Talk Opening Song and Welcome

**Friday**
12:45 p.m. – 1:00 p.m.
River City Ballroom, Mardi Gras World

**ASH Talk #1: Learning in a Virtual Space: How trainees can capitalize social media and virtual tools**

**Friday**
1:00 p.m. – 1:20 p.m.
River City Ballroom, Mardi Gras World

**Speaker:**
ANGELA C. WEYAND, MD, University of Michigan, Ann Arbor, MI

**Blood Buddies (In-Person)**

**Friday**
1:30 p.m. – 2:00 p.m., 2:40 p.m. – 3:10 p.m., 4:35 p.m. – 5:00 p.m.
River City Ballroom, Mardi Gras World

**Adult Clinical Classical Hematology**

GOWTHAMI M. AREPALLY, MD, Duke University Medical Center, Durham, NC
MARC CARRIER, MD, MSc, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada
ANNEMARIE E. FOGERTY, MD, Massachusetts General Hospital, Boston, MA
ALICE MA, MD, University of North Carolina At Chapel Hill, Chapel Hill, NC
ENRICO M. NOVELLI, MD, University of Pittsburgh, Pittsburgh, PA

**Adult Clinical Malignant Hematology**

HETTY E. CARRAWAY, MD, MBA, Cleveland Clinic, Cleveland, OH
DAVID L. GRINBLATT, MD, NorthShore University HealthSystem, Evanston, IL
MATTHEW ULRICKSON, MD, Banner/MD Anderson Cancer Center, Gilbert, AZ
ALISON R. WALKER, MD, The Ohio State University Medical Center, Powell, OH
BMT Peds and Adult
HANY ELMARIAH, MD, MS, Moffitt Cancer Center, Tampa, FL
DEEPA JAGADEESH, MD, Cleveland Clinic, Cleveland, OH
JAMES LABELLE, MD, PhD, University of Chicago, Chicago, IL
KRISTIN M. PAGE, MD, Duke University Medical Center, Durham, NC

Diversity, Equity, and Inclusion (DEI)
LANETTA BRONTÉ-HALL, MPH, MSPH, MD, The Foundation of Sickle Cell Disease Research, Hollywood, FL
PATRICK T. MCGANN, MD, PhD, Children's Hospital Medical Center, Providence, RI
WALLY R. SMITH, MD, Virginia Commonwealth University, Richmond, VA
DEIRTRA R. TERRELL, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Medical Education
TAMARA J. DUNN, MD, Stanford University, Stanford, CA
HIRA LATIF, MD, MedStar Washington Hospital Center, Baltimore, DC
TIFFANY LIN LUCAS, MD, University of California—San Francisco, San Francisco, CA
USHAR PEPEU, MBBS, University of Iowa Hospitals and Clinics Program, Iowa City, IA

Medical Student & Residents
MARThA L. ARELLANO, MD, Winship Cancer Institute of Emory University, Atlanta, GA
ROBERT D. BONA, MD, Frank H. Netter, M.D., School of Medicine at Quinnipiac University, Hamden, CT
ALEXANDER A. BOUCHER, MD, University of Minnesota Medical School, Plymouth, MN
MARIA OLIVARES BOUCHER, MD, Albany Medical Center, Albany, NY
LAURA DECASTRO, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
REED E. DREWS, MD, Beth Israel Deaconess Medical Center, Boston, MA
ANNIE IM, MD, University of Pittsburgh Cancer Institute, Pittsburgh, PA
ALFRED I. LEE, MD, PhD, Yale University School of Medicine, New Haven, CT
MICHAEL LINENBERGER, MD, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
RAKHI P. NAiK, MD, Johns Hopkins Hospital, Baltimore, MD
SANA SAiF Ur REHMAN, MD, Washington University School of Medicine, Saint Louis, MO

Pediatric Clinical Classical Hematology
LEILA JEROME CLAY, MD, Johns Hopkins University, St Petersburg, FL
JILL DE JONG, MD, PhD, University of Chicago, Chicago, IL
SEETHAL A. JACOB, MD, MS, Riley Hospital For Children, Indianapolis, IN
JULIE JAFFRAY, MD, MS, Children’s Hospital of Los Angeles, Los Angeles, CA

Pediatric Clinical Malignant Hematology
KARA M. KELLY, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY
JENNIFER L. MCNEER, MD, University of Chicago, Chicago, IL
ANDREW E. PLACE, MD, PhD, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA
RAYNE H. ROUCE, MD, Clinical Care Center-Texas Children’s Hospital, Houston, TX

PhD/ Lab & Translational Hematology
DAVID M. BODINE, PhD, National Institutes of Health, Bethesda, MD
ANDREs CHANG, MD, PhD, Emory University, Atlanta, GA
RANDAL J. WESTRICK, PhD, Oakland University, Rochester, MI
ISHAC NAZy, PhD, McMaster University, Hamilton, Ontario, Canada
JEREMY P. WOOD, PhD, University of Kentucky, Lexington, KY

Quality Improvement
NATHAN T. CONNeLL, MD, Brigham and Women’s Hospital, Boston, MA
MARIA I. JUAREZ, MD, Dallas Oncology Consultants, Duncanville, TX
JORDAN K. SCHAEFER, MD, University of Michigan, Ann Arbor, MI

Blood Drops
FRIDay 1:30 p.m. – 1:40 p.m.,
1:50 p.m. – 2:00 p.m.
River City Ballroom, Mardi Gras World

Clinical Research Training Institute (CRTI)
JEFFREY D. LEBENSbURGER, DO, University of Alabama at Birmingham, Birmingham, AL

Diversity, Equity, and Inclusion
TAMARA J. DUNN, MD, Stanford University, Stanford, CA,

Malignant Hematology
BRIAN A. JONAS, MD, PhD, University of California, Davis, Sacramento, CA

Minority Medical Student Award Program (MMSAP)
PhD
ZE ZHENG, MBBS, PhD, Columbia University, Milwaukee, WI
Quality Improvement
ADAM CUKER, MD, MS, University of Pennsylvania, Philadelphia, PA

Research Training Award Fellows (RTAF)
ADAM YUH LIN, MD, PhD, Northwestern University, Chicago, IL

Sickle Cell Disease
JANE S. HANKINS, MD, MS, St. Jude Children’s Research Hospital, Memphis, TN

Wellness
LAURA DE CASTRO, MD, MBBS, University of Pittsburgh Medical Center, Pittsburgh, PA

ASH Talk #2: The Resilient Trainee
Friday 2:10 p.m. – 2:30 p.m.
River City Ballroom, Mardi Gras World
Speaker:
ATHALIA PYZER, MD, PhD, University of Chicago Medicine, Chicago, IL

Blood Drops
Friday 2:40 p.m. – 3:00 p.m., 3:00 p.m. – 3:10 p.m.
River City Ballroom, Mardi Gras World

ASH-Harold Amos Medical Faculty Development Program (AMFDP)
JUSTIN TAYLOR, MD, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL

Sickle Cell Disease
SOPHIE M. LANZKRON, MD, Johns Hopkins Medicine, Baltimore, MD

Translational Research Training in Hematology (TRTH)
ANDRES CHANG, MD, PhD, Emory University, Atlanta, GA

Wellness
PAUL A. S. FISHKIN, MD, Illinois Cancer Care, Peoria, IL

ASH-Harold Amos Medical Faculty Development Program (AMFDP)
JUSTIN TAYLOR, MD, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL

Blood Drops
Friday 4:35 p.m. – 4:45 p.m., 4:50 p.m. – 5:00 p.m.
River City Ballroom, Mardi Gras World

SCHOLAR
SHANNON ELF, PhD, Division of Biological Sciences, The University of Chicago, Chicago, IL

ASH Medical Educators Institute (ASH MEI)
SRIKANTH NAGALLA, MD, MS, UT Southwestern, Dallas, TX

Diversity, Equity, and Inclusion
ALAN E. MAST, MD, PhD, Versiti (Blood Center of Wisconsin), Milwaukee, WI

Malignant Hematology
ALLISON WALKER, Comprehensive Cancer Center, The Ohio State University, Columbus, OH

PhD

Physician-Scientist Award (Phy-Sci)
ALEXANDER F. M. CRAIG, MPHIL, Stanford University Medical Center, Stanford, CA

Quality Improvement
DONALD M. ARNOLD, MD, MSc, McMaster University, Hamilton, ON, Canada

Sickle Cell Disease
Wellness
PETER A. KOUNDES, MD, Rochester General Hospital, Rochester, NY

Trainee Welcome Reception
Friday 5:00 p.m. – 7:00 p.m.
Float Den, Mardi Gras World
SATURDAY

**Career Development Lunch**

**Saturday 11:15 a.m. – 12:15 p.m.**
St. Charles Ballroom, Hilton New Orleans Riverside

This session will provide an intimate venue for trainees to meet with leaders in hematology to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research, PhD careers, careers in industry settings, and careers in private and clinical practice.

A boxed lunch is provided. There will be one hematology leader, assigned with a topic, at a table where trainees are welcome to eat lunch and chat about that topic.

**Adult and Pediatric BMT**
Mohamed A. Kharfan-Dabaja, MD, MBA, Division of Hematology/Oncology and Blood and Marrow Transplantation and Cellular Therapy, Mayo Clinic, Jacksonville, FL
Lori Muffly, MD, Division of BMT and Cellular Therapy, Stanford University, Stanford, CA
Rachel Phelan, MD, MPH, Department of Pediatrics, Division of Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI

**Adult Clinical Classical Hematology**
Shruti Chaturvedi, MBBS, Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Anjlee Mahajan, MD, UC Davis Comprehensive Cancer Center, Sacramento, CA
Stephan Moll, MD, Division of Hematology-Oncology, University of North Carolina School of Medicine, Chapel Hill, NC
Anita Rajasekhar, MD, University of Florida - Shands Hospital, Gainesville, FL

**Adult Clinical Malignant Hematology**
Karen Carlson, MD, PhD, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
Hetty E. Carraway, MD, MBA, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Leukemia Program, Cleveland Clinic, Cleveland, OH
Courtney D. Dinardo, MD, MSCE, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Anthony R. Mate, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY

**Clinical Careers in Hematology (Private Practice)**

**Careers**
Peter A. Koides, MD, Department of Medicine, Mary M. Gooley Hemophilia Center, Rochester, NY

**Global Hematology**
Eugenia Vicky V. Asare, BSc, Ghana Institute of Clinical Genetics, Accra, Ghana
Ali Bazarbachi, MD, PhD, Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
Adlette Inati, MD, FAAP, Lebanese American University, School of Medicine, Byblos, Lebanon
Russell E. Ware, MD, PhD, Division of Hematology, Children's Hospital Medical Center, Cincinnati, OH

**Industry Careers**
Gregory J. Kato, MD, Heart, Lung and Blood Vascular Medicine Institute/Division of Hematology-Oncology/Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
Weili Sun, MD, PhD, Department of Pediatrics, City of Hope Medical Center, Duarte, CA

**Laboratory and Translational Hematology**
Olga A. Guryanova, MD, PhD, University of Florida, Gainesville, FL
Andrew Volk, PhD, Division of Hematology/Oncology, Cincinnati Childrens Hospital Medical Center, Cincinnati, OH
Alisa S. Wolberg, PhD, UNC Blood Research Center, University of North Carolina At Chapel Hill, Chapel Hill, NC

**Medical Educators in Hematology**
Nadja D. Ali, MD, Section of Hematology, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Andrew RW O'Brien, MD, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN

**PhD Careers**
Margaret A. Goodell, PhD, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX
Courtney L. Jones, PhD, University of Toronto, Toronto, ON, Canada
Ze Zheng, MBBS, PhD, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

**Systems-Based Hematology**
David A. Garcia, MD, Division of Hematology, University of Washington, Seattle, WA
TRAINEE ACTIVITIES

Friday–Monday

SUNDAY – MONDAY

Trainee Didactic Sessions

Offered during lunch on Sunday and Monday, the Trainee Didactic Sessions are designed to offer trainees an overview of timely and relevant career-oriented issues.

Trainee Didactic Session: How to Transition from Trainee to Faculty

Sunday 11:15 a.m. – 12:15 p.m.
220-222

Chair: Julian Sprague, MD, PhD, Vermont Cancer Center, Burlington, VT

Speakers:
Andrew Volk, PhD, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Lachelle D. Weeks, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Trainee Didactic Session: Writing a Good CV, Portfolio, and Biosketch

Sunday 11:15 a.m. – 12:15 p.m.
217-219

Chair: Julian Sprague, MD, PhD, Vermont Cancer Center, Burlington, VT

Speakers:
Leslie R. Ellis, MD, MSHPEd, FACP, Wake Forest University School of Medicine, Winston Salem, NC
Andres Gomez De Leon, Hospital Universitario, Mexico City, Mexico
Shannon McKinney-Freeman, PhD, St. Jude Children’s Research Hospital, Memphis, TN

Trainee Didactic Session: Entrepreneurship

Monday 12:15 p.m. – 1:15 p.m.
217-219

Chair: Julian Sprague, MD, PhD, Vermont Cancer Center, Burlington, VT

Speakers:
Terry J. Fry, MD, CCR, National Cancer Institute, National Institutes of Health, Aurora, CO
Ajay Major, MD, MBA, University of Colorado, Denver, CO

Trainee Didactic Session: Giving A Scientific Presentation

Monday 12:15 p.m. – 1:15 p.m.
220-222

Chair: Julian Sprague, MD, PhD, Vermont Cancer Center, Burlington, VT

Speakers:
Julia E. Maxson, Oregon Health & Science University, Portland, OR
Sonali M. Smith, MD, University of Chicago, Chicago, IL
MK-2140-003
• Evaluating MK-2140, an investigational antibody-drug conjugate (ADC), in combination with chemotherapy, for relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

MK-2140-004
• Evaluating MK-2140, an investigational antibody-drug conjugate (ADC) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have not responded to other treatment options

MK-2140-006
• Evaluating MK-2140, an investigational antibody-drug conjugate (ADC), as a monotherapy and in combination for participants with aggressive and indolent B-cell malignancies

MK-1026-003
• Evaluating MK-1026, an investigational inhibitor of Bruton’s tyrosine kinase (BTK), in multiple relapsed/refractory hematologic malignancies (including CLL/SLL, Richter’s transformation, marginal zone lymphoma [MZL], MCL, FL, and Waldenström’s macroglobulinemia [WM])

MK-1026-008
• Evaluating MK-1026, an investigational inhibitor of Bruton’s tyrosine kinase (BTK), versus chemoimmunotherapy for previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma without TP53 aberrations

MK-1026-010
• Evaluating MK-1026 (an investigational inhibitor of Bruton’s tyrosine kinase [BTK]) plus venetoclax, versus venetoclax plus rituximab, in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma following at least 1 prior therapy

MK-3475-667
• Evaluating pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma with inadequate (slow early) response to frontline chemotherapy

MK-4280-003
• Evaluating a combination of MK-4280, an investigational lymphocyte activation gene-3 (LAG3) inhibitor, and pembrolizumab in participants with hematologic malignancies

MK-4280A-008
• Evaluating MK-4280A, an investigational coformulation of MK-4280 (an investigational lymphocyte activation gene-3 [LAG3] inhibitor) plus pembrolizumab versus physician’s choice chemotherapy in PD-(L)1-refractory, relapsed, or refractory classical Hodgkin lymphoma

For more information and to see if your patients may qualify, visit MerckClinicalTrials.com/Oncology
EDUCATION PROGRAM
EDUCATION SESSIONS

The Education Program will be held from Saturday, December 10, through Monday, December 12. A question-and-answer period will occur at the end of each individual speaker presentation. Chapters based on these sessions will be published in Hematology 2022, the ASH Education Program.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Autoimmune Hemolytic Anemias (AIHA)

**Saturday 9:30 a.m. – 10:45 a.m.**

**Chair:**

**David J. Kuter, MD, DPhil,** Massachusetts General Hospital, Boston, MA

**Speakers:**

**David J. Kuter, MD, DPhil,** Massachusetts General Hospital, Boston, MA

*Catherine Broome, MD,* Georgetown Hospital, Washington, DC

*Sue T. Johnson, MSTM, MLS(ASCP)SBB,* Blood Center of Wisconsin, Milwaukee, WI

*Evaluate the Difficulties of Evaluating AIHA Patients in the Reference Lab of the Blood Bank and the Best Transfusion Management Strategies*

Controversies in Aggressive NHL

**Saturday 9:30 a.m. – 10:45 a.m.**

**Chair:**

**Christopher R. Flowers, MD, MD Anderson Cancer Center,** Houston, TX

**Speakers:**

**Kate Cwynarski, MBBS, PhD, FRCP, FRCPATH,** University College London Hospitals, London, England, United Kingdom

*CNS Prophylaxis in Aggressive B-Cell Lymphoma*

**Christopher R. Flowers, MD, MD Anderson Cancer Center,** Houston, TX

*Sequencing Therapy in Relapsed DLBCL*

**Anita Kumar, MD,** Memorial Sloan Kettering Cancer Center, New York City, NY

*What Is the Role of Upfront Autologous Stem Cell Transplant in Mantle Cell Lymphoma?*

JAK/STAT Inhibition and Beyond in Ph Negative MPNs

**Saturday 9:30 a.m. – 10:45 a.m.**

**Chair:**

**Kristen M. Pettit, MD,** University of Michigan, Ann Arbor, MI

**Speakers:**

**Alessandro Vannucchi, MD,** University of Florence, Firenze, Italy

*Molecular Prognostication in Ph Negative MPNs in 2022*

**Kristen M. Pettit, MD,** University of Michigan, Ann Arbor, MI

*New Approaches to Tackle Cytopenic Myelofibrosis*

**Rajit Rampal, MD, PhD,** Memorial Sloan Kettering Cancer Center, New York City, NY

*Management of Accelerated and Blast Phase MPN*

Multiple Myeloma: Assessing the Patient and the Disease

**Saturday 9:30 a.m. – 10:45 a.m.**

**Chair:**

**Natalie Callander, MD,** University of Wisconsin, Madison, WI

**Speakers:**

**Clara L. Freeman, MSc, FRCPATH, MBChir, MRCP, BC Cancer,** Tampa, FL

*Fitness and Frailty in Myeloma*

**Timothy Martin Schmidt, MD,** Emory University/Winship Cancer Institute, Madison, WI

*High or Low? Assessing Disease Risk in Multiple Myeloma*

**Taxiarchis Kourelis, MD,** Mayo Clinic, Rochester, MN

*The Burden of Myeloma: Novel Approaches to Disease Assessment*

*Of interest to PhD attendees. CME credit is not offered.*
## Late Effects of Curative Therapy for Sickle Cell Disease

**Saturday 2:00 p.m. – 3:15 p.m.**  
**Hall E**

**Chair:**  
**Courtney D. FitzHugh, MD,** National Institutes of Health (Hematology), Bethesda, MD

**Speakers:**  
**Courtney D. FitzHugh, MD,** National Institutes of Health (Hematology), Bethesda, MD  
**Shalini Shenoy, MD,** Washington University Medical Center, St. Louis, MO  
**Debra Friedman, MD,** Vanderbilt-Ingram Cancer Center, Nashville, TN

- *Knowledge to Date on Secondary Malignancy*  
- *Organ Function Indications and Potential Improvements*  
- *Long-term health effects of curative therapies for SCD*

---

## Prophylactic Platelet Transfusions

**Saturday 2:00 p.m. – 3:15 p.m.**  
**243-245**

**Chair:**  
**Monica B. Pagano, MD,** University of Washington, Seattle, WA

**Speakers:**  
**Zbigniew Macdonald Szczepiorkowski, MD, PhD,** Dartmouth-Hitchcock Medical Center, Lebanon, NH  
**John D. Roback, MD, PhD,** Emory University Hospital Blood Bank, Atlanta, GA  
**Dana V. Devine, PhD,** Canadian Blood Services UBC Centre for Blood Research, Vancouver, British Columbia, Canada

- *Evaluate how hospitals are approaching the recent FDA guidance to reduce the risk of bacterial contamination, including pathogen reduction technology and large volume delayed sampling*  
- *Donor Pool*  
- *Assess New Alternatives for Platelets, including cold (4o) platelets*

---

## Thrombosis and Anticoagulation: Clinical Considerations in Selected Populations

**Saturday 2:00 p.m. – 3:15 p.m.**  
**Great Hall A/D**

**Chair:**  
**Alfred I. Lee, MD, PhD,** Yale University School of Medicine, New Haven, CT

**Speakers:**  
**Bethany T. Samuelson Bannow, MD,** Oregon Health & Science University, Portland, OR  
**Anticoagulant Therapy for Women**  
**Pante Angchaisuksi, MD,** Ramathibodi Hospital, Bangkok, Thailand  
**Thrombosis and Anticoagulation: Clinical Issues of Special Importance to Hematologists Who Practice in Asia**  
**Alfred I. Lee, MD, PhD,** Yale University School of Medicine, New Haven, CT  
**Thrombosis Questions from the Inpatient Wards**

---

## von Willebrand Disease

**Saturday 2:00 p.m. – 3:15 p.m.**  
**208-210**

**Chair:**  
**Paula D. James, MD, FRCP, Queen’s University, Kingston, Ontario, Canada**

**Speakers:**  
**Michelle Lavin, MB, PhD, FRCPath, Haemostasis Research Lab, Dublin, Ireland**  
**Diagnostic Pitfalls and Conundrums**  
**Paula D. James, MD, FRCP, Queen’s University, Kingston, Ontario, Canada**  
**Special Considerations in GI Bleeding**  
**Michelle Sholzberg, MD, St. Michael’s Hospital, Toronto, Ontario, Canada**  
**What Have We Learned About the Patient’s Experience with von Willebrand Disease?**
Where Are We Headed in Hodgkin Lymphoma?

**Saturday 2:00 p.m. – 3:15 p.m.**
New Orleans Theater AB

**Chair:**
Alison J. Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

**Speakers:**
Alex F. Herrera, MD, City of Hope, Duarte, CA
Incorporating Novel Agents in Frontline Treatment of HL

Sven Borchmann, MD, Uniklinik Köln, Cologne, Germany
Management of Nodular Lymphocyte Predominant HL

Alison J. Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY
Do All Patients with Primary Refractory/First Relapse of HL Need Autologous Stem Cell Transplant?

Anxiety Provoking Consultations: Mast Cells and Eosinophils

**Saturday 4:00 p.m. – 5:15 p.m.**
295-296

**Chair:**
Jason Gotlib, MD, MS, Stanford Cancer Center, Stanford, CA

**Speakers:**
Cem Akin, MD, University of Michigan, Ann Arbor, MI
How to Evaluate the Patient with a Suspected Mast Cell Disorder and How/When to Manage Symptoms

Amy D Klion, MD, National Institutes of Health, Bethesda, MD
How to Evaluate the Patient with a Suspected Eosinophil Disorder and How/When to Manage Symptoms

Jason Gotlib, MD, MS, Stanford Cancer Center, Stanford, CA
Available and Emerging Therapies for Bona Fide Advanced Systemic Mastocytosis and Primary Eosinophilic Neoplasms

Immunotherapy in Multiple Myeloma

**Saturday 4:00 p.m. – 5:15 p.m.**
Hall E

**Chair:**
Suzanne Trudel, MSc, MD, McLaughlin Centre for Molecular Medicine, Toronto, Ontario, Canada

**Speakers:**
Paula Rodriguez Otero, MD, PhD, Clinica Universidad de Navarra, Pamplona, Spain
Cellular Therapy for Multiple Myeloma: What’s Now and What’s Next

Suzanne Trudel, MSc, MD, McLaughlin Centre for Molecular Medicine, Toronto, Ontario, Canada
Antibodies and Bispecifics for Multiple Myeloma: Effective Effector Therapy

Sarah A. Holstein, MD, PhD, Nebraska Medical Center, Omaha, NE
Beyond the Cell: Novel Non-Cellular Immunotherapy Approaches to Multiple Myeloma

Managing Thrombocytopenia in Challenging Situations

**Saturday 4:00 p.m. – 5:15 p.m.**
243-245

**Chair:**
Hanny Al-Samkari, MD, Massachusetts General Hospital, Harvard Medical School, Cambridge, MA

**Speakers:**
Hanny Al-Samkari, MD, Massachusetts General Hospital, Harvard Medical School, Cambridge, MA
Chemotherapy-Induced Thrombocytopenia

Adam Cuker, MD, MS, University of Pennsylvania, Philadelphia, PA
Thrombocytopenia in Liver Disease

Alyson M. Pishko, MD, Hospital of University of Pennsylvania, Bryn Mawr, PA
Thrombocytopenia in Pregnancy
**Novel Approaches in MDS**

**Saturday** 4:00 p.m. – 5:15 p.m.  
288-290

**Chair:**  
UMA BORATE, MD, The Ohio State University, Columbus, OH

**Speakers:**  
MARIO CAZZOLA, MD, University of Pavia, Pavia, Italy
Risk Stratifying MDS in the Time of Precision Medicine

AMIT VERMA, MD, Albert Einstein College of Medicine, Bronx, NY
Targeting Inflammation in Lower Risk MDS

UMA BORATE, MD, The Ohio State University, Columbus, OH
New Investigational Combinations For Higher-Risk MDS

**Update in Hemophilia**

**Saturday** 4:00 p.m. – 5:15 p.m.  
291-292

**Chair:**  
REBECCA KRUSE-JARRES, MD, MPH, University of Washington, Seattle, WA

**Speakers:**  
MARILYN J MANCO-JOHNSON, MD, Mountain State Regional Hemophilia & Thrombosis Center, Aurora, CO
Long-Term Prophylaxis - What Are Our Options and How to Define Success?

REBECCA KRUSE-JARRES, MD, MPH, University of Washington, Seattle, WA
Peri-Operative Hemostasis

AMIT C. NATHWANI, MD, PhD, University College London, London, England, United Kingdom
Gene Therapy

**Are Alternative Donors Now Mainstream in Allogeneic Transplant?**

**Saturday** 4:00 p.m. – 5:15 p.m.  
Great Hall B/C

**Chair:**  
MONZR M. AL MALKI, MD, City of Hope, Duarte, CA

**Speakers:**  
MONZR M. AL MALKI, MD, City of Hope, Duarte, CA
New Strategies for Mismatched Unrelated Donors

STEPHEN R. SPELLMAN, National Marrow Donor Program, Minneapolis, MN
What Is Complete HLA Match in 2022?

ARNON NAGLER, MD, Chaim Sheba Medical Center, Tel Hashomer, Israel
In 2022, Which is Preferred: Haploidentical or Cord Transplant?

**Acute Myeloid Leukemia: Improving Outcomes in Challenging Subsets**

**Sunday** 9:30 a.m. – 10:45 a.m.  
Great Hall B/C

**Chair:**  
ALICE S. MIMS, MD, The Ohio State University, Columbus, OH

**Speakers:**  
CHRISTOPHER S. HOURIGAN, MD, DPHIL, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Achieving MRD Negativity in AML: How Important Is This and How Do We Get There?

KEITH W. PRATZ, MD, Johns Hopkins University, Baltimore, MD
Optimizing Outcomes in Secondary AML

ALICE S. MIMS, MD, The Ohio State University, Columbus, OH
Novel Investigational Approaches for High-Risk Molecular Subsets: TP53, MLL, FLT3

**Maximizing Outcomes in CLL**

**Sunday** 9:30 a.m. – 10:45 a.m.  
265-268

**Chair:**  
JENNIFER R. BROWN, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

**Speakers:**  
JENNIFER R. BROWN, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
Selecting Initial Therapy in CLL

LYDIA SCARFO, MD, Ospedale San Raffaele, Milano, Italy
Novel Therapies and Combinations in CLL Refractory to BTK Inhibitors and Venetoclax
EDUCATION SESSIONS

10–12 Dec 2022

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

### Treatment of Richter’s Syndrome

**TANYA SIDDIQI, MD, City of Hope National Medical Center, Duarte, CA**

**Reproductive and Sexual Health in Sickle Cell Disease**

**Chair:**

**IBRAHIM MUSA IDRIS, MBBS, MPH, FMCPATH, Aminu Kano Teaching Hospital, Kano, Nigeria**

**Speakers:**

**IBRAHIM MUSA IDRIS, MBBS, MPH, FMCPATH, Aminu Kano Teaching Hospital, Kano, Nigeria**

1. **Epidemiology and Treatment of Priapism in Sickle Cell Disease**
   - **LYDIA H. PECKER, MD, MHS, Johns Hopkins University, Baltimore, MD**
   - **Fertility of Women with Sickle Cell Disease**
   - **LILLIAN R. MEECHAM, MD, Children’s Healthcare of Atlanta, Decatur, GA**
   - **Decision Making for Reproductive Health in Sickle Cell Disease**

### Beyond Routine Frontline Therapy of CML

**Chair:**

**TIMOTHY P. HUGHES, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute, Adelaide, Australia**

**Speakers:**

**TIMOTHY P. HUGHES, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute, Adelaide, Australia**

1. **Management of Early Relapsed Follicular Lymphoma**
   - **JESSICA OKOSUN, MB BCHIR PhD, Barts Hospital, London, England, United Kingdom**
   - **Pathogenesis of Follicular Lymphoma**
   - **LUCA ARCAINI, MD, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy**
   - **Management of Marginal Zone Lymphoma**

### Obstetric Management and Complications in Sickle Cell Disease in High- and Low-Income Countries

**Chair:**

**EUGENIA VICKY ASARE, BSc, Ghana Institute of Clinical Genetics, Accra, Ghana**

**Speakers:**

**EUGENIA VICKY ASARE, BSc, Ghana Institute of Clinical Genetics, Accra, Ghana**

1. **Epidemiology of Obstetric Complications Among women with Sickle Cell Disease**
   - **BOSEDE AFOFALABI, DM, University of Lagos College of Medicine, Ibi-Araba, Lagos, Nigeria**
   - **Evidence-Based Obstetric Management of Women with Sickle Cell Disease in Low Income Countries**
   - **EUGENE OTENG-NITIM, PhD, MBBS, Guy’s and St Thomas’ NHS Foundation Trust, London, England, United Kingdom**
   - **Evidence-Based Management of Pregnant Women with Sickle Cell Disease in High Income Countries**

### What’s New in Indolent Lymphoma

**Chair:**

**TYCEL J. PHILLIPS, MD, University of Michigan, Ann Arbor, MI**

**Speakers:**

**TYCEL J. PHILLIPS, MD, University of Michigan, Ann Arbor, MI**

1. **Management of Early Relapsed Follicular Lymphoma**
   - **NICOLAS KROEGER, MD, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany**
   - **Transplantation in CML in the TKI Era: Who, When, How?**
   - **JANET F. APPERLEY, FRCP, FRCPATH, MB, Hammersmith Hospital, Imperial College, London, England, United Kingdom**
   - **Treatment of CML in Pregnancy**
Improving Outcomes in ALL

**Monday**
10:30 a.m. – 11:45 a.m.
R02-R05

**Chair:**
MATTHEW J. WIEDWILT, MD, PhD, University of California—San Diego, San Diego, CA

**Speakers:**
NICOLAS BOISSEL, MD, PhD, Hôpital St. Louis / Université Paris, Paris, France
*New Developments in ALL in AYA*

KRISTEN M. O’DWYER, MD, University of Rochester Medical Center, Rochester, NY
*Optimal Approach to T-Cell ALL*

MATTHEW J. WIEDWILT, MD, PhD, University of California—San Diego, San Diego, CA
*Ph+ ALL in 2022: Is There an Optimal Approach?*

Treatment Approaches for the Multiple Myeloma Patient in 2022

**Monday**
2:45 p.m. – 4:00 p.m.
Great Hall A/D

**Chair:**
YVONNE A. EFEBERA, MD, MPH, The Ohio State University Comprehensive Cancer Center, Columbus, OH

**Speakers:**
SIGRUN THORSTEINSDOTTIR, MD, PhD, Rigshospitalet, Copenhagen, Denmark
*The Consultant’s Guide to Smoldering Multiple Myeloma*

CAITLIN COSTELLO, MD, University of California—San Diego, San Diego, CA
*Newly Diagnosed Multiple Myeloma: Making Sense of the Menu*

YVONNE A. EFEBERA, MD, MPH, The Ohio State University Comprehensive Cancer Center, Columbus, OH
*The First Relapse in Multiple Myeloma – How to Pick the Next Best Thing*

Updates in Targeted Therapy in Pediatric Leukemia

**Monday**
2:45 p.m. – 4:00 p.m.
343-345

**Chair:**
SARAH K. TASIAN, MD, Children’s Hospital of Philadelphia, Philadelphia, PA

**Speakers:**
SARAH K. TASIAN, MD, Children’s Hospital of Philadelphia, Philadelphia, PA
*Clinical Screening for Ph-like ALL and the Developing Role of TKIs*

KATHERINE TARLOCK, MD, University of Washington, Seattle, WA
*The Evolution of Targeted Therapy in Pediatric AML: Small Molecule Inhibitors and Immunotherapeutic Strategies*

RISHI SURY KOTECHA, PhD, FRACP, MBBCHIR, MRCP, University of Western Australia, Perth, WA, Australia
*Updates in Infant Leukemia and the Potential for Targeted Therapy*

What is New in Classical Bone Marrow Failure Syndromes? (focus on management)

**Monday**
2:45 p.m. – 4:00 p.m.
260-262

**Chair:**
SHARON A. SAVAGE, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD

**Speakers:**
JEAN DONADEU, MD, PhD, Hospital Trousseau, Paris, France
*Severe Congenital Neutropenia*

CARLO DUFOUR, G. Gaslini Children’s Hospital, Genova, Italy
*Fanconi Anemia*

SHARON A. SAVAGE, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD
*Dyskeratosis Congenita & Telomere Biology Disorders*
Thrombosis Prevention and Treatment

**Monday**  4:30 p.m. – 5:45 p.m.  
R02-R05

**Chair:**  
Tzu-Fei Wang, MD, MPH, The University of Ottawa, Ottawa, Ontario, Canada

**Speakers:**  
Tzu-Fei Wang, MD, MPH, The University of Ottawa, Ottawa, Ontario, Canada  
The 5 Most-Frequently-Asked Questions About FXa Inhibitors

Alex C. Spyropoulos, MD, Northwell, West Harrison, NY  
Controversies in VTE Prevention for Medical Inpatients

Walter Ageno, MD, University of Insubria, Varese, Italy  
Coming Soon to a Pharmacy Near You? FXa Inhibitors and Other Novel Strategies to Prevent or Treat Venous Thromboembolism

Junior Faculty Career Development Education Session

**Monday**  4:30 p.m. – 5:45 p.m.  
New Orleans Theater AB

**Chair:**  
Yvonne A. Efebura, MD, MPH, Ohio Health, Columbus, OH

**Speakers:**  
Alison W. Loren, MD, Perelman Center for Advanced Medicine, Philadelphia, PA  
Negotiation, It’s More Than Just the Money

Cecelia Calhoun, MD, MBA, MPH, Washington University School of Medicine in St. Louis, St. Louis, MO  
Negotiation, It’s More Than Just the Money

Pallawi Torka, MD, Roswell Park Cancer Institute, Buffalo, NY

Ursula Durani, MD, MPH, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Pasadena, CA  
Should I Stay or Should I Go?

Late Effects Monitoring for Survivors of Pediatric Hematologic Malignancies

**Monday**  4:30 p.m. – 5:45 p.m.  
288-290

**Chair:**  
Eric J. Chow, MD, MPH, Seattle Children’s, Seattle, WA

**Speakers:**  
Eric J. Chow, MD, MPH, Seattle Children’s, Seattle, WA  
Mitigating, Monitoring, and Managing Long-Term Chemotherapy- and Radiation-Induced Cardiac Toxicity

Kevin R. Krull, PhD, St. Jude Children’s Research Hospital, Memphis, TN  
Risk Factors and Screening for Neurocognitive Impacts of Therapy

Smita Bhatia, MD, MPH, University of Alabama at Birmingham, Birmingham, AL  
Germ Line Risk Factors for Second Malignant Neoplasms After Treatment for Pediatric Hematologic Malignancies

To Transplant or Not to Transplant in Active or High-Risk Myeloid Disease

**Monday**  4:30 p.m. – 5:45 p.m.  
343-345

**Chair:**  
Coleman Lindsley, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

**Speakers:**  
Daniel J. Weisdorf, MD, University of Minnesota, Minneapolis, MN  
Transplant in Those with High-Burden Disease: Refractory AML and High-Risk MDS

Charles Craddock, FRCP, FRCPATH, CBE, PHI, Queen Elizabeth Hospital, Birmingham, England, United Kingdom  
Transplant in AML with Measurable Residual Disease: Proceed or Defer?
INVITES YOU TO ATTEND

How to Peer Review a Scientific Paper

The Blood Advances Editor-in-Chief, Dr. Catherine Bollard will lead a panel discussion with editors, Dr. Leslie Kean and Dr. Andrew Weyrich as panelists on How to Peer Review a Scientific Paper. The session will provide valuable information on the best practices of peer review from the editorial perspective for both basic and clinically relevant manuscripts. There are professional benefits to becoming a reviewer. It allows the hematologist to stay current on research and developments in the field and can help in patient care, both in the lab and classroom. The reviewer also can get recognized by their colleagues and demonstrate professional development with their institution.

FEATURING (recorded):
Catherine Bollard, MD
Editor-in-Chief,
Blood Advances
Children’s National Hospital
Washington, DC

ASH® 2022 Annual Meeting in New Orleans
Sunday December 11, 2022  •  In-Person
11:15am – 12:15pm CST
Ernest N. Morial Convention Center Room 252-254

Annual Meeting Virtual Platform/Webcast
Requires ASH 2022 registration or webcast purchase

► Register to attend this session in-person, or via the Virtual Platform/Webcast
hematology.org/annual-meeting

PANELIST (in-person):
LESLIE KEAN, MD, PhD
Boston Children’s Hospital
Boston, MA

PANELIST (in-person):
Andrew Weyrich, PhD
Oklahoma Medical Research Foundation
Oklahoma City, OK
EDUCATION SPOTLIGHT SESSIONS

Education Spotlight Sessions are intended to provide an in-depth review on specific scientific topics. This year, speakers will discuss current challenges and controversies in eight exciting topics, addressing the current state of knowledge, translational and clinical applications, and future directions.

Each 75-minute session will be presented once in a small-venue format on either Sunday or Monday and will include ample time for audience questions and participation. These sessions are restricted to medical and research professionals only; no businesspersons or media will be admitted.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SUNDAY

Bone Marrow Failure Syndromes: Diagnostic Principles in 2022

Sunday  4:30 p.m. - 5:45 p.m.  
260-262

CHAIR:  
JEFFERY KLCO, MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN

Speakers:  
MARK D. FLEMING, MD, DPHIL, Boston Children’s Hospital, Boston, MA  
Pathology vs molecular genetics: comprehensive microscopic evaluation will remain the essential initial step

SARA LEWIS, MS, St. Jude Children’s Research Hospital, Memphis, TN  
Genetic Counseling: Ethical Considerations during the Diagnostic Process and How to Avoid Confusing Situations

New Horizons for Histiocyte Disorders

Sunday  4:30 p.m. - 5:45 p.m.  
275-277

Chair:  
P A U L  C. HENDR I E, MD, PhD, University of Washington, Seattle, WA

Speakers:  
ELI L DIAMOND, MD, Memorial Sloan Kettering Cancer Center, New York, NY  
How and When to Incorporate Targeted Therapy into the Treatment of Histiocytic Disorders

CARL E. ALLEN, MD, Texas Children’s Cancer Center, Houston, TX  
Updates on Genetic Drivers of Histiocyte Disorders

Survivorship In Adult Patients With Lymphoma

Sunday  4:30 p.m. - 5:45 p.m.  
Great Hall A/D

Chair:  
JAVID J. MOSLEHI, MD, Vanderbilt School of Medicine, San Francisco, CA

Speakers:  
JAVID J. MOSLEHI, MD, Vanderbilt School of Medicine, San Francisco, CA  
Prevention, screening, and treatment of treatment related cardiomyopathy

CARRIE A. THOMPSON, MD, Mayo Clinic, Rochester, MN  
Screening for Radiation and Chemotherapy Late Effects (except cardiac)
MONDAY

Debate: Most/All Patients With Acquired (Immune) Thrombotic Thrombocytopenic Purpura (TTP) Receive Caplacizumab

Monday 10:30 a.m. - 11:45 a.m.
295-296

Chair:
Mark Crowther, MD, St. Joseph’s Hospital, Hamilton, ON, Canada

Speakers:
Camila Masias, MD, MPH, Miami Cancer Institute, Miami, FL
FOR (All/most patients should receive caplacizumab)

George Goshua, MD, MSc, Yale School of Medicine, New Haven, CT
AGAINST (most/all patients with Acquired TTP should receive caplacizumab)

Underrepresented Minorities In Clinical Trials For Hematologic Malignancies: What’s The Data On The Data?

Monday 10:30 a.m. - 11:45 a.m.
R06-R09

Chair:
Kenneth C. Anderson, MD, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA

Speakers:
Luciano J. Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL
Discuss historical percentages of URM enrollment in clinical trials and theories for this data

Sikander Ailawadhi, MD, Mayo Clinic, Jacksonville, FL
Discuss approaches to improve enrollment and outcomes

Rayne H. Rouse, MD, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX
Discuss approaches to increase the proportion of underrepresented minorities in the clinical investigator/clinical research pathway.

Immunotherapies For Myeloid Neoplasms: Are We Ready For Primetime?

Monday 2:45 p.m. - 4:00 p.m.
New Orleans Theater AB

Chair:
Hongtao Liu, MD, PhD, University of Chicago, Chicago, IL

Speakers:
Sarit Assouline, MD, MSc, FRCPC, McGill University Jewish General Hospital, Montreal, Quebec, Canada
BITES, immune checkpoint molecules, macrophage checkpoint molecules for AML and high grade MDS-

Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA
CAR-T therapy for high grade myeloid neoplasms—what are the barriers and how do we overcome?

Point/Counterpoint: The Case For/Against Thrombophilia Testing In Many/Most Adults With Unprovoked Thrombosis.

Monday 2:45 p.m. - 4:00 p.m.
288-290

Chair:
Wendy Lim, MD, MSc, McMaster University, Hamilton, Ontario, Canada

Speakers:
Stephan Moll, MD, University of North Carolina School of Medicine, Chapel Hill, NC
Point/Counterpoint: There case FOR thrombophilia testing in many/most adults with unprovoked thrombosis.

Deborah M. Siegal, MD MSc FRCP, Thrombosis Clinic, Juravinski Hospital, Ottawa, Ontario, Canada
Point/Counterpoint: There case AGAINST thrombophilia testing in many/most adults with unprovoked thrombosis
## SATURDAY

### Can We Move Toward a Precision Medicine Approach for the Treatment of Higher Risk Myelodysplastic Syndromes

**Saturday 8:30 a.m. – 9:30 a.m.**  
Marlborough A, Hilton New Orleans Riverside  

**Speaker:**  
Olatoyosi Odenike, MD, University of Chicago, Chicago, IL

### ITP/TTP – and Other Scary Causes of Thrombocytopenia - Saturday

**Saturday 8:30 a.m. – 9:30 a.m.**  
Camp, Hilton New Orleans Riverside  

**Speaker:**  
Hanny Al-Samkari, MD, Massachusetts General Hospital, Harvard Medical School, Cambridge, MA

### Sickle Cell Disease – Where do Gene Therapy and Hematopoietic Cell Transplantation Fit into the Future Landscape

**Saturday 8:30 a.m. – 9:30 a.m.**  
Commerce, Hilton New Orleans Riverside  

**Speaker:**  
Courtney D. FitzHugh, MD, National Institutes of Health (Hematology), Bethesda, MD

### The Case for MRD Testing and the Relevance to Treatment Decisions and Outcomes in AML.

**Saturday 8:30 a.m. – 9:30 a.m.**  
Canal, Hilton New Orleans Riverside  

**Speaker:**  
Christopher S. Hourigan, MD, National Heart, Lung, and Blood Institute, Bethesda, MD

---

**Ticket Prices (per session)**

<table>
<thead>
<tr>
<th>Category</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active or International Member</td>
<td>$75</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$75</td>
</tr>
<tr>
<td>Associate, International Associate, Resident, or Graduate/Medical Student, or Honorary/Emeritus Member</td>
<td>$50</td>
</tr>
<tr>
<td>Non-Member in Training</td>
<td>$50</td>
</tr>
<tr>
<td>Allied Health Professional</td>
<td>$50</td>
</tr>
</tbody>
</table>

---

Attention Trainees!

A number of tickets for these sessions will be reserved for trainees. Proof of status as an Associate, International Associate, Resident, or Graduate/Medical Student member, or Non-Member in Training will be required to purchase a ticket.

---

All events take place in the Ernest N. Morial Convention Centre unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.
SUNDAY

Thrombosis and Anticoagulation – Duration of Therapy, Thrombophilia

Sunday 8:30 a.m. – 9:30 a.m. 
Marlborough A, Hilton New Orleans Riverside

Speaker:
STEPHAN MOLL, MD, University of North Carolina School of Medicine, Chapel Hill, NC

Too Many Mast Cells and Eosinophils – How to Exclude (or Treat) Neoplastic Causes.

Sunday 8:30 a.m. – 9:30 a.m. 
Camp, Hilton New Orleans Riverside

Speaker:
JASON GOTLIB, MD, MS, Stanford Cancer Center, San Carlos, CA

vWD and Other Bleeding Disorders – Diagnostic Pitfalls and Special Situations

Sunday 8:30 a.m. – 9:30 a.m. 
Canal, Hilton New Orleans Riverside

Speaker:
MICHHELLE SHOLZBERG, MDCM, MSc, St. Michael’s Hospital, Toronto, Ontario, Canada
American Society of Hematology
Helping hematologists conquer blood diseases worldwide

blood® INVITES YOU TO ATTEND

How to Get Published in a Peer-Reviewed Journal

The ability to communicate one’s work effectively by publication in high-impact journals is a benchmark for success in academic medicine. Even high-quality work may not be accepted if not presented in a well-crafted manuscript. Dr. Berliner will lead a panel discussion that will provide insight into the elements of a high-quality manuscript worthy of publication in Blood and tips on avoiding common errors that might result in rejection.

ASH® 2022 Annual Meeting in New Orleans
Saturday, December 10, 2022 • In-Person
11:15am – 12:15pm CST
Ernest N. Morial Convention Center, Room 243-245

Annual Meeting Virtual Platform/Webcast
Requires ASH 2022 registration or webcast purchase

▶ Register to attend this session in-person, or via the Virtual Platform/Webcast
hematology.org/annual-meeting

CHAIR:
Nancy Berliner, MD
Editor-in-Chief, Blood
Brigham and Women’s Hospital
Boston, MA

PANELIST:
Andrew Roberts,
MBBS, PhD
Deputy Editor, Blood
Peter MacCallum Cancer Centre
Melbourne, Australia
FOR MYELOFIBROSIS PATIENTS, ONE SIZE DOES NOT FIT ALL

Myelofibrosis (MF) presents with substantial heterogeneity in patients’ symptoms and course of disease.\(^1\) An unmet need remains in understanding the pathogenesis of anemia in MF.\(^2\)


TO LEARN MORE, VISIT MYELOFIBROSISINSIGHTS.COM

Trademark are owned by or licensed to the GSK group of companies.

©2022 GSK or licensor.
MMLJRNA220004 October 2022
Produced in USA.
SCIENTIFIC PROGRAM
The Scientific Program will be held Saturday, December 10, through Monday, December 12. There will be a panel discussion at the end of the session during which questions from the audience will be entertained. There will be no Q&A after each individual speaker’s presentation.

Scientific Program Co-Chairs:
DAVID M. BODINE, PhD, National Institutes of Health, Bethesda, MD
CATHERINE J. WU, MD, Dana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorders Center, Boston, MA

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Aplastic Anemia, Dysimmunity and Mutant Clones

Chair: JEAN SOULIER, MD, PhD, Hospital Saint-Louis, Centre Hayem, Paris, France

Speakers:
NEAL S. YOUNG, MD, National Institutes of Health, Bethesda, MD
Immune Deregulation in Aplastic Anemia
DARIA V. BABUSHOK, MD, Hospital of the University of Pennsylvania, Philadelphia, PA
HLA-restricted Attack and Clonal Evolution in Aplastic Anemia
AUSTIN KILASEKARAJ, MD, MBBS, King’s College Hospital, London, England, United Kingdom
New Biological Insights on Clonal Evolution in the Eltrombopag Era

Emerging Technologies in Hemostasis

Chair: KEITH B. NEEVES, PhD, University of Colorado—Denver, Denver, CO

Speakers:
CHRISTIAN J. KASTRUP, PhD, University of British Columbia, Vancouver, BC, Canada
Gene Therapies to Enhance the Hemostatic Function of Platelets

ASHLEY BROWN, PhD, North Carolina State University, Raleigh, NC
Engineered Biomaterials for Hemostasis
DAVID BARK, PhD, Washington University, St. Louis, MO
Microsystems Based Technologies to Measure and Model Hemostasis

Overcoming T-cell Burnout and Exhaustion

Chair: LESLIE S. KEAN, MD, PhD, Boston Children’s Hospital, Boston, MA

Speakers:
ANDREA SCHEITINGER, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY
T-Cell Exhaustion: Molecular Mechanisms in CAR-T and Beyond
EVAN WEBER, PhD, Stanford University, Stanford, CA
An Integrated View of T-Cell Exhaustion
GIEDRE KRENCHUTE, PhD, St. Jude Children’s Research Hospital, Memphis, TN
CAR-T Cell Dysfunction: Revitalizing the Living Drug
Joint Session: New Tools to Optimize Platelet Transfusion Therapy

Saturday  4:00 p.m. – 5:35 p.m.  
252-254

*Scientific Committee on Megakaryocytes and Platelets & Scientific Committee on Transfusion Medicine*

**Co-Chairs:**
- **Maureane Hoffman**, MD, PhD, Durham VA Medical Center, Durham, NC
- **Kellie Machlus**, PhD, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

**Speakers:**
- **Marie Alice Hollenhorst**, MD, PhD, Stanford University, Stanford, CA
- **Dianne Evertdina van der Wal**, PhD, The Australian Red Cross, Alexandria/Sydney, New South Wales, Australia
- **Martin Schreiber**, MD, Oregon Health & Science University, Portland, OR
- **Martha Sola-Visner**, MD, Children’s Hospital Boston, Boston, MA

**Glycan Regulation of Immune and Hemostasis Function in Platelet Biology and Transfusion Speakers**

**Platelet Clearance by Direct and Indirect Mechanisms: Implications for Platelet Transfusion and Treatment of Different Pathologic Conditions Speakers**

**Platelets in Whole Blood Transfusion, Cold Stored Platelets**

**Platelet Transfusion Outcomes in the Preterm Infant – The Intersection Between Hemostatic Efficacy and Immune/Inflammatory Modulation of Platelets**

---

Joint Session: Cell Competition and Clonal Hematopoiesis

Sunday  9:30 a.m. – 11:05 a.m.  
New Orleans Theater AB

*Scientific Committee on Hematopoiesis & Scientific Committee on Stem Cells and Regenerative Medicine*

**Co-Chairs:**
- **Fernando D. Camargo**, PhD, Harvard Stem Cell Institute, Boston, MA
- **Louise E. Purton**, PhD, St. Vincent’s Institute, Fitzroy, Victoria, Australia

**Speakers:**
- **Laura A. Johnston**, PhD, Columbia University, New York City, New York
- **Alejo E. Rodriguez-Fraticelli**, PhD, IRB Barcelona, Barcelona, Spain
- **Ann Mullally**, MD, Brigham and Women’s Hospital, Boston, MA

**Cell Competition and Fitness Concept**

**MPNs as a Paradigm for Clonal Dominance and Myeloid Transformation**

**Cell Competition in the Hematopoietic Niches**

---

Joint Session: Seed and Soil: The Role of Inflammation in Myeloid Malignancies

Saturday  4:00 p.m. – 5:35 p.m.  
R02-R05

*Scientific Committee on Myeloid Biology & Scientific Committee on Myeloid Neoplasia*

**Co-Chairs:**
- **Kimberly Stegmaier**, MD, Dana-Farber Cancer Institute, Boston, MA
- **Fabiola Traina**, MD, PhD, University of Sao Paulo at Ribeirão Preto Medical School, Ribeirão Preto, Brazil

**Speakers:**
- **Katherine Y. King**, MD, PhD, Baylor College of Medicine, Houston, TX
- **Cristina Lo Celso**, PhD, Imperial College London, London, England, United Kingdom
- **Eric Pietras**, PhD, University of Colorado, Aurora, CO
- **Daniel T. Starczynowski**, PhD, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

**Inflammatory Signaling and Clonal Hematopoiesis**

**Contribution of the Bone Marrow Microenvironment to Leukemogenesis**

**Dysregulated Inflammatory Signaling in the Pathogenesis of Myeloid Malignancies**

**Therapeutic Implications of Inflammatory Signaling in Myeloid Malignancies**
Joint Session: The Lymphoma Microenvironment and Its Impact on Therapy

Sunday 9:30 a.m. – 11:05 a.m.  
R02-R05

Scientific Committee on Lymphoid Neoplasia & Scientific Committee on Transplantation Biology & Cellular Therapies

Co-Chairs:  
Michael R. Green, PhD, MD Anderson Medical Center, Houston, TX  
Kelli McDonald, PhD, Queensland Institute of Medical Research, Brisbane, Queensland, Australia

Speakers:  
Maher K. Gandhi, PhD, University of Queensland  
Ecotypes in Lymphoma  
Diamantina Institute, Brisbane, Queensland, Australia  
Leandro Cerchietti, MD, Weill Cornell Medical College, New York City, NY  
Stromal Cells in Lymphoma  
Frederick L. Locke, MD, Moffitt Cancer Center, Tampa, FL  
Mapping Effects of the Tumour Microenvironment on CAR T Responses in NHL  
Saad S. Kenderian, MD, Mayo Clinic, Rochester, MN  
Cellular and Cytokine Modulation of the Tumour Microenvironment

New Therapeutic Targets for Thrombosis That Do Not Cause Bleeding

Sunday 4:30 p.m. – 5:45 p.m.  
293-294

Scientific Committee on Thrombosis and Vascular Biology

Chair:  
Wilbur A. Lam, MD, PhD, Emory University/Georgia Tech, Atlanta, GA

Speakers:  
Helen Phillipou, PhD, University of Leeds, Leeds, England, United Kingdom  
FXII Inhibition in Prevention of Thrombosis Without Causing Bleeding  
Cristina Puy, PhD, Oregon Health & Science University, Portland, OR  
FXI Inhibition in Prevention of Thrombosis Without Causing Bleeding

Childhood Red Cell Disorders: Embracing Technology to Improve How We Manage Challenging Anemias

Monday 10:30 a.m. – 11:45 a.m.  
343-345

Scientific Committee on Blood Disorders in Childhood

Chair:  
Irene Roberts, MD, Weatherall Institute of Molecular Medicine, Oxford, England, United Kingdom

Speakers:  
Deena Iskander, MD, PhD, Imperial College London, London, England, United Kingdom  
Dissecting Heterogeneity in Diamond-Blackfan Anemia: Insight from Single Cell Studies and Clinical Findings  
Wilbur A. Lam, MD, PhD, Emory University/Georgia Tech, Atlanta, GA  
New Technologies for Assessment of Anemia and Other Hematologic Disorders in Resource Limited Settings  
Julie Makani, MD, PhD, Muhimbili University, Dar es Salaam, Tanzania  
Managing Severe Sickle Cell Disease- How Can We Deliver Novel Therapies in Resource-Poor Settings?

Plasma Cell Dyscrasias: Resistance to Immunotherapy: Mechanisms and Monitoring

Monday 10:30 a.m. – 11:45 a.m.  
New Orleans Theater AB

Scientific Committee on Plasma Cell Neoplasia

Chair:  
Ravi Vij, MD, MBBS, Washington University School of Medicine at St. Louis, St. Louis, MO
Speakers:

**Flavia Pichiorri**, PhD, City of Hope, Duarte, CA
*Resistance to CD38 and BCMA Targeted Therapies*

**Sarah Gooding**, MD, PhD, University of Oxford, Oxford, England, United Kingdom
*Resistance to Immunomodulatory Drugs*

**Jens G. Lohr**, MD, PhD, Harvard Medical School, Boston, MA
*Cell Free DNA Analysis*

---

**Iron and Red Cells: A Co-Dependent Relationship**

**Monday** 2:45 p.m. – 4:00 p.m.
275-277

**Scientific Committee on Iron and Heme**

**Chair:**
**Tomas Ganz**, MD, PhD, University of California—Los Angeles, Los Angeles, CA

**Speakers:**

**Shang Ma**, PhD, Scripps Research, San Diego, CA
*Piezo1 in Anemia and Iron Overload*

**Robin Van Bruggen**, MD, PhD, Sanguin, Amsterdam, Netherlands
*Iron Recycling in the Spleen*

**Sarah H. Atkinson**, MD, London School of Hygiene & Tropical Medicine, London, England, United Kingdom
*Anemia and Iron Homeostasis in Malaria*

---

**Metabolic Regulation and Implications for Red Cells**

**Monday** 4:30 p.m. – 5:45 p.m.
275-277

**Scientific Committee on Red Cell Biology**

**Chair:**
**Vijay G. Sankaran**, MD, PhD, Boston Children’s Hospital, Boston, MA

**Speakers:**

**Navdeep S. Chandel**, PhD, Northwestern University, Chicago, IL
*Overview of Metabolic Regulation*

**Leonard I. Zon**, MD, Harvard University, Boston, MA
*Regulation of Metabolism in Hematopoietic Differentiation*

**Jian Xu**, PhD, Children’s Research Institute at UT Southwestern Medical Center, Dallas, TX
*Regulation of Erythroid Metabolism*
The Scientific Symposia feature transformative basic, translational, and clinical research poised to advance the field of hematology. There will be a panel discussion at the end of each session during which questions from the audience will be entertained. There will be no Q&A after each individual speaker’s presentation.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

**SATURDAY**

### Biology and Translation of NK Cells

**Saturday 2:00 p.m. – 3:15 p.m.**

**Chair:**
KATY REZVANI, MD, The University of Texas M D Anderson Cancer Center, Houston, TX

**Speakers:**
RIZWAN ROMEY, MD, Dana Farber Cancer Institute, Boston, MA

*Fundamentals of NK Cell Biology*

KATY REZVANI, MD, The University of Texas M D Anderson Cancer Center, Houston, TX

*NK Cell Engineering: The Next Frontier in Cancer Immunotherapy*

JEFFREY S. MILLER, MD, University of Minnesota, Minneapolis, MN

*Novel Immunomodulatory Agents to Harness NK Cell Mediated Anti-Tumor Responses*

### Genetic and Functional Heterogeneity in Megakaryocytes and Platelets

**Saturday 2:00 p.m. – 3:15 p.m.**

**Chair:**
KELLY H. MACHLUS, PhD, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

**Speakers:**
DIANE S. KRAUSE, MD, PhD, Yale University, New Haven, CT

*Differentiation of Bipotent Progenitors to the Megakaryocytic versus Erythroid Lineages*

ALASTAIR W. POOLE, VET.MB, MA, PhD, School of Medical Sciences, Bristol, United Kingdom

*Highly Efficient In Vitro Platelet Generation in Lung Vasculature Reproduced by Microfluidics*

ANANDI KRISHNAN, PhD, Stanford University School of Medicine, Stanford, CA

*Genetic Heterogeneity in Platelets - Towards Personalized Medicine*

**SUNDAY**

### Building Dietary Evidence for Hematologic Malignancies - Mechanistic Insights

**Sunday 9:30 a.m. – 10:45 a.m.**

**Chair:**
URVI A. SHAH, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

**Speakers:**
CATHERINE R. MARINAC, PhD, Dana-Farber Cancer Institute, Boston, MA

*Nutrition Metabolism Connection (Epidemiologic Focus)*

MATTEO BELLONE, MD, Istituto Scientifico H. San Raffaele, Milan, MI, Italy

*Nutrition Gut Microbiome Connection (Translation Focus)*

IRIT AVIY, MD, Tel Aviv University, Tel Aviv, Israel

*Nutrition Immune Connection (Clinical Focus)*
Targeting Endogenous Retroelements and Viral Mimicry in Therapy of Hematologic Malignancies

**Sunday**  
9:30 a.m. – 10:45 a.m.  
288-290

**Chair:**  
Megan E. McNerney, MD, PhD, University of Chicago, Chicago, IL

**Speakers:**
- Gabriel K. Griffin, MD, Brigham and Women’s Hospital, Boston, MA  
  *Introduction to Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy*
- Daniel B. Lipka, MD, German Cancer Research Center (DKFZ), Heidelberg, Germany  
  *Viral Mimicry Induced by Hypermethylating Agents in Acute Myeloid Leukemia*
- Katherine Chiappinelli, PhD, George Washington University School of Medicine and Health Sciences, Washington, DC  
  *New Therapeutic Approaches to Engage Viral Mimicry Response*

**MONDAY**

### Special Symposium on the Basic Science of Hemostasis and Thrombosis

**Monday**  
4:30 p.m. – 6:05 p.m.  
208-210

**Co-Chairs:**  
Kellie R. Machlus, PhD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA  
Keith B. Neeves, PhD, University of Colorado Denver, Aurora, CO  
Wilbur A. Lam, MD, PhD, Emory University/Georgia Tech, Atlanta, GA

**Speakers:**
- Julie Rayes, PhD, Institute of Cardiovascular Science, University of Birmingham, Birmingham, United Kingdom  
  *Coordinated Platelet Activation and Netosis Drive Thrombo-Inflammation during Sepsis*
- Evi X. Stavrou, MD, Case Western Reserve University, Cleveland, OH  
  *Role of Factor XII in Sepsis*
- Robert FlAumenhaft, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA  
  *Targeting the Endothelium to Prevent Thrombus Formation in Sepsis*
- Sean Quinn, PhD, Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, PA  
  *Abstract 397: An Antibody Targeting Human FV Promotes Thrombin Generation and Reduces Bleeding in a Hemophilic Mouse Model*
Scientific Spotlight Sessions are intended to cover niche topic areas that are of interest to special researchers in hematology. Each 75-minute session will be presented once in a small-venue format on either Sunday or Monday and will include ample time for audience questions and participation. These sessions are restricted to medical and research professionals only; no businesspersons or media will be admitted.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SUNDAY

Platelet Factor 4-Mediated Immunothrombosis: Insights from the Novel Syndrome of Vaccine-Induced Thrombosis and Thrombocytopenia (VITT)

Sunday 4:30 p.m. - 5:45 p.m.
291-292

Co-Chairs:
Vivien Chen, PhD, MBBS, Concord Hospital, Sydney, New South Wales, Australia

Jonathan M. Coutinho, MD, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands

Speakers:
Vivien Chen, PhD, MBBS, Concord Hospital, Sydney, New South Wales, Australia
PF4 Autoantibodies and Thrombosis

Jonathan M. Coutinho, MD, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands
Cerebral Venous Sinus Thrombosis: Risk Factors and Biology

MONDAY

Sowing the Seeds of Leukemia Before Birth

Monday 2:45 p.m. - 4:00 p.m.
271-273

Co-Chairs:
Anindita Roy, MD, PhD, University of Oxford, Oxford, England, United Kingdom

Jyoti Nangalia, MBBChir, PhD, Wellcome Sanger Institute, Saffron Walden, England, United Kingdom

Speakers:
Anindita Roy, MD, PhD, University of Oxford, Oxford, England, United Kingdom
Acute Lymphoblastic Leukemia: How Fetal-Specific Gene Expression Programs Cooperate with MLL-AF4 to Initiate and Maintain Leukemia

Jyoti Nangalia, MBBChir, PhD, Wellcome Sanger Institute, Saffron Walden, England, United Kingdom
Myeloproliferative Neoplasms: Adult Diseases with a Fetal Origin?
ASH | Image Bank

OVER 2,000 Images!

The American Society of Hematology Image Bank is a peer-reviewed web-based image library and free resource* that offers a comprehensive collection of images relating to a wide range of hematologic topics.

*Commercial use requires a copyright license from Copyright Clearance Center

imagebank.hematology.org
Scientific Workshops are interactive discussions of the latest science developments in a particular field of hematology. Please check this page closer to the meeting for additional information about each workshop program.

All registered ASH annual meeting attendees are welcome to attend these workshops. There is no additional fee to attend.

**Scientific Workshop on Advancing Decentralized Clinical Trials in Hematology**

2:00 p.m. – 5:00 p.m.  
275-277

**Chairs:**  
KAMI J. MADDOCKS, MD, Ohio State University Hospital, Columbus, OH  
FANGXIN HONG, PhD, Dana-Farber Cancer Institute, Boston, MA

2:00 p.m. – 2:03 p.m. Opening Remarks  
2:03 p.m. – 2:23 p.m. Keynote Address: What is a Decentralization of Clinical Trials? – Overview  
2:23 p.m. – 3:15 p.m. Decentralized Clinical Trials in Hematology – Why and How  
3:15 p.m. – 4:10 p.m. Decentralization of Clinical Trials – Innovative Approaches and Technologies  
4:10 p.m. – 4:55 p.m. Decentralization of Clinical Trials - Moving Forward  
4:55 p.m. – 5:00 p.m. Closing Remarks

**Scientific Workshop on Bedside to Bench: Dissecting Emergent CAR T-cell Toxicities beyond CRS and ICANS**

2:00 p.m. – 5:00 p.m.  
271-273

**Chairs:**  
NIRALI N. SHAH, MD, National Cancer Institute/NIH, Bethesda, MD  
FREDERICK L. LOCKE, MD, Moffitt Cancer Center, Tampa, FL

**Scientific Workshop on Gene Editing in Hematology: Here to Stay**

2:00 p.m. – 5:00 p.m.  
288-290

**Chairs:**  
MATTHEW H. PORTEUS, MD, PhD, Stanford Medical School, Stanford, CA  
PAULA RIO, PhD, CIEMAT-Hematopoietic Innovative Therapies, Madrid, Spain

**Fabrica Perna, MD, Indiana University, Indianapolis, IN**  
MELODY SMITH, MD, MS, Memorial Sloan-Kettering Cancer Center, Stanford, CA

2:00 p.m. – 2:10 p.m. Opening Remarks  
2:10 p.m. – 3:00 p.m. Rare and Unique Presentations of ICANS and On-Target/Off-Tumor Toxicity Considerations  
3:00 p.m. – 4:00 p.m. CAR T-cell Toxicities and Associations with Cytokine Profiling and the Gut Microbiome  
4:00 p.m. – 4:50 p.m. CAR T-cell Associated Coagulopathies and Cytopenias  
4:50 p.m. – 5:00 p.m. Closing Remarks
### Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

**Chairs:**
- **Lucy A. Godley, MD, PhD**, Univ. of Chicago Med. Ctr., Chicago, IL
- **Marcin W. Włodarski, MD, PhD**, University Medical Center Freiburg, Freiburg, Germany

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 2:02 p.m.</td>
<td>Opening Remarks</td>
</tr>
<tr>
<td>2:03 p.m. – 2:43 p.m.</td>
<td>Models and Mechanistic Insights</td>
</tr>
<tr>
<td>2:44 p.m. – 3:32 p.m.</td>
<td>Clonal Hematopoiesis and Inflammation in Patients with Germline Predisposition Syndromes</td>
</tr>
<tr>
<td>3:33 p.m. – 4:25 p.m.</td>
<td>New Insight in Established Syndromes</td>
</tr>
<tr>
<td>4:26 p.m. – 4:58 p.m.</td>
<td>Discoveries of New Predisposition Disorders/Genes</td>
</tr>
<tr>
<td>4:58 p.m. – 5:00 p.m.</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>

### Scientific Workshop on Hematology and Aging

**Chairs:**
- **Heidi Klepin, MD, MS**, Wake Forest University School of Medicine, Winston Salem, NC
- **Ashley E. Rosko, MD**, The Ohio State University, Columbus, OH

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 2:05 p.m.</td>
<td>Opening Remarks</td>
</tr>
<tr>
<td>2:05 p.m. – 2:45 p.m.</td>
<td>Hematopoietic Stem Cell Mechanisms of Aging</td>
</tr>
<tr>
<td>2:45 p.m. – 3:25 p.m.</td>
<td>Implications of the Aging Microenvironment</td>
</tr>
<tr>
<td>3:25 p.m. – 4:15 p.m.</td>
<td>Emerging Science from Emerging Investigators in Hematology and Aging</td>
</tr>
<tr>
<td>4:15 p.m. – 4:55 p.m.</td>
<td>Thrombosis and Aging</td>
</tr>
<tr>
<td>4:55 p.m. – 5:00 p.m.</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>

### Scientific Workshop on Interplay between Coagulation and Malignancy

**Chairs:**
- **Lisa Baumann Kreuziger, MD**, Bloodcenter of Wisconsin, Menomonee Falls, WI
- **Jeffrey I. Zwicker, MD**, Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 2:05 p.m.</td>
<td>Opening Remarks</td>
</tr>
<tr>
<td>2:05 p.m. – 2:50 p.m.</td>
<td>Platelets and Tumor Growth</td>
</tr>
<tr>
<td>2:50 p.m. – 3:50 p.m.</td>
<td>Extracellular Vesicles and Cancer</td>
</tr>
<tr>
<td>3:50 p.m. – 4:55 p.m.</td>
<td>Thrombosis in Patients with Myeloproliferative Neoplasms</td>
</tr>
<tr>
<td>4:55 p.m. – 5:00 p.m.</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>

### Scientific Workshop on Leveraging Digital Technology to Modernize and Enhance Observational Studies

**Chairs:**
- **Wendy Cozen, DO, MPH**, Univ. of Southern California Norris Cancer Ctr., Manhattan Beach, CA
- **James R. Cerhan, MD, PhD**, Mayo Clinic, Rochester, MN
- **James M. Foran, MD**, Mayo Clinic Florida, Jacksonville, FL
- **Neil Zuckai**, Fletcher Allen Health Care, University of Vermont, Burlington, VT

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 2:02 p.m.</td>
<td>Opening Remarks</td>
</tr>
<tr>
<td>2:02 p.m. – 3:24 p.m.</td>
<td>Using Natural Language and Artificial Intelligence to Enhance Observational Studies in Hematology.</td>
</tr>
<tr>
<td>3:24 p.m. – 4:22 p.m.</td>
<td>Use of Electronic Health Records in Observational Studies of Benign and Malignant Hematology.</td>
</tr>
<tr>
<td>4:22 p.m. – 4:59 p.m.</td>
<td>New Digital Tools and Technology to Enhance Observational Studies of Benign and Malignant Hematology</td>
</tr>
<tr>
<td>4:59 p.m. – 5:00 p.m.</td>
<td>Closing Remarks</td>
</tr>
<tr>
<td>Scientific Workshop on Myeloid Development</td>
<td>Scientific Workshop on Translational Molecular Diagnostics: Genomic Reclassification of Blood Cancer</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>2:00 p.m. – 5:00 p.m.</strong></td>
<td><strong>2:00 p.m. – 5:00 p.m.</strong></td>
</tr>
<tr>
<td>New Orleans Theater AB</td>
<td><strong>298-299</strong></td>
</tr>
<tr>
<td><strong>Chairs:</strong></td>
<td><strong>Chairs:</strong></td>
</tr>
<tr>
<td>Patricia Ernst, PhD, University of Colorado Denver, Aurora, CO</td>
<td>Piers Blombery, MBBS, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia</td>
</tr>
<tr>
<td>Ross L. Levine, MD, Memorial Sloan Kettering Cancer Center, New York, NY</td>
<td>Torsten Hafnerlach, MD, MLL Munchner Leukame Labor Gmbh, Munchen, Germany</td>
</tr>
</tbody>
</table>

**Scientific Workshop on Myeloid Development**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 2:01 p.m.</td>
<td>Opening Remarks</td>
<td>Patricia Ernst, PhD, Ross L. Levine, MD</td>
</tr>
<tr>
<td>2:02 p.m. – 2:42 p.m.</td>
<td>Myeloid Malignancies</td>
<td></td>
</tr>
<tr>
<td>2:42 p.m. – 3:35 p.m.</td>
<td>Stem Cells</td>
<td></td>
</tr>
<tr>
<td>3:35 p.m. – 4:15 p.m.</td>
<td>Signaling and Developmental Hematopoiesis</td>
<td></td>
</tr>
<tr>
<td>4:15 p.m. – 4:55 p.m.</td>
<td>Transcription Factors</td>
<td></td>
</tr>
<tr>
<td>4:55 p.m. – 5:00 p.m.</td>
<td>Closing Remarks</td>
<td></td>
</tr>
</tbody>
</table>

**Scientific Workshop on Thrombotic Microangiopathies**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 2:03 p.m.</td>
<td>Opening Remarks</td>
<td>Shrutic Chaturvedi, MD, Spero Cataland, MD, Marie Scully, MD</td>
</tr>
<tr>
<td>2:03 p.m. – 2:47 p.m.</td>
<td>New Tools and Approaches for Genomic Classification of Blood Cancer</td>
<td></td>
</tr>
<tr>
<td>2:47 p.m. – 3:31 p.m.</td>
<td>Novel Genomic Blood Cancer Entities - Part 1</td>
<td></td>
</tr>
<tr>
<td>3:31 p.m. – 4:15 p.m.</td>
<td>New Classifications Systems in Blood Cancer</td>
<td></td>
</tr>
<tr>
<td>4:15 p.m. – 4:59 p.m.</td>
<td>Novel Genomic Blood Cancer Entities - Part 2</td>
<td></td>
</tr>
<tr>
<td>4:59 p.m. – 5:00 p.m.</td>
<td>Closing Remarks</td>
<td></td>
</tr>
</tbody>
</table>
BLOOD AND BEYOND

The Pandemic of the Past and Present in Context of the History of American Medicine
THE GREAT INFLUENZA/COVID-19

ASH® 2022 Annual Meeting in New Orleans
Sunday December 11, 2022 • In-Person
4:30 PM – 6:00 PM
Ernest N. Morial Convention Center Room 265-268

Annual Meeting Virtual Platform/Webcast
Requires ASH 2022 registration or webcast purchase

Register to attend this session in-person, or via the Virtual Platform/Webcast
hematology.org/annual-meeting

John M. Barry has had considerable influence on both pandemic policy and flood protection. Both the Bush and Obama administrations sought his advice on influenza preparedness and response, and he was a member of the original team which developed plans for non-pharmaceutical interventions to mitigate a pandemic. Barry has served on advisory boards at M.I.T’s Center for Engineering Systems Fundamentals and the Johns Hopkins Bloomberg School of Public Health as well as on the board of the Society of American Historians. John M. Barry is Distinguished Scholar at both the Tulane University School of Public Health and Tropical Medicine and Tulane’s Bywater Institute. Barry concludes in The Great Influenza that “The final lesson of 1918, a simple one yet one most difficult to execute, is that...those in authority must retain the public’s trust. The way to do that is to distort nothing, to put the best face on nothing, to try to manipulate no one. Lincoln said that first, and best. A leader must make whatever horror exists concrete. Only then will people be able to break it apart.”
ASH POSTER WALKS

Check the mobile app or the ASH annual meeting website for a detailed list of posters that will be discussed and the most up-to-date scheduling information.

The ASH Poster Walks are curated groups of poster presentations selected by ASH Committees, Task Forces, and volunteers, which focus on a specific disease state or scientific research topic. These sessions will provide an opportunity to view up to six pre-selected poster presentations accompanied by a moderated discussion with the authors and key opinion leaders in the field. These sessions will be held Wednesday, December 14, through Thursday, December 15.

ASH Poster Walks are not offered for CME credit.

DATES/TIMES to be announced. Please check the mobile app or the ASH Annual Meeting website for more information.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

WEDNESDAY AND THURSDAY

ASH Poster Walk on Diversity, Equity, and Inclusion in Hematologic Malignancies and Cellular Therapy

Please check the mobile app for the date and time.
VIRTUAL PROGRAM

Organizer:
Warren Fingrut, MD, Harvard T.H. Chan School of Public Health, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY

Beyond Hematology: Clinical and Mechanistic Links between Clonal Hematopoiesis and Non-Hematological Disorders

Please check the mobile app for the date and time.
VIRTUAL PROGRAM

Organizer:
Klaus Metzeiler, MD, University Hospital Leipzig, Leipzig, Germany

Platelets from Bench to Bedside

Please check the mobile app for the date and time.
VIRTUAL PROGRAM

Organizer:
Warren Fingrut, MD, Harvard T.H. Chan School of Public Health, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY

The Spectrum of Hemostasis and Thrombosis Research

Please check the mobile app for the date and time.
VIRTUAL PROGRAM

Organizer:
Lisa Baumann Kreuziger, MD, Versiti, Blood Research Institute, Milwaukee, WI, Medical College of Wisconsin, Milwaukee, WI

What’s Hot in Sickle Cell Disease Research 2022

Please check the mobile app for the date and time.
VIRTUAL PROGRAM

Organizer:
Elizabeth Klings, MD, Boston University School of Medicine, Boston University, Boston, MA

CME credit is not offered.
MEET THE EXPERTS

These sessions will provide an opportunity for a small number of attendees to meet with a scientific expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. A boxed lunch will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Tickets may be purchased on site during registration hours beginning Thursday, December 8, at the Ticketed Sessions Counter in the Great Hall Pre-Function.

**SATURDAY**

**Acute Myeloid Leukemia Genomics**

*Saturday 8:00 a.m. – 9:00 a.m.*
Jackson, Hilton New Orleans Riverside

**Speaker:**
TIMOTHY J. LEY, MD, Washington University in St. Louis, Saint Louis, MO
*Acute Myeloid Leukemia Genomics*

**Clonal Analysis of Dnmt3a-mutant Premalignant Hematopoiesis**

*Saturday 8:00 a.m. – 9:00 a.m.*
Magazine, Hilton New Orleans Riverside

**Speaker:**
ALEJO E. RODRIGUEZ-FRATICELLI, PhD, Boston Children’s Hospital, Barcelona, Spain
*Clonal Analysis of Dnmt3a-mutant Premalignant Hematopoiesis*

**Hemoglobin Switching**

*Saturday 8:00 a.m. – 9:00 a.m.*
Prince of Wales, Hilton New Orleans Riverside

**Speaker:**
VIJAY G. SANKARAN, MD, PhD, Boston Children’s Hospital, Boston, MA
*Hemoglobin Switching*

**T Cell Exhaustion**

*Saturday 8:00 a.m. – 9:00 a.m.*
Royal, Hilton New Orleans Riverside

**Speaker:**
ANDREA SCHIETINGER, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
*T Cell Exhaustion*

**Ticket Prices (per session)**

- Active or International Member: $75
- Non-Member: $75
- Associate, International Associate, Resident, or Graduate/Medical Student, or Honorary/Emeritus Member: $50
- Non-Member in Training: $50
- Allied Health Professional: $50

**Attention Trainees!**

A number of tickets for these sessions will be reserved for trainees. Proof of status as an Associate, International Associate, Resident, or Graduate/Medical Student member, or Non-Member in Training will be required to purchase a ticket.
SUNDAY

**CAR -T Cell Analysis and Lymphoma Genomics**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>Marlborough B, Hilton New Orleans Riverside</td>
</tr>
</tbody>
</table>

**Speaker:**

Michael R. Green, PhD, University of Texas MD Anderson Cancer Center, Friendswood, TX

**Hematopoietic Cell Competition**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>Jackson, Hilton New Orleans Riverside</td>
</tr>
</tbody>
</table>

**Speaker:**

Laura A. Johnston, PhD, Columbia University, New York, NY

**Multiple Myeloma**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>Prince of Wales, Hilton New Orleans Riverside</td>
</tr>
</tbody>
</table>

**Speaker:**

Katherine Y. King, MD, PhD, Baylor College of Medicine, Houston, TX

**Tumor Cell Imaging**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>Magazine, Hilton New Orleans Riverside</td>
</tr>
</tbody>
</table>

**Speaker:**

Peter K. Sorger, PhD, Harvard University, Harvard, MA

*of interest to PhD attendees. CME credit is not offered.*
Platelet Supply Problem?

If your hospital has experienced a platelet supply shortage in the last year, you are not alone. In a recent survey of 481 US hospitals, over 22% of the institutions surveyed reported shortages at least once a month or more, with nearly half of the high-volume transfusion facilities reporting the same.*

Secure Transfusion Solutions (STS) can help

STS owns and operates commercial blood centers under the name Trusting Heart Blood Center. Our goal is to provide a safe, reliable additional source of pathogen-reduced apheresis platelets to hospitals throughout the country.

Our innovative approach utilizes:

- **100% pathogen-reduced components.** STS utilizes the Cerus INTERCEPT® system on all collected platelet units.
- **Best in class safety standards.** STS performs infectious disease testing on all donors on two separate occasions.
- **World class donor experience.** Our spa-like donor centers deliver an enjoyable and relaxing donor experience while attracting a younger donor demographic.
- **Responsible compensated donor model.** STS taps into a dedicated, pre-screened donor base.

Platelet Donation Center locations:

- Edina, Minnesota
- Raleigh, North Carolina
- Beaverton, Oregon

Additional sites in 2023-24.

Learn more

To learn more, or to schedule an introductory call, email info@securetransfusion.com

ABSTRACT SESSIONS
2022 SCIENTIFIC CATEGORIES

For the 2022 64th Annual Meeting, abstracts were submitted in 65 different categories in 9 larger topics. For your ease in finding the oral and poster abstracts on topics of interest to you, the abstract program has been organized by category number.

100s—Red Cell Physiology and Disorders
101 Red Cells and Erythropoiesis, Excluding Iron
102 Iron Homeostasis and Biology
112 Thalassemia and Globin Gene Regulation
113 Hemoglobinopathies, Excluding Thalassemia: Basic and Translational
114 Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological

200s—Leukocytes, Inflammation, and Immunology
201 Granulocytes, Monocytes, and Macrophages
203 Lymphocytes and Acquired or Congenital Immunodeficiency Disorders

300s—Hemostasis, Thrombosis, and Vascular Wall Biology
301 Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational
311 Disorders of Platelet Number or Function: Clinical and Epidemiological
321 Coagulation and Fibrinolysis: Basic and Translational
322 Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological
331 Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological
332 Thrombosis and Anticoagulation: Clinical and Epidemiological

400s—Transfusion Medicine
401 Blood Transfusion

500s—Hematopoiesis
501 Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational
503 Clonal Hematopoiesis, Aging and Inflammation
506 Bone Marrow Microenvironment
508 Bone Marrow Failure: Acquired
509 Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital

600s—Hematologic Malignancy
602 Myeloid Oncogenesis: Basic
603 Lymphoid Oncogenesis: Basic
604 Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms
605 Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
612 Acute Lymphoblastic Leukemias: Clinical and Epidemiological
613 Acute Myeloid Leukemias: Clinical and Epidemiological
614 Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies
615 Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
616 Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
617 Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis

Oral Sessions’ titles begin with the category number and name. They are listed in the Program at a Glance by date, time, and then by category number. The In-Person and Virtual Poster Hall is arranged by category number.
| 618 | Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis |
| 621 | Lymphomas: Translational—Molecular and Genetic |
| 622 | Lymphomas: Translational—Non-Genetic |
| 623 | Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological |
| 624 | Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological |
| 626 | Aggressive Lymphomas: Prospective Therapeutic Trials |
| 627 | Aggressive Lymphomas: Clinical and Epidemiological |
| 631 | Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational |
| 632 | Chronic Myeloid Leukemia: Clinical and Epidemiological |
| 634 | Myeloproliferative Syndromes: Clinical and Epidemiological |
| 636 | Myelodysplastic Syndromes—Basic and Translational |
| 637 | Myelodysplastic Syndromes—Clinical and Epidemiological |
| 641 | Chronic Lymphocytic Leukemias: Basic and Translational |
| 642 | Chronic Lymphocytic Leukemia: Clinical and Epidemiological |
| 651 | Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational |
| 652 | Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological |
| 653 | Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials |
| 701 | Experimental Transplantation: Basic and Translational |
| 703 | Cellular Immunotherapies: Basic and Translational |
| 704 | Cellular Immunotherapies: Early Phase and Investigational Therapies |
| 705 | Cellular Immunotherapies: Late Phase and Commercially Available Therapies |
| 711 | Cell Collection and Processing |
| 721 | Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities |
| 722 | Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution |
| 723 | Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence |
| 731 | Autologous Transplantation: Clinical and Epidemiological |
| 732 | Allogeneic Transplantation: Disease Response and Comparative Treatment Studies |
| 800s—Gene Therapies, Chemical Biology, and Emerging Diagnostics |
| 801 | Gene Therapies |
| 802 | Chemical Biology and Experimental Therapeutics |
| 803 | Emerging Tools, Techniques and Artificial Intelligence in Hematology |
| 900s—Health Services and Outcomes Research |
| 901 | Health Services and Quality—Non-Malignant Conditions |
| 902 | Health Services and Quality—Lymphoid Malignancies |
| 903 | Health Services and Quality—Myeloid Malignancies |
| 904 | Outcomes Research—Non-Malignant Conditions |
| 905 | Outcomes Research—Lymphoid Malignancies |
| 906 | Outcomes Research—Myeloid Malignancies |
The Oral Abstract Sessions will be held Saturday, December 10, through Monday, December 12. Each abstract presentation will be followed immediately by a question-and-answer period with the presenter. The Plenary Scientific Session will be held Sunday, September 11, from 2:00–4:00 p.m. The Oral Abstract Sessions are not offered for CME credit.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

**SATURDAY**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 a.m. – 11:00 a.m.</td>
<td>Oral Abstract Sessions (non-CME)</td>
<td></td>
</tr>
<tr>
<td>201. Granulocytes, Monocytes, and Macrophages II (13–18)</td>
<td>295-296</td>
<td></td>
</tr>
<tr>
<td>311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Special Populations and Long-term Outcomes in ITP (19–24)</td>
<td>275-277</td>
<td></td>
</tr>
<tr>
<td>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Practice-changing Information from Datasets and Registries on Bleeding Disorders (25–30)</td>
<td>271-273</td>
<td></td>
</tr>
<tr>
<td>602. Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies (37–42)</td>
<td>359-355</td>
<td></td>
</tr>
<tr>
<td>612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Management of Novel ALL Subsets in Different Age Groups (49–54)</td>
<td>243-245</td>
<td></td>
</tr>
<tr>
<td>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication for Patients with Acute Myeloid Leukemia (55–60)</td>
<td>208-210</td>
<td></td>
</tr>
<tr>
<td>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological I (73–78)</td>
<td>La Nouvelle Orleans Ballroom C</td>
<td></td>
</tr>
<tr>
<td>632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Agents (79–84)</td>
<td>217-219</td>
<td></td>
</tr>
<tr>
<td>636. Myelodysplastic Syndromes—Basic and Translational: Clonal Trajectories and Novel Therapies (85–90)</td>
<td>260-262</td>
<td></td>
</tr>
<tr>
<td>642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations (91–96)</td>
<td>La Nouvelle Orleans Ballroom AB</td>
<td></td>
</tr>
<tr>
<td>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational (97–102)</td>
<td>R06-R09</td>
<td></td>
</tr>
<tr>
<td>656. Myelodysplastic Syndromes—Basic and Translational: Clonal Trajectories and Novel Therapies (85–90)</td>
<td>260-262</td>
<td></td>
</tr>
<tr>
<td>662. Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies (37–42)</td>
<td>359-355</td>
<td></td>
</tr>
<tr>
<td>672. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Studies Exploring the Immunobiology of HCT (109–114)</td>
<td>252-254</td>
<td></td>
</tr>
<tr>
<td>673. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP (115–120)</td>
<td>278-282</td>
<td></td>
</tr>
<tr>
<td>801. Gene Therapies: Addressing Challenges &amp; Opportunities in Pre-clinical Settings (121–126)</td>
<td>Great Hall B/C</td>
<td></td>
</tr>
<tr>
<td>903. Health Services and Quality—Myeloid Malignancies I (127–132)</td>
<td>388-390</td>
<td></td>
</tr>
<tr>
<td>12:00 p.m. – 1:30 p.m.</td>
<td>Oral Abstract Sessions</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------</td>
<td></td>
</tr>
<tr>
<td>332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Controversies in Anticoagulation and Venous Thromboembolism (139–144)</td>
<td>Great Hall B/C</td>
<td></td>
</tr>
<tr>
<td>653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma (157–162)</td>
<td>R02-R05</td>
<td></td>
</tr>
<tr>
<td>704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Lymphoma (163–168)</td>
<td>La Nouvelle Orleans Ballroom AB</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2:00 p.m. – 3:30 p.m.</th>
<th>Oral Abstract Sessions</th>
</tr>
</thead>
<tbody>
<tr>
<td>113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Cognitive Deficit, Pain, and Inflammation in Sickle Cell Disease: What We Learned from Mouse Models (175–180)</td>
<td>275-277</td>
</tr>
<tr>
<td>508. Bone Marrow Failure: Acquired: Biology (193–198)</td>
<td>260-262</td>
</tr>
<tr>
<td>604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Targeted Protein Degradation and Emerging Small Molecule Inhibitors in Myeloid Neoplasms (199–204)</td>
<td>343-345</td>
</tr>
<tr>
<td>615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: New Approaches to Combination Chemotherapy and Venetoclax Plus Hypomethylating Agent Therapy in AML (217–222)</td>
<td>Great Hall B/C</td>
</tr>
<tr>
<td>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Lesions and Therapeutic Implications (223–228)</td>
<td>291-292</td>
</tr>
<tr>
<td>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III (229–234)</td>
<td>New Orleans Theater C</td>
</tr>
<tr>
<td>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational (241–246)</td>
<td>R06-R09</td>
</tr>
<tr>
<td>652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (RRMM) (247–252)</td>
<td>R02-R05</td>
</tr>
<tr>
<td>703. Cellular Immunotherapies: Basic and Translational I (253–258)</td>
<td>La Nouvelle Orleans Ballroom C</td>
</tr>
<tr>
<td>705. Cellular Immunotherapies: Novel Predictors of Response or Toxicity to Cellular Therapies (259–264)</td>
<td>La Nouvelle Orleans Ballroom AB</td>
</tr>
<tr>
<td>732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Real World Studies Based on Database Analyses (265–270)</td>
<td>391-392</td>
</tr>
<tr>
<td>802. Chemical Biology and Experimental Therapeutics I (271–276)</td>
<td>353-355</td>
</tr>
<tr>
<td>906. Outcomes Research—Myeloid Malignancies II (277–282)</td>
<td>220-222</td>
</tr>
</tbody>
</table>
### ORAL ABSTRACT SESSIONS

**Saturday–Monday 10–12 Dec 2022**

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

**4:00 p.m. – 5:30 p.m.  Oral Abstract Sessions**  

<table>
<thead>
<tr>
<th>101.</th>
<th>Red Cells and Erythropoiesis, Excluding Iron I (283–288)</th>
<th>391-392</th>
</tr>
</thead>
<tbody>
<tr>
<td>508.</td>
<td>Bone Marrow Failure: Acquired: Clinical Studies (289–294)</td>
<td>260-262</td>
</tr>
<tr>
<td>602.</td>
<td>Myeloid Oncogenesis: Basic: Chromatin Organization and Metabolism (295–300)</td>
<td>293-294</td>
</tr>
<tr>
<td>617.</td>
<td>Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Molecular Features and Response to Treatment in AML (301–306)</td>
<td>388-390</td>
</tr>
<tr>
<td>624.</td>
<td>Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Advanced Stage and Relapsed Hodgkin Lymphoma (313–318)</td>
<td>278-282</td>
</tr>
<tr>
<td>632.</td>
<td>Chronic Myeloid Leukemia: Clinical and Epidemiological: Molecular Predictors and Advanced Phase Disease (331–336)</td>
<td>266-268</td>
</tr>
<tr>
<td>642.</td>
<td>Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Combination Treatments and Richter’s Transformation (343–348)</td>
<td>R06-R09</td>
</tr>
<tr>
<td>703.</td>
<td>Cellular Immunotherapies: Basic and Translational II (355–360)</td>
<td>393-396</td>
</tr>
<tr>
<td>723.</td>
<td>Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence II (373–378)</td>
<td>353-355</td>
</tr>
<tr>
<td>906.</td>
<td>Outcomes Research—Myeloid Malignancies I (385–390)</td>
<td>220-222</td>
</tr>
</tbody>
</table>

**SUNDAY**

**9:30 a.m. – 11:00 a.m.  Oral Abstract Sessions**  

| 321. | Coagulation and Fibrinolysis: Basic and Translational (397–402) | 293-294 |
| 503. | Clonal Hematopoiesis, Aging and Inflammation: Insights from Animal Models (403–408) | 271-273 |
| 509. | Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Biology to Therapeutics (409–414) | 260-262 |
| 603. | Lymphoid Oncogenesis: Basic: Mechanisms in Leukemogenesis (415–420) | 393-396 |
| 613. | Acute Myeloid Leukemias: Clinical and Epidemiological: Clinical Care and Observations in Acute Myeloid Leukemia (421–426) | 278-282 |
| 617. | Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Treatment-related Biomarkers (427–432) | Hall E |
| 618. | Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: B-lineage ALL: Molecular Characterization and Targeted Therapies (433–438) | Great Hall A/D |
| 626. | Aggressive Lymphomas: Prospective Therapeutic Trials: Immune Based and Targeted Therapies in Relapsed/Refractory Large B-Cell Lymphoma (439–444) | La Nouvelle Orleans Ballroom AB |
### Saturday–Monday 10–12 Dec 2022

**ORAL ABSTRACT SESSIONS**

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 p.m. – 1:30 p.m.</td>
<td>Oral Abstract Sessions</td>
<td><strong>non-CME</strong></td>
</tr>
<tr>
<td>101.</td>
<td>Red Cells and Erythropoiesis, Excluding Iron II (511–516)</td>
<td><strong>243-245</strong></td>
</tr>
<tr>
<td>506.</td>
<td>Bone Marrow Microenvironment: Contribution of Immune Signaling to the Microenvironment (523–528)</td>
<td><strong>260-262</strong></td>
</tr>
<tr>
<td>602.</td>
<td>Myeloid Oncogenesis: Basic: Epigenetics and Transcriptional Regulation (529–534)</td>
<td><strong>275-277</strong></td>
</tr>
<tr>
<td>613.</td>
<td>Acute Myeloid Leukemias: Clinical and Epidemiological: Long-term Outcomes in Clinically Defined Subgroups of Patients with Acute Myeloid Leukemia (535–540)</td>
<td><strong>271-273</strong></td>
</tr>
<tr>
<td>621.</td>
<td>Lymphomas: Translational—Molecular and Genetic: ctDNA and Prognostication (541–546)</td>
<td><strong>Great Hall B/C</strong></td>
</tr>
<tr>
<td>627.</td>
<td>Lymphomas: Clinical and Epidemiological: Real World Evidence for Management of CNS Lymphoma and Post CAR T-cell relapse for aggressive B-cell NHL (553–558)</td>
<td><strong>R02-R05</strong></td>
</tr>
<tr>
<td>631.</td>
<td>Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Molecular Consequences of MPN Driver and Co-mutations (451–456)</td>
<td><strong>275-277</strong></td>
</tr>
<tr>
<td>637.</td>
<td>Myelodysplastic Syndromes – Clinical and Epidemiological III (463–468)</td>
<td><strong>252-254</strong></td>
</tr>
<tr>
<td>703.</td>
<td>Cellular Immunotherapies: Basic and Translational IV (481–486)</td>
<td><strong>388-390</strong></td>
</tr>
<tr>
<td>731.</td>
<td>Autologous Transplantation: Clinical and Epidemiological: Lymphoma, AML, and Multiple Sclerosis (487–492)</td>
<td><strong>220-222</strong></td>
</tr>
<tr>
<td>803.</td>
<td>Emerging Tools, Techniques and Artificial Intelligence in Hematology: New Molecular Tools for Precision Diagnostics in Hematology (493–498)</td>
<td><strong>208-210</strong></td>
</tr>
<tr>
<td>901.</td>
<td>Health Services and Quality—Non-Malignant Conditions: Cell Line Down! Optimizing Diagnosis and Management of Isolated Cytopenias (499–504)</td>
<td><strong>291-292</strong></td>
</tr>
<tr>
<td>904.</td>
<td>Outcomes Research—Non-Malignant Conditions: Classical Hematology: From Horses to Zebras (505–510)</td>
<td><strong>295-296</strong></td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Oral Abstract Sessions</td>
<td><strong>non-CME</strong></td>
</tr>
<tr>
<td>627.</td>
<td>Lymphomas: Clinical and Epidemiological: Real World Evidence for Management of CNS Lymphoma and Post CAR T-cell relapse for aggressive B-cell NHL (553–558)</td>
<td><strong>R02-R05</strong></td>
</tr>
<tr>
<td>637.</td>
<td>Myelodysplastic Syndromes – Clinical and Epidemiological IV (559–564)</td>
<td><strong>265-268</strong></td>
</tr>
<tr>
<td>653.</td>
<td>Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Novel Drugs and Optimized Approaches in Myeloma (565–570)</td>
<td><strong>New Orleans Theater C</strong></td>
</tr>
<tr>
<td>722.</td>
<td>Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Critical Advances in GVHD Management (571–576)</td>
<td><strong>208-210</strong></td>
</tr>
<tr>
<td>904.</td>
<td>Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease Therapies &amp; Outcomes (577–582)</td>
<td><strong>R06-R09</strong></td>
</tr>
</tbody>
</table>
**ORAL ABSTRACT SESSIONS**

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

**4:30 p.m. – 6:00 p.m.  Oral Abstract Sessions  (non-CME)**

|---|---|

**MONDAY**

**10:30 a.m. – 12:00 p.m.  Oral Abstract Sessions  (non-CME)**

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans (679–684) 278-282</td>
<td>618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: High-risk T-ALL and Prognostic Biomarkers (715–720) Great Hall B/C</td>
</tr>
<tr>
<td>603. Lymphoid Oncogenesis: Basic: Mechanisms in Lymphomagenesis (703–708) 208-210</td>
<td>---</td>
</tr>
</tbody>
</table>
**ORAL ABSTRACT SESSIONS**

**Saturday–Monday 10–12 Dec 2022**

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>641.</td>
<td>Chronic Lymphocytic Leukemias: Basic and Translational: Novel Therapies and Biomarkers (745–750)</td>
<td>La Nouvelle Orleans Ballroom AB</td>
</tr>
<tr>
<td>705.</td>
<td>Cellular Immunotherapies: Real World Outcomes and Special Populations Treated with Cellular Therapy (763–768)</td>
<td>393-396</td>
</tr>
<tr>
<td>637.</td>
<td>Myelodysplastic Syndromes – Clinical and Epidemiological I (853–858)</td>
<td>243-254</td>
</tr>
<tr>
<td>615.</td>
<td>Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Advances in Mutation-targeted Therapy for AML (829–834)</td>
<td>R02-R05</td>
</tr>
<tr>
<td>617.</td>
<td>Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Venetoclax, HMA, and Reponse to Treatment in AML (835–840)</td>
<td>295-296</td>
</tr>
<tr>
<td>602.</td>
<td>Myeloid Oncogenesis: Basic: DNA Damage and Genetic Evolution (823–828)</td>
<td>293-294</td>
</tr>
<tr>
<td>301.</td>
<td>Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Mechanistic Insights That Suggest Novel Diagnostic or Therapeutic Strategies (811–816)</td>
<td>353-355</td>
</tr>
<tr>
<td>112.</td>
<td>Thalassemia and Globin Gene Regulation I (799–804)</td>
<td>220-222</td>
</tr>
<tr>
<td>311.</td>
<td>Disorders of Platelet Number or Function: Clinical and Epidemiological: Mechanisms and Treatment of ITP (913–918)</td>
<td>388-390</td>
</tr>
<tr>
<td>102.</td>
<td>Iron Homeostasis and Biology I (907–912)</td>
<td>388-390</td>
</tr>
<tr>
<td>311.</td>
<td>Disorders of Platelet Number or Function: Clinical and Epidemiological: Mechanisms and Treatment of ITP (913–918)</td>
<td>220-222</td>
</tr>
</tbody>
</table>

---

**Saturday 9 Dec 2022**

**8:30 a.m. – 11:30 a.m.  Oral Abstract Sessions**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>641.</td>
<td>Chronic Lymphocytic Leukemias: Basic and Translational: Novel Therapies and Biomarkers (745–750)</td>
<td>La Nouvelle Orleans Ballroom AB</td>
</tr>
<tr>
<td>705.</td>
<td>Cellular Immunotherapies: Real World Outcomes and Special Populations Treated with Cellular Therapy (763–768)</td>
<td>393-396</td>
</tr>
<tr>
<td>637.</td>
<td>Myelodysplastic Syndromes – Clinical and Epidemiological I (853–858)</td>
<td>243-254</td>
</tr>
<tr>
<td>615.</td>
<td>Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Advances in Mutation-targeted Therapy for AML (829–834)</td>
<td>R02-R05</td>
</tr>
<tr>
<td>617.</td>
<td>Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Venetoclax, HMA, and Reponse to Treatment in AML (835–840)</td>
<td>295-296</td>
</tr>
</tbody>
</table>

---

**Saturday 10 Dec 2022**

**2:45 p.m. – 4:15 p.m.  Oral Abstract Sessions**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>112.</td>
<td>Thalassemia and Globin Gene Regulation I (799–804)</td>
<td>220-222</td>
</tr>
<tr>
<td>301.</td>
<td>Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Mechanistic Insights That Suggest Novel Diagnostic or Therapeutic Strategies (811–816)</td>
<td>353-355</td>
</tr>
<tr>
<td>602.</td>
<td>Myeloid Oncogenesis: Basic: DNA Damage and Genetic Evolution (823–828)</td>
<td>293-294</td>
</tr>
<tr>
<td>615.</td>
<td>Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Advances in Mutation-targeted Therapy for AML (829–834)</td>
<td>R02-R05</td>
</tr>
<tr>
<td>617.</td>
<td>Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Venetoclax, HMA, and Response to Treatment in AML (835–840)</td>
<td>295-296</td>
</tr>
</tbody>
</table>

---

**Saturday 11 Dec 2022**

**4:30 p.m. – 6:00 p.m.  Oral Abstract Sessions**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>102.</td>
<td>Iron Homeostasis and Biology I (907–912)</td>
<td>388-390</td>
</tr>
<tr>
<td>311.</td>
<td>Disorders of Platelet Number or Function: Clinical and Epidemiological: Mechanisms and Treatment of ITP (913–918)</td>
<td>220-222</td>
</tr>
</tbody>
</table>
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Disease and Aging (919–924) 393-396
503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Human Cohorts And Biosamples (925–930) 252-254
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease Detection in AML and Single Cell Investigations (943–948) New Orleans Theater C
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological II (949–954) R06-R09
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Drugs in Development and COVID-19 (961–966) 243-245
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Disease Monitoring (967–972) 278-282
703. Cellular Immunotherapies: Basic and Translational III (973–978) La Nouvelle Orleans Ballroom C
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities I (985–990) 260-262
902. Health Services and Quality—Lymphoid Malignancies: Time for Change: Health Care Delivery and Disparities (991–996) La Nouvelle Orleans Ballroom AB
Blood Advances is a semimonthly medical journal published by the American Society of Hematology. It is a peer-reviewed, online-only open access journal.

Blood Advances covers all aspects of hematology, including disorders of leukocytes, both benign and malignant, erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology.

**FEATURING**

- **Blood Advances Talks (BATs):** Articles featuring podcast reviews
- **Point-Counterpoint:** Debate based articles presenting contradicting opinions
- **Clinical Guidelines:** Includes recommendations based on a high level of evidence relevant to patient care
- **Health Services & Health Outcomes:** Articles analyzing systems of health care
- **Drug Advances:** Covers both the preclinical development and clinical applications of a new drug or indication relevant to hematology
- **Original Research:** Articles describing basic laboratory, translational, and clinical investigations in hematology

JOIN THE CONVERSATION TODAY

bloodadvances.org
POSTER PRESENTATIONS

The Poster Hall will be open for in-person and Virtual attendees. The Poster Hall is located in the Ernest N. Morial Convention Center, Hall D. Presenters will stand beside their posters during the evening Presentation times.

Virtual poster presentations will be shared via a brief PowerPoint presentation with accompanying audio. The Virtual Poster Hall will allow attendees to browse a new set of posters starting at 9:00 a.m. (Central time) each day, as well as access posters from previous days.

The Poster Hall hours are as follows:
Saturday, December 10  9:00 a.m. – 7:30 p.m.
Sunday, December 11  9:00 a.m. – 8:00 p.m.
Monday, December 12  9:00 a.m. – 8:00 p.m.

Poster Sessions are not offered for CME credit.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY, DECEMBER 10, 2022

9:00 a.m. – 7:30 p.m.  Poster Session I – Viewing
5:30 p.m. – 7:30 p.m.  Poster Session I – Presentations

Hall D, Ernest N. Morial Convention Center

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I (1003–1017)
102. Iron Homeostasis and Biology: Poster I (1018–1028)
112. Thalassemia and Globin Gene Regulation: Poster I (1029–1036)
113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster I (1037–1054)
201. Granulocytes, Monocytes, and Macrophages: Poster I (1084–1098)
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1099–1107)
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I (1108–1126)
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1127–1138)
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I (1147–1171)
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1209–1221)
503. Clonal Hematopoiesis, Aging and Inflammation: Poster I (1222–1233)
506. Bone Marrow Microenvironment: Poster I (1234–1244)
508. Bone Marrow Failure: Acquired: Poster I (1245–1257)
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1258–1266)
602. Myeloid Oncogenesis: Basic: Poster I (1267–1299)
603. Lymphoid Oncogenesis: Basic: Poster I (1300–1314)
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I (1367–1380)
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1420–1439)
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1461–1500)
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1501–1516)
621. Lymphomas: Translational—Molecular and Genetic: Poster I (1517–1543)
622. Lymphomas: Translational—Non-Genetic: Poster I (1544–1562)
10–12 Dec 2022

**Saturday-Monday**

**Poster Presentations**

*All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.*

<table>
<thead>
<tr>
<th>Session III – Presentations</th>
<th>Session III – Viewing</th>
</tr>
</thead>
<tbody>
<tr>
<td>616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2756–2776)</td>
<td>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2777–2817)</td>
</tr>
<tr>
<td>618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2818–2834)</td>
<td>621. Lymphomas: Translational—Molecular and Genetic: Poster II (2835–2862)</td>
</tr>
</tbody>
</table>

**MONDAY, DECEMBER 12, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session III – Viewing</th>
<th>Session III – Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m. – 8:00 p.m.</td>
<td>Poster Session III – Viewing</td>
<td>Poster Session III – Presentations</td>
</tr>
</tbody>
</table>

**Hall D, Ernest N. Morial Convention Center**

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III (3639–3653)
102. Iron Homeostasis and Biology: Poster III (3654–3664)
112. Thalassemia and Globin Gene Regulation: Poster III (3665–3672)
113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster III (3673–3690)
201. Granulocytes, Monocytes, and Macrophages: Poster III (3720–3733)
CME credit is not offered. Poster Presentations

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.
Satellite Symposia will take place on Friday, December 9, 2022, preceding the ASH annual meeting. ASH appreciates its corporate and nonprofit partners for their participation in this program. The Society values its partnerships and the supportive role that members of the community play in an effort to provide hematologists with quality educational programs. Satellite Symposia are not CME-accredited through ASH and are planned solely by the sponsoring organizations. Each symposium lists a contact person for accreditation information. An ASH meeting badge is not needed to attend these symposia.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

FRIDAY MORNING SYMPOSIA
7:00 A.M. – 10:00 A.M.

A Thread to Pull: Unraveling the Complexities of Myeloid Malignancies

7:00 a.m. – 10:00 a.m.
VIRTUAL PROGRAM

This program is provided by Cleveland Clinic and supported by Cleveland Clinic and AAMDSIF.

Chair:
Sudipto Mukherjee, MD, PhD, MPH, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Speakers:
Rodrigo T. Calado, MD, PhD, Hospital das Clínicas de Ribeirão Preto, São Paulo, Brazil
Gabriela S. Hobbs, MD, Massachusetts General Hospital, Boston, MA
Bhumika J. Patel, MD, Prisma Health, University Medical Group, University of South Carolina School of Medicine Greenville, Greenville, SC
Guillermo Sanz, MD, PhD, Hospital Universitario La Fe, Valencia, Spain
Craig S. Sauter, MD, Cleveland Clinic, Cleveland, OH
Roland B. Walter, MS, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA

Contact: Kristin Bower
Email: bowerk@ccf.org

Acute Myeloid Leukemia: Reviewing Current Best Practice and Exploring Novel Paradigms Ahead

7:00 a.m. – 10:00 a.m.
Celestin EFGH
Hyatt Regency New Orleans

This program is provided by National Comprehensive Cancer Network and supported by educational grants from Astellas, Daiichi Sankyo, Servier, and Syndax Pharmaceuticals Inc., and an independent educational grant from Gilead Sciences, Inc. Provided by NCCN in partnership with Clinical Care Options, LLC.

Chair:
Daniel A. Pollyea, MD, MS, University of Colorado, Aurora, CO

Speakers:
Courtney D. DiNardo, MD, MSCE, MD Anderson Cancer Center, Houston, TX
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

Contact: Kristin Hasson
Email: hasson@nccn.org
**Application of the Latest Data in CLL/SLL: Guidance for Current and Future Treatment Strategies**

**7:00 a.m. – 10:00 a.m.**
**Elite B**
**Hyatt Regency New Orleans**

This program is provided by National Comprehensive Cancer Network and supported by educational grants from AstraZeneca, BeiGene, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Provided by NCCN in partnership with Clinical Care Options, LLC.

**Chair:**
Jennifer A. Woyach, MD, The Ohio State University, Columbus, OH

**Speakers:**
Brian T. Hill, MD, PhD, Cleveland Clinic Foundation, Cleveland, OH
Deborah M. Stephens, DO, Huntsman Cancer Institute, Salt Lake City, UT

Contact: Kristin Hasson
Email: hasson@nccn.org

**Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet Needs**

**7:00 a.m. – 10:00 a.m.**
**Grand Ballroom A/B**
**Sheraton New Orleans**

This program is provided by PeerView Institute for Medical Education and supported by Sanofi.

**Chairs:**
Sigbjørn Berentsen, MD, PhD, Haugesund Hospital, Haugesund, Norway
Ilene C. Weitz, MD, University of Southern California, Los Angeles, CA

Contact: Margaret Walker
Email: margaret.walker@peerview.com

**Fixing the Target on Aggressive Lymphoma: Insights on the Next Phase of Integrating Targeted Agents into MCL and DLBCL Management**

**7:00 a.m. – 10:00 a.m.**
**Empire CD**
**Hyatt Regency New Orleans**

This program is provided by PeerView Institute for Medical Education and supported by AstraZeneca and Lilly.

**Chair:**
Toby A. Eyre, MBChB, Diploma in Medical Education, MRCP, FRCPATH, MD, Oxford University Hospitals NHS Foundation Trust, Oxford, England, United Kingdom

**Speakers:**
Jia Ruan, MD, PhD, The New York and Presbyterian Hospital, New York City, NY
Paolo Strati, MD, MD Anderson Cancer Center, Houston, TX

Contact: Margaret Walker
Email: margaret.walker@peerview.com


**7:00 a.m. – 10:00 a.m.**
**Napoleon B 1-3 + Corridor A/B**
**Sheraton New Orleans**

This program is provided by PeerView Institute for Medical Education and supported by Jazz Pharmaceuticals.

**Chair:**
Gail J. Roboz, MD, Weill Cornell Medicine and The New York Presbyterian Hospital, New York City, NY

**Speaker:**
Harry P. Erba, MD, PhD, Duke University Medical Center, Durham, N
Tapan Kadia, MD, MD Anderson Cancer Center, Houston, TX

Contact: Margaret Walker
Email: margaret.walker@peerview.com
Myelodysplastic Syndromes 2022: Today and Tomorrow

7:00 a.m. – 10:00 a.m.
La Nouvelle Orleans Ballroom AB

This program is provided and supported by MDS Foundation, Inc.

Co-Chairs:
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Valeria Santini, MD, AOU Careggi-University of Florence, Florence, Italy

Speakers:
Rafael Bejar, MD, PhD, University of California, San Diego, La Jolla, CA
Rena Buckstein, Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada
Jane Churpek, MD, University of Wisconsin Madison, Madison, WI
Theo M De Witte, MD, Radboud University Medical Centre, Nijmegen, Netherlands
Peter C. Grayson, MD, MSc, Tenure Track Investigator, National Institutes of Health, Bethesda, MD
Elizabeth A. Griffiths, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Yasushi Miyazaki, MD, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
Sophie Park, MD, PhD, CHU Centre hospitalo-universitaire (CHU) Grenoble Alpes, Grenoble, France
Lewis R. Silverman, MD, Icahn School of Medicine at Mount Sinai, Director Translational Research Center for the Myelodysplastic Syndrome, Tisch Cancer Institute, New York City, NY

Contact: Lea Harrison
Email: lharrison@mds-foundation.org

Navigating the Frontier of Hematologic Malignancy Therapies

7:00 a.m. – 10:00 a.m.
Great Hall A/D
For In-Person Participants Only

This program is jointly provided by RMEI Medical Education LLC and The Leukemia & Lymphoma Society, and is supported by AstraZeneca Pharmaceuticals LP and The Leukemia & Lymphoma Society.

Chair:
Helen E. Heslop, MD, DSc (Hon), Baylor College of Medicine, Houston, TX

Speakers:
Katherine Donovan, PhD, Dana-Farber Cancer Institute, Boston, MA
Soheil Meshinchi, M.D., Ph.D., Fred Hutchinson Cancer Research Center, Seattle, WA
Mark Roschewski, MD, National Cancer Institute, Bethesda, MD
Saad Z. Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Cherie Haley
Email: chaley@rmei.com

Putting the CAR(T) Before the Horse: Practicalities of T Cell–Activating Therapies in Multiple Myeloma

7:00 a.m. – 10:00 a.m.
VIRTUAL PROGRAM

This program is provided by RedMedEd and supported by The Multiple Myeloma Research Foundation with funding provided by Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Legend Biotech USA Inc.

Co-Chairs:
Hearn J. Cho, MD, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, Icahn School of Medicine at Mount Sinai, New York, NY
Paul G. Richardson, MD, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
Keith Stewart, MBCnB, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Speakers:
Amrita Y. Krishnan, MD, FACP, City of Hope Medical Center, Duarte, CA
Suzanne Lentzsch, MD, PhD, Columbia University, New York City, NY

Contact: Karen Tenaglia
Email: ktenaglia@redmeded.com
<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Location</th>
<th>Chair</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Real-World, Real Innovation in DLBCL:</strong> Perspectives on Integrating Novel Antibody Platforms into Patient Care</td>
<td>7:00 a.m. – 10:00 a.m.</td>
<td>Rhythms Ballroom, Sheraton New Orleans</td>
<td>Grzegorz (Greg) Nowakowski, MD, Mayo Clinic, Rochester, MN</td>
<td>Margaret Walker</td>
</tr>
<tr>
<td><strong>The Road to Remission in Multiple Myeloma:</strong> Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes</td>
<td>7:00 a.m. – 10:00 a.m.</td>
<td>Grand Ballroom C, Sheraton New Orleans</td>
<td>Nikhil C. Munshi, MD, PhD, Dana-Farber Cancer Institute, Boston, MA</td>
<td>Margaret Walker</td>
</tr>
<tr>
<td><strong>The Rising Tide of CAR-T in Lymphoma:</strong> Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of Care</td>
<td>7:00 a.m. – 10:00 a.m.</td>
<td>Empire B, Hyatt Regency New Orleans</td>
<td>Jason Westin, MD, MD Anderson Cancer Center, Houston, TX</td>
<td>Margaret Walker</td>
</tr>
<tr>
<td><strong>The Sequel to the Targeted Therapy Era in CML:</strong> Guidance on Sequential Care and Integrating Established and Novel Options into Cohesive Management Plans</td>
<td>7:00 a.m. – 10:00 a.m.</td>
<td>Napoleon C 1-3 + Corridor C/D, Sheraton New Orleans</td>
<td>Jerald P. Radich, MD, Fred Hutchinson Cancer Research Center, Seattle, WA</td>
<td>Margaret Walker</td>
</tr>
</tbody>
</table>
The Winning Way with BTK Inhibitors in CLL: Evidence-Informed Choices on Treatment Selection, Safety, and Therapeutic Sequencing

7:00 a.m. – 10:00 a.m.
Empire A
Hyatt Regency New Orleans

This program is provided by PeerView Institute for Medical Education and supported by AstraZeneca.

Chair:
John C. Byrd, MD, University of Cincinnati College of Medicine, Cincinnati, OH

Speakers:
Jacqueline C. Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell Feinstein Institutes for Medical Research, Mount Sinai Medical Center, Comprehensive Cancer Center, Miami, FL
Nicole Lamanna, MD, Columbia University Medical Center, New York City, NY

Contact: Margaret Walker
Email: margaret.walker@peerview.com

FRIDAY EARLY AFTERNOON SYMPOSIA
11:00 A.M. – 2:00 P.M.

A Conversation With the Myeloma Experts: Making Sense of the Evolving Treatment Landscape

11:00 a.m. – 2:00 p.m.
Elite B
Hyatt Regency New Orleans

This program is provided by Clinical Care Options, LLC and supported by educational grants from Amgen, Janssen Biotech, Inc., Karyopharm Therapeutics Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Takeda Pharmaceuticals U.S.A., Inc.

Chair:
Brian G.M. Durie, MD, Cedars Sinai Cancer Center, Los Angeles, CA

Speakers:
Shaji K. Kumar, MD, Mayo Clinic, Rochester, MN
Thomas Martin, MD, University of California, San Francisco, CA
Philippe Moreau, MD, University Hospital Hôtel-Dieu, Nantes, France
S. Vincent Rajkumar, MD, Mayo Clinic, Rochester, MN
Jesús San-Miguel, MD, PhD, Clinica Universidad De Navarra, Pamplona, Spain

Contact: Patience Merullo
Email: customersupport@cealliance.com

Acute Lymphoblastic Leukemia Data and Case Discussion on the Use of Asparaginase Therapy in Young and Older Adults

11:00 a.m. – 2:00 p.m.
Napoleon C 1-3 + Corridor C/D
Sheraton New Orleans

This program is provided by Clinical Care Options, LLC and supported by an educational grant from Jazz Pharmaceuticals.

Chair:
Daniel J. DeAngelo, MD, PhD, Harvard Medical School, Boston, MA

Speakers:
Kjeld Schmiegelow, MD, DMSc, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Emily K. Curran, MD, University of Cincinnati Cancer Center, Cincinnati, OH

Contact: Patience Merullo
Email: customersupport@cealliance.com
Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia - What Clinicians Want to Know (Part 1 of a 3-part CME-accredited Symposia Series)

11:00 a.m. – 2:00 p.m.
Celestín ABCD
Hyatt Regency New Orleans

This program is provided by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Lilly, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC.

Chair:
Neil Love, MD, Research To Practice, Miami, FL

Speakers:
Alexey Danilov, MD, PhD, City of Hope National Medical Center, Duarte, CA
Matthew S. Davids, MD, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA
Arnon P. Kater, MD, PhD, Academic Medical Center, Amsterdam Zuidoost, NH, Netherlands
Lindsey E. Roeker, MD, Memorial Sloan Kettering Cancer Center, New York City, NY
Philip A. Thompson, MBBS, MD Anderson Cancer Center, Houston, TX

Contact: Sylvia Eriksen
Email: meetings@researchtopractice.com

Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias

11:00 a.m. – 2:00 p.m.
243-245

This program is provided by Physicians’ Education Resource, LLC and supported by Agios Pharmaceuticals, Inc., Apellis Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Rigel Pharmaceuticals.

Chair:
Carlos M. de Castro, MD, Duke University, Durham, NC

Speakers:
Ara Metjian, MD, University of Colorado, Anshutz School of Medicine, Aurora, CO
Caroline I. Piatak, MD, University of Southern California / LAC-USC Medical Center, Santa Monica, CA
Jennifer A. Rothman, MD, Duke University Medical Center, Durham, NC
Phillip Scheinberg, MD, Hospital A Beneficência Portuguesa, São Paulo, Brazil

Contact: Dayna Kleinstein
Email: info@gotoper.com

An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches

11:00 a.m. – 2:00 p.m.
Napoleon B 1-3 + Corridor A/B
Sheraton New Orleans

This program is provided and provided by Clinical Care Options, LLC and supported by educational grants from Bristol Myers Squibb, Geron Corporation, Karyopharm Therapeutics Inc., and Novartis Pharmaceuticals Corporation.
Chair: Ramí S. Komrokji, H. Lee Moffitt Cancer Center, Tampa, FL

Speakers: María Diez-Campeo, MD, PhD, Hematology Service, University Hospital of Salamanca and IBSAL, Salamanca, Spain
Amer M. Zeidan, MD, Yale University and Yale Cancer Center, East Haven, CT

Contact: Patience Merullo Email: customersupport@cealliance.com


11:00 a.m. – 2:00 p.m.
VIRTUAL PROGRAM

This program is provided by Physicians’ Education Resource, LLC and supported by Genmab.

Chair: Andre H. Goy, MD, MS, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

Speakers: Lorenzo Falchi, MD, Columbia University Medical Center, New York City, NY
Lori Leslie, MD, Hackensack Meridian School of Medicine, Hackensack, NJ

Contact: Dayna Kleinstein Email: info@gotoper.com

Complement Clinical Cases: Navigating Care for Patients with aHUS, PNH, and HSCT-TMA

11:00 a.m. – 2:00 p.m.
Empire B
Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by Alexion Pharmaceuticals, Inc.

Chair: Jeff Szer, MBBS, FRACP, Royal Melbourne Hospital, Melbourne, Victoria, Australia

Speakers: Fadi Fakhouri, MD, PhD, Universite de Lausanne, Lausanne, Switzerland
Sonata Jodele, MD, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Contact: Vikki Chavis Email: vchavis@medscapelive.com

Elevating Equity in Caring For Patients With Hematologic Malignancies

11:00 a.m. – 2:00 p.m.
Celestin EFGH
Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Pharmacies, Regeneron, Gilead Sciences, Inc., and Lilly.

Chair: Adrienne A. Phillips, MD, MPH, Weill Cornell Medicine, New York City, NY

Speakers: Laura Ortiz-Ravick, MA, The Leukemia & Lymphoma Society, Rye Brook, NY
Amber Thomassen, APRN-BC, AOCNP, University of Miami, Miami, FL

Contact: Vikki Chavis Email: vchavis@medscapelive.com

Expert Illustrations & Commentaries™: Visualizing New Treatment Pathways for Anemia in Chronic Kidney Disease

11:00 a.m. – 2:00 p.m.
217-219

This program is provided by Physicians’ Education Resource, LLC and supported by GlaxoSmithKline.

Chair: Steven Fishbane, MD, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/Refractory Disease?

11:00 a.m. – 2:00 p.m.
Great Hall B/C

This program is provided by RMEI Medical Education, LLC and supported by Regeneron Pharmaceuticals, Inc.

Chair:
Sundar Jagannath, Mount Sinai Medical Center, New York City, NY

Speakers:
Ellie Kelepouris, MD, FACP, FAHA, University of Pennsylvania, Philadelphia, PA
Nupur Upal, MD, Northwell Health Physician Partners Kidney and Hypertension Specialists at Great Neck, Great Neck, NY
Jay Wish, MD, Indiana University School of Medicine, Indianapolis, IN

Contact: Dayna Kleinstein
Email: info@gotoper.com

How We Do It™: Application of State-of-the-Art MF and PV Care Today... With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow

11:00 a.m. – 2:00 p.m.
Grand Ballroom DE
Sheraton New Orleans

This program is provided by Physicians’ Education Resource, LLC and supported by Incyte Corporation, Protagonist Therapeutics, SDP Oncology, and PharmaEssentia USA.

Speakers:
Prof. Dr. med. Barbara Eichhorst, University Hospital Cologne, Cologne, Germany
Nitin Jain, MD, MD Anderson Cancer Center, Houston, TX
Anthony R. Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York City, NY

Contact: Margaret Walker
Email: margaret.walker@peerview.com

Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care with Groundbreaking Treatment

11:00 a.m. – 2:00 p.m.
Empire A
Hyatt Regency New Orleans

This program is provided by PeerView Institute for Medical Education and supported by AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Lilly, Merck & Co., Inc., and Pharmacies LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Chair:
Prof. John G. Gribben, MD, DSc, Barts Cancer Institute, London, England, United Kingdom

Medical Crossfire™: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult

11:00 a.m. – 2:00 p.m.
La Nouvelle Orleans Ballroom C

This program is provided by Physicians’ Education Resource, LLC and supported by Amgen, Inc., Jazz Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., and Takeda Pharmaceuticals USA, Inc.

Chair:
Elias Jabbour, MD, University of Texas, MD Anderson Cancer Center, Houston, TX
Speakers:
SABINA CHIARETTI, MD, PhD, AOU Policlinico, Umberto I - Rome, Rome, Italy
HAGOP KANTARJIAN, MD, MD Anderson Cancer Center, Houston, TX
ROB PIETERS, PROF. MD, PhD, Princess Maxima Center Pediatric Oncology, Utrecht, Netherlands
BIJAL D. SHAH, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Contact: Dayna Kleinstein
Email: info@gotoper.com

MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes

11:00 a.m. – 2:00 p.m.  
343-345

This program is provided by Physicians’ Education Resource, LLC and supported by AbbVie, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi.

Speakers:
OLGA LANDGREN, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
AARON C. LOGAN, MD, PhD, University of California—San Francisco, San Francisco, CA

Contact: Dayna Kleinstein
Email: info@gotoper.com

Navigating a Changing Landscape Together: Gene Therapy for Hemophilia

11:00 a.m. – 2:00 p.m.  
393-396

This program is provided by The France Foundation and supported by BioMarin Pharmaceutical Inc., CSL Behring, and Spark Therapeutics, Inc.

Chair:
MICHAEL RECHT, MD, PhD, MBA, Yale University School of Medicine, New Haven, CT

Practice-Changing Data in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Integrating Novel Treatment Strategies in the Clinic

11:00 a.m. – 2:00 p.m.  
Grand Ballroom C  
Sheraton New Orleans

This program is provided by Medscape LLC and supported by ADC Therapeutics America, Inc., Genmab, and Gilead Sciences, Inc.

Chair:
JULIE M. VOSE, MD, MBA, University of Nebraska Medical Center, Omaha, NE

Speakers:
SCOTT F. HUNTINGTON, MD, MPH, Yale School of Medicine, New Haven, CT
CARON A. JACOBSON, MD, Dana-Farber Cancer Institute, Boston, MA

Contact: Vikki Chavis
Email: vchavis@medscapelive.com

Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic

11:00 a.m. – 2:00 p.m.  
Empire CD  
Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by Bristol Myers Squibb, Janssen Biotech, Inc., GlaxoSmithKline, Karyopharm Therapeutics, and Sanofi.

Chair:
AJAI CHARI, MD, Mt. Sinai School of Medicine, New York City, NY
<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Location</th>
<th>Chair</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections</strong></td>
<td>11:00 a.m. – 2:00 p.m.</td>
<td>La Nouvelle Orleans Ballroom AB</td>
<td>Genovefa A. Papanicolaou, MD, Memorial Sloan Kettering Cancer Center, New York City, NY</td>
<td>Ajay K. Nooka, MD, MPH, FACP, Winship Cancer Institute of Emory University, Atlanta, GA&lt;br&gt;Krina Patel, MD, MSc, MD Anderson Cancer Center, Houston, TX&lt;br&gt;rinak Patel, MD, MSc, MD Anderson Cancer Center, Houston, TX&lt;br&gt;Guenter Koehne, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY</td>
</tr>
<tr>
<td><strong>Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient’s Lifespan</strong></td>
<td>11:00 a.m. – 2:00 p.m.</td>
<td>Great Hall A/D</td>
<td>Biree Andemariam, MD, University of Connecticut Health Center, West Hartford, CT</td>
<td>Nelson J. Chao, MD, MBA, Duke University Medical Center, Durham, NC&lt;br&gt;Sung W. Choi, MD, MS, University of Michigan Health System, Ann Arbor, MI</td>
</tr>
<tr>
<td><strong>Taking Stock of the Evolving Treatment Landscape for Acute GvHD in HSCT</strong></td>
<td>11:00 a.m. – 2:00 p.m.</td>
<td>Grand Ballroom A/B</td>
<td>Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, New York City, NY</td>
<td>Raffaella Colombatti, MD, PhD, University of Padova, Padova, Italy&lt;br&gt;Modupe Idowu, MD, University of Texas—Houston, Houston, TX&lt;br&gt;Nirmish Shah, MD, Duke University Health System, Durham, NC</td>
</tr>
<tr>
<td><strong>Understanding the Biology and Addressing the Management Challenges of Cytopenic Myelofibrosis</strong></td>
<td>11:00 a.m. – 2:00 p.m.</td>
<td>Grand Ballroom A/B</td>
<td>John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York City, NY</td>
<td></td>
</tr>
</tbody>
</table>
FRIDAY LATE AFTERNOON SYMPOSIA
3:00 P.M. – 6:00 P.M.

A Light at the End of the Treatment Tunnel – Exploring the Potential Role for Gene Therapy in Hemophilia B

3:00 p.m. – 6:00 p.m.
217-219

This program is provided by Physicians’ Education Resource, LLC and supported by CSL Behring LLC.

Chair:
CHRISTINE L. KEMPTON, MD, MSc, Emory University, Atlanta, GA

Speakers:
ANDREW D. LEAVITT, MD, University of California—San Francisco, San Francisco, CA
STEVEN W. PIPE, MD, University of Michigan, Ann Arbor, MI
ANNETTE VON DRYGALSKI, MD, PHARM D, University of California—San Diego Health, San Diego, CA

Contact: Dayna Kleinstein
Email: info@gotoper.com

Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma - What Clinicians Want to Know (Part 2 of a 3-part CME-accredited Symposia Series)

3:00 p.m. – 6:00 p.m.
Celestin ABCD
Hyatt Regency New Orleans

This program is provided by Research To Practice and supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Kite, a Gilead Company, MEI Pharma Inc., Novartis, and Seagen Inc.

Chair:
NEIL LOVE, MD, Research To Practice, Miami, FL

Speakers:
JONATHAN W. FRIEDBERG, MD, MMSc, University of Rochester, Rochester, NY
BRAD S. KAHL, MD, Washington University School of Medicine in St. Louis, Saint Louis, MO
DAVID G. MALONEY, MD, PhD, Fred Hutchinson
LORETTA J. NASTOUPIL, MD, MD Anderson Cancer Center, Houston, TX
Cancer Research Center, Seattle, WA
SONALI M. SMITH, MD, University of Chicago, Chicago, IL

Contact: Sylvia Eriksen
Email: meetings@researchtopractice.com

A Review of Next-Generation Therapeutics and Contemporary Management of Myelofibrosis

3:00 p.m. – 6:00 p.m.
Rhythms Ballroom
Sheraton New Orleans

This program is provided and provided by Clinical Care Options, LLC and supported by educational grants from AbbVie and CTI Biopharma.

Chair:
SRDAN VERSTOVSEK, MD, PhD, MD Anderson Cancer Center, Houston, TX

Speakers:
BRADY L. STEIN, MD, MHS, Northwestern University, Chicago, IL
ABDULRAHEEM YACOUB, MD, University of Kansas, Leawood, KS

Contact: Vikki Chavis
Email: vchavis@medscapelive.com

Contact: Patience Merullo
Email: customersupport@cealliance.com
AGGRESSIVE B-CELL LYMPHOMAS: EXPERTS DISCUSS NEW CARE STANDARDS AND EVOLVING TREATMENT STRATEGIES

3:00 p.m. – 6:00 p.m.
Napoleon B 1-3 + Corridor A/B
Sheraton New Orleans

This program is provided by Clinical Care Options, LLC and supported by educational grants from Bristol Myers Squibb, Genmab US, Inc., AbbVie, Karyopharm Therapeutics Inc., and Regeneron Pharmaceuticals, Inc.

Chair:
John P. Leonard, MD, Weill Cornell Medical College, Pelham Manor, NY

Speakers:
John N. Allan, MD, Weill Cornell Medicine, New York City, NY
Laurie H. Sehn, MD, MPH, British Columbia Cancer Centre, Vancouver, British Columbia, Canada

Contact: Patience Merullo
Email: customersupport@cealliance.com

AL AMYLOIDOSIS: ADVANCES IN EARLY DIAGNOSIS, TREATMENT OPTIONS, AND INDIVIDUALIZED CARE

3:00 p.m. – 6:00 p.m.
Elite B
Hyatt Regency New Orleans

This program is provided by Clinical Care Options, LLC and supported by educational grants from Alexion Pharmaceuticals and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Chair:
Angela Dispensieri, MD, Mayo Clinic, Rochester, MN

Speakers:
Anita D’Souza, MD, MS, The Medical College of Wisconsin Inc., Milwaukee, WI
Jeffrey A. Zonder, MD, Karmanos Cancer Institute, Detroit, MI

Contact: Patience Merullo
Email: customersupport@cealliance.com

BLAZING THE TRAIL TO BETTER PATIENT OUTCOMES: ERYTHROID MATURATION AGENTS IN β-TALASSEMIAS

3:00 p.m. – 6:00 p.m.
La Nouvelle Orleans Ballroom C
For In-Person Participants Only

This program is provided by Answers in CME Inc. and supported by an educational grant from Bristol Myers Squibb.

Chair:
Ashutosh Lal, MD, UCSF Benioff Children’s Hospital, Oakland, CA

Speaker:
Sujit Sheth, MD, Cornell University, New York City, NY

Contact: Answers In CME Inc
Email: aubrie.rudnick@answersincme.com

CHALLENGING CASES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

3:00 p.m. – 6:00 p.m.
Empire A
Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by Bristol Myers Squibb and Epizyme, Inc.

Chair:
Carla Casulo, MD, James P. Wilmot Cancer Center, Rochester, NY

Speakers:
Jeremy S. Abramson, MD, MMSc, Massachusetts General Hospital Cancer Center, Boston, MA
Gilles Salles, MD, PhD, Memorial Kettering Cancer Center, New York City, NY

Contact: Vikki Chavis
Email: vchavis@medscapelive.com

“D” IS FOR DIAGNOSIS: DECIPHERING UNCOMMON HEMATOLOGIC DISORDERS THROUGH THE EYES OF A DETECTIVE

3:00 p.m. – 6:00 p.m.
Grand Ballroom C
Sheraton New Orleans

This program is provided by Physicians’ Education Resource, LLC and supported by Sanofi.
Chair: 
Pramod K. Mistry, MD, PhD, FRCP, Yale University, New Haven, CT

Speaker: 
Nichola Cooper, MD, Imperial College, London, England, United Kingdom
Eli Muchtar, MD, Mayo Clinic College of Medicine and Science, Rochester, MN

Contact: Dayna Kleinstein
Email: info@gotoper.com

Experts Under the Microscope: Evaluating the Role of Maintenance Therapy in Long-Term Management of AML

3:00 p.m. – 6:00 p.m.
343-345
For In-Person Participants Only

This program is provided by Haymarket Medical Education and supported by Haymarket Medical Education and Bristol Myers Squibb.

Chair: 
Amir T. Fathi, MD, Massachusetts General Hospital Cancer Center, Cambridge, MA

Speakers: 
Maximilian F. Stahl, MD, Instructor of Medicine Harvard Medical School, Boston, MA
Andrew H. Wei, MBBS, PhD, Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

Contact: Beth Kurdock
Email: beth.kurdock@haymarketmedical.com

JAK Inhibitors in Myelofibrosis: Expert Insights on Cases in Personalizing Therapy

3:00 p.m. – 6:00 p.m.
Empire B
Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by Bristol Myers Squibb and Sierra Oncology, a GlaxoSmithKline company.

Chair: 
Ruben Mesa, MD, FACP, UT Health San Antonio Cancer Center, San Antonio, TX

Speakers: 
Claire Harrison, DM, FRCP, FRCPATH, Guy's and St. Thomas' NHS Foundation Trust, London, England, United Kingdom
Nikolai A. Podoltsiev, MD, PhD, Yale University School of Medicine, New Haven, CT

Contact: Vikki Chavis
Email: vchavis@medscapelive.com

Let’s Talk About Sickle Cell Disease: Perspectives, Case Challenges, and Clinical Pearls

3:00 p.m. – 6:00 p.m.
Empire CD
Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by Global Blood Therapeutics, Inc.

Chair: 
Maureen M. Achebe, MD, MPH, Hematology Division, Brigham and Women's Hospital, Boston, MA
Madhav Vissa, MD, UCSF Benioff Children's Hospitals, Oakland, CA

Speakers: 
Julie Kanter, MD, University of Alabama at Birmingham, Birmingham, AL

Contact: Vikki Chavis
Email: vchavis@medscapelive.com

Let’s Talk: Community Perspectives on Acute Myeloid Leukemia and Myelodysplastic Syndrome

3:00 p.m. – 6:00 p.m.
Celestin EFGH
Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by AbbVie, Actinium Pharmaceuticals, BioMea Fusion, Gilead Sciences, Inc., and Glycomimetics, Inc.

Chair: 
Naval Daver, MD, MD Anderson Cancer Center, Houston, TX

Speakers: 
David A. Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL
Rory Michael Shallis, MD, Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Contact: Vikki Chavis
Email: vchavis@medscapelive.com

Medical Crossfire®: Maximizing Our Clinical Practices for Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings

3:00 p.m. – 6:00 p.m.
208-210

This program is provided by Physicians’ Education Resource, LLC and supported by Seagen Inc., Takeda Pharmaceuticals U.S.A., Inc.

Chair:
David J. Straus, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

Speakers:
Sharon M. Castellino, MD, MSc, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA
Joseph M. Connors, MD, FRCP, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, British Columbia, Canada
Doris M. Ponce, MD, Associate Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Pier Luigi Zinzani, Istituto Di Ematologia, Bologna, Italy

Contact: Dayna Kleinstein
Email: info@gotoper.com

Navigating New Terrain in Chemotherapy-Induced Anemia: Hem/Onc Perspectives and Evidence-Supported Strategies for Improving Care with Intravenous Iron

3:00 p.m. – 6:00 p.m.
393-396

This program is provided by Creative Educational Concepts and supported by American Regent.

Chair:
George M. Rodgers, MD, PhD, University of Utah Medical Center, Salt Lake City, UT

Speakers:
Michael Auerbach, MD, Auerbach Hem-Onc Associates, Inc., Baltimore, MD
Patricia A. Ford, MD, University Of Pennsylvania, Penn Medicine, Philadelphia, PA
David H. Henry, MD, Abramson Cancer Center, Philadelphia, PA
Joseph D. Khoury, MD, FCAP, University of Nebraska Medical Center, Omaha, NE
Michael R. Savona, MD, Vanderbilt University School of Medicine, Nashville, TN

Contact: Jessica Hall
Email: jhall@ceconcepts.com

Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy

3:00 p.m. – 6:00 p.m.
243-245

This program is provided by Physicians’ Education Resource, LLC and supported by ImmunoGen, Inc., Menarini-Stemline, and Mustang Bio, Inc.

Chair:
Naveen Pemmaraju, MD, MD Anderson Cancer Center, Department of Leukemia, Houston, TX
The Future is Now in MDS: Guidance on Integrating Innovative, Risk-Adapted Therapeutic Options into Patient Management

3:00 p.m. – 6:00 p.m.
Grand Ballroom A/B
Sheraton New Orleans

This program is provided by PeerView Institute for Medical Education and supported by Geron and Gilead Sciences, Inc.

Chair:
Guillermo Garcia-Manero, MD, MD Anderson Cancer Center, Department of Leukemia, Houston, TX

Speakers:
Joseph D. Khoury, MD, FCAP, University of Nebraska Medical Center, Omaha, NE
Michael R. Savona, MD, Vanderbilt University School of Medicine, Nashville, TN

Contact: Margaret Walker
Email: margaret.walker@peerview.com

FRIDAY EVENING SYMPOSIA
7:00 P.M. – 10:00 P.M.

Addressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know (Part 3 of a 3-part CME-accredited Symposia Series)

7:00 p.m. – 10:00 p.m.
Celestin ABCD
Hyatt Regency New Orleans

This program is provided by Research To Practice and supported by educational grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, and Sanofi.

Chair:
Neil Love, MD, Research To Practice, Miami, FL

Speakers:
Jesus G. Berdeja, MD, Sarah Cannon Research Institute, Nashville, TN
Rafael Fonseca, Mayo Clinic, Phoenix, AZ
Sagar Lonial, MD, Emory University School of Medicine, Atlanta, GA
Robert Z. Orlowski, MD, PhD, MD Anderson Cancer Center, Houston, TX
Noopur Raje, MD, Mass General Hospital Cancer Center, Boston, MA

Contact: Sylvia Eriksen
Email: meetings@researchtopractice.com

Breakthrough Therapeutics for CLL and Other B-Cell Malignancies: Focus on BTK Inhibitors From Development to Clinical Integration

7:00 p.m. – 10:00 p.m.
Elite B
Hyatt Regency New Orleans

This program is provided by Clinical Care Options, LLC and supported by educational grants from BeiGene and Lilly.

Chair:
Jeff P. Sharmar, MD, US Oncology Research, Eugene, OR

Speakers:
Ian W. Flinn, MD PhD, Sarah Cannon Research Institute, Nashville, TN
Susan O’Brien, MD, UCI Cancer Center, Orange, CA

Contact: Patience Merullo
Email: customersupport@cealliance.com
### Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GvHD?

**7:00 p.m. – 10:00 p.m.**  
**Grand Ballroom DE**  
**Sheraton New Orleans**

This program is provided by Physicians’ Education Resource, LLC and supported by Incyte Corporation, Orca Bio, Pharmacyclics, and ST Shared Services, LLC, a Mallinckrodt Company.

**Chair:**  
Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute, Boston, MA

**Speakers:**  
Sergio A. Giralt, MD, FACP, FASTCT, Memorial Sloan Kettering Cancer Center, New York City, NY  
Catherine J. Lee, MD, University of Utah, Salt Lake City, UT  
Doris M. Ponce, MD, Associate Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY

Contact: Dayna Kleinstein  
Email: info@gotoper.com

### Transfusion-Related Iron Overload – Evidence-Based Approaches to Improve Chelation Outcomes

**7:00 p.m. – 10:00 p.m.**  
**VIRTUAL PROGRAM**

This program is provided by Physicians’ Education Resource, LLC and supported by Chiesi USA.

**Chair:**  
Trisha E. Wong, MD, MS, Division of Hematology and Oncology, School of Medicine, Oregon Health & Sciences University, Portland, OR

Contact: Dayna Kleinstein  
Email: info@gotoper.com
Product Theaters feature exhibitor presentations on the clinical benefit or scientific research relating to the development of an approved pharmaceutical product and may include information on new uses, combinations, or therapies for the approved product. The Product Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

**Sponsored by Novo Nordisk**

**Are Higher Factor Levels a Rising Consideration When Selecting a Hemophilia Treatment?**

*non-CME*

**Saturday** 11:30 a.m. – 12:30 p.m.

Hall J - Theater 6

For in-person participants only

Speakers:

Stephanie Seremetis, MD, Novo Nordisk

Adam R. Wufsus, PhD, Novo Nordisk

**Sponsored by AbbVie**

**Data Worth Stopping For: New 5-year Follow-Up Data for an Oral-Based CLL Regimen with a Fixed Treatment Duration**

*non-CME*

**Saturday** 11:30 a.m. – 12:30 p.m.

Hall J - Theater 1

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

Ahmed Kotb, MD, AbbVie

**Sponsored by Apellis Pharmaceuticals, Inc.**

**Evolving Treatment Expectations in PNH**

*non-CME*

**Saturday** 11:30 a.m. – 12:30 p.m.

Hall J - Theater 2

For in-person participants only

Speakers:

Peter Hillmen, MB ChB, PhD, Apellis Pharmaceuticals, Inc.

Stephanie Moncrieff, BSN, RN, Apellis Pharmaceuticals, Inc.

**Sponsored by Bristol Myers Squibb**

**Treatment Options in Relapsed/Refractory Multiple Myeloma: Clinical Studies and Patient Cases**

*non-CME*

**Saturday** 11:30 a.m. – 12:30 p.m.

Hall J - Theater 4

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

unicel-anne Flores, PharmD, Bristol Myers Squibb
SUNDAY

Sponsored by Bristol Myers Squibb

A Treatment Option for Patients with Myelodysplastic Syndromes (non-CME)

Sunday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 7

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Speaker:
CHRISTINA HUGHES, PhD, Bristol Myers Squibb

Sponsored by Global Blood Therapeutics/Pfizer, Inc

Discussion on the Treatment of Sickle Cell Disease, Moving Beyond Pain as a Primary Target (non-CME)

Sunday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 4

For in-person participants only
Speaker:
CLARK BROWN, MD, Global Blood Therapeutics / Pfizer, Inc

Sponsored by CSL Behring

Gene Therapy for Hemophilia B: A Look Into New Advancements (non-CME)

Sunday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 2

For in-person participants only
Speaker:
DEBBIE BENSEN-KENNEDY, MD, CSL Behring

Sponsored by Genentech

Pivotal Phase 3 data in Newly Diagnosed AML: Exploring the Efficacy, Safety, and Patient Management of Evolving AML Treatment Paradigms (non-CME)

Sunday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 6

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Speaker:
MELISSA MONTEZ, PHARM.D, Genentech

Sponsored by Genentech

Genentech Lymphoma Product Presentation (non-CME)

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 4

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Speaker:
GINNA LAPORT, Genentech
Sponsored by Adaptive Bio Therapeutics

The Clinical Actionability of ClonoSEQ MRD Assessment in Lymphoid Malignancies

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 1

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Speaker:
ALLISON JACOB, MS, Adaptive Bio Therapeutics

Sponsored by Kite, a Gilead Company

Kite, The Leader in Cell Therapy: Leading the Way in Large B-Cell Lymphoma Care

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 7

For in-person participants only
Speakers:
WARNER BIDDLE, Gilead Sciences, Inc.
FRANK NEUMANN, MD, PhD, Gilead Sciences, Inc.
CHRISTOPHER MCDONALD, MBA, Gilead Sciences, Inc.

Sponsored by Bristol Myers Squibb

Treatment Option in AML

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 2

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Speaker:
SARAH CHITTENDEN, RN, MSN, FNP-C, Bristol Myers Squibb

Sponsored by Janssen Biotech, Inc.

What’s Next for Patients with Relapsed or Refractory Multiple Myeloma after Multiple Lines of Therapy?

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 6

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Speakers:
JESSICA FOWLER, PhD, Janssen Biotech, Inc.
THOMAS LIN, MD, PhD, Janssen Biotech, Inc.
SAURABH PATEL, MD, Janssen Biotech, Inc.

MONDAY

Sponsored by Sanofi

A Breakthrough for Patients: Complement inhibition in Cold Agglutinin Disease

Monday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 6

This presentation is intended for U.S. based registered meeting attendees
Speaker:
MATIAS CORDOBA, MD, Sanofi

Sponsored by Takeda Pharmaceuticals

First and Only: VONVENDI® [von Willebrand factor (recombinant)] for Prophylaxis and More

Monday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 2

For in-person participants only
Speaker:
PETER L. TURECEK, Baxalta Innovations GmbH, part of Takeda

Sponsored by Pharmacyclics LLC and Janssen Biotech, Inc.

Multidisciplinary Discussion on Incorporating IMBRUVICA® (ibrutinib) Into Treatment Strategies

Monday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 7

For in-person participants only
Speakers:
JAMES P. DEAN, MD, PhD, Pharmacyclics LLC, an AbbVie Company
CHRISTOPHER CAMPEN, PHARM.D, Janssen Biotech, Inc.
SANDRA KNIGHT, MN, BC-APN, CNS, AOCN, Pharmacyclics LLC, an AbbVie Company
Sponsored by Janssen Pharmaceuticals, Inc.

Perspectives on the Treatment of DVT/PE and Reduction in the Risk of Recurrent DVT/PE, Including Patients with Obesity and/or Cancer

Monday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 5

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Speaker:
Keturah Reid Robinson, PharmD, BCPS, LSSBB, The Janssen Pharmaceutical Companies of Johnson & Johnson

Sponsored by ADC Therapeutics

ZYNLONTA®: The First and Only CD19-Directed ADC For 3L DLBCL

Monday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 4

This presentation is intended for U.S. based registered meeting attendees
Speaker:
Joseph Camardo, MD, ADC Therapeutics, Inc.

Sponsored by Sanofi

An Innovative Treatment Option for Appropriate Patients With cGVHD

Monday 12:15 p.m. – 1:15 p.m.
Hall J - Theater 7

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Speaker:
Kathy Marshall, RN, MSN, APRN, AOCNS, Sanofi

Sponsored by Janssen Biotech, Inc.

Darzalex & Darzalex Faspro: A Frontline Treatment Approach for a Variety of Newly Diagnosed Multiple Myeloma Patient Types

Monday 12:15 p.m. – 1:15 p.m.
Hall J - Theater 5

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Speaker:
Annelore Cortoos, MD, Janssen Biotech, Inc.

Sponsored by Genentech

DLBCL Treatment Landscape Overview for Fellows and APPs

Monday 12:15 p.m. – 1:15 p.m.
Hall J - Theater 2

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Industry Theaters as of October 22, 2022.
Check the mobile app for an updated list of Industry Theaters.

Industry Theater presentations are company developed presentations that highlight medical devices, medical technology, non-FDA approved pharmaceutical products, investigational products or devices in pipeline or clinical trial phases, and patient treatment resources. The Industry Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

### SATURDAY

**Sponsored by AstraZeneca**

**Emerging AstraZeneca Hematology Pipeline**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>Hall J - Theater 5</td>
</tr>
</tbody>
</table>

For in-person participants only

**Speakers:**
- Robert Chen, MD, AstraZeneca
- Raoul Tiber, MD, AstraZeneca
- Nina Shah, MD, AstraZeneca
- Anas Younes, MD, AstraZeneca

**Sponsored by Gilead Sciences**

**Investigating the Biological Mechanisms of HR-MDS: Role of the Immune System During Disease**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>Hall J - Theater 3</td>
</tr>
</tbody>
</table>

For in-person participants only

**Speaker:**
- Carol O’Hear, MD, PhD, Gilead Sciences Inc

**Sponsored by Pfizer Inc.**

**Pfizer Oncology: Pursuing Scientific Breakthroughs for Patients with Hematologic Malignancies**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>Hall J - Theater 7</td>
</tr>
</tbody>
</table>

**Speakers:**
- Suneet Varma, MBA, Pfizer Inc.
- Dany Habr, MD, Pfizer Inc.
- Sriram Krishnaswami, PhD, Pfizer Inc.

### SUNDAY

**Sponsored by Vertex Pharmaceuticals**

**Gene Therapy for the Hemoglobinopathies: Translating Complex Science to Inform the Physician-Patient Dialogue**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>Hall J - Theater 1</td>
</tr>
</tbody>
</table>

For in-person participants only

**Speakers:**
- Mark Mogul, MD, Vertex Pharmaceuticals
- Tony E. Boitano, PhD, Vertex Pharmaceuticals
- Marjorie Dejoie-Brewer, MD, Vertex Pharmaceuticals

This presentation is intended for U.S. based registered meeting attendees

Industry Theaters CME credit is not offered.
Sponsored by Sanofi

Sanofi Hematology Clinical Pipeline

Sunday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 5

Speakers:
Karin Knober, MD, PhD, Sanofi
Craig Benson, MD, Sanofi
Michelle Lee, MD, Sanofi

Sponsored by Karyopharm Therapeutics, Inc.

Investigating the Function of Tumor Suppressor Proteins in Myelofibrosis (MF) and Myelodysplastic Neoplasms (MDS)

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 5

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Speaker:
Reshma Rangwala, MD, PhD, Karyopharm Therapeutics, Inc.

Sponsored by AstraZeneca

Protection Onboard: A Clinical Approach to Preventing COVID-19 in At-Risk Patients

Sunday 11:00 a.m. – 12:00 p.m.
Hall J - Theater 3

Speaker:
Mark Esser, PhD, AstraZeneca

Sponsored by Rigel Pharmaceuticals

A Clinical Overview of Olutasidenib: An Investigational Therapy, Currently Under FDA Review, For the Potential Treatment of Patients with Relapsed/Refractory mIDH1 AML

Monday 12:15 p.m. – 1:15 p.m.
Hall J - Theater 4

Speakers:
Aaron Sheppard, PhD, Rigel Pharmaceuticals
Patrick Kelly, MD, PhD, Rigel Pharmaceuticals

Sponsored by Cytiva

From Science Fiction to Standard of Care: Developing the next wave of Genomic Medicines for Hematology

Monday 12:15 p.m. – 1:15 p.m.
Hall J - Theater 6

For in-person participants only
Speaker:
Sadik Kassim, PhD, Danaher Genomic Medicines
COMPANY SHOWCASES

Company Showcases as of October 22, 2022. Check the mobile app for an updated list of Company Showcases.

Company Showcase presentations are 15-minute promotional presentations that provide an overview of the companies’ services, pipeline products, clinical trials, or mission-based initiatives for a company, non-profit organization, or contract/clinical research organization. The Company Showcase sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Saturday

Sponsored by Labcorp Oncology

Powering Better Decisions: A Comprehensive Hematopathology Analysis Case Study

Saturday 1:30 p.m. – 1:45 p.m.
Hall J - Theater 6

For in-person participants only

Speaker:
ERIC A. SEVERSON, MD, PhD, MMSc, Labcorp Oncology

Sponsored by TwinStrand Biosciences

Ultra-low Frequency Variant Detection in AML with Duplex Sequencing Technology

Saturday 3:30 p.m. – 3:45 p.m.
Hall J - Theater 6

For in-person participants only

Speakers:
CLINT VALENTINE, MSc, TwinStrand Biosciences
JACOB HIGGINS, PhD, TwinStrand Biosciences

Sunday

Sponsored by Mission Bio

AML Single-cell Multi-omics MRD (scMRD) and the Horizon of Clinical Utility

Sunday 4:00 p.m. – 4:15 p.m.
Hall J - Theater 6

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:
AARON LLANSO, Mission Bio
MONDAY

Sponsored by Karius

PICKUP Study: Pneumonia in the ImmunoCompromised – Use of the Karius Test® for the Detection of Undiagnosed Pathogens

Monday 10:15 a.m. – 10:30 a.m.
Hall J - Theater 6

This presentation is intended for U.S. based registered meeting attendees
For in-person participants only
Speaker:
DAVID M. Berman, DO, FAAP, FPIDS, Karius
2seventy bio
https://www.2seventybio.com
Booth: 1928

Our name, 2seventy bio™, is inspired by the maximum speed of translating human thought into action – 270 miles per hour. At 2seventy, we think in the language of time. It’s about time we outmaneuver cancer so the people we serve can have MORE...more time building stories with families and friends, experiencing their passions, and living their best lives in the big and small moments. Too many have lost time to cancer and we are wildly impatient to change that.

AbbVie
https://www.abbvie.com
Booth: 2825, Virtual

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.

ABHH - Brazilian Association of Hematology, Hemotherapy and Cellular Therapy
http://www.abhh.org.br
Booth: 2722

The Brazilian Association of Hematology, Hemotherapy and Cellular Therapy -ABHH - is a nonprofit that started in 2008. The outcome of the merger of the Brazilian Society of Hematology and Hemotherapy and the Brazilian Collegiate of Hematology, ABHH gathers years of expertise on the field. We annually hold the largest Brazilian Congress of Hematology, Hemotherapy, and Cell Therapy - HEMO. The Congress includes 4200 participants, 1200 scientific works, and 80 exhibitors in a 4-day event.

Abiosciences, Inc.
https://www.abiosciences.com
Booth: 2842

Abiosciences, Inc. is a therapeutic discovery company harnessing the power of single-cell multi-omics and bioinformatics to gain molecular insights into human diseases. Our mission is to accelerate the development of novel therapeutics. Guided by science and data, the company generates new knowledge and gains insight into the identification and validation of novel drug targets and biomarkers, leading to next-generation breakthrough therapeutics and diagnostics.

Acrotech Biopharma
https://acrotechbiopharma.com/news-events/
Booth: 2015

Acrotech Biopharma Inc. is a pharmaceutical company built as global platform to develop and commercialize innovative proprietary medications, starting with the US market. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients first as well as all healthcare stakeholders. Acrotech Biopharma Inc. aspires to be a patient-focused, research-based organization that strives to launch treatments which are accessible to the patients that need them.

Actinium Pharmaceuticals
http://www.actiniumpharma.com/
Booth: 1829

Actinium is a late-stage clinical pharma company developing targeted radiotherapies to deliver cancer-killing radiation with cell-level precision to treat patients with high unmet needs. Our pipeline is led by radiotherapies for targeted conditioning to selectively deplete disease or cancer and certain immune cells prior to a BMT, gene, or cell therapy (e.g., CAR-T) to enable engraftment of transplanted cells with minimal toxicities. The goal is to improve outcomes and access to curative treatments by reducing the non-targeted chemotherapy standardly used for conditioning.
Adaptive Biotechnologies Corporation
Booth: 930
https://www.clonoseq.com/congress/
Biotechnology, Diagnostic Services/Testing
Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. Adaptive's goal is to develop and commercialize immune-driven diagnostics and therapeutics tailored to each individual patient.

ADC Therapeutics
Booth: 2533, Virtual
https://www.adctherapeutics.com
Biotechnology, Clinical Research, Oncology Pharmaceuticals, Patient Education Materials, Pharmaceuticals
Confronting cancer with the full potential of our science. ADC Therapeutics is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). ADC Therapeutics is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

Advanced Instruments
Booth: 1921
http://www.aicompanies.com
Cell Counters, Hematology Analyzers
Advanced Instruments is trusted in laboratories worldwide. Chemistry labs depend on our easy-to-use osmometers that provide accurate and precise results with secure and efficient electronic data management. Microbiology labs have confidence in our Advanced™ Anoxomat® III anaerobic jar system because it efficiently achieves desired environments in just a few minutes. Hematology labs rely on the GloCyte® Automated Cell Counter System as the only CSF counter that is FDA cleared to count down to 0

Agios Pharmaceuticals
Booth: 2433
https://www.agios.com
Biotechnology, Genetic Testing, Pharmaceuticals
Agios is passionately committed to applying our leadership in the field of cellular metabolism to create life-changing therapies for people living with genetically defined diseases. The bonds we build with patient communities, healthcare professionals, partners and colleagues help elevate our thinking and propel our science to new heights. These connections, combined with our cellular metabolism expertise, have fueled the development of our first-in-class pyruvate kinase (PK) activator, mitapivat, as well as other investigational therapies.

Allogene Therapeutics
Booth: 1222, 3713
https://allogenevirtualexperience.com/
Biotechnology, Immunotherapy
Allogene Therapeutics is a clinical-stage biotechnology company developing a pipeline of “off-the-shelf” CAR T cell therapy candidates (AlloCAR T™) with the goal of delivering readily available cell therapy faster, more reliably and at greater scale.

Alnylam Pharmaceuticals
Booth: 1919, 1923
https://www.alnylam.com
Biotechnology, Pharmaceuticals
Alnylam is leading the translation of RNA interference (RNAi) into a new class of medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics are a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is headquartered in Cambridge, MA. For more information visit www.alnylam.com.

American Association for Cancer Research
Booth: 2615
https://www.aacr.org
Association, Cancer/Chemotherapy, Clinical Research, Publisher, Research Grants
The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

American Porphyria Foundation
Booth: 2429
http://www.porphryiafoundation.org
Educational, Non Profit, Patient Education Materials, Patient Services, Registry
Our mission is to improve the health and well-being of all individuals and families impacted by Porphyria. We have maintained a relentless focus on education, advocacy, support services and research for the prevention, treatment, and cure of the Porphyrias.
American Society of Hematology  Booth: 1333, Virtual
http://hematology.org
The Society’s mission is to foster high quality, equitable care, transformative research, and innovative education to improve the lives of patients with blood and bone marrow disorders.

American Society of Pediatric Hematology Oncology (ASPHO)  Booth: 2525
http://www.aspho.org
Association, Educational, Market Research, Non Profit
The American Society of Pediatric Hematology/Oncology (ASPHO) is the professional organization for nearly 2,000 member physicians and other healthcare professionals dedicated to promoting the optimal care of children, adolescents and young adults with blood disorders and cancer by advancing research, education, treatment, and professional practice. ASPHO sponsors educational and professional development programs. ASPHO’s diversity statement welcomes diverse and inclusive participation within the profession and the Society’s membership.

Amgen  Booth: 943
http://www.amgenoncology.com
Biotechnology, Cancer/Chemotherapy, Clinical Research, Immunotherapy, Oncology Pharmaceuticals
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakthrough potential.

Amyloidosis Research Consortium (ARC)  Booth: 2618
https://www.arci.org
Educational, Non Profit, Patient Education Materials, Patient Services, Research Affairs
The Amyloidosis Research Consortium (ARC) is a patient-focused nonprofit, harnessing the power of collaboration and innovation to advance science and both improve and extend the lives of those with amyloidosis.

Amyloidosis Support Groups  Booth: 2417
http://www.amyloidosissupport.org
Educational, Non Profit, Patient Education Materials, Patient Services, Registry
The Amyloidosis Support Groups is dedicated to providing peer group support to patients, caregivers, families and friends of those touched by all types of amyloidosis. We host meetings in 33 cities across the US. Additionally, we provide online support groups and live webinars that offer disease education to patients around the globe. An educational booklet and video are available on our website at https://www.amyloidosissupport.org/amyloid_aware.html.

Anucell Biosystems  Booth: 400
http://www.anucellbio.com
Biotechnology, Cell Separators, Immunotherapy, New Exhibitor, Startup (Organization is less than 5 years old and has 10 or fewer employees)
Anucell Biosystems is a company focused on providing novel solutions to emerging difficulties in cell processing: mitigating the impacts of over-processing of primary cells for treatments including CAR-T therapies. We employ a proprietary technology to enable true bead-free enrichments of T-cells from PBMC or Leukopak inputs without need to add additional chemistries or exchange cells from their culture media. Enriched T-cells are functionally fit and ready for downstream processing with no requirement for bead removal or media exchange following enrichment.

Apellis Pharmaceuticals  Booth: 501, 601, 700, Virtual
https://www.apellis.com
Biotechnology, Immunotherapy, Pharmaceuticals
At Apellis, we are committed to developing therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system.
Aplastic Anemia and MDS International Foundation, Inc.  
Exhibitors  
Booth: 1642  
http://www.aamds.org  
Non Profit, Patient Education Materials

The Aplastic Anemia and MDS International Foundation (AAMDSIF) is the world's leading non-profit health organization dedicated to supporting patients and their families who are living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH) and related bone marrow failure diseases. Founded in 1983, AAMDSIF provides patient education resources, professional education programs, research grants and advocacy for bone marrow failure disease research funding.

AplusA  
Booth: 1428  
https://www.aplusaresearch.com/  
Cancer/Chemotherapy, Oncology Pharmaceuticals, Other, Registry

argenx  
Booth: 543  
http://www.argenx.com  
Pharmaceuticals

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan and the EU. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, Instagram and Facebook.

ARUP Laboratories  
Booth: 3629  
http://www.aruplab.com

Ascentage Pharma  
Booth: 2318  
https://www.ascentage.com/

ASCLO  
Booth: 2425  
https://www.asco.org  
Non Profit

The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) are multidisciplinary oncology organizations representing nearly 45,000 members from every cancer specialty. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.

ASH Research Collaborative  
Booth: Virtual  
http://ashresearchcollaborative.org  

The ASH Research Collaborative (ASH RC) is a non-profit organization established by the American Society of Hematology in 2018 to foster collaborative partnerships that accelerate progress in hematology, with the goal of improving the lives of people affected by blood diseases. The foundation of the ASH RC is its Data Hub and Clinical Trials Network. The Data Hub is a technology platform that facilitates the exchange of information by aggregating research-grade data on hematologic diseases. As a major initiative within the ASH RC, the Data Hub aims to create the largest shared information resource within the global hematology community. The Sickle Cell Disease Clinical Trials Network is designed to accelerate the development and evaluation of therapies in a large proportion of the United States population affected by SCD. Through the Data Hub, the SCD Clinical Trials Network, and projects still to come, the ASH RC will transform research and practice in classical (nonmalignant) and malignant hematologic diseases throughout the world, for the benefit of patients and the hematology community. Visit the ASH RC kiosk located within ASH Central to learn more.

Associates of Cape Cod, Inc.  
Booth: 404  
http://www.acciusa.com  
Biotechnology

Associates of Cape Cod, Inc. (ACC) is a global biopharmaceutical company specializing in endotoxin and glucan detection. ACC was the first company licensed by the FDA to manufacture LAL for use as a quality control test for endotoxin in the pharmaceutical and medical device industry. ACC also operates a contract testing service.
ASTCT | American Society for Transplantation and Cellular Therapy  
 Booth: 2518  
 https://www.astct.org  
 Association, Non Profit

The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional membership association of more than 3,000 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. We strive to be the leading organization promoting research, education, and clinical practice in the field.

Astellas Pharma US, Inc.  
 Booth: 1234  
 https://www.astellasoncology.com  
 Pharmaceuticals

Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world. 075-0155-PM 11/2021.

Astex Pharmaceuticals, Inc.  
 Booth: 343  
 https://www.astx.com  
 Oncology Pharmaceuticals, Pharmaceuticals

Astex Pharmaceuticals, Inc. (“Astex”) is committed to the fight against cancer. Astex is developing a proprietary pipeline of novel therapies for the treatment of solid tumors and hematological malignancies. Astex is a member of the Otsuka group of pharmaceutical companies. The group also includes Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd and Taiho Oncology, Inc. Subject to regulatory approvals, Astex’s products will be commercialized in the US and Canada by Taiho subsidiaries, and the rest of the world by Otsuka subsidiaries.

AstraZeneca  
 Booth: 619, Virtual  
 http://www.astrazeneca-us.com  
 Cancer/Chemotherapy, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. For more information, please visit www.astrazeneca-us.com.

Atara Biotherapeutics, Inc.  
 Booth: 646  
 http://www.atarabio.com  
 Bone Marrow Transplantation Research, Immunotherapy

Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases. Atara's pipeline includes tabelecleucel for EBV-driven post-transplant lymphoproliferative disease (PTLD) and other EBV-associated diseases, next-generation CAR T therapies for cancers, and ATA188 for Multiple Sclerosis.

AVM Biotechnology LLC  
 Booth: 504  
 https://avmbiotech.com  
 Cancer/Chemotherapy, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals

AVM Biotechnology, a clinical-stage company, advancing AVM0703 for expeditious FDA approval in patients with relapsed/refractory Non-Hodgkin’s Lymphoma/Leukemia. AVM0703 rapidly induces, expands, and mobilizes endogenous bispecific γδ TCR+ invariant TCR+ NKT-like cells by a glucocorticoid-receptor-independent mechanism and potentiates chemotherapy and CAR-T response in pre-clinical models. Durable clinical responses achieved with strong safety profile. Ph 2/3 actively enrolling. Seeking additional trial sites & strategic partners for commercial launch in 2024.

AXON  
 Booth: 549  
 http://www.axon-com.com  
 AXON is a global healthcare communications agency that ignites change in healthcare. Through the power of life-changing communications, we contribute to medical advances that improve lives. We specialize in advising clients on medical affairs, clinical studies, real-world evidence, marketing, advocacy, and communications, all underpinned by insights and creative strategy. AXON has an international reach, with offices in Copenhagen, London, New York, and Toronto, and a worldwide affiliate network. AXON is proudly an AVE-NIR GLOBAL company.

Bayer  
 Booth: 1529  
 https://pharma.bayer.com  
 Coagulation Products, Oncology Pharmaceuticals

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing aging population. Bayer is committed to the principles of sustaining development, and the Bayer brand stands for trust, reliability, and quality throughout the world.
Beckman Coulter Life Sciences  Booth: 2018
https://www.beckman.com/
Cell Separators, Clinical Research, Diagnostic Reagents, Flow Cytometry, Research Reagents
Life sciences. Research. Precision manufacturing. If your life’s calling is in any of these or related fields, you need to know Beckman Coulter Life Sciences. Our mission is to empower those seeking answers to life’s important scientific and healthcare questions. For more details, visit beckman.com.

BeiGene  Booth: 2543, Virtual
https://www.beigene.com
Biotechnology, Cancer/Chemotherapy, Clinical Research, Oncology Pharmaceuticals, Pharmaceuticals
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 7,000 colleagues across five continents.

Binding Site, Inc.  Booth: 2119
https://www.bindingsite.com/
Coagulation Products, Diagnostic Assay Kits, Diagnostic Reagents, Research Immunochemicals
Binding Site is a world leader in providing specialized diagnostic products to clinicians and laboratory professionals worldwide. Our market-leading Freelite® serum free light chain tests are used as an aid in the diagnosis and monitoring of Multiple Myeloma and related plasma cell disorders. We are dedicated to improving patient lives, delivering innovative medical solutions that improve the diagnosis and management of blood cancers and immune system disorders.

Bio Products Laboratory USA, Inc.  Booth: 843
https://www.coagadex.com/hcp
Coagulation Products, Plasma Derivatives
Bio Products Laboratory (BPL) is committed to providing a continuous and reliable supply of high quality, plasma-based products to the patients, healthcare professionals, and customers we serve.

Biomea Fusion, Inc  Booth: 3342
https://biomeafusion.com/
Biotechnology, New Exhibitor
We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. Our mission is to revolutionize medicine by creating therapies that cure patients of their disease.

Blue Spark Technologies, Inc.  Booth: 1543
https://www.temptraq.healthcare
Bone Marrow Transplantation Research, Cancer/Chemotherapy, Diagnostic Services/Testing, Immunotherapy, Point-of-Care Testing
TempTraq®, is the only clinically tested, disposable Bluetooth®, wearable temperature monitor in the form of a soft, comfortable patch that continuously, safely and comfortably monitors body temperature for up to 72 hours and sends notifications to Apple® or Android™ compatible mobile devices. TempTraq Connect is the HIPAA-compliant cloud service supported by Google Healthcare Cloud Platform that enables patients and caregivers to monitor body temperature from anywhere. The system is FDA, CE, Health Canada and TGA cleared.

bluebird bio  Booth: 1228
https://www.bluebirdbio.com/
Biologics, Biotechnology, Clinical Research
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Blueprint Medicines  Booth: 1655
https://www.blueprintmedicines.com
Oncology Pharmaceuticals, Pharmaceuticals
Blueprint Medicines is a global precision therapy company that aims to invent life-changing medicines for people with cancer and blood disorders.
BMS/Pfizer  Booth: 1515
https://bmspfizercongressresources.com/show/booth
Pharmaceuticals
The Bristol Myers Squibb and Pfizer alliance is a worldwide collaboration bringing together two leading companies focused on cardiovascular disease with a shared vision to reduce NVAF-related stroke and treat DVT/pulmonary embolism events.

BostonGene  Booth: 2214
https://www.bostongene.com/
Immunotherapy, Software
BostonGene's mission is to power healthcare's transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

BPS Bioscience  Booth: 2428
https://www.bpsbioscience.com/
Cancer/Chemotherapy, Cell Culture, Immunotherapy, New Exhibitor, Research Reagents
BPS Bioscience's purpose is to advance new scientific discoveries that lead to therapies by creating innovative solutions for research. Our focus areas are immunotherapy, epigenetics, coronavirus, CRISPR, cell signaling, and others, providing 4500+ high quality recombinant cell lines, lentiviruses, proteins and biochemical and cell-based assay kits. As a primary manufacturer, we can supply products in large-scale bulk quantities, as well as custom manufacturing. Our biochemical and cell-based screening services are also available to accelerate your research.

Calithera Biosciences  Booth: 2229
https://www.calithera.com
Biotechnology, Cancer/Chemotherapy, Clinical Research, Oncology Pharmaceuticals
Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies for biomarker-specific patient populations. Calithera is advancing a pipeline of investigational small molecules targeting genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers with a high unmet need. The oral SYK inhibitor, mivavotinib, is being studied in R/R non-GCB DLBCL. Sapanisertib, an oral mTORC1/2 inhibitor, is being evaluated in R/R NRF2m sqNSCLC.

Cancer Science Institute of Singapore (CSI Singapore)  Booth: 2725
https://www.csi.nus.edu.sg
Cancer/Chemotherapy, Educational, Non Profit
The Cancer Science Institute of Singapore (CSI Singapore) is hosted by the National University of Singapore (NUS), a globally leading, research-intensive University. Our mission is to better understand the causes of human cancer across Asia, and thereby improve its detection, treatment and prevention. Our outstanding researchers and exceptional facilities create an energetic environment for ground-breaking science and world-class training. Extensive cancer research ranging from basic cancer studies to experimental therapeutics are conducted to improve cancer treatment.

Cardinal Health  Booth: 401
http://www.cardinalhealth.com
Cardinal Health Specialty Solutions partners with physicians to help them deliver cost effective care to patients managing complex diseases. We provide reliable, cost-effective access to specialty medications and innovative tools to help physicians run more efficient practices. We work to ensure physicians get fairly reimbursed for delivering quality care to patients.

CellPoint  Booth: 800
https://www.cellpoint.bio
Biotechnology, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Point-of-Care Testing
CellPoint (a Galapagos company) believes the future of cell therapy is at the point-of-care, near the patient. The company is developing point-of-care candidate CAR-T therapies that could potentially solve unmet needs of patients with hematological cancer and offer the potential for more rapidly available, affordable treatments. Phase I/II clinical trials with CellPoint candidate CAR-T constructs are currently ongoing in various haematological malignancies.

Bristol Myers Squibb  Booth: 1615, Virtual
https://www.bmsvirtualcongress.com/ASH2022
Biologics, Cancer/Chemotherapy, Immunotherapy, Monoclonal Antibodies, Pharmaceuticals
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
Cellworks
https://www.cellworks.life/
Biotechnology, Cancer/Chemotherapy, Clinical Research, Oncology Pharmaceuticals, Software
Cellworks is a leader in Precision Biosimulation Services for Personalized Oncology and Drug Development. Using OMICs modeling, computational biosimulation and AI heuristics, Cellworks provides biopharma companies with biosimulation services that accelerate drug development and clinicians with patient-specific therapy predictions. Precision Biosimulation improves patient outcomes by accelerating the availability of new drugs and personalizing therapy selection. www.cellworks.life

Cepheid
http://www.cepheid.com
Diagnostic Reagents, Genetic Testing, Leukemia/Lymphoma Detection, Molecular Biology
Cepheid is the leading innovator in the field of molecular diagnostics. The Company is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use systems and tests. By automating highly complex procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated molecular testing that can dramatically enhance the management of cancer and infectious diseases.

Certara
https://www.certara.com/
New Exhibitor, Software
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

Champions Oncology
https://www.championsoncology.com/
Biotechnology, Cancer/Chemotherapy, Clinical Research, Contract Research Organization, Flow Cytometry
Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharma-co-pheno-multiiomic integration. For more information, please visit www.championsoncology.com

Chiesi Global Rare Diseases
https://chiesirarediseases.com/
Pharmaceuticals
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focuses on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders to patient advocacy, research and patient care.

Children’s Hospital of Philadelphia
https://www.chop.edu/
Bone Marrow Transplantation Research, Cancer/Chemotherapy, Clinical Research, Immunotherapy, Non Profit
The Cancer Center at Children’s Hospital of Philadelphia is internationally recognized for its expert staff and game-changing innovations. Our pediatric oncologists treat patients using an evidence-based approach backed by the latest research. We offer a range of therapies, from standard treatment protocols to groundbreaking clinical trials available only at CHOP. Our care is comprehensive, including extensive psychosocial support, programs for cancer predisposition and survivorship, and more.

CIBMTR (Center for International Blood & Marrow Transplant Research)
https://www.cibmtr.org
Bone Marrow Transplantation Research, Clinical Research, Registry
The CIBMTR facilitates critical cellular therapy research through a clinical database with >600,000 patients from >350 centers worldwide and a biospecimen repository with >195,000 samples. Collaborate with us on one of our ~225 current studies. Visit www.cibmtr.org.

City of Hope Comprehensive Cancer Center
http://www.cityofhope.org/ash22
Bone Marrow Transplantation Research, Cancer/Chemotherapy, Genetic Testing, Immunotherapy, Leukemia/Lymphoma Detection
City of Hope is an NCI-designated comprehensive cancer center and a global pioneer in breakthrough treatments for hematologic cancers, having performed over 17,000 bone marrow transplants to date with exceptional survival rates, according to the Center for International Blood & Marrow Transplant Research. We are also home to one of the most comprehensive CAR T
cell programs in the world, with nearly 1,000 patients treated in immune effector cell trials. With our acquisition of Cancer Treatment Centers of America, City of Hope now serves approximately 115,000 patients every year.

**Cleveland Clinic Taussig Cancer Institute  Booth: 810**
https://my.clevelandclinic.org/
Bone Marrow Transplantation Research, Cancer/Chemotherapy, Clinical Research, Leukemia/Lymphoma Detection, Non Profit

Cleveland Clinic Cancer Center provides comprehensive care enhanced by innovative research. Our more than 700 caregivers treat thousands of cancer patients yearly and provide access to a wide range of clinical trials. Cleveland Clinic Cancer Center unites clinicians and researchers in Taussig Cancer Institute and Cleveland Clinic’s 25 other institutes, as well as cancer specialists at our regional hospitals, health centers and Cleveland Clinic Florida.

**Clinical Advances in Hematology and Oncology  Booth: 2021**
http://www.hematologyandoncology.net
Books/Journals
CAH&O is an independent PubMed-indexed peer-reviewed journal reaching over 26,000 hem/onc clinicians on a monthly basis. CAH&O also published high quality industry-supported educational supplements and clinical monographs.

**Cogent Biosciences  Booth: 642**
https://www.cogentbio.com/
Biotechnology, Clinical Research, Oncology Pharmaceuticals, Pharmaceuticals
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients. We have ongoing clinical research programs in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST).

**College of American Pathologists  Booth: 2516**
https://www.cap.org
Association, Books/Journals, Non Profit
The College of American Pathologists offers two monthly publications: CAP TODAY and the Archives of Pathology & Laboratory Medicine. CAP TODAY brings monthly business and medical news in the clinical laboratory. The Archives of Pathology & Laboratory Medicine is one of the best-read journals among pathologists and laboratory directors. Samples are available.

**Cooley’s Anemia Foundation  Booth: 2614**
https://www.thalassemia.org/
Non Profit, Research Grants
Cooley’s Anemia Foundation advances the treatment and cure for thalassemia, enhances quality of life of patients and educates the medical profession, trait carriers & the public about thalassemia. The Foundation funds fellowships & medical research.

**Correspondances en Onco-hematologie  Booth: 322**
http://www.edimark.fr/correspondances-onco-hematologie
Books/Journals, Publisher
Correspondances en Onco-hematologie is a French bimonthly publication specialized in oncology, which editor in chief is Pr Noel Milpied. The readership is composed of hematologists, oncologists, geriatrists. Correspondances en onco-hematologie is published in 4500 copies.

**CRISPR Therapeutics  Booth: 315**
https://www.crisprtx.com
Biotechnology, Bone Marrow Transplantation Research, Cancer/Chemotherapy, Immunotherapy, Oncology Pharmaceuticals
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. This revolutionary gene editing technology allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

**Cryoport Systems  Booth: 229**
https://www.cryoport.com/integrated-supply-chain-platform
Human Biologicals, New Exhibitor
Cryoport and BioLife Cellular Therapy Services, part of the global biopharma company, Takeda Pharmaceutical Company, have joined forces in a strategic relationship to establish an integrated supply chain platform to offer standardized cell therapy collection, processing, storage, and distribution services. The platform will provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cellular therapies. The relationship aims to shorten processing & logistics time and standardize collections to accelerate cell therapy programs.
CSL Behring
https://www.cslbehring.com
Booth: 3519

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients' needs using the latest technologies to develop and deliver innovative therapies. The company offers a broad range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and chronic inflammatory demyelinating polyneuropathy (CIDP). CSL Behring's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

CTI BioPharma Corp.
http://www.ctibiopharma.com
Booth: 351

CTI Biopharma is a Seattle based biopharmaceutical company focused on acquisition, development, and commercialization of novel targeted therapies for blood-related cancers that offer options to patients and healthcare providers. CTI has one FDA-approved product VONJO® (pacritinib). See full prescribing information at www.VONJO.com. Contact: 3010 Western Avenue, #800 Seattle, WA 98121 800-215-2355

Curis, Inc.
https://www.curis.com
Booth: 604

Curis is a biotechnology company focused on the development of first-in-class and innovative therapeutics for cancer, with a pipeline of differentiated small molecule hematology and oncology drug candidates. Currently Curis has two drugs candidates in development; CA-4948 an orally available small molecule inhibitor of IRAK4 kinase in non-Hodgkin’s lymphoma and leukemia (AML/MDS), and CI-8993 a clinical-stage human IgG1 kappa monoclonal antibody designed to antagonize the VISTA signaling pathway in advance solid tumors.

Cytiva
https://www.cytiva.com
Booth: 2259

Cytiva provides complete solutions for epigenetics research in immuno-oncology, neuroscience, and more. Our comprehensive approach to gain insights into RNA, DNA, and chromatin analysis from solid tumor to liquid biopsy samples with experimentally-validated, easy-to-use solutions and services give researchers the success to move from research to translational and clinical applications.

Daiichi Sankyo – Medical
https://www.dsvirtualexhibit.com/medical
Booth: 2633

Daiichi Sankyo – Medical is committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Located in Boston, MA, Dana-Farber is a founding member of Dana-Farber/Harvard Cancer Center, an NCI designated Comprehensive Cancer Center. Dana-Farber is the nation's top academic recipient of grant funding from the NCI and offers more than 1,100 clinical trials. Visit us at booth #2419 to learn more.

Dana-Farber Cancer Institute
https://www.dana-farber.org/
Booth: 2419

Dana-Farber Cancer Institute is committed to providing adults and children with cancer with the best treatment available today while developing tomorrow’s cures through cutting-edge research. Located in Boston, MA, Dana-Farber is a founding member of Dana-Farber/Harvard Cancer Center, an NCI designated Comprehensive Cancer Center. Dana-Farber is the nation’s top academic recipient of grant funding from the NCI and offers more than 1,100 clinical trials. Visit us at booth #2419 to learn more.

DAVA Oncology
http://www.davaonc.com
Booth: 2659

DAVA Oncology is the leading provider of clinical trial acceleration services and oncology drug development consulting products designed to accelerate research and development timelines. DAVA’s primary focus is to accelerate the successful completion of cancer clinical trials through the deployment of experienced medical oncologists.

Diagenode, Inc.
http://www.diagenode.com
Booth: 411

Diagenode provides complete solutions for epigenetics research in immuno-oncology, neuroscience, and more. Our comprehensive approach to gain insights into RNA, DNA, and chromatin analysis from solid tumor to liquid biopsy samples with experimentally-validated, easy-to-use solutions and services give researchers the success to move from research to translational and clinical applications.
Diamond Blackfan Anemia Canada  Booth: 2717
http://www.dbacanada.com
Association, Educational, Non Profit, Patient Education Materials, Patient Services
Diamond Blackfan Anemia Canada's mission is to provide education, support, and resources to Canadian families and individuals affected by Diamond Blackfan Anemia. Additionally, in collaboration with the Diamond Blackfan Anemia Foundation, we fund much needed research into this rare disorder.

Diamond Blackfan Anemia Foundation  Booth: 2715
http://www.dbafoundation.org
Non Profit, Patient Education Materials, Patient Services, Registry, Research Grants
The mission of the Diamond Blackfan Anemia Foundation is to advance research initiatives that promote a better understanding, therapeutic strategies and a cure for this rare bone marrow failure syndrome. We are dedicated to providing patient advocacy, support and education services to individuals, families and medical professionals resulting in improvements in the diagnosis, clinical treatment and management of the disorder, while enhancing the quality of life of affected families worldwide.

Doximity  Booth: 410
http://www.doximity.com
Educational, Other
Doximity is the largest social network for healthcare professionals, with over 1 million members on our platform. Our free app offers services such as referrals, HIPAA secure faxing and messaging, colleguing, CME, privately calling patients from your cell phone, and more. Over 80% of all US physicians are a part of Doximity - using our services to connect, communicate, and help improve patient care.

ECD Global Alliance  Booth: 2619
https://www.erdheim-chester.org/
Cancer/Chemotherapy, Non Profit, Patient Education Materials, Patient Services, Research Grants
The ECD Global Alliance is dedicated to the awareness, support, education, and research related to Erdheim-Chester Disease (ECD). ECD is an ultra-rare type of blood cancer that is difficult to diagnose and can manifest in a variety of complex ways. Hematologists, together with other clinicians, pathologists, and radiologists, play a vital role in identifying ECD. There are viable FDA-approved and off-label treatments available to improve the quality of life and slow the progression of the life-threatening disease. The key to a successful or more positive outcome is early diagnosis.

Editas Medicine  Booth: 1918
https://www.editasmedicine.com/
Biotechnology, Cancer/Chemotherapy
Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into treatments for people living with serious diseases around the world.

Eli Lilly and Company  Booth: 3014, 3513, Virtual
http://www.LillyLoxoOncologyPipeline.com/
Oncology Pharmaceuticals, Pharmaceuticals
Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients.

Elsevier  Booth: 2242
http://Us.elsevierhealth.com
Books/Journals, Clinical Research
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, and deliver better care.

Emmaus Medical, Inc.  Booth: 555
http://www.emmausmedical.com
Pharmaceuticals
Emmaus Medical, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. We are currently focused on sickle cell disease (SCD), a genetic disorder with a significant unmet medical need. Our lead product, Endari® (L-glutamine oral powder), received FDA approval on July 7, 2017. With this approval, Endari® is available to reduce the acute complications of sickle cell disease in adults and children 5 years and older. For more information, please read the Full Prescribing Information for Endari® at http://www.EndariRx.com.

Enable Injections  Booth: 3450
https://www.enableinjections.com/
Biotechnology, Other, Pharmaceuticals
Enable Injections is a global healthcare innovation company developing and manufacturing drug delivery systems designed to improve the patient experience. Enable's body-worn enFuse® delivers high-volume
pharmaceutical and biologic therapeutics via subcutaneous administration with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. Enable Injections is redefining drug delivery for the benefit of patients, providers, payers and partners.

**EpigenDx**  
*Booth: 3322*  
[https://labs.epigendx.com](https://labs.epigendx.com/)

*Biotechnology, Clinical Research, Diagnostic Assay Kits, Diagnostic Services/Testing, Genetic Testing*

With 15+ years of experience in genetic & epigenetic clinical research, EpigenDx offers high quality products & laboratory services focused on DNA methylation analysis, gene expression profiling, & mutation analysis. Our scientific teams carefully evaluate each project & establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, & GeneChip Microarray. Our popular services include Line-1 global methylation tests & Foxp3-TSDR analysis.

**Eurasian Hematology Oncology Group**  
*Booth: 2524*  
[http://www.ehog.net/](http://www.ehog.net/)

*Association, Educational*

Hematology Specialist Association taking it as a mission, has been working to protect rights of medical doctors who became Specialists in Hematology and have been working in this area for a long time period. Further, the mission is also to introduce Turkish Hematology in all around the world and practice and develop hematology related applications of all kinds.

**European Hematology Association**  
*Booth: 2822*  
[http://www.ehaweb.org](http://www.ehaweb.org)

*Association, Educational*

THE EUROPEAN HEMATOLOGY ASSOCIATION PROMOTES EXCELLENCE IN PATIENT CARE, RESEARCH, AND EDUCATION IN HEMATOLOGY. We serve medical professionals, researchers, and scientists with an active interest in hematology. We are proud to be the largest European-based organization connecting hematologists worldwide to support career development and research, harmonize hematology education, and advocate for hematologists and hematology.

**EUSA Pharma**  
*Booth: 1553*  

*Monoclonal Antibodies, Oncology Pharmaceuticals*

EUSA Pharma is a global biopharmaceutical company committed to transforming the lives of people affected by cancer or rare disease. We Change Lives, Patient by Patient.

**Evident**  
*Booth: 611*  
[http://www.olympus-ossa.com](http://www.olympus-ossa.com)

**Exelixis, Inc. - Medical Affairs**  
*Booth: 1057*  
[https://www.exelixismedicalaffairs.com/](https://www.exelixismedicalaffairs.com/)

*Oncology Pharmaceuticals*

Exelixis is an oncology-focused biotechnology company that strives to accelerate the discovery, development, and commercialization of new products for difficult-to-treat cancers. Our efforts have resulted in four approved products available to patients worldwide. Our clinical development program focuses on our pipeline products as well as evaluation of cabozantinib in new tumor types and combinations. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities.

**Fidelis Research AD**  
*Booth: 1115*  
[http://www.fidelis-research.com](http://www.fidelis-research.com)

*Bone Marrow Products, Cell Culture, Flow Cytometry, Plasma Derivatives, Specimen Collection/Transport*

Fully custom offerings that meet your needs for biospecimen collections, processing, preparation and shipping. Fidelis is specialized in the procurement of high-quality human biological specimens and value-adding ancillary services. We support researchers globally by collecting and processing a broad range of disease-state and healthy control samples accompanied by comprehensive annotated data. Our goal is to accelerate research and innovation that help our partner’s translational science.

**Flow Contract Site Laboratory**  
*Booth: 202*  
[https://www.fcslaboratory.com](https://www.fcslaboratory.com)

*Clinical Research, Contract Research Organization, Flow Cytometry, Immunotherapy, New Exhibitor*

Flow Contract Site Laboratory is a specialized CRO offering flow cytometry services for research, nonclinical and clinical drug development. Our capabilities include multi-color antibody panels for immunophenotyping, receptor occupancy, intracellular cytokine and phospho-protein detection and cellular functional assays. We are proficient in processing a multitude of specimen types including whole blood, tissue, frozen PBMCs and tumors for pre-clinical model systems and human clinical trials.
Follicular Lymphoma Foundation  Booth: 2729  
https://www.thelf.org/  
Immunotherapy, Non Profit, Patient Education Materials, Patient Services, Research Grants

The Follicular Lymphoma Foundation is the only lymphoma charity dedicated to finding a cure for Follicular Lymphoma (FL) – and finding it fast. Incurable is not good enough. All our programmes aim to accelerate a transformative change in FL scientific research, putting patients at the heart of everything we do. We aim to link research and clinical communities, together with patients, to help ensure their views and experiences are part of the development process for new treatments and a cure.

Forma Therapeutics  Booth: 143  
https://www.formatherapeutics.com/  
Biotechnology, Pharmaceuticals

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our work has generated a broad, proprietary portfolio of programs with the potential to provide profound patient benefit, including our sickle cell disease program, etavopivat (FT-4202), and our metastatic, castration-resistant prostate cancer program, FT-7051. Click the link above to visit our corporate website or visit us in person at booth #143.

Foundation for Sickle Cell Disease Research  Booth: 2623  
http://www.fscdr.org  
Clinical Research, Patient Services

We are a Non-Profit Organization with a Mission to tirelessly research, inform, hear, respect, treat and support all individuals living with Sickle Cell Disease. We are driven to make this disorder a livable, non-threatening condition.

Foundation for the Accreditation of Cellular Therapy (FACT)  Booth: 2714  
https://www.factglobal.org/  
Bone Marrow Transplantation Research, Cord Blood Banking, Educational, Non Profit, Self-Assessment Program

FACT is a non-profit corporation founded for the purpose of voluntary inspection and accreditation in the field of cellular therapy, cord blood banking, and regenerative medicine. The objective of FACT is to improve the quality of cellular therapy through peer-developed standards, education and accreditation for the benefits of patients. FACT is the standards setting and accreditation arm of the International Society for Cellular Therapy (ISCT) and the American Society of Blood and Marrow Transplantation (ASBMT).

Fred Hutchinson Cancer Center  Booth: 2622  
http://www.fredhutch.org  
Bone Marrow Transplantation Research, Clinical Research, Immunotherapy, Patient Services

Fred Hutchinson Cancer Center unites comprehensive care and advanced research to provide the latest cancer treatment options and accelerate discoveries that prevent, treat and defeat cancer and infectious diseases worldwide. Based in Seattle, Fred Hutch is an independent, nonprofit organization and is the only National Cancer Institute-designated cancer center in Washington.

Fresenius Kabi  Booth: 510  
http://www.fresenius-kabi.us  
Biologics, New Exhibitor, Oncology Pharmaceuticals, Pharmaceuticals

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, and we supply the US oncology market with one of the largest injectable oncology portfolios in the industry. We’re now committed to launching a range of biosimilars in the U.S. with our BioSpecialized approach to healthcare. From the collaborative way we work with healthcare professionals to how we manufacture and deliver our products, we are committed to going beyond medicines to support patient care.

Fulgent Oncology  Booth: 2328  
https://www.fulgentoncology.com/  
Biotechnology, Clinical Research, Diagnostic Services/Testing, Genetic Testing

Fulgent Oncology offers expert-driven analysis coupled with individually-curated reports, giving you the insights you need for optimizing patient care. Reports provide guidance for appropriate therapeutic considerations, including immunotherapy and clinical trials eligibility. The LumeraTM Xpanded Profile, our flagship pan-cancer NGS solid tumor profile, offers the unique advantage of a comprehensive summary report that includes pathology consultation and case review.

Gamida Cell  Booth: 1823  
https://www.gamida-cell.com  
Bone Marrow Transplantation Research, Immunotherapy

Gamida Cell is the leader in pioneering NAM-enabled cell therapies designed as a curative approach for patients with blood cancers and other serious diseases. We are harnessing the power of our proprietary NAM-enabled technology to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create cell therapy candidates with potential to redefine standards of care and significantly improve patient outcomes and health equity.
Geisinger

http://www.geisinger.org/careers

Non Profit, Patient Services, Physician Recruitment

Geisinger is committed to making better health easier for the more than 1 million people it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes ten hospital campuses, a 550,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. With nearly 24,000 employees and more than 1,600 employed physicians, Geisinger boosts its hometown economies in Pennsylvania by billions of dollars annually.

GemPharmatech

https://www.gempharmatech.us/en/

Contract Research Organization, Immunotherapy, Molecular Biology, Startup (Organization is less than 5 years old and has 10 or fewer employees)

GemPharmatech is a leading provider of animal models and services to global preclinical R&D communities. We specialize in developing animal models using cutting edge gene-editing technologies with a large collection of conditional knockout/knockout mice, humanized mice, immunodeficient mice, and germ-free mice. GemPharmatech provides an expansive array of preclinical services, including mouse model customization, pharmacology services such as drug efficacy testing and mouse phenotyping, CRISPR/Cas9 gene-editing, and customized breeding.

Genentech USA, Inc.

http://www.gene.com

Biotechnology, Clinical Research, Coagulation Products, Oncology Pharmaceuticals, Pharmaceuticals

Every person with a blood disease has their own story; and each unique story shapes ours, fueling our dedication to pursue science and bring the best care to each individual. Our power is in discovering innovative medicines and personalizing patient care. For more than 40 years, we’ve been following the science and seeking solutions to unmet medical needs. Building on our legacy as the pioneer in blood cancer innovation, Genentech, a proud member of the Roche Group, has the opportunity to revolutionize new approaches to a spectrum of blood diseases.

Genmab

https://www.genmab.com

Biotechnology, Cancer/Chemotherapy, Immunotherapy, Monoclonal Antibodies, Oncology Pharmaceuticals

Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. For more information, please visit Genmab.com

Genomic Testing Cooperative

https://www.genomictestingcooperative.com

Diagnostic Reagents, Diagnostic Services/Testing, Genetic Testing, Immunotherapy, Leukemia/Lymphoma Detection

GTC offers advanced genomic profiling of DNA/RNA for hematologic cancers. We have a fast TAT of 5-10 days and a QNS rate of <1%. We are excited to introduce Liquid Trace, a comprehensive liquid biopsy analyzing cfDNA and cfRNA that will reduce the need for bone marrow biopsies. Our co-op model allows us to support labs to internalize NGS testing, while providing bioinformatics and reporting. In addition we do all of the R&D work to keep the assays up to date with the science and disperse that innovation to our co-op lab members. GTC also can operate as traditional reference lab.

GenPath

https://www.genpathdiagnostics.com/

Coagulation Testing, Cytogenics, Diagnostic Services/Testing, Flow Cytometry, Genetic Testing

GenPath®, a division of BioReference, is a leading expert in cancer diagnostics, offering a comprehensive portfolio to support the continuum of care of cancer patients— from risk assessment to treatment planning. Backed by a team of specialized pathologists, GenPath delivers cutting-edge solutions that meet the unique needs of oncologists and pathologists, ranging from routine clinical and special coagulation to complex genomic testing for tumor sequencing and hereditary cancer syndromes.

Geron Inc.

http://www.geron.com

Geron Corporation 149 Commonwealth Drive Menlo Park, CA 94025 USA Tel: 650-473-7700 Fax: 650-473-7750 Email: info@geron.com

Gilead and Kite Oncology


Biotechnology, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals

Gilead and Kite Oncology are creating the future of oncology. From antibody-drug conjugates and small molecules to cell therapy-based approaches, our R&D programs and partnerships are creating possibilities for people with overlooked, underserved and difficult-to-treat cancers. We are focused on helping to bring
Global Blood Therapeutics

https://www.gbtvirtual.com

Biotechnology, Pharmaceuticals

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease.

Global Pediatric MDS Initiative

https://www.pediatricmds.org

GRAIL, LLC

https://www.galleri.com/

Diagnosis Services/Testing

GRAIL is a healthcare company whose mission is to detect cancer early when it can be cured and is focused on saving lives and improving health by pioneering new technologies for early cancer detection. Their first product, the Galleri® multi-cancer early detection test, complements guideline-recommended screenings, and can detect a cancer signal across more than 50 types of cancer through a routine blood draw for adults with elevated risk, such as aged 50 or older. When cancer is detected, the Galleri test can predict the cancer signal origin.

Grifols Laboratory Solutions, Inc.


Pharmaceuticals

Grifols is a global healthcare company whose mission is to improve the health and well-being of people around the world. We have three primary divisions – Bioscience, Diagnostic and Hospital – that develop, produce and market our innovative products and services to medical professionals in more than 100 countries around the world.

GSK

https://www.gsk.com/

Cancer/Chemotherapy, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals

GSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination. NX-GBL-ON-OGM-210034. December 2021.

Gundersen Health System

https://www.gundersenhealth.org/careers

Physician Recruitment

Gundersen Health System is a top-rated healthcare organization based in La Crosse, Wis. Gundersen offers top-quality primary and specialty healthcare usually found only in larger metropolitan areas. We are anchored by one of the largest multi-specialty group practices linking us with our regional clinics and affiliated hospitals via telemedicine, distance learning, digital imaging and other services. Our system serves the western Wisconsin, southeastern Minnesota and northeastern Iowa areas.

Harborside

http://www.harborsidenexus.com

Books/Journals, Educational, Oncology Pharmaceuticals, Pharmaceuticals, Publisher

Harborside is a medical communications company and publisher of The ASCO Post, Journal of Oncology Practice, Journal of the Advanced Practitioner in Oncology (JADPRO), and JNCCN-Journal of the National Comprehensive Cancer Network. The company also manages the advertising sales for ASCO’s suite of publications, including the Journal of Clinical Oncology (JCO), the Journal of Global Oncology, JCO Clinical Cancer Informatics, and JCO Precision Oncology. In addition, Harborside also produces live events for practicing nurse practitioners, PA’s, and pharmacists.

Haymarket Oncology

https://www.cancertherapyadvisor.com/

Publisher

CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients. Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.

HealthTree Foundation

https://www.healthtree.org

Cancer/Chemotherapy, Clinical Research, Non Profit, Patient Education Materials, Patient Services

The HealthTree Foundation (formerly Myeloma Crowd) puts patients first, builds trusted patient communities, accelerates research, and drives to a cure. We currently support myeloma, AML, MDS, and Kidney disease patients with a suite of tools such as free coaching, attending an educational event, finding a disease specialist, or learning in HealthTree University. In Cure Hub find your genetic twin and see personalized treatment options or clinical trials. Data is merged into a
collective network with other patient data that provides validated real-world data for research.

**HealthWell Foundation**  
Booth: 2828  
http://www.healthwellfoundation.org

*Non Profit*

The HealthWell Foundation is an independent non-profit dedicated to reducing financial barriers to care for underinsured Americans with chronic and life-altering medical conditions. HealthWell offers a financial lifeline to adults and children who desperately need critical medical treatments but can’t afford them by assisting with their cost-sharing obligations. Learn more: www.HealthWellFoundation.org.

**HEMA Biologics**  
Booth: 2455  
https://www.hemabio.com/

*Biologicals, Coagulation Products*

HEMA Biologics is a privately held biopharmaceutical company focused on the rarest bleeding disorders. We aspire to support patients living with these disorders, partner with the broader community that cares for them, and bring meaningful treatments and services to help better their daily lives.

**HematoLogics, Inc.**  
Booth: 1214  
https://www.hematologics.com

*Bone Marrow Transplantation Research, Cytogenics, Flow Cytometry, Genetic Testing, Leukemia/Lymphoma Detection*

HematoLogics, Inc. is a privately owned laboratory with a focus on medicine and scientific discovery. We have an international reputation for our study of myelodysplasia, MRD detection, and the integration of technologies to detect and monitor treatment of hematopoietic diseases. Our approaches are validated through international collaborations and clinical trials. Our experience ensures these innovative techniques support a service oriented hematopathology referral group.

**Hemophilia Federation of America (HFA)**  
Booth: 2528  
http://www.hemophiliafed.org

*Association, Educational, Non Profit, Patient Education Materials, Patient Services*

HFA is a national non-profit organization serving the needs of the bleeding disorders community. Through programming and listening to their needs, we work to advance patients’ rights and access to care, be a resource to patients and their families, and to provide educational opportunities to give patients the tools they need to advocate for themselves. We aim to improve the care and quality of life for those with bleeding disorders by removing barriers to diagnosis, treatment, and cure.

**Ichnos Sciences**  
Booth: 3127  
https://www.ichnossiences.com/

*Biotechnology, Human Biologicals, New Exhibitor, Oncology Pharmaceuticals, Pharmaceuticals*

Ichnos Sciences has a mission to provide breakthrough therapies that will extend and improve lives. A clinical-stage biotech with the spirit of a start-up, Ichnos aims to shift the way the world thinks about innovation through its research and development of transformative bi/multispecific antibody therapies in oncology. Headquartered in New York, N.Y., Ichnos is using its patented BEAT® technology platform to advance a pipeline of drug candidates to treat hematologic cancers and solid tumors.

**ICON**  
Booth: 2023  
https://www.ICONplc.com

*Biotechnology, Clinical Research, Contract Research Organization, Hematology Cytocentrifuge, Oncology Pharmaceuticals*

PRA Health Sciences is now an ICON plc company. ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON operates from 150 locations in 47 countries and has approximately 38,000 employees.

**Imaging Endpoints II, LLC**  
Booth: 2059  
https://www.imagingendpoints.com/

*Clinical Research, Contract Research Organization, Digital Imaging Systems, New Exhibitor, Oncology Pharmaceuticals*

Imaging Endpoints (IE) is the largest oncology-focused imaging CRO globally and is widely recognized for conducting the industry’s largest, most complex, and most successful imaging trials for both solid and liquid tumor indications. IE is based in Scottsdale, AZ with offices around the world including Cambridge, MA; London, United Kingdom; Basel, Switzerland; Leiden, Netherlands; Hyderabad, India; and Shanghai, China. Visit imagingendpoints.com to learn more!

**Imago Biosciences**  
Booth: 2559  
https://www.imagobio.com/

*Biotechnology, Clinical Research, New Exhibitor, Oncology Pharmaceuticals, Pharmaceuticals*

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecules that target lysine-specific demethylase 1 (LSD1), an essential enzyme in the production of blood cells in the bone marrow. Bomedemstat, an orally available LSD1 inhibitor discovered by Imago being
tested in clinical studies as a potentially disease-modifying therapy for myeloproliferative neoplasms (MPNs), a family of chronic cancers of the bone marrow, including essential thrombocythemia (ET), myelofibrosis (MF), and polycythemia vera (PV).

ImmunoGen, Inc.

https://www.immunogen.com

Booth: 3320

Biotechnology, Clinical Research

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™. Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Incyte Corporation

http://www.incyte.com

Clinical Research, Immunotherapy, Oncology Pharmaceuticals

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development, and commercialization of proprietary therapeutics. We are advancing a growing portfolio of medicines across oncology and inflammation & autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For more information visit incyte.com and follow @incyte.

Intermountain Healthcare

https://intermountainhealthcare.org/careers/explore-careers/physician-jobs

Non Profit

Intermountain Healthcare is a team of nearly 60,000 caregivers who serve the healthcare needs of people across the Intermountain West, primarily in Utah, Idaho, Nevada, Colorado, Montana, Wyoming, and Kansas. We are an integrated, non-profit health system based in Salt Lake City, with clinics, a medical group, affiliate networks, hospitals, homecare, telehealth, health insurance plans, and other services, along with wholly owned subsidiaries including SelectHealth, Saltzer Health, Castell, Tellica, and Classic Air Medical.

International Myeloma Society

https://www.myelomasociety.org/

Association, Cancer/Chemotherapy, Clinical Research, Molecular Biology, Other

The International Myeloma Society (IMS) promotes education, research and clinical care globally by building a global myeloma community, educating for today and the future, fostering clinical and translational research in myeloma and assuring clinical excellence worldwide.

International Society on Thrombosis and Haemostasis (ISTH)

http://www.isth.org

Books/Journals, Non Profit

The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live.

Interpace Pharma Solutions

http://www.flagshipbio.com

Clinical Research, Contract Research Organization, Cytogenetics, Flow Cytometry, Genetic Testing

Flagship Biosciences is a leader in spatial biology and biomarker analytics specializing in histology, advanced molecular biomarker solutions, flow cytometry, cytogenetics, and bioinformatics solutions. Our team of experts in pathology, molecular sciences, and regulatory strategy offers advanced end-to-end biomarker and analytics services to support drug trials, biomarker discovery, and clinical diagnostics.

Intrinsic LifeSciences

http://www.intrinsiclifesciences.com

Biotechnology, Clinical Research, Diagnostic Reagents, Diagnostic Services/Testing, Research Reagents

Intrinsic LifeSciences LLC provides superior, innovative & patent-protected research test kits and certified diagnostics & clinical research CLIA services for hepcidin and erythroferrone (ERFE), the key indicators of anemia, inflammation and pregnancy disorders. Our CAP accredited clinical lab, IntrinsicDx™, offers the Intrinsic Hepcidin IDx™ Test service. We also provide RUO immunoassay testing for other related biomarkers. To learn more visit www.IntrinsicDx.com, www.intrinsiclifesciences.com.

Invivoscribe, Inc.

https://www.invivoscribe.com/

Diagnostic Assay Kits, Diagnostic Services/Testing, Flow Cytometry, Leukemia/Lymphoma Detection, Software

Invivoscribe is a global leader in hemat-oncology diagnostics. Our flow & molecular assays, reagents, controls, bioinformatics & services focus on actionable biomarkers supporting therapeutic decisions, MRD testing, stratification & CDx development.
Ipsen

**Booth: 1815**

**https://www.ipsenus.com**

**Biotechnology, Clinical Research, Oncology Pharmaceuticals, Pharmaceuticals**

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing medicines in three key therapeutic areas – Oncology, Rare Disease and Neuroscience. We are dedicated to providing hope for patients whose lives are challenged by unmet medical needs. Our North American operations are located in Cambridge, Massachusetts, one of the company’s three global hubs. For more information please visit www.ipsenus.com.

IQVIA Biotech

**Booth: 704**

**http://www.iqviabiotech.com**

**Biotechnology, Clinical Research, Contract Research Organization, Immunotherapy, Oncology Pharmaceuticals**

IQVIA Biotech delivers flexible clinical solutions designed to help biotech and emerging biopharma companies get treatments to patients. When you partner with our clinical development team, you gain expertise from two decades of planning and executing clinical trials exclusively for biotech companies. With more than 500 oncology studies in the last five years, and a focus on hematologic oncology and cell therapy, our dedicated teams have the experience to support your clinical trial.

IsoPlexis

**Booth: 507**

**https://www.isoplexis.com**

**Biotechnology, Diagnostic Services/Testing, Immunotherapy, Monoclonal Antibodies, Oncology Pharmaceuticals**

IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies and by 45% of comprehensive cancer centers. Visit www.isoplexis.com to learn more.

JAMA Network

**Booth: 500**

**https://www.jamanetwork.com**

**Books/Journals, Publisher**

JAMA Network advances the science and practice of hematology with high-impact journals including JAMA, JAMA Oncology, and JAMA Network Open. We publish research, reviews, and opinions shaping the future of medicine. Explore booth #500 at ASH to read the latest hematology articles from our journals and learn more about publishing with the JAMA Network. Learn more at https://www.jamanetwork.com.

Janssen Biotech, Inc.

**Booth: 429**

**https://www.janssen.com**

**Pharmaceuticals**

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenUS.

Janssen Biotech, Inc. – Medical Affairs

**Booth: 2215**

**http://www.janssen.com**

**Pharmaceuticals**

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal.

Janssen Pharmaceuticals Inc.

**Booth: 443**

**https://www.janssen.com**

**Pharmaceuticals**

About the Janssen Pharmaceutical Companies of Johnson & Johnson - At Janssen, we’re creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Jazz Pharmaceuticals, Inc.  
http://www.jazzpharma.com  
Cancer/Chemotherapy, Pharmaceuticals  
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing medicines for people with serious diseases — often with limited or no options.

John Theurer Cancer Center  
http://www.jtcancercenter.org/  
Bone Marrow Transplantation Research, Cancer/Chemotherapy, Clinical Research, Genetic Testing, Immunotherapy  
John Theurer Cancer Center at Hackensack University Medical Center is among the nation's top 50 U.S. News and World Report Best Hospitals – the highest ranked in New Jersey. It is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.

Karius  
http://www.kariusdx.com  
Diagnostic Services/Testing, Genetic Testing  
Karius is a life science company focused on advancing diagnostic science and technology for infectious disease. The Karius Test® is a liquid biopsy for infectious diseases that, from a single blood sample, can non-invasively and rapidly detect over 1000 pathogens causing both deep-seated and bloodstream infections. The Karius Test helps clinicians avoid invasive, low-yield, and sequential diagnostic tests that can delay treatment for the most vulnerable hospitalized patients.

Karyopharm Therapeutics Inc.  
https://www.karyopharm.com  
Biotechnology, Oncology Pharmaceuticals, Pharmaceuticals  
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies dedicated to the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers.

Kedrion Biopharma Inc.  
http://www.kedrionusa.com/  
Biologics, Biotechnology, Coagulation Products, Human Biologicals, Pharmaceuticals  
Kedrion Biopharma is a leading international biopharmaceutical company that specializes in the development, production, and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders, and conditions such as immune system deficiencies and coagulation disorders. Kedrion has special expertise in the treatment of rare diseases and the manufacture of hyper-immune products such as anti-hepatitis B, anti-tetanus, and RhoGAM® for prophylaxis against Rh sensitization and subsequent hemolytic disease of the fetus and newborn.

Kronos Bio  
http://www.kronosbio.com  
Biotechnology, Clinical Research, Leukemia/Lymphoma Detection, New Exhibitor, Oncology Pharmaceuticals  
Kronos Bio is advancing three investigational compounds in clinical trials for patients with cancer. The company's lead compound, the SYK inhibitor entospletinib, is being evaluated in the registrational Phase 3 AGILITY trial for newly diagnosed NPM1-mutated acute myeloid leukemia (AML). The company is also developing the CDK9 inhibitor, KB-0742, and lanraplenib, a next-generation SYK inhibitor. Kronos Bio's scientific focus is the dysregulated transcription that is the hallmark of cancer.

Kura Oncology  
http://kuraoncology.com  
Biotechnology, Oncology Pharmaceuticals, Pharmaceuticals  
Kura Oncology is a clinical-stage biopharmaceutical company whose mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. We are advancing a number of precision medicines for the treatment of solid tumors and hematologic malignancies including ziftomenib (KO-539), a menin inhibitor, which is being studied in genetically defined subsets of patients that includes NPM1 mutant and KMT2A-rearranged acute myeloid leukemia.

Kyowa Kirin, Inc.  
https://www.kkna.kyowakirin.com  
Biologicals, Monoclonal Antibodies, Oncology Pharmaceuticals  
Kyowa Kirin is a global specialty pharmaceutical company with US Headquarters based in Bedminster, NJ. The company is focused primarily on developing and commercializing biopharmaceuticals that help improve the health and well-being of people through innovative and state-of-the-art technologies in various
therapeutic areas including oncology, neurology, nephrology, and immunology. For additional information, you can visit us at www.kkna.kyowakirin.com.

Labcorp Oncology  
Booth: 2322  
https://oncology.labcorp.com/  
*Cancer/Chemotherapy, Clinical Research*

Labcorp Oncology is committed to advancing cancer care by pioneering scientific breakthroughs, powering better decisions through actionable data-driven patient insights and bringing healthcare within reach for all cancer patients throughout their continuum of care. With our comprehensive, specialized diagnostic services and our drug development capabilities, Labcorp is uniquely positioned to support you, from discovery through post-marketing and commercialization—using a biomarker-driven strategy throughout the entire process. https://oncology.labcorp.com/

Legend Biotech  
Booth: 914  
https://experiencelegendbiotech.com  
*Biotechnology, Clinical Research, Immunotherapy*

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 900 employees across the US, China and Europe, along with our differentiated technology, global development, and manufacturing expertise, provide us with the strong potential to discover, develop, and manufacture cutting-edge cell therapies for patients in need.

Lymphoma Coalition  
Booth: 2728  
http://www.lymphomacoalition.org  
*Non Profit, Patient Education Materials, Patient Services*

Lymphoma Coalition, a worldwide network of patient groups with a full or partial focus on providing support to patients with lymphoma, was formed in 2002 and incorporated as a not-for-profit organization in 2010. Today, there are over 80 member organizations from over 50 countries. LC’s current strategy is focused on ensuring impact within two pillars: information and advocacy. VISION: EQUITY IN LYMPHOMA OUTCOMES ACROSS BORDERS. MISSION: ENABLING GLOBAL IMPACT BY FOSTERING A LYMPHOMA ECOSYSTEM THAT ENSURES LOCAL CHANGE AND EVIDENCE-BASED ACTION.

M2GEN  
Booth: 3628  
https://www.m2gen.com  
*Biotechnology, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Other*

M2GEN is an oncology-focused informatics solutions company advancing precision medicine and transforming cancer care through linked clinical and deep molecular data. In collaboration with leading academic cancer centers, biopharmaceutical companies and patients, we have developed a unique data-driven ecosystem to provide cancer researchers and clinicians with insights to make informed decisions faster. We focus on the areas of greatest unmet need in oncology, including hematological malignancies. For more information, visit www.M2GEN.com.

Machaon Diagnostics, Inc.  
Booth: 610  
http://www.machaondiagnostics.com  
*Bleeding/Clotting Tests, Clinical Research, Coagulation Testing, Diagnostic Services/Testing, Genetic Testing*

Machaon Diagnostics specializes in the diagnosis of bleeding and clotting disorders, as well as rare disease genetics. Headquartered in Oakland, California, we also operate Louisiana Coagulation in New Orleans, LA. We provide the highest quality and fastest turnaround times for testing of platelets, thrombosis, hemostasis and rare disease genetics for both our hospital and pharmaceutical company clients. Machaon Diagnostics can offer courier services and interface options.

Mayo Clinic Referring Provider Office  
Booth: 2220  
https://www.mayoclinic.org/medical-professionals  
*Cancer/Chemotherapy, Diagnostic Services/Testing, Genetic Testing, Non Profit, Patient Services*

More than 150,000 people with cancer come to Mayo Clinic each year. They find experts with extensive experience in the diagnosis and treatment of virtually every kind of cancer and the resources to provide excellent care tailored to their needs. A multispecialty cancer team and Mayo Clinic’s clinical expertise drives strong collaboration with referring physicians throughout their patient’s care. Visit Mayo Clinic at booth #2220 to learn more.

MD Anderson Cancer Center  
Booth: 2219  
http://www.mdanderson.org  
*Biologicals, Cancer/Chemotherapy, Clinical Research, Immunotherapy, Physician Recruitment*

MD Anderson is renowned for breakthrough discoveries and exceptional patient care. We’re proud to be ranked No. 1 in cancer care by U.S. News & World Report. Our research enterprise is rooted in interdisciplinary collaboration, benefiting patients faster than ever through our expansive clinical trials program. Our work has led to new treatments like CAR T cell therapy, eliminated the need for chemotherapy for some leukemia patients and improved outcomes for stem cell transplant patients. Visit booth 2219 to meet our experts, discuss clinical trials and learn about open positions.
MDoutlook  
http://www.mdoutlook.com  
Booth: 2329

*Educational, Market Research, Physician Recruitment*

MDoutlook is a leading disease intelligence organization, headquartered since 2008 in Atlanta, GA. Our solutions include disease insight, ThoughtLeader and physician identification, targeting and engagement. Clients are life sciences companies and service providers. Governed by top ThoughtLeaders and driven by in-house medical experts, MDoutlook® is the largest, single global intelligence source directly accessing 85,000+ validated and verified cancer treaters.

Med Learning Group  
https://www.medlearninggroup.com/  
Booth: 855

*Cancer/Chemotherapy, Clinical Research, Educational, Leukemia/Lymphoma Detection, Patient Education Materials*

This Virtual Reality Room invites learners to experience a virtual world illustrating the pathogenesis and mechanisms therapies targeting novel pathways in hematologic malignancies. Through this sensory-immersive experience, a series of virtual reality animations will allow learners to visualize the pathophysiology underlying hematologic malignancies, identify therapeutics mechanisms, and recognize both existing and novel therapies in development to diversify the range of treatment options available to patients.

Medexus Pharma  
Booth: 2315

*Bone Marrow Products, Bone Marrow Transplantation Research, Coagulation Products, Pharmaceuticals*

Medexus Pharma is a wholly owned subsidiary of Medexus Pharmaceuticals, Inc. Based in Chicago, Illinois, Medexus Pharma focuses on the development and commercialization of novel treatments and near market opportunities.

Medidata, a Dassault Systèmes company  
https://www.medidata.com/  
Booth: 2159

*Clinical Research, Software*

Medidata AI, a Dassault Systèmes company, combines data, technology, and deep expertise to help life sciences companies deliver actionable insights.

Medpace Inc.  
http://www.medpace.com  
Booth: 3314

*Clinical Research, Contract Research Organization, Immunotherapy, Oncology Pharmaceuticals, Research Affairs*

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including hematology and oncology.

Medscape Oncology & Hematology  
https://www.medscape.com/oncology  
Booth: 3153

*Educational, Market Research, Patient Education Materials, Publisher, Research Reagents*

Medscape Oncology is a leading source of oncology & hematology news and information for physicians and other healthcare professionals worldwide. We offer medical news, including practice guidelines, FDA announcements, journal articles, conference news, and thought leader perspectives; point-of-care clinical reference tools; and continuing medical education in a variety of engaging formats. medscape.com/oncology

MEI Pharma, Inc.  
https://www.meipharma.com/  
Booth: 3247

*Clinical Research, Oncology Pharmaceuticals*

MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing new therapies for cancer. MEI Pharma’s portfolio of clinical stage drug candidates includes the lead candidate zandelisib (ME-401), an oral PI3Kd inhibitor differentiated by its unique dosing schedule currently under evaluation for R/R FL and MZL in Phase 2 (NCT03768505) and Phase 3 (NCT04758832) clinical trials intended to support market authorization applications, as well as voruciclib, an oral CDK9 inhibitor currently evaluated in a Phase 1 (NCT03547115) clinical trial for R/R B-cell malignancies and AML.

Menarini Silicon Biosystems  
https://www.siliconbiosystems.com/en-us/  
Booth: 3633

*Biotechnology, Cell Counters, Clinical Research*

Menarini Silicon Biosystems’ new Circulating Multiple Myeloma Cell (CMMC) Enumeration assay directly measures levels of plasma cells in peripheral blood. This test provides complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, the test monitors plasma cell burden over time without requiring repeated bone marrow biopsies. Through our technology platforms and global lab services, we have standardized serial monitoring through cell-based liquid biopsy for a variety of conditions.

Menarini Stemline  
http://www.menarini.com  
Booth: 3321

Menarini/Stemline are committed to make a difference in cancer patients lives. We invest in the development...
of precision medicine through our pipeline of investigational drugs, which includes small molecules & biologics in hematologic & solid tumors.

Merck & Co., Inc.  
Booth: 3333  
https://www.merck.com  
Clinical Research, Oncology Pharmaceuticals

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.

Miltenyi Biotec  
Booth: 3355  
http://www.miltenyibiotec.com  
Cell Separators, Clinical Research

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. We are committed to supporting clinical innovators, physicians, and cell manufacturers with solutions that enable scalable clinical translation of novel cell and gene therapies and engineered grafts for hematopoietic stem cell transplant. Visit our web page and discover a selection of useful resources to enhance your development of advanced therapies.

Mission Bio  
Booth: 2014  
https://www.missionbio.com/  
Clinical Research, Genetic Testing, Research Reagents

Mission Bio is a life sciences company that accelerates discoveries and cures by equipping researchers with the tools they need to improve how we measure and predict our resistance and response to precision therapies. With the Tapestri Platform, the only commercialized platform capable of analyzing DNA and protein simultaneously with single-cell resolution, Mission Bio’s multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health.

MJH Life Sciences  
Booth: 2118  
https://www.mjhlifesciences.com/  
Books/Journals, Educational, Other, Publisher

MJH Life Sciences is home to iconic health care brands across hematology and oncology. We are dedicated to providing health care professionals with the resources and education needed to optimize patient outcomes and improve care. Our hematology-focused brands include OncLive®, Targeted Oncology™, CURE®, CancerNetwork®, HCPLive®, CGTLive™ and Physician’s Education Resource®, all offering unparalleled multimedia access to recent data, insights, and thought leadership, and committed to helping provide the most relevant information to health care providers and patients.

MLM Medical Labs  
Booth: 2323  
https://www.mlm-labs.com/  
Clinical Research, Coagulation Testing, Flow Cytometry, Molecular Biology

MLM Medical Labs is an industry-leading specialty and central laboratory with comprehensive standard and fully customizable biological research services and analytical capabilities across a wide spectrum of therapeutic areas. Our strong reputation for scientific expertise, passionate customer care, and quality data adds value at every stage of the product development process, empowering our customers to reach confident clinical decisions that improve patient lives. Our expertise includes biomarkers, assay development, immunoncology, coagulation, and platelets.

Moffitt Cancer Center  
Booth: 1922  
https://www.Moffitt.org  
Cancer/Chemotherapy, Clinical Research, Immunotherapy, Non Profit

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet status, its highest distinction. With more than 7,500 team members, Moffitt has an economic impact in the state of $2.4 billion.

MorphoSys  
Booth: 3115  
https://www.morphosys.com/  
Biotechnology, Immunotherapy, Oncology Pharmaceuticals

At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter and LinkedIn.

MPLT Healthcare  
Booth: 2320  
https://www.mplthealthcare.com

MPLT Healthcare specializes in placing highly qualified physicians and advanced practice clinicians in locum, locum-to-perm and direct hire staff positions. We will always be people helping people, striving to earn the loyalty of our clients, providers and employees.
through selfless service, relentless focus on quality and a culture of excellence.

**Multiple Myeloma Research Foundation**
Booth: 2629
https://themmrf.org/

*Clinical Research, Educational, Non Profit, Patient Education Materials*

The Multiple Myeloma Research Foundation (MMRF) leads the way in accelerating a cure for each and every myeloma patient. One important initiative is the MMRF CureCloud®. This longitudinal IRB-approved research study includes the first at-home genomic testing program for multiple myeloma patients. Our goal: harness a vast amount of genomic, clinical—and eventually—patient immune and other kinds of data—to accelerate research into smarter treatments for every patient. Ultimately, this research study will inform personalized treatment options to consider with your patients.

**National Blood Clot Alliance**
Booth: 2620
http://www.stoptheclot.org

*Educational, Non Profit, Patient Education Materials*

The National Blood Clot Alliance (NBCA) is a 501(c)(3), non-profit, voluntary health organization dedicated to advancing the prevention, early diagnosis and successful treatment of life-threatening blood clots such as deep vein thrombosis, pulmonary embolism, and clot-provoked stroke. NBCA works on behalf of people who may be susceptible to blood clots, including, but not limited to, people with clotting disorders, atrial fibrillation, cancer, traumatic injury, and risks related to surgery, lengthy immobility, childbirth and birth control.

**National Cancer Institute**
Booth: 2616
https://www.cancer.gov

*Cancer/Chemotherapy, Research Grants*

NCI is the federal government’s principal agency for cancer research and training. NCI leads, conducts, and supports cancer research across the nation to advance scientific knowledge and help all people live longer, healthier lives.

**National Comprehensive Cancer Network (NCCN)**
Booth: 2716
https://www.nccn.org/

*Cancer/Chemotherapy, Clinical Research, Educational, Non Profit, Patient Education Materials*

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 32 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system.

**National Heart, Lung, and Blood Institute**
Booth: 2314
http://www.nhlbi.nih.gov

*Clinical Research, Research Grants*

The National Heart, Lung, and Blood Institute (NHLBI) plans and directs research in the development and evaluation of prevention, treatment, and rehabilitation of patients suffering from diseases of the heart, blood vessels, lung, and blood, obesity, and sleep disorders. NHLBI conducts educational activities, including development and dissemination of materials in the above areas. Contact NHLBI by email: nhlbiinfo@nhlbi.nih.gov or phone: 301-592-8573.

**NEJM Group**
Booth: 600
https://www.nejmgroup.org/

*Books/Journals, Educational, Publisher*

NEJM Group creates high-quality medical resources for research, learning, practice and professional development designed to meet the demand for essential medical knowledge among academic researchers and teachers, physicians, clinicians, executives and others in medicine and health care. NEJM Group brings together the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst, NEJM Journal Watch, NEJM Knowledge+, NEJM Resident 360, NEJM Healer, NEJM Medicine前沿, and NEJM CareerCenter. For more information visit www.nejmgroup.org.

**NeoGenomics Laboratories**
Booth: 3415
https://www.neogenomics.com

*Clinical Research, Diagnostic Services/Testing, Flow Cytometry, Immunotherapy, Registry*

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. >600 tests including molecular profiling in myeloid disorders and leukemias, cfDNA/RNA assays for biopsy-free evaluation of hematologic cancers, and >20 HemeFISH™ panels. Our Pharma Services division serves pharmaceutical clients in clinical trials and drug development from biomarker discovery thru CDx validation and commercialization.

**NMDP/Be The Match**
Booth: 2517
https://bethematchclinical.org/

*Bone Marrow Products, Bone Marrow Transplantation Research*

The National Marrow Donor Program (NMDP)/Be The Match manages the most diverse registry of potential donors for patients with life-threatening illnesses who need a bone marrow or stem cell transplant.
unrelated blood stem donors and cord blood and partners to provide cures to patients with life-threatening blood disorders. They support therapy development and delivery through Be The Match BioTherapies and are also a leader in research through the CIBMTR (Center for International Blood and Marrow Transplant Research)—investing in and managing studies to help patient outcomes.

Northside Hospital  
Booth: 1114  
http://www.northside.com

Bone Marrow Transplantation Research, Cancer/Chemotherapy, Clinical Research, Immunotherapy, Leukemia/Lymphoma Detection

The Blood and Marrow Transplant, Leukemia and Immunotherapy Programs at Northside Hospital, Atlanta GA, strives to be the premier blood cancer treatment center in the Southeast by achieving outstanding patient outcomes and satisfaction. We are dedicated to providing patient-focused care through research, leading edge treatments and clinical excellence. Our patients and their families are at the center of our program, and we are committed to treating each individual with respect, dignity and compassion while providing them with the clinical and ongoing support they need.

Notable Labs  
Booth: 2022  
http://www.notablelabs.com

Biotechnology, Cancer/Chemotherapy, Flow Cytometry, New Exhibitor, Oncology Pharmaceuticals

Notable a clinical-stage platform therapeutics, & drug development company featuring revolutionary predictive precision medicine platform that matches individual cancer patients responses to therapies with up to 100% accuracy based on results of 4 clinical validation studies. A team of highly collaborative medical & technology visionaries have harnessed a combination of therapeutics, diagnostics, software, engineering, machine learning & automation, to develop proprietary, platform that bio-simulates patient’s cancer treatment with high fidelity to actual treatment.

Novo Nordisk  
Booth: 3143  
https://www.novonordisk-us.com/  
Coagulation Products, Pharmaceuticals

Novo Nordisk, a global health care company, has been committed to discovering and developing innovative medicines to help people with serious chronic conditions lead longer, healthier lives with fewer limitations. We’re working toward a future where fewer people get chronic diseases, everyone is diagnosed, and all patients receive adequate treatment.

Nucleus Biologics  
Booth: 1959  
https://nucleusbiologics.com/  
Cell Culture, Clinical Research, New Exhibitor, Research Reagents

Nucleus Biologics, The Cell Performance Company™, is the leading provider of custom cell-growth media, tools, and technologies for cell and gene therapy. Its mission is to speed the time from scientific discovery to cure by delivering innovative, transparent, and cGMP products and services. From design to delivery, we offer an entire ecosystem of cell culture media solutions that seamlessly interface with one another, facilitating easy formulation, configuration, ordering, and manufacture of media, while addressing the environmental impacts of cell culture media fulfillment.

NuProbe USA, Inc.  
Booth: 1157  
https://www.nuprobe.com

Biotechnology, Clinical Research, Diagnostic Assay Kits, Molecular Biology

NuProbe is a cutting-edge genomics and molecular diagnostics company with revolutionary molecular technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe has sites in Houston, USA, Shanghai, China and Suzhou, China. NuProbe's vision is to offer affordable, timely, and accurate disease state information to enable precision medicine and improve patient outcomes.

Omeros Corporation  
Booth: 2149  
https://eisthreat.com/  
Biotechnology

Endothelial injury syndromes (EIS) resulting from hematopoietic stem cell transplant (HSCT) encompass numerous serious and potentially fatal complications. Endothelial injury, including HSCT-TMA, can occur prior to, during, and after HSCT.
ONO Pharma USA, Inc.  
Booth: 249, Virtual  
https://www.ono-usa.com/  
_Cancer/Chemotherapy, Pharmaceuticals_

ONO PHARMA USA, INC. is pursuing the clinical development of new drug candidates and aiming to commercialize in the US. ONO PHARMA USA, INC. was established as a US subsidiary of Ono Pharmaceutical Co., Ltd. (ONO) in 1998. ONO was founded in Osaka, Japan, in 1717. ONO is an R&D-oriented pharmaceutical company committed to discovering and developing “first-in-class” medicines, like nivolumab, an anti-PD-1 antibody drug, focusing on oncology, immunology, neurology, and specialty research.

OPIS  
Booth: 3226  
https://opisresearch.com/  
_Clinical Research_

OPIS is an international CRO (Contract Research Organization), with 23 years of experience in conducting more than 1400 Phase I-IV clinical trials, including non-interventional, medical devices and nutraceutical studies on an international level. With 10 offices across Europe and more locations growing overseas worldwide, OPIS offers a full range of integrated clinical research services as scientific advice, medical writing, trial start-up, monitoring, study management, data management, statistics, pharmacovigilance as well as quality assurance and training.

OPTOLANE Technologies, Inc.  
Booth: 1942  
http://www.optolane.com  
_Cancer/Chemotherapy, Diagnostic Assay Kits, Genetic Testing, Leukemia/Lymphoma Detection, Molecular Biology_

Optolane is a digital real-time PCR platform manufacturing company. Utilizing the high sensitivity of digital PCR, we have been developing liquid biopsy products for cancer starting from the BCR-ABL1 Major Kit which can detect the BCR-ABL1 transcript up to MR5.3. We continue to develop diagnostic tools for the fast and proper treatment of cancer. We also provide digital PCR cartridges for research use for extensive utilization of our platform. Our platform is applicable for use in absolute quantification, CNV, SNP/mutation/methylation detection, and NGS library analysis.

OrganaBio  
Booth: 2143  
https://www.organabio.com/  
_Biotechnology, Cell Culture, Human Biologicals, Immunotherapy, Other_

OrganaBio’s unique, flexible model combines proprietary and scalable tissue sourcing with advanced processed and highly characterized perinatal and adult tissues (including umbilical cord blood and leukopaks). With the ability to tailor products and services to a customers’ evolving needs, OrganaBio rapidly manufactures a variety of isolated cells such as CD34+ HSCs, T, B & NK Cells, and macrophages from tissues for pre-clinical research use as well as in the manufacturing of clinical-grade cell therapies.

Parexel International  
Booth: 149  
https://www.parexel.com/experience/therapeutic-expertise/oncology-study-experience  
_Clinical Research, Contract Research Organization_

As a leading global CRO, Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life sciences and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From decentralized clinical trials to regulatory consulting services and leveraging real-world insights, our therapeutic, technical, and functional ability is underpinned by a patient-first culture embedded in our DNA. What we do, we do With Heart™.

Pfizer (MM)  
Booth: 1833  
https://www.pfizeroncologycongresshub.com/ASH2022  
_Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals_

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

Pfizer (Oncology)  
Booth: 1215, Virtual  
https://www.pfizeroncologycongresshub.com/ASH2022  
_Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals_

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

Pfizer (Rare Disease)  
Booth: 648  
https://www.pfizer.com  
_Biotechnology, Clinical Research, Pharmaceuticals_

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly
improve their lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Pfizer, Inc.  
Booth: 206, 4114  
http://www.pfizer.com

About Pfizer: Breakthroughs That Change Patients’ Lives. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Pharmacosmos Therapeutics Inc.  
Booth: 847  
https://www.monoferric.com

Pharmacosmos Therapeutics Inc. is a U.S. specialty pharmaceutical company dedicated to providing patient care through the commercialization of Monoferric® (ferric derisomaltose) injection and through exceptional resources to support this treatment. We are the U.S. affiliate of the Denmark-based Pharmacosmos Group. Please visit us at www.monoferric.com to learn more.

Pharmacyclics LLC, An AbbVie Company  
Booth: 415  
http://www.abbvie.com

Pharmacyclics is an AbbVie Company in South San Francisco, California, developing and commercializing small-molecule medicines for which there is great unmet medical need.

PharmaEssentia Corporation  
Booth: 235  
http://www.pharmaessentia.com/

PharmaEssentia Corporation, based in Taipei, Taiwan, is a rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea. Visit our website to learn more.

Pharming Healthcare, Inc.  
Booth: 3529  
https://www.pharming.com

Pharming Healthcare, Inc. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

PicnicHealth  
Booth: 321  
https://www.picnichealth.com/

New Exhibitor, Registry, Software
PicnicHealth is building deep real-world datasets to fuel cutting-edge research while giving patients control of their own medical records. These complete, clinically-rich datasets produce unique insights to ultimately get the right treatments into patients’ hands faster. We do this by working directly with patients and leveraging human-assisted machine learning to transform messy medical records into structured research-ready datasets. To date, we’ve helped tens of thousands of patients securely access their records and contribute to research that impacts their lives.

Platelet Disorder Support Association  
Booth: 2514  
https://www.pdsa.org

Association, Non Profit, Patient Services
The Platelet Disorder Support Association, patient-founded in 1998, is dedicated to enhancing the lives of people with immune thrombocytopenia (ITP) and other platelet disorders through education, advocacy, research and support.

PlatformQ Health  
Booth: 547  
http://www.PlatformQ.com

New Exhibitor
PlatformQ Health is the leading provider of interactive digital medical education for clinicians, patients, and caregivers. To improve patient care, PlatformQ Health Education creates video-first educational modules with premier partners, so learners can better understand conditions, available treatment options, and the latest research. The company’s proprietary platform allows participants to engage in real-time discussion with scientific, research, and patient care experts.

Precision for Medicine  
Booth: 420  
https://www.precisionformedicine.com/

Clinical Research, Contract Research Organization
Premier Research

https://www.premier-research.com

Clinical Research, Contract Research Organization

Premier Research, a product development company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier Research specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Premier Research is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.

Protagonist Therapeutics, Inc

Booth: 713, Virtual

https://www.protagonist-inc.com

Biotechnology, Clinical Research, Pharmaceuticals

Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide, PN-943, and PN-235 in different stages of clinical development, all derived from the Company’s proprietary technology platform. Rusfertide, a mimic of the natural hormone hepcidin, is the Company’s lead drug candidate. VERIFY, the global Phase 3 registration study of rusfertide in polycythemia vera, is currently underway.

Prothena

Booth: 3059

http://www.prothena.com

Biologicals, Clinical Research, Monoclonal Antibodies

Prothena is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for rare peripheral amyloid and neurodegenerative diseases.

Q2 Solutions

Booth: 2542

https://www.q2labsolutions.com

Clinical Research, Contract Research Organization, Flow Cytometry, Molecular Biology

Q Squared Solutions is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions. We provide scientific expertise and innovative solutions for ADME, bioanalytical, genomics, vaccines, and central laboratory services, including flow cytometry, anatomic pathology, immunoassay, molecular companion diagnostics, with meticulous regional and global clinical trial implementation support and high-quality data delivery.

Rapid Novor Inc.

Booth: 2743

https://www.byopsy.com

Flow Cytometry, Genetic Testing

Rapid Novor Inc is developing a sensitive and non-invasive blood based liquid biopsy (EasyM) to monitor the minimal residual disease and detect early relapse for Multiple Myeloma. EasyM is sensitive enough to determine MM relapse 6-8 months earlier than traditional tests.

Regeneron Pharmaceuticals

Booth: 1847

http://www.regeneron.com

Monoclonal Antibodies, Oncology Pharmaceuticals

Regeneron is a leading biotechnology company that invents life-transforming medicines for serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies. Visit www.Regeneron.com to learn more.

Rigel Pharmaceuticals

Booth: 2815

http://www.rigel.com

Biotechnology, Oncology Pharmaceuticals

Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the development and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and sees great opportunity to help patients who have diseases where few to no approved treatment options exist. Rigel’s first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018. Please visit www.TAVALISSEhcp.com to see the full Prescribing Information and learn more.

Rutgers Cancer Institute of New Jersey/
RWJBarnabas Health

Booth: 311

https://www.cinj.org

Clinical Research, Immunotherapy, New Exhibitor, Patient Services, Physician Recruitment

As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health offers innovative cancer treatment including CAR-T cell therapy, stem cell transplant, proton therapy, clinical trials, and immunotherapy. More than 230 faculty in interdisciplinary programs, including pediatric hematology/oncology, focus on basic, clinical, translational, and population research that drives outstanding contributions towards reducing cancer incidence and improving patient outcomes.
S. Karger Publishers, Inc.  
Booth: 2418  
https://www.karger.com/

*Karger Publishers*, headquartered in Basel, Switzerland, is an independent, globally active publishing house in health sciences. Committed to Connecting and Advancing Health Sciences, the emphasis is on providing customized solutions for all industry partners. Among Karger's compelling advantages are access to key opinion leaders, leading medical societies, and a global community of healthcare professionals. Karger builds a strong global alliance through its engagement with these communities.

**Sampled**  
Booth: 204  
https://sampled.com/

Sampled is a next-generation laboratory that unlocks the valuable data in any biological sample. Through our integrated “SMART Lab” services, we can Store, Manage, Analyze, Research and Transport biological materials, offering partners a seamless solution for all research samples. Our vision is a world where we make it faster and easier for health innovators to improve human health, with a mission to be the SMART Lab behind every transformative health innovation.

**Sanius Health**  
Booth: 300  
http://www.saniushealth.com

*Sanius Health* is focused on accelerating personalised medicine, drug discovery and clinical research on sickle cell disease and other rare conditions. People with rare diseases spend 99% of their lives outside of the hospital, yet their care is based solely on what's seen in appointments. Sanius Health goes beyond hospital data so that clinical decisions can be based upon the full picture, not just 1% of it. They partner with passionate patients, treatment centres, researchers, and developers of therapeutics in advancing outcomes for patients.

**Sanofi**  
Booth: 643, Virtual  
https://www.sanofi.us

*Sanofi* is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.

**Sanyou Biopharmaceuticals Co. Ltd**  
Booth: 2058  
www.sanyoubio.com

**Sarah Cannon Research Institute**  
Booth: 1914  
http://www.sarahcannon.com

*Sarah Cannon Research Institute* offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the US and UK. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses - 1,400 stem cell transplants performed annually throughout the Sarah Cannon Transplant and Cellular Therapy Network, hundreds of clinical trials, and molecular profiling capabilities.

**Saudi Society of Blood & Marrow Transplantation (SSBMT)**  
Booth: 2723  
http://www.ssbmt.org.sa

The Saudi Scientific Society of Blood and Marrow Transplantation (SSBMT) is a professional non-profit organization, aiming to promote and enhance science, research and proper practice with the vision to be a high-standard resource for healthcare workers, patients and the public in the field of specialization. Scope of Specialization:• Stem Cell Transplantation & other stem cell applications• Blood disorders and cancers• Hematopathology and related specialties and technologies

**Scientific Education Support**  
Booth: 301  
https://scientificeducationsupport.com/

*Scientific Education Support* (SES) is a medical education provider, building healthcare professional and patient networks that facilitate open access, science-driven, unbiased disease education through multichannel communications.

**Seagen**  
Booth: 1943, Virtual  
https://www.seagen.com

*Seagen* is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.
Secura Bio Inc.  
https://www.securabio.com  
Booth: 1415

Biotechnology, Oncology Pharmaceuticals

Secura Bio is an integrated, commercial-stage biopharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies for physicians and their patients. For more information, please visit www.securabio.com.

Secure Transfusion Solutions  
http://securetransfusion.com  
Booth: 613

New Exhibitor, Other

Secure Transfusion Solutions (STS) owns and operates commercial blood centers under the name Trusting Heart Blood Center. Our goal is to help hospitals around the country build a robust, resilient supply of pathogen-reduced apheresis platelets to meet patient needs.

Servier Pharmaceuticals  
https://www.servier.us/  
Booth: 1735

Clinical Research, Oncology Pharmaceuticals, Patient Education Materials

Servier Pharmaceuticals is a commercial-stage pharmaceuticals company with a passion for innovation and improving the lives of patients, their families and caregivers. In the United States, Servier Pharmaceuticals is committed to building a robust portfolio, starting with oncology, with future growth driven by innovation in other areas of unmet medical need, leveraging Servier's global portfolio and seeking acquisitions, licensing deals and partnerships.

Shwachman-Diamond Syndrome Foundation  
https://www.shwachman-diamond.org  
Booth: 2814

Bone Marrow Transplantation Research, Non Profit, Patient Services, Registry, Research Grants

Shwachman-Diamond Syndrome Foundation has educated medical professionals and the public about this ultra rare disease since 1994. We have provided education, answers, support and hope to SDS patients and their families. We advocate for and fund research to improve treatment and curative therapies. We reach our families and medical professionals through our website, Facebook page, newsletters, and medical conferences.

Singleron Biotechnologies GmbH  
https://www.singleron.bio/  
Booth: 3351

Biotechnology, Clinical Research, Molecular Biology, New Exhibitor, Research Reagents

Singleron Biotechnologies develops and commercializes single-cell multi-omics products that can be used in both research and clinical settings. Its current product portfolio includes instruments, microfluidic devices, reagents, software analysis and database solutions that facilitate high-throughput single-cell analysis. The company currently has offices, laboratories, and manufacturing facilities in Germany, Singapore, China, and the US. Its products are used in over 1,600 laboratories in hospitals, research institutes, and pharmaceutical companies.

siParadigm Diagnostic Informatics  
https://www.siparadigm.com/  
Booth: 2422

Cytogenics, Diagnostic Services/Testing, Flow Cytometry, Genetic Testing, Molecular Biology

siParadigm Laboratories is a leading cancer diagnostic reference laboratory with unsurpassed expertise in Hematopathology and latest Oncology Diagnostics working with physicians, clinicians, patients, and providers, to inform timely and appropriate patient CARE through Communication, Accuracy and Reliability. Our areas of expertise include cancer cytogenetics with industry-leading turnaround times (TAT); hematologic and solid tumor testing. siParadigm has earned national accreditation by both CLIA and CAP, in addition to receiving local licensing in several states.

Sobi, Inc.  
https://sobi-northamerica.com/  
Booth: 3343

Bone Marrow Transplantation Research, Clinical Research, Immunotherapy, Monoclonal Antibodies, Pharmaceuticals

As the North America affiliate of biopharmaceutical company Sobi™, our team is committed to Sobi's vision of bringing innovative therapies and services to make a difference in the lives of those affected by a rare disease, from the patient to their families and caregivers. We bring a rare strength to our work – a superior focus, commanding agility and the power of the people we are dedicated to serving. Our key therapeutic areas include rare diseases in hematology and immunology, as well as a portfolio of specialty care products.

Society for Immunotherapy of Cancer (SITC)  
https://www.sitcancer.org  
Booth: 2515

Educational, Immunotherapy, Non Profit

The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. SITC is a 501(c)(3) not-for-profit medical professional society of more than 4,650 influential research scientists, physician scientists, clinicians and more dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. SOHO represents physicians and other health care professionals from all corners of the world. The SOHO global network supports and is supported by members from more than 110 countries, who are leading the vital efforts to further treatments for those afflicted by these diseases.

SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a health care technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.

Spark Therapeutics, Inc.

At Spark Therapeutics, we are leveraging our unique technical and R&D expertise as we strive to bring gene therapies to patients. One of our areas of research is hemophilia A, an inherited bleeding disorder caused by mutations in the F8 gene that encodes coagulation factor VIII. Led by researchers and clinicians with long-standing commitment to the hemophilia community, we recognize the essential need to understand and gain important perspectives from patients, caregivers and leaders in the community. Spark Therapeutics is a member of the Roche Group.

Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs and commercial capabilities to address modern market realities. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
Taiho

http://www.taihooncology.com

Pharmaceuticals

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established a world class clinical development organization that works urgently to develop innovative cancer treatments and has built a commercial business in the U.S. Taiho Oncology has an oral oncology pipeline consisting of selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. It’s our work; it’s our passion; it’s our legacy.

Takeda Hematology

https://www.takeda.com

Biotechnology, Pharmaceuticals

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. www.takeda.com

Takeda Oncology

https://takedaoncologyvirtualexperience.com/

Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialization to rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide. For more information, visit www.takedaoncology.com.

Takeda Pharmaceuticals - LSD Division

http://www.takeda.com

Millennium Pharmaceuticals wants to be the drug company for the new millennium. Operating as Millennium: The Takeda Oncology Company, it’s a subsidiary of Japan’s Takeda Pharmaceutical. The company’s cancer drug Velcade is approved as a treatment for multiple myeloma (a blood cancer) and mantle cell lymphoma (or MCL, an aggressive form of non-Hodgkin’s lymphoma). Millennium boasts more than a dozen other drug candidates in the pipeline, most of them cancer-related. Its oncology-focused sales force, in partnership with Johnson & Johnson, markets the drug, with Millennium handling sales in the US and various J&J subsidiaries handling sales in Europe and most other countries where Velcade is approved.

Team Telomere

http://teamtelomere.org

Genetic Testing, Non Profit, Patient Education Materials, Registry, Research Grants

Team Telomere is a 501(c)3 registered disease advocacy group that spreads awareness & encouragement to those affected by Dyskeratosis Congenita & Telomere Biology Disorders by providing medical information, advocating on the patient/caregiver's behalf, and focusing on outreach programs to better the lives of those affected by DC/TBD. Team Telomere aims to improve diagnosis by educating providers and influence research by working alongside researchers/scientists.

Telo Genomics

https://www.telodx.com

Leukemia/Lymphoma Detection

Telo Genomics pioneers the most comprehensive 3-dimensional telomere analytics platform to assess risk of progression, treatment outcome or active monitoring of multiple myeloma patients and other cancers. TeloView®, the company’s ground-breaking single-cell analysis platform, utilizes a proprietary algorithm to quantify genomic disease signals enabling dynamic assessment of genomic changes and empowering precision medicine treatment decisions. TeloView technology is applicable to liquid biopsy.

Tempus

http://www.tempus.com

Clinical Research, Diagnostic Services/Testing, Genetic Testing, Molecular Biology, Patient Services

Data-driven precision medicine. Bringing the power of data and artificial intelligence to healthcare.

The MDS Foundation, Inc.

https://www.mds-foundation.org/

Clinical Research, Non Profit

The MDS Foundation, Inc. is a global non-profit advocacy organization that for over 25 years has supported patients and their families as well as healthcare providers in the fields of MDS and its related diseases. The Foundation supports and educates patients, their communities, and healthcare providers, and contributes to innovative research in the fields of MDS and its related continuum of diseases to better diagnose, control and ultimately cure these diseases.
Theradex Oncology  
http://www.theradex.com/  
Contract Research Organization  

Booth: 3913

---

ThermoFisher  
http://www.oncomine.com  
Genetic Testing, Research Reagents

Thermo Fisher Scientific is the world leader in serving science. We offer leading next-generation sequencing (NGS) solutions for the study of myeloid and lymphoid malignancy samples. Our portfolio of assays enable a range of applications, including genomic profiling and clonality detection. Using our latest platform, you can have sequencing results in as fast as 1 day. To learn how you can see us during the meeting visit: www.oncomine.com/ash2022

Booth: 3542

---

ThinkCyte, Inc  
https://thinkcyte.com/  
Biotechnology, Cell Separators, Flow Cytometry, Immunotherapy, New Exhibitor

ThinkCyte has pioneered Ghost Cytometry, a proprietary AI-based, label-free cell sorting technology with partners in major global biopharmaceutical companies and leading academic research institutes. www.thinkcyte.com. Our system provides researchers with a powerful tool to study solid tumor and hematological cancers, isolate live cells with defined phenotypes such as non-exhausted or activated T-cells, and characterize subtle phenotypes that aren’t detectable by current approaches.

Booth: 1843

---

TwinStrand Biosciences  
https://twinstrandbio.com/applications/aml-mrd/  
TwinStrand Biosciences is leading the way in identifying ultra-low frequency genomic variants that are undetectable by conventional methods. The company’s highly sensitive and specific Duplex Sequencing technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health, and other fields on a faster timescale, where actions are most impactful.

Booth: 1224

---

United Porphyrias Association  
https://www.porphyria.org/  

Booth: 2718

---

University of Colorado Denver  
http://www.ucdenver.edu/education  
The Executive MBA in Health Administration program provides healthcare Professionals and leaders the knowledge and tools to manage complex issues within the healthcare industry. Accelerate your career with a specialized MBA degree completed in two years in a hybrid format.

Booth: 2721

---

Vaniam Group  
https://www.vaniamgroup.com  
Biotechnology, Educational, Market Research, Oncology Pharmaceuticals, Pharmaceuticals

A premier network of independent communications agencies, we help biopharma companies realize the full potential of their oncology and hematology discoveries -- through early asset planning, insights gathering, clinical trial optimization, scientific content development, publications, and market access strategies. For more than 15 years, we’ve studied the evolving treatment landscape, championed meaningful collaboration between the scientific and medical communities, and communicated data with clarity. Ultimately, we hope our work has helped improve patients’ lives.

Booth: 2757

---

Vertex Pharmaceuticals Inc.  
https://www.vrtx.com/  
Biotechnology, Bone Marrow Transplantation Research, Pharmaceuticals

Vertex Pharmaceuticals and CRISPR Therapeutics are researching the use of CRISPR/Cas9 gene editing to develop potential new treatments aimed at the underlying genetic causes of human disease, including transfusion-dependent β-thalassemia and severe sickle cell disease.

Booth: 1854, 2447, Virtual

---

Viatris  
http://www.VIATRIS.com  
Pharmaceuticals

VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions and improving patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities.

Booth: 304

---

Waldenstrom’s Macroglobulinemia Foundation  
https://www.iwmf.com  
Educational, Non Profit, Patient Education Materials, Publisher, Research Grants

The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-driven international nonprofit organization with a simple but compelling vision and mission. OUR VISION: A world without WM (Waldenstrom’s macroglobulinemia) OUR MISSION: Support and educate everyone affected by Waldenstrom’s macroglobulinemia

Booth: 2621
The IWMF is committed to creating a world without WM by finding a cure. Since 1999, the IWMF has invested over $21 million in WM research projects throughout the world.

WellSpan Health
Booth: 2719
http://www.joinwellspan.org/oncology
New Exhibitor, Non Profit
At WellSpan, the work we do makes a difference because our patients are at the forefront of everything that we do. As part our cancer program, we have an expanded collaboration with Johns Hopkins Medicine providing access to clinical trials, cancer subspecialists for second opinions, and improved genomics capabilities. Our goal is to provide high-quality, seamless, advanced cancer care for our patients who trust us with their cancer journey.

Wolters Kluwer
Booth: 711
https://shop.lww.com
Books/Journals, Publisher
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers, and the next generation of healthcare providers. With a focus on clinical effectiveness, research and learning, safety and surveillance, and interoperability and data intelligence, our proven solutions drive effective decision-making and consistent outcomes across the continuum of care. Visit us at booth 711 or online at https://shop.lww.com. Save 25% with promo code WNA022AA at checkout. Exclusions apply.

Worldwide Clinical Trials
Booth: 2224
http://www.worldwide.com
Biotechnology, Clinical Research, Contract Research Organization, Oncology Pharmaceuticals, Pharmaceuticals
Worldwide Clinical Trials is a global, midsize contract research organization that provides top-performing bioanalytical and Phase I-IV clinical development services to the biotechnology and pharmaceutical industries. Founded in 1986 by physicians committed to advancing medical science, our full-service clinical experience ranges from early phase and bioanalytical sciences through late phase studies, post approval, and real-world evidence. Major therapeutic areas of focus include cardiovascular, metabolic, neuroscience, oncology, and rare diseases.

X4 Pharmaceuticals
Booth: 2115
https://www.x4pharma.com/
Biotechnology, Clinical Research, Genetic Testing, Other
X4 is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. X4's pipeline is comprised of a first-in-class, oral, small molecule antagonist of chemokine receptor CXCR4, which has the potential to treat a broad range of rare diseases resulting from dysfunction of the CXCR4 receptor pathway, including primary immunodeficiencies, neutropenia, and certain cancers.

X4 Pharmaceuticals (Commercial)
Booth: 2321
http://www.x4pharma.com
Clinical Research, Genetic Testing
X4 is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. X4's pipeline is comprised of a first-in-class, oral, small molecule antagonist of chemokine receptor CXCR4, which has the potential to treat a broad range of rare diseases resulting from dysfunction of the CXCR4 receptor pathway, including primary immunodeficiencies, neutropenia, and certain cancers.
Blood® Podcast

Weekly highlights of select articles in each issue

SUBSCRIBE TODAY
SAVE THE DATE
December 9-12, 2023
San Diego, CA

65th ASH®
Annual Meeting and Exposition
ELEVATE YOUR KNOWLEDGE

View head-to-head and ~5-year data* at Booth #619 during the 2022 ASH Annual Meeting

*At median 58.2-month follow-up (range: 0.0-72.0 months).1


CALQUENCE®
acalabrutinib 100 mg tablets

NEW TABLET FORMULATION

CALQUENCE is a registered trademark of the AstraZeneca group of companies.
©2022 AstraZeneca. All rights reserved. US-69037 9/22